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  Abstract 
 
Abstract (English) 
 
 This thesis contains several independent projects, covering three aspects of organic 
chemistry: natural product synthesis, C–H-activation, and organocatalysis. The total synthesis 
part is concerned about the synthesis of Amphidinolide Q. The C–H-activation part is devoted 
its application towards natural products -Lycorane and Palonosetron. The third part describes 
the catalysis development and application of a new phosphoric acid based catalyst. 
structure of the work 
 
 
 
Amphidinolides are a family of cytotoxic macrolides with significant antitumor properties. This 
family has two 12-membered Amphidinolides, named Amp Q and Amp W. Structurally both 
Amphidinolides are significantly different. Amp Q was isolated from the cultured dinoflagellate 
Amphidinium sp (Y-5 strain). It exhibits moderate cytotoxicity against murine lymphoma 
L1210 cells in vitro (IC50 = 6.4 g/mL). It has a very noble structure which contains one ,-
unsaturated ester, one exomethylene, one hydroxy and four methyl units generating all together 
five stereocenteres, which attracted us for synthesis. Starting from meso-2,4-dimethylglutaric 
anhydride we had successfully completed a formal total synthesis of the Amphidinolide Q. The 
key steps of this synthesis include a Noyori transfer hydrogenation, Ferringa-Minnaard 
asymmetric cuprate addition, Mannich reaction, and Yamaguchi macrolactonization. 
Tautomycetin is a polyketide, which was isolated from the culture of Streptomyces 
griseochromogenes in 1989. It exhibits cytotoxicity against fungi, yeasts and animal cells. It 
was synthesized by Oikawa and Shibasaki groups. We were interested in the study of a 
reductive aldol reaction towards the synthesis of the C1–C18 fragment of tautomycetin. 
C–H-activation is a powerful tool towards the synthesis of complex structures. Till the time its 
application in the synthesis of natural product was rarely known. We have successfully applied 
this technique in the synthesis of derivatives of-Lycorane and a fragment of Palonosetron. 
The synthesis of complex bioactive molecules would not be possible without having suitable 
synthetic methods. Therefore, development of new synthetic methodologies is required. Within 
Thesis
Natural Product
Synthesis of  
Amphidinolide Q
Synthesis towards 
Tautomycetin
C–H-activation
towards -Lycorane
towards Palonosetron
Catalysis
Organocatalytic Indole 
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Pd-catalyzed Indanone 
synthesis
Abstract 
 
the huge collections of synthetic approaches, the highest diversity and productivity is provided 
by catalytic methods. We have developed a phosphoric acid based chiral catalyst which is 
capable to promote enantioselective indole alkylation with imines. 
The whole study uses NMR as the main analytical tool. Other methods used in confirmation of 
the compounds are X-ray structure analysis and high resolution mass spectrometry (ESI-
HRMS).  
  Abstract 
 
 
Abstract (German) 
 
 Diese Arbeit enthält mehrere unabhängige Projekte, die sich auf drei Aspekte der 
organischen Chemie beziehen: Synthese von Amphidinolid Q, C–H-Aktivierung und 
asymmetrische Organokatalyse. Amp Q zeigt in vitro eine mäßige Zytotoxizität gegenüber 
murinen Lymphom-L1210-Zellen (IC50 = 6.4 g/ml). Wir haben erfolgreich die formale 
Totalsynthese des Amp Q ausgehend von meso-2,4-Dimethylglutarsäureanhydrid realisiert. Die 
wichtigsten Schritte dieser Synthese sind die Noyori-Transferhydrierung, die asymmetrische 
Feringa-Minnaard-Cuprat-Addition, die Mannich-Reaktion und die Yamaguchi-
Makrolactonisierung. Die C–H-Aktivierung ist ein mächtiges Werkzeug zur Synthese 
komplexer Strukturen. Bis dahin war seine Anwendung bei der Synthese von Naturprodukten 
kaum bekannt. Wir haben diese Technik erfolgreich bei der Synthese von Derivaten von -
Lycoran und einem Fragment von Palonosetron angewendet. Innerhalb der riesigen Sammlung 
synthetischer Methoden wird die höchste Diversität und Produktivität durch katalytische 
Ansätze gewährleistet. Wir haben einen chiralen Katalysator auf Phosphorsäurebasis 
entwickelt, der in zur enantioselektiven Alkylierung von Indolen mit Iminen fähig ist.
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Formal Total Synthesis of the Macrolide Amphidinolide Q 
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1 Introduction 
 
 Among nature’s creation, macrolides are versatile and exciting natural products due to 
their diverse biological activities such as antibiotic, cytotoxic, or antiangiogenic. Several 
macrolides and polyketides have been isolated from symbiotic marine dinoflagellates.1 Many 
of them show potent cytotoxicity against murine lymphoma L1210 cells. Macrolactones vary 
in size from 8-membered (octalactins-1-2) to 60-membered (quinolidomicins) (Figure 1). 
Erythromycin (1-1) a macrolide isolated in 1952 is widely used to treat bacterial infections, and 
because of its safety and efficacy, it is still a preferred therapeutic agent for the treatment of 
respiratory infections. Apoptolidin a 20-membered macrolide, selectively induces apoptosis in 
rat glia cells transformed with adenovirus E1A oncogene in the presence of normal cells and 
inhibits the mitochondrial F0F1-ATPase.2 Actin-binding marine macrocyclic lactones, and 
benzolactone enamides are also possessing potent antitumor activity. 
 
Figure 1. Examples of naturally occurring macrolactones. 
 
A marine microorganism such as bacteria, cyanobacteria, or dinoflagellates produces toxins for 
their defense mechanism. These toxins are the primary source of fish and algae poisoning. 
Though these poisons in microgram scale can kill a person but if used in medically administered 
could be useful for treatment of many fatal diseases such as cancer. Many bioactive substances 
isolated from marine invertebrates such as sponges, tunicates, and so on have proved to be 
essential tools in biology for example, neurotoxins like maitotoxins helped to understand the 
2  Introduction 
 
molecular basis of cellular excitability.3 Biologically significant secondary metabolites isolated 
from symbiotic marine dinoflagellates Amphidinium sp. called as Amphidinolides. Amp B (1-
6) increased the ATPase activity of myofibrils and natural actomyosin, resulting increased in 
contractile responses of myofilaments. Amp H (1-7) is a novel F-actin stabilizer that covalently 
binds on actin.4 It stabilizes actin similar to phalloidin (1-9) but the Amp-H-binding does not 
compete with phalloidin-binding to F-actin (Figure 2).5 
 
Figure 2. Chemical structure of amphidinolide B, H, W and phalloidin. 
 
Amphidinolide W (1-8) and Q (1-14) both are 12-membered macrolides and exhibite 
cytotoxicity against murine lymphoma L1210 cells. Amp W is quite unique as it is the first and 
only macrolide in its family without an exomethylene unit. The gross structure of the C9–C16 
moiety of amphidinolide W corresponds to that of C6–C15 of amp H, which was isolated from 
strain Y-42, suggesting that amphidinolide W may be biogenetically related to amphidinolide 
H.6 Recently four new polyketides, amphidinins C-F have been isolated from the culture broth 
of symbiotic dinoflagellate Amphidinium sp (Figure 3). They showed antimicrobial activity 
against bacteria and/ or fungi. Amphidinin D and F are the first glycosides related to 
amphidinolides. Spectral analysis led to the suggestion that amphidinins C-F (1-10–1-13) are 
4,5-seco-analogues of amp Q (1-14).7  
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Figure 3. Amphidinins C-F and amphidinolide Q. 
 
Malignancy is a class of epidemic disease related to abnormal cell growth, division and death. 
Early stage treatment of cancer can decrease the fatality rate. There are several techniques to 
treat cancer such as surgery, radiotherapy, immunotherapy, chemotherapy etc. In chemotherapy 
the treatment is done by the use of a pharmaceutical product. It was found, that some 
amphidinolides exhibits very high cytotoxicity. In this chapter we will discuss about biology of 
amp H, previous synthesis of amp Q along our investigations. 
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2 Literature review 
 
2.1 Amphidinolide as anticancer drug 
In recent years several proteins have been identified whose overexpression results in several 
kinds of cancer.8 The mechanical strength to the cell and its cytoplasmic constituents is 
provided by the cytoplasmic skeleton. All cytoskeletons contain three constituents units. 
Microtubules are the largest filament having a diameter of about 25 nm. The structural unit of 
microtubules is tubulin and the smallest constituent are actin filaments which are 6 nm in 
diameter and made up of actin protein. 
Toxins bind to actin filaments to destabilize it at two distinct regions of actin monomer: (a) the 
ATP-binding cleft and (b) the barbed end. Actin filaments are dynamic in nature. Amp H forms 
a residue-specific covalent bond with actin. This interaction occurs between the epoxide and 
Tyr198 (Tyr200 in mammalian actin) on subdomain 4 of actin. One molecule of toxin seems to 
bind per actin monomer. Amp H is close to the actin-actin of subdomain 4 of one subunit and 
subdomain 1 of the diagonally located other subunit in F-actin. This suggests it acts in similar 
fashion as phalloidin, jasplakinolide and dolastatin do.9 
2.2 Biosynthesis of amphidinolides 
Polyketides were biosynthesized by a complex collection of enzymes known as a polyketide 
synthase (PKS);10 the process operates by repeated thio-Claisen condensation of malonyl-Co-
A and its derivatives 11 in a manner analogous to fatty acid biosynthesis 12 to produce -
ketoester intermediate. The basic enzymatic mechanism involves repetitive arrangement of 
three fundamental catalytic units such as Ketosynthase (KS), acyltransferase (AT) and acyl 
carrier protein (ACP). The number of modules present in the PKS is in proportion to the length 
of the carbon chain of the final product. In addition the modules may also possess modifying 
domains arranged in various configurations that promote access to the -hydroxy unit 
(Ketoreductase, KR), conjugated E alkenes (dehydratase, DH) and fully saturated product 
(enoyl reductase, ER), terminal thioester domain (TE) responsible for release from enzyme 
complex depending on the intra or intermolecular availability of nucleophile which may lead 
the formation of macrolactone or seco-acid respectively (Figure 4). 
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Figure 4. PKS chain elongation of a malonyl-CoA derivative displaying the consensus 
mechanism for the essential KS-AT-ACP catalytic triad. (R = methyl). 
 
The biosynthetic pattern of amphidinolides were demonstrated13 on the basis of 2D NMR data 
of 13C-enriched samples obtained by feeding experiments with [1-13C], [2-13C], and [1,2-13C2] 
sodium acetates in cultures of a marine dinoflagellate Amphidinium sp. These incorporation 
pattern shows for 1-8 (Figure 5) that 8 acetate units were directly incorporated for C-3/C-4, C-
6/C-7, C-8/C-9, C-10/C-11, C-12/C-13, C-14/C-15, C-16/C-17, and C-19/C-20. The C-6–C-17 
portion was likely classical polyketide chains derived from six acetate units, whereas in 1-7 10 
acetate units were directly incorporated for C-3/C-4, C-5/C-6, C-7/C-8, C-9/C-10, C-11/C-12, 
C-13/C-14, C-17/C-18, C-19/C-20, C-23/C-24, and C-25/C-26 (Fig. 2). These results suggested 
that three parts from C-3 to C-14, from C-17 to C-20, and from C-23 to C-26 were likely to be 
classical polyketide chains derived from six, two, and two acetate units, respectively. The four 
C1 branches of 1-8 at C-21, C-22, C-23, C-24 and 1-7 at C-27, C-28, C-29, C-30, C-31, and C-
32 were all derived from C-2 of acetates, in which the carbonyl carbons were lost. While three 
irregular labeling patterns (m–m) derived only from C-2 of acetates were observed in 1-7 for 
C-1/C-2, C-15/C-16, and C-21/C-22.  
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Figure 5. Labeling pattern of amphidinolide W (1-8) and amphidinolide H (1-7) resulting from 
feeding experiments with 13C labelled acetates. (m-methyl carbon atom (C1), c-carbonyl carbon 
atom). 
 
Wright et al. postulated the biosynthesis of DTX-4 and amphidinolides J on the basis of isolated 
carbon atoms from a polyketide chain shown in Scheme 1.14 
 
Scheme 1. Proposed mechanism for the generation of isolated carbons derived from the methyl 
group of acetate in the polyketide by Wright et al. 
 
2.3 Previous synthesis 
The structure of amphidinolide-Q was elucidated by NMR spectroscopy and could be proved 
by synthesis.15  The retrosynthesis proposed by Kobayashi et al. is outlined in Figure 6. 
Amphidinolide Q was disconnected at the lactone bond; seco-acid 2-1 was derived from ketone 
2-3 and aldehyde 2-2.via condensation. The key aldehyde 2-2 containing four stereocenters was 
prepared from iodide 2-4 via Myers alkylation and Julia coupling of sulfone 2-6 with aldehyde 
2-5 could furnish iodide 2-4. 
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Figure 6. Retrosynthesis of Amphidinolide-Q by Kobayashi et al. 
 
The aldehyde obtained from alcohol 2-8 was transformed into a -hydroxy sulfone via Julia 
coupling with sulfone 2-6, which after oxidation and reductive removal of the sulfone moiety 
provide ketone 2-9 (Scheme 2). 
 
Scheme 2. Synthesis of the C8-C14 segment of amphidinolide Q. 
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The configuration of alcohol 2-11 at C11 was elucidated by a modified Mosher’s ester analysis 
(Figure 7).  
 
Figure 7.  Values [ (in ppm) = S–R] obtained for (S)- and (R)-MTPA ester at C11 (2-
13 and 2-14, respectively) of alcohol 2-11. 
 
The exomethylene function was installed in 2-16 by a Wittig reaction followed by Appel 
reaction to achieve iodide 2-4 (Scheme 3). 
 
Scheme 3. Synthesis of C8-C16 segment of amp Q from alcohol 2-11. 
 
The other diastereomer 2-10 was converted to building block 2-17 as shown in Scheme 4. 
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Scheme 4. Synthesis of the C8-C16 segment of amp Q from alcohol 2-10. 
 
Myers alkylation of iodide 2-4 with propionamide derivative 2-21 gave essentially 2-22 as a 
single diastereocenter (C7). KHMDS mediated aldol reaction of the aldehyde, obtained after 
oxidation of 2-22, with methyl ketone 2-3 produced -hydroxy ketone 2-23. Luche reduction 
of ketone 2-23 produced a diastereomeric mixture of allyl alcohol 2-24 (Scheme 5). Pinnick 
oxidation of the aldehyde obtained from alcohol 2-24 followed by Yamaguchi 
macrolactonization of seco-acid 2-1 and TBAF mediated cleavage of silyl ether furnished amp 
Q (1-14). 
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Scheme 5. Myers alkylation of 2-4 with 2-21, aldol reaction of 2-3 with 2-2, and Yamaguchi 
lactonization of 2-1. 
 
The synthetic strategy described by Nishiyama et al. (Figure 8) outlines the possibility of 
constructing amp Q by joining segment 2-26 and 2-27 followed by macrolactonization.16 
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Figure 8. Retrosynthetic analysis by Nishiyama et al. 
 
The synthesis of fragment 2-26 began with the epoxidation of alcohol 2-31 obtained from 1,3-
propanediol (2-30). E-selective methylation of the propiolic ester part using a PhS group as an 
auxiliary,17 afforded the -unsaturated ester 2-26 (Scheme 6). 
 
Scheme 6. Synthesis of fragment 2-26 from diol-2-30. 
 
The synthesis of ethyl ketone 2-27 was initiated from the ascorbic acid derivative 2-34. 
Introduction of the Evans auxiliary in acid 2-36, followed by methylation leads to the C9 
stereocenter. Parikh-Doering oxidation of 2-38 and a Horner-Wadsworth-Emmons reaction 
gave 2-40; after routine functional group manipulation and Peterson’s olefination introduce the 
exo-methylene function in 2-41 (Scheme 7). 
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Scheme 7. Synthesis of fragment 2-27 from the derivative of ascorbic acid 2-34. 
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Aldol reaction of both fragments (2-26 & 2-27) under acidic condition gave undesirable 
elimination whereas under basic conditions the reaction suffered from moderate yield. 
Moreover, the keto function at C8 still has to be removed. 
 
Scheme 8. Aldol reaction of aldehyde 2-26 and ketone 2-27. 
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3 Goal of the research  
 
It is evident from the literature that Amphidinolide Q has moderate cytotoxicity. Several 
analogues of Amp Q are present in nature; some of them have been isolated recently. The 
analogues are also biologically active compounds. A little modification in the natural macrolide 
delivered significant changes in the biological activity. As the isolated amounts of the 
amphidinolides are rather small, total synthesis is the only alternative to secure material for 
further biological studies.18 Though Amp Q is rather simple but till the time only one total 
synthesis was known so far. Therefore we became interested in the synthesis of amp Q (1-14). 
 
Scheme 9. Retrosynthetic plan for the synthesis of amphidinolide Q. 
 
As an initial toehold in the retrosynthetic analysis we recognized the presence of the syn-1,3-
dimethyl groups at C7 and C9. Accordingly, our aim was to trace back the carbon skeleton of 
1-14 to meso-diol 3-6. Thus, seco acid 3-1 could be disconnected to known aldehyde19 3-2 and 
methyl ketone 3-3. The butenyl fragment attached to C13 was thought to come from a Mannich 
reaction and a substitution reaction on an allylic alcohol derivative. This led to -unsaturated 
thioester 3-5 as an advanced precursor. Brown allylation of an aldehyde followed by cross-
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metathesis with S-ethyl prop-2-enethioate could generate the unsaturated thioester 3-5. An 
alternative includes a Noyori transfer hydrogenation on an alkynone to establish the 
stereocenter at C11 and a Wittig reaction. The thioester 3-4 could be obtained via a Feringa-
Minnaard asymmetric methylcuprate addition to an unsaturated thioester. 
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4 Results and discussion 
 
4.1 Synthesis of methyl ketone 3-3 
Methyl ketone 3-3 is the major fragment of this synthesis. It features four stereocenters and one 
exo-methylene unit. The stereocenter’s at C7, C9, and C13 are occupied with methyl groups 
whereas C11 contains hydroxyl function. We have chosen meso-diol 3-6 as precursor for this 
synthesis (Scheme 10) therefore it requires desymetrization into a corresponding asymmetric 
compound. 
 
Scheme 10. Sequence representing synthesis of methyl ketone 3-3 from 2,4-dimethylglutaric 
anhydride (3-7). 
4.1.1 Enzymatic desymmetrization 
The world contains a vast number of biologically active chiral compounds. The synthesis of 
enantiomerically pure compounds is always demanding. Enzymes are biocatalysts which 
accelerate the rate of a reaction. In recent years enzymes have also been used as catalysts for 
chemical transformations due to the following reasons: 
a) Enzymatic reactions are highly chemo, regio, and stereoselective. 
b) Enzymes are environmentally benign.  
c) Enzymatic transformations complete under mild conditions. 
d) Enzymes immobilized on a solid surface can be used several times. 
In spite enzymes are very sensitive catalysts and exert their activity mainly in aqueous solutions. 
Therefore organic chemists hesitate to employ them in synthesis. Recently some advances have 
been made such as: 
a) A broad range of substrates can be transformed in nonaqueous medium.20  
b) Immobilization techniques have simplified their handling.21 
There are two main groups of chemical transformations which can be done using enzymes: 
a) Asymmetric synthesis  
b) Kinetic resolution of racemic mixtures. 
They differ conceptually in the fact that by asymmetric synthesis formation of one or more 
chirality elements happens within a substrate molecule, whereas by kinetic resolution one of 
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the enantiomer is converted to a separable derivative. The theoretical yield in the latter case 
can’t exceed 50% and practically is even lower. This could be a significant drawback when 
only one enantiomer is required. The desymmetrization of symmetric compounds (usually 
meso-compounds) consists of elimination of symmetry elements in the substrate molecule. 
When these symmetry elements (e.g. mirror plane) preclude chirality, enantioselectivity can be 
achieved. Desymmetrization belongs to asymmetric synthesis; the maximum yield of 
theoretically 100% could be achieved. 
The most frequent enzymatic transformation includes hydrolysis of ester and vice versa. The 
enzyme responsible for such transformations is lipase (or hydrolase). For kinetic resolution 
esterification, hydrolysis, or transesterification can be chosen (Scheme 11). 
 
Scheme 11. Scope of reaction catalyzed by hydrolases. 
 
The mechanism of enzyme catalysis has been thoroughly investigated and found that lipases 
contain a catalytic triad, a sequence of three amino acids, aspartic acid, histidine and serine22 
The OH residue present in serine functions as “nucleophile”, imidazole ring of histidine as a 
“base” and the carboxyl group of aspartic acid works as “acid” (Figure 9). 
 
Figure 9. Topographical representation of the active center of a lipase 
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An ester has been chosen to demonstrate the principle of enzymatic, enantioselective 
hydrolysis. A covalent bound complex is formed by the attack of the serine hydroxyl function 
to the carbonyl group (Figure 10). The negatively charged oxygen atom of the tetrahedral 
intermediate forms two hydrogen bonds with the amide proton of serine and glutamine, thus 
generating an “oxyanion hole”. At the same time alkoxy residue tends to fit in the “active site 
pocket” of the enzyme. If one enantiomer of alkoxide fits better than the other, this results in 
an optically enriched product. 
 
Figure 10. Formation of covalent bound complex between substrate and enzyme. 
 
Alcohol (Figure 11) and acylated enzyme will be formed on disruption of the tetrahedral 
intermediate. The acylated enzyme then reacts with water in a similar way, which releases 
acetic acid and recovers the serine hydroxyl function. 
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Figure 11. Collapse of the tetrahedral intermediate and release of the alcohol. 
 
A comprehensive review entitled “enantioselective enzymatic desymmetrization in organic 
synthesis” has been published by Gotor et al.23 
Enzymes are catalysts which increase the rate of reaction by lowering the free energy barrier 
between reactants and products. As enzymes equilibrate reactants and products therefore, to 
drive a reaction up to completion, one needs some special acylation agents (e.g. irreversible 
acyl transfer agents). A recent investigation addresses the use of enol ethers.24 Vinyl acetate is 
commonly available and used in polymer synthesis, produced on industrial scale, and would be 
the simplest acylation agent. The transesterification of an alcohol with vinyl acetate gives 
unstable ethenol which tautomerizes into acetaldehyde and blocks the reverse reaction. It was 
also found that active carbonyl compounds such as acetaldehyde or acetone can deactivate 
enzymes, possibly by reaction with free –NH2 residues present in lysine amino acids, which are 
located at the surface. To overcome with this adversity use of O-acylated oximes has been 
suggested.25 
Panek prepared enantioenriched crotylsilanes by enzymatic resolution of allylic alcohol 4-1 
(Scheme 12).26 The alcohol 4-2 and mixed ester 4-3 could be separated and be converted into 
a useful building block for total synthesis of natural products. 
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Scheme 12. Kinetic resolution of allyl alcohol. 
 
Dolabrifera, a secondary metabolite present in anaspidean mollusk was synthesized in five steps 
(58% overall yield) via enzymatic desymmetrization of diol 4-4 catalyzed by Candida rugosa 
lipase (Scheme 13).27 Compound 4-4 on enzymatic esterification gave monoester 4-5 in 
excellent yield and ee when molecular sieves were added to trap the acetaldehyde byproduct 
from reaction medium. Steroselective acylation of meso-polyol 4-6 with vinyl acetate in the 
presence of lipase from porcine pancreas afforded monoacetate 4-7 in good yield and 
enantiomeric purity.28 This reaction seems to be highly regioselective for a primary alcohol end 
group, the unprotected secondary alcohol functions were left unaffected. 
 
Scheme 13. Preparation of poyketide building blocks by desymmetrization. 
 
In some cases, hydrolysis of the diacetate was found superior over acylation of the 
corresponding diol. PFL mediated hydrolysis of 2-ethylpropan-1,3-diol diacetate 4-8 proceeds 
with 94% ee whereas acylation of 2-ethylpropan-1,3-diol only gave 46% ee (Scheme 14).29 In 
most cases (not for all) hydrolysis of the diacetate would give best enantiomeric purity.30 
 
Scheme 14. Desymmetrization of prochiral acetates. 
 
Optically active heterocycles having alcohols function such as aziridine and piperdine are 
important building blocks in the synthesis of pharmaceutical compounds (Scheme 15). The 
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Amano PS lipase-catalyzed desymetrization of aziridines31 4-12 gave monoacylated derivatives 
in high yield and ee. Chenevert & co-workers found good yield and ee while investigating 
desymmetrization of cis-2,6 4-14 and cis,cis-2,4,6-substituted piperidine derivative.32 
 
Scheme 15. Desymmetrization of heterocyclic meso-compounds. 
 
Different meso and prochiral esters possessing a prochirality element in the alkyl chain need to 
be discussed. Öhrlein and co-workers did desmmetrization of diethyl 3-hydroxyglutarate 
derivatives 4-16 into 4-17, which could be a building block of statins.33 Prochiral diethyl 3-
[3ʹ,4ʹ-dichlorophenyl]-glutarate 4-18, is an intermediate in the synthesis of a series of 
neurokinin receptor antagonist, has been successfully desymmetrize into 4-19 (Scheme 16).34  
 
Scheme 16. Desymmetrization of prochiral diesters. 
 
Other useful steroselective enzyme catalyzed reactions include hydrolysis of amides, nitriles, 
and anhydrides. The scope of steroselective reduction of carbonyl compounds is limited due to 
stoichiometric requirement of cofactors. Steroselective hydroxylation of methylene 4-2235 and 
methyl 4-2036 groups are reported (Scheme 17). 
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Scheme 17. Enzyme catalyzed enantioselective hydroxylation. 
 
As reported in the literature separation of two diastereomers is required at a late stage of Amp 
Q synthesis therefore we decided to start our synthesis from a chiral building block. Chiral 
building block 3-24 was developed from 2,4-dimethyl-1,5-pentanediol 3-6; these compounds 
have already been reported in literature.37 Our group has extensively studied this reaction using 
three different enzymes such as Amano lipase AK, Amano lipase PS and Novazyme 435 in 
order to get best results.38 The results are summarized in Table 1. 
Table 1. Desymmetrization of 2,4-dimethyl-1,5-pentanediol. 
 
 
Enzyme Mono/diacetate ee% 
Amano lipase AK 6:1 98 
Amano lipase PS 4:1 30 
Novozyme 435 2:1 n.d. 
 
The best result was found with Amano lipase AK (Aldrich Cat. No.: 53, 473-10), The 
enantiomeric excess of the isolated mono-acetate was determined by Chiral GC and cross 
checked with classical Mosher ester techniques. We found an optical rotation of 3-24 exactly 
same as reported. 
4.1.1.1 Desymmetrization of meso-diol 3-6 
The standard reaction condition has been used which resulted in competitive formation of the 
2,4-dimethylpentane-1,5-diol diacetate 4-25. At this stage it is easy to separate mono and 
diacetate since they have large difference in Rf values therefore we decided to separate them by 
column chromatography to avoid complications in the next step. The monoacetate 4-24 was 
treated with TBSCl in the presence of imidazole to get silyl ether 4-26, which on further 
treatment with potassium carbonate in methanol furnished alcohol 4-27. 
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Scheme 18. Enzymatic desymmetrization of 2,4-dimethyl-1,5-lpentanediol (4-6). 
 
Finally, in conclusion enantioselective enzymatic desymmetrizations of meso and prochiral 
substrates have proven to be a powerful tool that allows the preparation of a wide range of 
optically active building blocks in a highly enantioselective fashion and in high yields. 
 
4.1.2 Carbon chain extension  
The chain extension of one carbon on alcohol 4-27 was carried out by nucleophilic substitution 
after tosylation39 of the alcohol in presence of a catalytic amount of KI. The tosylation was 
carried out in dichloromethane using pyridine as a base, only a little conversion was observed 
after 12 h under reflux. The yield was improved by using a catalytic amount of DMAP and 
excess of pyridine as solvent. Tosylate 4-28 was subjected to reaction with sodium cyanide in 
DMSO at rt for 18 h, which did not deliver the product, however the described condition in 
Scheme 19 gave cyanide 4-29 in quantitative yield. 
 
Scheme 19. Cyanide substitution of alcohol (4-27). 
 
After cyanide reduction with DIBAL-H, the resulting aldehyde 4-30 was subjected for Brown 
allylation using (+)-B-Allyldiisopinocampheylborane,40 resulting in a mixture of compounds 
along with the desired homoallylic alcohol (approx. 15%) together with recovered starting 
material, which could be explained by mismatch of the chiral centers. Then we started 
exploration of an alternative strategy explained in retrosynthesis. The aldehyde 4-30 was treated 
with lithium trimethylacetylide leading to propargyl alcohol 4-31 as a mixture of C11 
diastereomers (S/R : 60/40), which was further oxidized into alkynone 4-33 with Dess-Martin 
periodinane. First we looked the possibilities of ketone reduction into a chiral alcohol function. 
24  Results and discussion 
 
 
Scheme 20. Brown allylation and acetylation of aldehyde 4-30. 
 
4.1.3 Noyori reduction  
Natural products are rich in having stereocenters with OH and NH2 functions. They are 
responsible for bioactivity, which is based on hydrogen bonding with the cellular amino acids 
to change the function of the cell, only one enantiomer would be active as we discussed in the 
mechanism of enzyme action. Asymmetric hydrogenation of C=O and C=N bonds is the most 
fundamental molecular transformation in this aspect. Transfer hydrogenation of ketones using 
propanol as a hydrogen donor is a well known synthetic operation. A review describing 
asymmetric hydrogenation using molecular H2 and Ru-complexes as a catalyst has been 
published by Noyori.41 There are also some reports describing the reduction of enolate and 
enantotopic group using biocatalyst NADH dependent enolate reductase, obtained from yeast 
and HLADH (horse liver alcohol dehydrogenase) respectively.42 Asymmetric transfer 
hydrogenation of ketones has occurred by kinetic discrimination of the enantiofaces and which 
also stablishes equilibrium (Scheme 21).43  
 
Scheme 21. Equilibrium between reactant and product. 
 
This problem could be solved by developing such catalysts which lower the reversibility of the 
reaction in addition to the excellent enantioface-differentiation (4-34 (kSi/kRe) 99/1).44 It was 
proved that 4-35 catalyzes hydrogenation of acetophenone (4-36) into (R)-benzyl alcohol (4-
37) 100 times faster than (S)-benzyl alcohol (Figure 12). 
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Figure 12. Ru(II) complexes possessing the chiral tetradentate ligands. 
 
When acetophenone (4-36) was allowed to stand 10 h at 28 °C with [RuCl2(6-arene)2], N-p-
toluenesulfonyl-1,2-diphenyl ethylenediamine and KOH (Ketone:Ru:diamine:KOH = 
200:1:1:2, molar ratio) (S)-1-phenylethanol with 97% ee and 98% yield was obtaioned (Scheme 
22),45 whereas catalyst 4-34 (at 23 °C, 48 h) and 4-35 (at 45 °C, 7 h) gave (R)-1-phenylethanol 
with 18% ee, 3% yield and 97% ee, 93% yield respectively. 
 
Scheme 22. Conversion of acetophenone into (S)-1-phenylethanol. 
4.1.3.1 Generation of stereocenter C11 on alkynone 4-43 
It is clear from above comparative experimental findings that modification in the chiral ligand 
could lead to high reactivity and enantioselectivity. The catalyst 4-40 generated by the reaction 
of (1R,2R)-(+)-N-p-toluenesulfonyl-1,2-diphenylethylene-diamine (4-38) and dichloro(p-
cymene)ruthenium(II) (4-39) is now widely used in the reduction of prochiral keto functions 
(Scheme 23).46  
 
Scheme 23. Preparation of Noyori catalyst from diamine 4-38 and Ru-dimer 4-39. 
 
These catalysts allow highly selective reduction of structurally diverse acetylenic ketones to 
propargylic alcohols of high enantiomeric purity leaving the C≡C bond intact (Scheme 24).47 
(R,R)-4-40 catalyst accomplished the formation of alkynol (3R)-4-44 as essentially one 
diastereomer in high yield. While working on this reduction we observed that even a trace 
amount of the Dess-Martin periodinane can quench the catalyst, resulting no reaction. 
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Scheme 24. Enantioselective reduction of ketones 4-41 & 4-43 into propargylic alcohols. 
4.1.4 Oxidation of alkyne & Wittig reaction 
The secondary MOM or TBS group were introduced in the alcohol 4-44 followed by cleavage 
of the trimethylsilyl group from TMS alkyne in basic medium. 
 
Scheme 25. Etherification of propargyl alcohol 4-44 and desilylation of alkynes 4-45 & 4-46. 
 
The intermediates 4-47 and 4-48 were subjected for hydroboration oxidation; the MOM 
derivative 4-47 furnished undesirable alcohol 4-50 with low yield (21%), whereas with 4-48 a 
complex mixture was observed. Unfortunately we did not observe a reaction when alkyne 4-48 
was subjected for a test reaction to the Seth Herzon protocol.48  
Then we decided to follow a step wise transformation where alkyne 4-48 was first reduced 
using Lindlar hydrogenation into terminal alkene 4-49, which on hydroboration of the double 
bond using dicyclohexylborane followed by oxidative work-up led to primary alcohol 4-51 in 
good overall yield. The alcohol function was oxidized to aldehyde 4-53 by Swern oxidation 
(Scheme 26). 
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Scheme 26. Alkyne oxidation via hydroboration-oxidation. 
 
Wittig reagents of general structure (Ph)3PCHCO2R are powerful building blocks for two 
carbon chain extension in organic synthesis. The aldehyde 4-53 produced -unsaturated 
thioester 4-55 with S-ethyl 2-(triphenyl-5-phosphanylidene)ethanethioate49 (Scheme 27). 
 
Scheme 27. Wittig reaction of aldehyde 4-53 with 4-54. 
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4.1.5 Feringa-Minnaard asymmetric cuprate addition 
Once the -unsaturated thioester 3-5 in was hand, a reaction was required which would be 
stereoselective and add a methyl unit at C13 to generate C13-(R)-methyl 3-4 essentially a single 
diasteromer. The 1,4-addition of organometallic reagents to -unsaturated compounds is one 
of the most versatile approaches towards C-C bond formation. Hause et al. in 1966 revealed 
that reactive species of conjugate addition is lithium diorganocuprate (I), called “Gilman 
reagent” and in 1970s a single electron transfer (SET) mechanism for conjugate addition was 
proposed.50 The first catalytic approach for conjugate addition (CA) of diethyl zinc using 
monodentate phosphoramidite ligands 4-56 was developed by Feringa et al. in 1996 (Scheme 
28).51 
 
Scheme 28. Enantioselective CuOTf-catalyzed 1,4-addition of Et2Zn to 4-55 and 4-58 by 
Feringa and co-workers. 
 
Dialkylzinc reagents have distinct advantages; they show low reactivity in uncatalyzed reaction 
and high tolerance for functional groups both in the substrate and the zinc reagent. 
Functionalized organozinc such as alkylzinc halides result in very low enantioselectivities. 
However, they are easily obtained from the corresponding alkenes through a hydroboration 
alkyl-transfer procedure.52 Copper-catalyzed asymmetric conjugate additions of Grignard 
reagents is rather difficult due to high reactivity of the magnesium reagent which could allow 
uncatalyzed 1,2-addition. Grignard reagents are inexpensive and readily available, apart from 
this; there is little issue to use them. (1) How to achieve high ee and (2) minimize uncatalyzed 
reactions; this problem was solved by Feringa et al. by using ferrocenyl diphosphines bidentate 
ligands and CuCl or CuBr·SMe2 as a metal source (Scheme 29).53 
 
Scheme 29. Enantioselective conjugate addition of EtMgBr to cyclohexanone by Feringa and 
co-workers. 
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Loh et al. used Tol-BINAP and CuI for the enantioselective CA of EtMgBr to -unsaturated 
esters (Scheme 30).54 
 
Scheme 30. Enantioselective conjugate addition of EtMgBr to -unsaturated esters by Loh 
and co-workers. 
 
A recent review entitled “Highly enantioselective Cu(I)–Tol-BINAP-catalyzed asymmetric 
conjugate addition of Grignard reagents to -unsaturated esters” is published.55  However, 
1,4-addition of less reactive MeMgBr to-unsaturated esters gave poor yield 56 which was 
encountered by using more reactive but equally and readily accessible -unsaturated 
thioesters. The reduced electron delocalization in the thioester moiety, compared to oxoesters, 
results in a higher reactivity toward conjugate addition reactions.57 Josiphos/CuBr-catalyzed 
conjugate addition of Grignard reagents to -unsaturated thioesters provided a synthetically 
very useful methodology. However, it has some drawbacks, (I) addition of sterically hindered 
Grignard reagents proceeds with poor enantioselectivity and (II) aromatic substrates with 
substituents on the phenyl ring exhibit low reactivity toward the addition of MeMgBr (Table 
2). 
 
Figure 13. Josiphos and ent-Josiphos. 
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Table 2. Enantioselective conjugate addition of Grignard Reagents (R3MgBr) to -
unsaturated thioesters 4-69 by Feringa-Minnaard. 
 
 
entry R1 R2 Grignard yield 4-70 (%) ee (%) 
1 n-Pent Et MeMgBr 90 96 
2 n-Pent Me MeMgBr 93 96 
3 BnO(CH2) Et MeMgBr 94 95 
4 n-Pent Et EtMgBr 89 86 
5 Et Et n-PrMgBr 87 85 
6 n-Pent Et i-PrMgBr 93 25 
7 n-Pent Et i-BuMgBr 80 15 
 
In conjugate addition, it is found that the ee of the product depends linearly on the ee of the 
catalyst. Kinetic studies of methyl crotonate and EtMgBr catalyzed by (R,S)-Joshiphos (4-67) 
indicated that the rate of the reaction increases on increasing their concentrations. The order of 
reaction was found 1.1 with respect to the catalyst which suggests involvement of mononuclear 
species in the catalytic cycle (Figure 14). Cu-complex-A was generated by the alkyl transfer 
from the Grignard reagent which interacts with the carbonyl oxygen of the crotonate 4-72 and 
forms complex 4-73. Intramolecular rearrangement of -complex forms -complex 4-74, 
where Cu forms a -bond with -carbon of enoate and exists in equilibrium with -complex 4-
73. Reductive elimination of the -complex 4-74 delivers the product 4-75 and regenerates 
complex-A. 
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Figure 14. Catalytic cycle of conjugate addition. 
 
Cu-complex-A adopts a distorted tetrahedral geometry which is shown by optimized 
semiemperical calculations [PM3(tm)]. The Grignard reagent takes the position at the bottom 
face of the complex, whereas the enone approaches the complex from the least hindered side to 
form a -complex with Cu-complex-A using electrons of the sp2 hybridized carbon atom, this 
forces the Cu-complex-A to adopt a square pyramidal geometry. Rearrangement of the -
complex leads to a seven membered chair like transition state in which Cu (II) forms a -bond 
with the -carbon by approaching from the bottom side (Figure 15).58 The methyl group 
transfer from Cu (III) to the enone unit takes place in such a way that the cyclohexyl moiety 
present at phosphorous avoids steric interaction. 
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Figure 15. Model for the enantioselective conjugate addition of Grignard reagents (P1:PPh2, 
P2:PCy2 of Joshiphos). 
 
4.1.5.1 Conjugate addition of MeMgBr to -unsaturated thioester 3-5 
Tol-BINAP/CuI-catalyzed conjugate addition of Grignard reagents to -unsaturated 
thioesters attached to an aromatic subunit, and electron donating substituents on the phenyl ring 
displayed high enantioselectivity but low reactivity.59 It is believed that conjugation of double 
bond with aromatic ring reduced the reactivity. The highly desirable addition of MeMgBr to 
aliphatic -unsaturated thioesters 3-5 was achieved in good yield (97%) and high 
diastereoselectivity (Scheme 31). 
 
Scheme 31. Synthesis of 3-4 by asymmetric cuprate addition on 3-5. 
 
4.1.6 Mannich Reaction 
The behavior of dimethyl(methylene)ammonium iodide against nucleophiles was investigated 
by Eschenmoser 60 in 1971, which had also been used as a highly reactive “Mannich reagent”.61 
Originally the Eschenmoser salt was synthesized by heating ammonium salt 4-77 (Scheme 32) 
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in tetrahydrothiophene dioxide at ca. 150 °C which formed by dealkylation and elimination of 
iodide due to (𝑛 → 𝜎/𝜎 → 𝜋) fragmentation. 
 
Scheme 32. Synthesis of Eschenmoser salt by Eschenmoser and co-workers. 
 
The Eschenmoser salt is a very strong electrophile, which on reaction with a nucleophile results 
in aminomethylation. The reaction sequence (Scheme 33) shows a simple method of 
aminomethylation of a sterically unhindered corrin system. Aminomethylated compound 4-80 
could be converted into the 15-methylcorrin derivative by hydrogenolysis. 
 
Scheme 33. Preparation of 15-methylcorrin derivative from corrin chromophore by 
Eschenmoser & co-workers. 
 
Mechanistic studies demonstrate that enolates generated from aldehydes or ketones, are very 
strong nucleophiles, which attack the iminium ion and furnishes methylated product 4-83. The 
amine moiety from 4-83 can be eliminated via heating N-oxide 4-84 or ammonium salt 4-85 to 
get Mannich product 4-86 (Scheme 34). 
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Scheme 34. Mechanism of Mannich reaction. 
 
Exomethylene lactones are cyclic acrylates; which on ring opening polymerization produce 
polyesters. Exomethylene lactone 4-88 was synthesized during the synthesis of CP-263,114 
from 4-87 via the in situ generated lactone.62 
 
 
Scheme 35. One pot lactonization & methylation by Wood and co-workers. 
 
In our case the substrate aldehyde 4-89 was generated by DIBAL-H mediated reduction of 
thioester 3-4 at low temperature (Scheme 36), which on stirring at rt with Eschenmoser salt in 
CH2Cl2 for two days under basic condition produced enal 4-90. The 1H NMR signals at  9.51, 
6.20, 5.96 ppm corresponding to the CHO and H2C=CCHO groups, respectively confirmed the 
enal formation. 
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Scheme 36. Synthesis of enal 4-90 by Mannich reaction. 
 
4.1.7 Completion of methyl ketone 3-3 synthesis 
The DIBAL-H mediated reduction of the aldehyde function of enal 4-90 produced allyl alcohol 
4-91 which on further reaction with TsCl in presence of triethyl amine at 0 °C gave a low yield, 
possibly due to elimination and chloride substitution as shown in Figure 16.63 
 
Figure 16. Reaction mechanism of Tosylate substitution by Et3N·HCl proposed by Qi et al. 
 
This problem we tackled by using para-toluene sulfonic anhydride. The coupling of crude 
tosylate 4-92 with dimethyl cuprate at low temperature completed the right region of the 
fragment (Scheme 37). 
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Scheme 37. Introduction of a methyl unit. 
 
Conversion of 4-93 to methyl ketone 3-3 involved selective cleavage of the primary silyl ether, 
oxidation of alcohol 4-94 to aldehyde 4-95, reaction of 4-95 with methyllithium, and Swern 
oxidation of the intermediate secondary alcohol to ketone 3-3. 
 
Scheme 38. Synthesis of methyl ketone fragment from primary silyl ether 4-93. 
 
4.2 Synthesis of methyl 3-methyl-4-oxo-2(E)-butenoat (3-2)64 
The aldehyde 3-2, which is a second fragment of our synthesis, was synthesized from 
hydroxyacetone 4-97. First [(trimethylsilyl)oxy]acetone 4-98 was accomplished on distillation 
of the filtrate obtained from NaH mediated reaction of hydroxyacetone with TMSCl. The 
Wadsworth-Emmons reaction of acetone 4-98 with methyl(diethoxyphosphinyl)acetate 4-99 
furnished -unsaturated ester 4-100, which was subjected for the next steps without further 
purification. Desilylation followed by oxidation with PCC furnished aldehyde 3-2, which was 
confirmed by NMR. 
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Scheme 39. Synthesis of aldehyde 3-2 from hydroxyacetone 4-97. 
 
4.3 Completion of the formal total synthesis of Amphidinolide Q 
 
4.3.1 Asymmetric aldol reactions 
Carbon-carbon bond formation between two carbonyl compounds which is called “aldol 
reaction” was discovered independently by Charles-Adolphe Wurtz and Alexander Borodin in 
1872. Many natural products, mainly poyketides, contain sequences of alternating methyl and 
hydroxyl groups in the carbon backbone.65 The relative configuration of vicinal methyl and 
hydroxyl groups can be controlled by the enolate configuration. E-enolates of ketones or ester 
derivatives produce anti aldol whereas Z-enolates produce syn aldol products provided that the 
reaction proceeds via a chair-like transition sate (Figure 17) known as Zimmerman-Traxler 
model, proposed by Zimmerman.66  
 
Figure 17. Zimmerman-Traxler transtion states for E- and Z-enolates. 
 
Chiral adducts could be made by introduction of chirality either in the enolate or in the 
aldehyde. Evans introduced oxazolidinones as chirals auxiliaries to make diastereoselective syn 
aldol products. 67 The acylated oxazolidinone can only produce the Z-enolate on treatment with 
dibutylboron triflate in presence of a tertiary amine due to a relatively short bond between boron 
and oxygen, leading to a tight six-membered chair like transition state, which stipulates 
preferential formation of the syn adduct. 
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Figure 18. Evans aldol reaction. 
 
Diastereoselectivity is due to the blockage of one side of the enolate by the bulky group in the 
oxazolidinone ring (Figure 19). In the transition state, the carbonyl group of the oxazolidinone 
and the C-O bond of the enolate tend to arrange in an anti-fashion to minimize dipole-dipole 
repulsions. Therefore, the aldehyde is only allowed to approach the enolate from the less 
hindered side of the chiral auxiliary. 
 
Figure 19. Transition state for Evans aldol reaction. 
 
With chiral aldehydes 1,2- and 1,3-asymmetric induction has been achieved for example during 
addition of metal enolates and enolsilanes to substituted aldehydes having polar and non-polar 
substituents at the -position. The best results were obtained with BF3·OEt2 in Mukaiyama 
aldol reactions (Table 3).68 It is believed that cooperative electrostatic and steric effects 
combine to influence the direction and degree of 1,3-induction. 
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Table 3. Aldol reaction of 3-methyl-2-butanone enolates with -substituted addehydes by 
Evans & co-workers. 
 
 
entry conditions metal (M) 103:104 106:107 
(X = PMB) (%) (X = TBS) (%) 
1 LDA Li 71:29 (100) 76:24 (91) 
2 TiCl4/i-Pr2NEt TiCln 60:40 (98) 58:42 (98) 
3 9-BBNOTf/i-Pr2NEt BR2 42:58 (82) 52:48 (79) 
4 BF3·OEt2 SiMe3 92:8 (91) 80:20 (84) 
 
Excellent 1,5 anti-diastereoselective induction was observed with dihydrocinnamaldehyde and 
enolate 4-108, due to similar steric requirements of the -substituents and partial responsibility 
of electrostatic effects for enolate face selectivity (Table 4).69 
 
Table 4. 1,5-Induction with various metal enolates by Evans & co-workers. 
 
 
entry M T (°C) solvent yield (%) anti/syn 
1 Cy2B –78 CH2Cl2 85 82:18 
2 Bu2B –78 CH2Cl2 80 87:13 
3 Bu2B –78 PhMe 81 94:06 
4 Bu2B –78 Et2O 83 94:06 
5 Bu2B –115 Et2O 85 98:02 
6 TMS/BF3·OEt2 –78 CH2Cl2 85 50:50 
7 Li –78 THF 79 40:60 
 
Good levels of 1,4-anti asymmetric induction was obtained in the TiCl3(i-PrO)-mediated aldol 
reaction of -benzyloxy methyl ketone 4-110 with achiral aldehyde 4-111 (Scheme 40).70  
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Scheme 40. Titanium-mediated aldol reaction of aldehyde 4-110 and isobutyraldehyde by Urpí 
& co-workers. 
 
(–)-Ipc2BCl and LDA mediated 1,4-anti asymmetric induction was reported during the 
synthesis of Chaetoquadrins A-C and Abyssomicin C, respectively (Scheme 41).71 
 
Scheme 41. (–)-Ipc2BCl and LDA mediated aldol reactions by Brimbley & Sorensen. 
 
4.3.1.1 1,4-Asymmetric aldol reactions of methyl ketone 3-3 and aldehyde 3-2 
It is clear from the above discussion that there is no evidence which shows very good 1,4-anti 
asymmetric induction without having a stereocenter in the aldehyde. With building block 3-3 
in hand, we now could focus on the crucial aldol reaction with aldehyde 3-2. Using LDA as 
base in THF at –78 °C a low yield of the hydroxyketones 4-121 was obtained (Table 5). The 
observed diastereoselectivity of 1:1 indicated that there was no substrate control operative. An 
even lower yield (14%) resulted when trichloro isopropoxy titanium was used for the 
enolization. Higher chemical yields were realized if boron enolates of methyl ketone 3-3 were 
employed. Thus, with dicyclohexylboron triflate (Cy2BOTf)/Et3N in CH2Cl2 the derived 
enolate reacted with aldehyde 3-2 in 71% yield (dr = 1:1). Even higher yields were observed 
when (–)-disopinocamphenyl boron triflate/Hünigs base was used for enolate formation. In this 
case, the desired C4 diastereomer was formed as the major one. Unfortunately, at this stage 
neither chromatographic separation nor the determination of relative amounts by 1H NMR was 
possible. We hoped that it would be possible to separate the isomers on the macrolactone stage. 
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Table 5. Attempted 1,4-asymmetric induction with various metal enolates. 
 
 
entry reagent enolization temp. yield % dr 
1 TiCl3(iPrO) –78 °C 14 1:1 
2 LDA –78 °C 24 1:1 
3 Cy2BOTf –78 °C 71 1:1 
4 (–)-(Ipc)2BOTf  –78 °C to rt 89 2:1 
5 (–)-(Ipc)2BOTf  –78 °C to –50 °C 80 2:1 
 
Once the aldol adduct was in hand, the -hydroxy group of the aldol product required protection 
to exclude side reactions such as retro-aldol and esterification to form a 5-membered lactone. 
Therefore 4-121 was subjected to methoxyethoxymethyl chloride (MEMCl) under basic 
conditions at room temperature but product delivery was not observed whereas decomposition 
was noticed. Then we tried to make silyl ether 4-123 using TIPSOTf under basic conditions at 
low temperature, but the yield was still poor. Then we noticed if TIPS cation is generated first 
by mixing TIPSOTf and lutidine at –78 °C, and then allowed to react with alcohol 4-121 the 
product delivery was excellent without any decomposition. It is believed that decomposition is 
due to retro-aldol reaction. 
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Scheme 42. Silylation of 4-121 into ketone 4-123. 
 
We also have tried reduction of keto function of 4-123 into alcohol 4-124 to separate the 
diastereomeric mixture at this stage but it was rather difficult. (Scheme 43). 
 
Scheme 43. Reduction of ketone 4-123 into alcohol 4-124. 
 
4.3.2 Ester hydrolysis 
The base mediated saponification turned out to be difficult. Mild and selective hydrolysis is 
crucial at late stage of a synthesis. During dibutyltin oxide-mediated O-methylation of 
compound 4-125 Giannis & co-workers observed the formation of methyl ester 4-126 as a side 
product without elimination and epimerization at the stereogenic center adjacent to the ester 
moiety (Scheme 44).72  
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Scheme 44. Dibutyltin oxide catalyzed transesterification of ethyl ester 4-125 into methyl 
ester 4-126 by Giannis & co-workers. 
 
Mascaretti & co-workers have reported the use of bis(tributyltin) oxide (BBTO) and 
trimethyltin hydroxide (TMTOH) for the chemoselective cleavage of alkyl and aromatic 
carboxylic esters (Scheme 45).73 
 
Scheme 45. Trimethyltin hydroxide mediated ester hydrolysis by Mascaretti & co-workers. 
 
Trimethylstannyl 2-phenylacetate (C6H5CH2CO2Sn(CH3)3) was isolated in the reaction of 
Me3SnOH mediated hydrolysis of methyl 2-phenylacetate and was characterized using IR, 1H, 
13C and 119Sn NMR spectroscopy. On the basis of these findings Mascaretti proposed 
mechanism of ester hydrolysis which is shown in Figure 20. 
 
Figure 20. Mechanism of TMTOH mediated ester hydrolysis proposed by Mascaretti. 
 
Nicolaou used Me3SnOH in 1,2-dichloethane at 60-80 °C for the hydrolysis of differently 
substituted “thiostreptones” and chlorinated (R)-Mosher amide-(R)-4-hydroxyphenylglycine 
derivative (Scheme 46).74 
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Scheme 46. Methyl ester hydrolysis of chlorinated (R)-Mosher amide-(R)-4-
hydroxyphenylglycine derivative. 
 
4.3.2.1 TMTOH mediated hydrolysis of ester 4-133 
It is evident from the above discussion that TMTOH mediated hydrolysis is highly 
chemoselective. The C11-silyl ether 4-123 was cleaved by acid induced transetherification to 
get substrate 4-133 for ester hydrolysis. Gratifyingly, at the stage of hydroxyl ester 4-133, 
separation of the C4 isomers was possible (2:1 mass ratio), which allowed determination of the 
ratio by weight (Scheme 47).  
 
Scheme 47. Transetherification of 4-123 and hydrolysis of 4-125 into seco-acid 3-1. 
 
4.3.3 Yamaguchi macrolactonization 
Now the next step of our synthesis is macrolactonization. Many efficient macrocyclization 
techniques have been developed over the years such as the RCM, intramolecular cross-
coupling, Nozaki-Hiyama-Kishi, and HWE reactions, but lactonization of seco-acids is still the 
most frequently used approach to obtain macrocyclic lactones. Direct cyclization of alcohol and 
carboxylic acid often is not possible due to entropic and enthalpic factors. Therefore one partner 
must be activated before cyclization. One of the most frequently used reagent for this purpose 
is 2,4,6-trichlorobenzoyl chloride (TCBC) which activates the acid part via a mixed anhydride 
in presence of triethylamine or Hünigs base (Figure 21).75 The mixed anhydride obtained in 
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this process is dissolved in toluene and slowly added by syringe pump to a highly diluted 
solution of DMAP (2-5 equiv.) at elevated temperature (80 oC or reflux). 
 
Figure 21. Mechanism of Yamaguchi macrolactonization. 
 
The use of the 2,6-dichloro derivative and pyrrolidinopyridine as supernucleophilic catalyst has 
also been described.76 Competitive formation of a symmetrical anhydride was observed during 
the total synthesis of hygrolidin.77 Evans reported the necessity of Et3N·HCl filtration in the 
synthesis of roxaticin to prevent the acid-promoted decomposition of the polyene unit.78 In the 
total synthesis of epothilone C a polymer-supported DMAP reagent has been used.79 There are 
several variations and modifications of the original Yamaguchi procedure. Two major 
modifications have been reported by Yonemitsu in several papers.80 The first modification in 
the Yamaguchi procedure was reported by Yonemitsu, known as “modified Yamaguchi 
conditions”, where a large amount of DMAP is added to the performed mixed anhydride at 
room temperature. These conditions have been utilized by Evans in the synthesis of oleandolide 
81 and bryostatin.82 The second modified Yamaguchi procedure is known as “Yonemitsu 
conditions”, in that DMAP is directly introduced at room temperature from the beginning. 
These less basic conditions became highly efficient and Evans used them in the total synthesis 
of rutamycin B.83 Keck, Mukaiyama, and Corey procedures gave mainly the deconjugated  
lactone as the major product and the classical Yamaguchi procedure gave a 1:1 mixture of the 
 and lactones (Scheme 48). 
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Scheme 48. Isomerization of the  to the double bond. 
 
The major disadvantage of the Yamaguchi macrolactonization is the use of the highly basic 
DMAP and high temperature. These aspects occasionally can lead to obnoxious side reactions 
such as to isomerization of conjugated double bonds, epimerization of susceptible chiral 
centers,84 and Z/E isomerization of conjugated double bonds (Scheme 49).85 
 
Scheme 49. Isomerization of conjugated double bonds under Yamaguchi conditions. 
 
A possible solution for the problem of Z/E isomerization could be macrolactonization of the 
ynoic seco-acid followed by hydrogenation of the triple bond (Scheme 50).86 A review partially 
devoted to the Yamaguchi macrolactonization protocol was composed by Campangne.87 
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Scheme 50. A possible solution to the isomerization of double bonds. 
 
4.3.3.1 Macrolactonization of seco-acid 2-1 
Subjecting the seco acid 2-1 to the modified conditions of a Yamaguchi macrolactonization led 
to two macrolactones 2-26 and (epi)-2-26 that indeed could be separated by chromatography 
even more easily than hydroxy ester 4-133. Therefore, in practice, the mixture of diastereomers 
from the aldol reaction was carried on to the macrolactone stage. The NMR data of the major 
isomer 2-26 perfectly matched with the published data.15 
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Scheme 51. Yamaguchi macrolactonization of seco-acid 2-1 into lactones 2-25 and (4-epi)-2-
25. 
4.4 Total synthesis of 4-epi Amphidinolide Q 
The macrolactone 2-26 was finally subjected for cleavage of silyl ether under strong basic 
(tetrabutylammonium fluoride) conditions at rt and –30 °C, but in both conditions only 
decomposition was observed. However, when (4-epi)-2-25 was subjected for deprotection the 
formation of epi-Amp-Q was possible (Scheme 52). 
 
Scheme 52. Desilylation of TIPS-ethers 2-25 and (4-epi)-2-25. 
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5 Conclusion I 
 
In summary, we developed a short and efficient formal total synthesis of Amphidinolide-Q and 
a total synthesis of its epimer. The seco acid 3-1 has been disconnected into fragments of 
unequal sizes suitable for an aldol reaction which is not common. The C5-C16 fragment 3-3 
was efficiently prepared from known alcohol 4-27, which itself is easily available from meso-
diol 3-6 via enzymatic desymmetrization. In a sequence of 22 steps key transformations include 
a Noyori transfer hydrogenation on alkynone 4-43, as we faced an unexpected problem during 
hydroboration oxidation of alkyne 4-48 into aldehyde 4-53. A Feringa-Minnard asymmetric 
cuprate addition was performed on gram scale on thioester 3-5 and a Mannich reaction on 
aldehyde 4-89. The resulting enal 4-90 served as entry point to create the butenyl terminus of 
this natural product. The derived allylic alcohol 4-91 was converted to the corresponding 
tosylate which upon reaction with dimethyl cuprate gave the required functionality. 
 
Scheme 53. Key intermediates in the synthesis of major fragment of Amphidinolide Q. 
 
Several reaction conditions have been screened for aldol reaction but unfortunately none of 
them had delivered good diastereoselectivity. The combination (–)-diisopinocampheylboron 
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triflate/Hünig base has been used for further studies which delivered 2:1 diastereoselection. At 
this stage the diastereomeric mixture was not possible to separate. We believed that it would be 
separable after macrolactonizatuion. The mixture after TBS-ether desilylation was separated 
for weight determination of both isomers. The separation at this stage is not that easy. Therefore, 
separation at the stage of the macrolactonization is recommended. 
 
Scheme 54. Aldol reaction and Yamaguchi macrolactonization along with cleavage silyether. 
 
Modified Yamaguchi macrolactonization conditions of seco-acid led to the formation of two 
C4 diasteromers (2:1 ratio). Both isomers have been subjected for ether cleavage but only (4-
epi)-2-25 delivered the product (4-epi) 1-14 whereas the major isomer was found unexpectedly 
decomposed. 
 
  
 
 
 
Chapter 2 
 
 
 
 
C–H-Activation Approach towards the Core Structure of the  
Alkaloid -Lycorane
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6 Introduction  
 
 Plants are used for the treatment of medical conditions from the ages as traditional 
medicines. They are rich sources of biologically active compounds such as alkaloids, terpenes 
etc. Amaryllidaceae, a family of herbaceous, perennial and bulbous (rarely rhizomatous) 
flowering plants (Figure 22), is an owner of an exclusive group of alkaloids; they have been 
isolated from the plants of all genera of the family. The Amaryllidaceae alkaloids represent a 
large group of tyrosine and phenyl alanine derived alkaloids. 
 
Figure 22. Amaryllidaceae species from genera such as Galanthus (snowdrops, left) and 
Narcissus (daffodils, right). 
 
A large number of structurally diverse Amaryllidaceae alkaloids could be classified mainly into 
eight skeletal systems (Figure 23).88 Crinine (6-1) alkaloids comprise a 2,3,4,4a-tetrahydro-
1H,6H-5,10b-ethanophenanthridine (cis-3a-aryloctahydroindole nucleus). They have been 
synthesized by the cyclizations of a bicyclic amine via an intramolecular Heck reaction 
followed by oxidation generating a tetracyclic spirocyclohexadione.89 They display interesting 
biological property such as immune-stimulatory, cytotoxic, antimalarial, and anticholinergic 
activities. Lycorine (6-2) alkaloids are tetracyclic pyrrolo-[d,e]phenanthridine frameworks 
(galanthan ring system) whereas galanthamine (6-3) type of alkaloids feature (4aS, 6R, 8aS)-
4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a, 3, 2-ef ][2]benzazepin-6-
ol and wear three chiral centers. Galanthamine hydrobromide is a tertiary alkaloid drug that has 
been developed and approved in the USA and several countries in Europe as a treatment for 
mild-to-moderate Alzheimer's disease.90 Phenanthridine (6-4) alkaloids include (±)-
pancratistatin and 3-epi-pancratistatin, structurally they have a B/C-trans fused ring junction. It 
was proved that pancratistatin selectively induces apoptotic cell death in a variety of human 
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cancer cells without affecting non-cancerous cells.91 Plicamine (6-5) is rare dinitrogenous 
alkaloids of the Amarayllidaceae family. It has an unusual tetracyclic core containing a 6,6-
spirocyclic system defining three stereogenic centers.92 At present there is no evidence for 
useful biological activity. Montanine (6-6) alkaloids are characterized by an unique 5,11-
methanomorphanthridine skeleton, they include brunsvigine, pancracine, montanine, coccinine, 
manthine and nangustine. Homolycorine (6-7) alkaloids are lactones with B/C-cis fused rings. 
Gracilamine (6-8) is a dinitrogenous alkaloid, which has a complex structure. 
 
Figure 23. Eight different ring systems found in amaryllidaceae alkaloids. 
 
The alkaloids isolated from the extract of Amarryllidaceae sp, have been investigated and 
chemically synthesized by various research groups in past three decades. They have been tested 
against diseases, some of them were found active against serious diseases such as cancer, 
pertussis, allergies etc. 
In this chapter we discuss the biosynthesis, biological activity and various synthesis related to 
lycorane along with our own invetigations. 
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7 Literature review 
 
7.1 Biosynthetic pathways 
In the biosynthesis of Amaryllidaceae alkaloids L-phenylalanine (7-1) and L-tyrosine (7-3) 
serve as primary precursors. Barton and Cohen postulated Amaryllidaceae alkaloids are the 
derivative of a common precursor “norbelladine” (Figure 24).93 The C6–C1 unit of the ring A 
comes from the phenylalanine whereas the ring C and the two-carbon side chain C6–C2–N 
originate from the tyrosine unit. The loss of NH3 is antiperiplaner from L-Phe, which is 
mediated by the enzyme phenylalanine ammonia lyase (PAL)94 to secure the trans-cinnamic 
acid (7-2). Hydroxylation of the benzene ring was catalyzed by cytochrome (P450s), cinnamate-
4-hydroxylase (Ca4H) and coumarate 3-hydroxylase (Ca3H), thereafter, loss of two carbon 
atoms leads to the formation of the C6–C1 precursor protocatechuic aldehyde (7-4). L-tyr 
degrades into tyramine (7-5) just before the formation of a Schiff base, which is reduced to 
norbelladine (7-6). 
 
Figure 24. Biosynthetic pathway to norbelladine. 
 
Methylation of one alcohol function of ring A generates O-methylnorbelladine (7-7) which 
undergoes oxidative coupling to generate intermediates for various alkaloids of the family. 
Labelling studies with [3H] at the third position of the aromatic ring in L-tyr appear later in 
norpluvine (7-11) at C2 (Figure 26), and which is subsequently retained in lycorine.95 Epoxide 
7-12 ring opening and allyl rearrangement provides the alcohol function at C2 with an inversion 
of tritium configuration in 7-13. The final step of the biosynthesis would be the conversion of 
the O-methoxyphenol to the methylenedioxy. 
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Figure 25. O-methylation and oxidative coupling of norbelladine (7-6). 
 
 
Figure 26. Lycorine biosynthesis via epoxidation and inversion of the configuration at C2. 
 
7.2 Biological activity of lycorine Alkaloids 
Lamoral-Theys, D. et al. have investigated 22 lycorine-related compounds for in vitro antitumor 
activity using four cancer cell lines displaying different levels of resistance to proapoptotic 
stimuli and two cancer cell lines sensitive to proapoptotic stimuli. They found that lycorine is 
more active than the other compounds. It also exhibits the highest potential (in vitro) therapeutic 
ratio, which is 15 times more active against cancer than normal cells.96 The presence of the diol 
functionality in the C-ring, stereochemistry of the C/D-ring junction and conformational 
freedom of the C-ring are crucial for anticancer activity. Both incorporation of an oxo group in 
the B-ring and quaternization of the amine reduce the activity. Lycorine is able to cross the 
blood brain barrier with respect to narciclasine97. In vivo lycorine seemed to be better than 
narciclasine, because it is less toxic and therefore easier to manage clinically. 
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7.3 Absolute configuration of a lycorine alkaloid of cis-cis fusion (Fortucine) 
The absolute configuration of fortucine was recently clasified by total synthesis.98 The 
precursor 7-14 was prepared using a Schotten-Baumann reaction from L-tyrosine methyl ester 
and an acid chloride. Dearomatization and subsequent stereoselective transformation led to 
bicyclic 7-15. Carbopalladation on TBS-O-vinyl ether derived from enone 7-16 cis-tetracyclic 
pyrrolo[d,e]phenanthridine skeleton 7-17 was generated. The cis stereochemistry was 
elucidated by the planar geometry upon lactam segment. The synthesized enantiomer has 
opposite sign of optical rotation and Cotton effect which suggest that the natural and 
synthesized compounds are mirror images (Scheme 55). 
 
Scheme 55 Synthesis of (+)-fortucine from L-tyrosine methyl ester. 
 
7.4 Degradation studies on lycorine 
The deoxygenated product of lycorine obtained after degradation is called -lycorane (7-24).99 
Lycorine on treatment with phosphoryl chloride loses two molecules of water and it forms 
anhydrodihydrolycorine (7-21) whereas under milder conditions (POCl3 and dil. HCl) it 
produces dihydrolycorinechlorohydrin (7-20), which on treatment with methanolic potassium 
hydroxide and zinc dust/acetic acid produces methyl ether 7-22 and monoene 7-23, 
respectively. The formation of (–)--lycorane was achieved by reduction of monoene 7-23 with 
Adams catalyst in presence of acetic acid (Scheme 56). 
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Scheme 56. Degradation of lycorine (7-19). 
 
Most of the lycorine alkaloids contain a trans-B/C ring junction, theire de-oxygenated product 
would be “-lycorane” whereas few lycorine alkaloids contain a cis-B/C junction such as (+)-
fortucine (7-18), (+)-kirkine (7-25) and (–)-siculinine (7-26). 
 
Figure 27. Lycorine type alkaloids having a cis-B/C ring fusion. 
 
The degradation products of cis-B/C ring fused alkaloids are called -lycorane (Figure 28).100 
 
Figure 28. Lycoranes with galanthane ring system. 
7.5 Privileged structures  
The main strategies towards lycorane skeletones 7-29 can be grouped according to formation 
of the final ring (Scheme 57).  
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Scheme 57. Major strategies for formation of the last ring of the galanthan ring system. 
 
7.5.1 Route “a” towards -lycoranes 
The major approach is to generate intermediate phenyl-octahydro-1H-indole derivatives 7-30 
and close ring B, for example by Pictet-Spengler cyclization (Scheme 58).101 The first approach 
towards the hydroindol demonstrated the utilization of triene 7-33 which was generated via 
cheletropic extrusion of SO2 from trihydrothiophene oxide, and then underwent [4+2] 
cycloaddition to produce cis & trans hydroindoles in 1:1.5 ratio.102 Condensation of aldehyde 
7-34 with -carboxy amine produces an iminium ylide, which is an unstable compound and 
undergoes [3+2] intramolecular cycloaddition to give trans-cis lycorane.103 In an association 
with Li2CuCl4 an aryl Grignard reagent favored -attack to the allylhalide, which enabled 
Bäckvall to introduce an aromatic unit into the hydroindol 7-35.104 Azides are used in the 
synthesis of triazoles. Thermal intramolecular 1,3-dipolar cycloaddition of 7-36 produced the 
triazoline intermediate 7-41 (Figure 29), with the all three rings cis fused, it decomposed into 
7-42. Internal alkylation from imine 7-43 to iminium ion 7-44 and reduction from the least 
crowded face furnished -lycorane.105 
 
Figure 29. Mechanism of triazoline decomposition and the formation of -lycorane (7-28). 
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Scheme 58. Different approaches to achieve hydroindol 7-30 for Pictet-Spengler cyclization. 
 
Silver mediated ring expansion of gem-dibromocyclopropane led to the formation of 
vinylbromohydroindole which after Suzuki cross-coupling and catalytic hydrogenation secured 
hydroindole derivative 7-37.106 The regioselective cyclization of a benzylalcohol into 
hydroindole opens a new synthetic approach to lycoranes.107 Lactone 7-39 in basic medium 
rearranged into a -hydroxy -lactam.108 Chemoselective conjugate addition of an aryllithium 
to the nitro-olefin moiety of a -nitro--unsaturated ester led to unsaturated ester 7-45, 
which underwent a stereoselective nitro-Michael cyclization. Nitronate (I, Scheme 59) anion 
approaches the unsatuaretd ester moiety anti to an Ar–C bond, producing a diastereomeric 
mixture of 7-46 and 7-47, however higher selectivity was observed with a -hydroxy nitronate 
(II, Scheme 59) generated from 7-48.109  
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Scheme 59. Chemoselective conjugate addition and stereoselective nitro-Michael cyclization. 
 
After the advent of asymmetric nitroallylation of arylboronic acids with nitroallyl acetate Gong 
demonstrated the asymmetric total synthesis of optically pure (+)--lycorane shown in Scheme 
60.110 
 
Scheme 60. Asymmetric nitroallylation of an arylboronic acid or aryl zinc chloride with 
nitroallylacetate 7-52 and conjugate addition of ester to the nitroalkene 7-52. 
 
Several catalysts have been developed for asymmetric nitro-Michael addition; pyrolidine 
catalyst 7-56 is selectively promoting the reaction between aldehyde 7-54 and nitroalkene 7-55 
to give the product 7-57.111 1,4-Conjugate addition of nitro dienyne 7-58 with di-tert-butyl 
malonate 7-59 in the presence of chiral diamine-NiBr2 complex provides 1,3-enyne 7-61 in 
93% ee. In the presence of a catalytic amount of TsOH (20 mol%) 1,3-enyne underwent 
hydration regioselectively to deliver enone 7-62 (Scheme 61).112 After reduction of the nitro 
function of ester 7-63 lactam formation led to hydroindol 7-64. 
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Scheme 61. Synthesis of hydroindole derivative 7-64 from 7-54 and 7-58. 
 
7.5.2 Route “b” towards -lycoranes 
It involves the N-alkylation of hydroindol 7-65 followed by Heck coupling or radical 
cyclization of compound 7-67 (Scheme 62).113 Several synthetic approaches to hydroindol 7-
65 have been demonstrated. 
 
Scheme 62. General synthetic approach of route “b”. 
 
The radical precursor 7-69 was synthesized by condensation of cyclohexane-1,2-dione and (–
)-(S)-1-phenylethyl amine followed by reaction with chloroacetyl iodide. Radical cyclization 
of iodoacetamide 7-69 provided an inseparable diasteromeric mixture of hydroindalones 7-70 
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and 7-71.114 The 5-exo-trig cyclization of haloamine 7-71 also gave a mixture of 7-73 and 7-74 
(Scheme 63).115 
 
Scheme 63. Synthesis of hydroindoles from 7-69 and 7-71. 
 
Padwa and co-workers synthesized hydroindol derivate 7-80 from furanyl carbamate 7-75 via 
nitrogen assisted ring opening of Diels-Alder adduct 7-78 demonstrated in Scheme 64.116 
 
Scheme 64. Diels-Alder reaction of 7-75 and nitrogen assisted ring opening of 7-78. 
 
Asymmetric allylic alkylation was first demonstrated by Mori and co-workers in 1995 using 
(S)-BINAPO.117 Later the work was extended by Ojima and co-workers for the synthesis of (+)-
-lycorane. Palladium-catalyzed alylic alkylation of allylic benzoate 7-81 with activated ester 
7-82 gave malonate half amide 7-84 as diastereomeric mixture (54/46) due to epimerization of 
the acidic methine of the malonate half amide moiety. However, it provided up to 99% 
enantiomerically pure one malonate half amide 7-84 determined on the basis of chiral HPLC 
analysis of compound 7-85, obtained from 7-84 via one-pot tandem allylic amination-
intramolecular Heck reaction.118 
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Scheme 65. Pd-catalyzed allylic alkylation & desymmetrization of 7-81. 
 
The aminal derived from aldehyde 7-86 and diamine 7-87 could be transformed into cyclic 
aminal 7-88 by treating it with required amount of NBS, which on hydrolysis delivered 
hydoindol 7-89 and opened the path for asymmetric synthesis of (–)--lycorane.119 
 
Scheme 66. Desymmetrization of amine 7-87 and hydrolysis of 7-88 into hexahydoindolone 7-
89. 
 
Another approach to hydroindolone 7-93, which includes aminocyclization of compound 7-92 
did not lead directly hydroindolone 7-93. However, the formation of cyclopropyl ketone 7-94 
was observed due to the presence of carbonyl function in ring C which activates the -position 
to attack the carbocation generated after bromination (Scheme 67).120 
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Scheme 67. Construction of the lycorine skeleton from intermediate 7-93 and nonclassical 
carbocation rearrangement. 
 
7.5.3 Route “c” towards -lycoranes 
A quite unique synthesis of lycorine (6-2) features an intramolecular Diels-Alder reaction to 
simultaneously create the B and C rings starting from 7-102 (Scheme 68).121 
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Scheme 68. Synthesis of lycorine derivative 7-106 from 7-102 via Diels-Alder reaction. 
 
Transition metal catalyzed asymmetric hydrogenation of configurationally labile substrate 7-
107 through dynamic kinetic resolution (DKR)122 enabled Zhou and co-workers to convert 
racemic -ethoxycarbonyl alkyl-’-arylcycloketone 7-107 into the corresponding diol 7-109, a 
precursor for (+)--lycorane (Scheme 69)123 and (–)--lycorane.124 
 
Scheme 69. Catalytic enantioselective synthesis of (+)--lycorane. 
 
In approach “c”, a phenanthridine nucleus is the core structure which is found in several natural 
products. It contains all three rings of the lycorane alkaloids except ring D and therefore it needs 
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to be ring D installed. There are several approaches towards the synthesis of phenanthridines 
such as Heck cyclization used in the synthesis of 7-deoxypancreastatin 7-115 (Scheme 70)125 
and C–H-activation strategies. 
 
Scheme 70. Synthesis of phenanthridine rings 7-112 and 7-114 fom 7-111 and 7-113 
respectively, via Heck coupling. 
 
7.6 C–H-activation towards isoquinolines 
Isoquinolines are present in several alkaloids and regarded as privileged structure. Rhodium 
catalyzed activation of aromatic C–H bonds with unsaturated substrates such as alkynes and 
alkenes provides a simple solution to isoquinoline synthesis starting from benzamides, 
benzimines, acetophenones etc. C–H-activation can be divided into two major categories sp2- 
and sp3 C–H-bond functionalization. Aromatic compounds are very common with functional 
groups such as ketones, aldehydes, carboxylic acids, alcohols, amides and imines. These 
functional groups could coordinate with the metal and the resulting complex would be 
thermodynamically less stable, which enabled functional groups to regulate the catalytic 
annulation on a particular position of the aromatic ring. Cp*Rh(III) complexes are regarded as 
catalysts for C–H bond annulation due to the following reasons: (a) Rh(III) is a good -acceptor 
(b) Cp* is a bulky and electronically rich species which stabilizes the organorhodium 
intermediate via coordination to the Rh center in one hand and on the other hand feciliates 
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reductive elimination.126 Several reviews on the Rh(III)-catalyzed C–H functionalization have 
been published.127 Here we describe the directional aspect of some functional groups in the 
annulation of alkynes, alkenes etc. 
7.6.1 Annulation of alkynes 
Larock demonstrated that substrates having both a nitrogen containing moiety and a carbon 
halide bond can undergo annulation with alkynes. Later strategies were developed where a C–
H bond was exploited in place of a C–X bond. In this view two types of methodologies have 
been ripened, one involving external oxidants (oxidative strategy) to re-activate the catalyst and 
the other exploiting the labile nature of a group present in the molecule undergoing annulation 
to activate the catalyst internally (redox strategy). Fagnou developed a regioselective indol 
synthesis from N-acetyl amines, utilizing its orthometalation property under cationic Rh(III) 
condition (Scheme 71).128 C–H-activation was observed on the less hindered C–H-bond of N-
acetyl amines. The regioselectivty was affected by the temperature and alkyne concentration. 
The catalyst was found more active when an external oxidant, Cu(OAc)2 in combination with 
molecular oxygen was used. Huang demonstrated the use of molecular O2 as a sole oxidant in 
Rh(III) catalyzed annulations of alkynes. O2 as a sole oxidant is very attractive since it allowed 
to substite the stoichiometric amounts of metal oxidant.129                                                                                                                              
 
Scheme 71. Alkyne insertion to acetanilide under external oxidant. 
 
The mechanism for acetanilide annulation proposed by Stuart is shown in Scheme 72. Jones 
admitted that the active metalating agent of benzylimines is a cationic complex.130 Alkyne 
coordination with the cationic complex and 1,2-migration of rhodium-carbon bond facilitates 
the formation of six-membered metallacycle III. Reductive elimination delivers the product 
and RhCp* (IV) complex, which is further reoxidized into active complex I by the Cu(II) 
oxidant. 
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Scheme 72. Proposed catalytic cycle under first-generation conditions. 
 
On the basis of kinetic data Stuart proposed revised mechanism showing the possibility of the 
formation of side product during oxidative C–H bond functionalization which is devised in 
Scheme 73.128(b) [RhCp*Cl2]2 complex reacts with one equivalent of acetate to generate active 
Rh species I, this could react with alkyne 7-117 first and generate unproductive complexes Ia 
and Ib, or after the coordination with the oxygen of the Lewis basic amide and C–H bond 
cleavage. Then the complex rearranges into six-membered rhodacycle V, which could undergo 
normal reductive elimination to give the compound 7-118 or may produce hydroarylation 
product 7-119 in presence of acid. 
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Scheme 73. Revised catalytic cycle for first and second generation conditions. 
 
The nitrogen of amides could also coordinate with rhodium since its loan pair is delocalized. 
Whenever the amide is tertiary the coordination of the metal with the oxygen is more favored. 
Fangau reported the oxidative annulation of N-tert-butylbenzaldimines 7-120 with internal 
alkynes which furnished isoquinoline 7-122.131 Rovis and Ackermann have successfully 
demonstrated the use rhodium and ruthenium metals for similar transformations (Scheme 
74).132  
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Scheme 74. Synthesis of isoquinoline 7-122 and isoquinolone 7-124 from 7-120 and 7-123 
respectively. 
 
The sp2 nitrogen of the imine has played a directing role in numerous oxidative coupling 
reactions via C–H bond cleavage. Imine 7-125 having -hydrogen undergoes alkyne insertion 
to cyclize into 7-126 whereas -substituted imines give isoquinoline derivatives like 7-127.133 
Similar results were obtained when aryl ketone O-acetyl oxime 7-128 and internal alkyne 7-
121 were treated with [Cp*RhCl2]2, NaOAc in MeOH at 60 °C, this mixture is able to 
differentiate between syn and anti-oxime, only the syn-oxime undergoes cyclization leaving 
behind the anti isomer unreacted in a “kinetic resolution”. A catalytic amount of Cu(OAc)2 
changes the reaction pathway and both syn & anti-oximes delivered the product 7-131.134 
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Scheme 75. Alkyne 7-121 insertion to benzylimine 7-125 and indole derivative 7-132. 
 
Alkyne insertion to the enamine 7-134 is affected by the presence of CO2R and CN at the - 
position of enamine; one goes under sp3 C–H activation whereas other follows the path of sp2 
C–H functionalization (Scheme 76).135 Pyridones were synthesized in the same line of the 
synthesis (Scheme 76).136 
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Scheme 76. Scope of alkyne insertion under external oxidant condition. 
 
Aldehydes and ketones have week coordination ability. Therefore they are not a very good 
choice for directing ability. Examples of catalytic annulation of aromatic aldehydes and ketones 
were described by Glorius and Cheng in 2011 as shown in Scheme 77. Ketones as a directing 
group were used in the synthesis of indenols via ketone assisted C–H-
activation/carbocyclization (Scheme 77).137 Intersting results were obtained; ketones having no 
-hydrogen gave indenols, whereas ketones having -hydrogen and electron rich phenones 
undergo dehydrogenation to give fulvenes. Phenones with electron withdrawing groups having 
a -hydrogen also furnished indenoles without undergoing dehydrogenation.  
 
Scheme 77. Carbocyclization of aryl ketones with alkynes. 
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The mechanism for indenol formation described by Cheng et al. is shown in Scheme 78. The 
catalytic cycle starts with Cl– ion removal from the precatalyst [RhCp*Cl2]2 by Ag+. 
Coordination of the catalyst to acetophenone 7-144 and subsequent C–H bond cleavage forms 
the five membered rhodacycle I. Alkyne insertion to rhodacycle transforms it into a seven 
membered rhodacycle II having -bonded keto-rhodium functionality. Then the carbonyl 
function gets inserted to produce rhodium alkoxide intermediate III, which on protonation 
delievered the indenol 7-143 and regenerates the active catalyst. 
 
Scheme 78. Proposed mechanistic pathway for the formation of indenol derivatives. 
 
Vinyl azides thermally decompose into strained three membered cyclic imines, 2H-azirines, 
which would be the equivalent to a vinyl nitrene. Chiba explored the directional property of 
vinyl nitrenes (Scheme 79).138 
 
Scheme 79. Isoquinoline synthesis from vinyl nitrene. 
 
The proposed mechanism for the formation of isoquinolines from azides is demonstrated in 
Scheme 80. 
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Scheme 80. Proposed reaction pathway for isoquinoline from vinyl nitrine. 
 
7.6.2 Annulation of phenyl ring 
A palldium mediated intermolecular C–C bond formation was coupled with another 
intramolecular C–N bond formation by Wang and co-workers. Phenanthridinone 7-150, a 
biologically important compound was prepared by the reaction of benzamide 7-148 and 
iodobenzene (7-149). In the course of the reaction, formation of palladacycles was directed by 
benzamide, thereafter aryl halide insertion takes place (Scheme 81).139 
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Scheme 81. Synthesis of phenanthridinones by palladium catalyzed reaction of N-
methoxybenzamides with aryl iodides. 
 
7.4.4 Annulation of alkenes 
Cramer and co-workers designed a C2-symmetric cyclopentadienyl (Cp) derivative, which 
could control the spatial arrangement of the transiently coordinated reactants around the central 
metal atom.140 They considered three criteria for developing the catalyst: (i) C2-symmetric Cp 
derivative could avoid formation of the diastereomer in coordination of the metal to either 
ligand face; (ii) restriction of rotation around the Cp-moiety and (iii) steric blocking 
perpendicular to the to the Cp plane to ensure approaching of the reactant from one side only. 
The performance of the catalyst is shown in Scheme 82. 
 
Scheme 82. Enantioselective annulation of alkene 7-151. 
 
The catalytic cycle of alkene annulation is shown in Scheme 83. The Rh(I) complex in oxidized 
with dibenzoxyperoxide into II, which converts into III by ligand exchange. Concerted 
cyclometalation/deprotonation and the loss of benzoic acid lead to a crucial cyclometalated 16-
electron intermediate IV. Olefin coordination takes place in a highly diastereoselective manner 
leading to 18-electron chiral-metal complex V, which converts into VI. Then ligand 
exchange/protonation by BzOH present in the system regenerates catalyst II and delivers the 
product. Generated t-BuHCO3 collapses into CO2 and t-BuOH without affecting the acidity of 
the system.  
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Scheme 83. Presumed catalytic cycle for the insertion and cyclization of alkenes. 
 
7.6.3 Redox C–H activation: 
Internal alkynes produce disubstituted heterocycles. However, Cu(OAc)2·H2O mediated 
dimerization of terminal alkynes is well known. Therefore, the terminal alkynes under the 
disccused conditions could not be annulated. In order to avoid alkyne dimeration Cu(II) free 
conditions are required. Guimond reported isoquinoline synthesis from benzamide 7-158141 and 
found external oxidant was not required to re-oxidize the rhodium catalyst. The N–O bond was 
cleaved during the course of reaction. The concept was also used in palladium catalyzed C–H-
functionalization by Hartwig, Cui and Wu.142 Terminal alkynes under this condition produce 
monosubstituted heterocycles in moderate to high yield. The regioselctivety is quite predictable, 
as the terminal end of the alkene is located at 4-position (Scheme 84).  
 
Scheme 84. Benzamide annulation with alkenes and alkynes. 
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C(sp2)-Rh species would be nucleophilic to attack on C=O or -halo ketones to produce -aryl 
ketones. Glorious and co-workers have annulated benzamides with -halo and pseudohalo 
ketones.143 Intramolecular rhodium catalyzed C–H annulation reaction provides isoquinolones 
with reverse regioselectivity.144 Ackerman demonstrated dehydrative alkyne annulation with 
free hydroxamic acid under Ru(II) catalysis in aqueous medium.145  
 
Scheme 85. Intra- and intermolecular annulation of 7-161 and hydroxamic acid 7-163, 
respectively. 
 
The mechanism for redox C–H activation is shown in Scheme 86. The catalyst I coordinates 
with 7-165 with the loss of attached acetate ion which is followed by C–H bond cleavage 
through concerted metalation-deprotonation to produce intermediate III. The bound acetic acid 
molecule is lost and acelylene is inserted. The reductive elimination allows C–N bond formation 
resulting in intermediate VII. Consequently a fast oxidative addition generates intermediate 
VIII, which is protonated by acetic acid to give product 7-124 and active catalyst I. 
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Scheme 86. DFT calculated catalytic cycle proposed by Guimond et al. 
 
A recent review entitled “designing catalysts for functionalization of unactivated C–H bonds 
based on the C–H activation Reaction” describes the different metal catalyst for C–H 
functionalization.146 Carboxylate-assisted Ru-catalyzed alkyne annulation is worthy to note.147 
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8 Goal of the research 
 
C–H-activation is the finest approach towards the synthesis of complex structures in a single 
shot. It is evident from the literature that a huge number of approaches have been published for 
lycorane synthesis. However, a close insight of literature indicates that synthesis of complex 
alkaloids such as lycorine, fortucine etc. utilizing lycorane synthetic techniques failed at some 
instances either in synthesis of desired alkaloid or delivery of the correct stereocenter. Here our 
approach is to develop such a method which could be applicable for a broad range of alkaloids 
with known stereochemistry at carbons. While lycoranes are not biologically active compounds 
though, they are the timeless synthetic targets for demonstrating potential of new strategies 
towards such polycyclic alkaloids. The C–H-activation generates B/C-cis fused tricyclic 
systems. The synthesis of lycorane like structures seemed to be possible by annexing the D-
ring to a properly substituted tetrahydrophenanthridinone (Scheme 87). However, this would 
require to study the effect of substituted benzamide derivatives on this Rh(III)-catalyzed 
phenanthridinone synthesis.  
 
Scheme 87. Possible route to lycorane derivatives via Rh(III)-catalyzed C–H-activation on 
benzamide derivatives with annulation of cyclohexadienes followed by formation of ring D. 
 
Our second approach is to generate first the A–B–D ring system of lycorane by C–H-activation 
and then annex the ring C on a dihydropyrrolo-isoquinolinone by Diels-Alder reaction. In this 
approach one would require a detailed study of allylic oxidation, Wittig reaction and Diels-
Alder cyclization. 
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Equation 88. A second possible route to lycorane derivatives via Rh(III)-catalyzed C–H-
activation on benzamide derivatives with annulation of alkyne 8-7 followed by formation of 
ring C by Diels-Alder reaction. 
 
In the next section we describe our findings towards the goal. 
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9 Results and discussion 
 
9.1 Preparation of model compound 
With a view towards the synthesis of lycorane using this strategy, 3,4-dialkoxy-substituted N-
(pivaloyloxy)-benzamide 9-6 was prepared as a model compound. The synthesis of this amide 
from vanillin is summarized in Scheme 89. 
 
Scheme 89. Synthesis of benzamide derivative 9-6 from vanillin (9-1). 
 
Thus, benzylation of 4-hydroxy-3-methoxy-benzaldehyde (vanillin, 9-1) to benzyl ether148 9-2 
was followed by oxidation149 of the aldehyde function to benzoic acid150 9-3. For the conversion 
of benzoic acid 9-3 to N-pivaloyloxy amide 9-6 two variants was explored. In the first one, acid 
9-3 was converted to ethyl benzoate151 9-4 under alkylating conditions. Subsequent reaction of 
9-4 with hydroxylamine led to hydroxamic acid 9-5.152 A final reaction with pivalic anhydride 
provided benzamide derivative 9-6. The second variant utilizes the acid chloride, derived from 
9-3. Its reaction with, O-pivaloylhydroxylamine,153 generated from its triflate salt with Na2CO3 
gave amide 9-6 as well. 
9.2 Model studies on C–H-activation 
9.2.1 Reaction screaning & optimization 
In order to do annulation of amide 9-6, diene and enones were screend. The results are 
summarized in Table 6. Annulation of amide 9-6 was not observed with 1,4-cyclohexadiene, 
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cyclopentenone and benzoquinone with high loading of the catalyst [RhCp*Cl2]2 (10 mol%). 
Using 1,3-cyclohexadiene with amide 9-6 underwent Rh(III) catalyzed annulation though the 
yield (10 %) was poor, but the palladium mediated annulation was not observed. Then we 
screaned varrients of benzamide such as hydroxamic acid 9-5 and benzylimine 9-17 with 1,3-
cyclohexadiene using [RhCp*Cl2]2  as a catalyst along the additives. However, none of them 
delivered the product. 
Table 6. Screening of benzamide and benzimine annulation. 
 
entry benzamide diene reaction condition time (h) product 
(expected) 
yield 
(%) 
1 
 
 
[RhCp*Cl2]2 (10 mol%), 
(2.0 eq.) CsOAc, MeOH 
(0.2 M), rt 
12 
 
00 
2 
 
 
[RhCp*Cl2]2 (10 mol%)., 
(2.0 eq.) CsOAc, MeOH 
(0.2 M), rt 
17 
 
00 
3 
 
 
[RhCp*Cl2]2 (10 mol%)., 
(2.0 eq.) CsOAc, MeOH 
(0.2 M), rt 
120 
 
00 
4 
 
 
Pd(OAc)2 (10 mol%), (20 
mol%) P(tol)3, (2.0 eq.) 
CsOAc, toluene, rt 
18 
 
00 
5 
 
 
[RhCp*Cl2]2 (10 mol%), 
(2.0 eq.) CsOAc, MeOH 
(0.2 M), rt 
18 
 
10 
6 
 
 
[RhCp*Cl2]2 (10 mol%), 
(2.0 eq.) CsOAc, toluene, 
rt 
24 
 
00 
Additive: PPh3, rt 24 
7 
 
 
[RhCp*Cl2]2 (10 mol%), 
(2.0 eq.) CsOAc, THF, rt 
37 
 
00 
Additive: CH3COOH (2 
drops), 60 oC 
30 
 
We observed annulation of benzamide 9-6 with 1,3-cyclohexadiene in 10% yield. Therefore a 
brief survey of reaction conditions was performed to enhance the isolated yield. The results 
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obtained on amount of catalyst [Cp*RhCl2]2,154 loading in different solvents are shown in Table 
7. In methanol the reaction led to successful C–H-activation, cross-coupling and cyclization. 
However, despite relatively high catalyst loadings (up to 5 mol%) the yield of tricyclic amide 
9-15 did not exceed 20%. Acetonitrile as solvent was even worse with a 10% yield of 9-15 in 
presence of 5 mol% catalyst. Much better results were obtained in ethanol as solvent. Here up 
to 55% of 9-15 (2.5 mol% of catalyst) could be obtained. 
Table 7. Screening of conditions for the Rhodium(III)-catalyzed synthesis of phenanthridinone 
9-15. 
 
 
entry Catalyst (mol%) solvent yield of 9-15 (%) 
1 5 MeOH 20 
2 2.5 MeOH 20 
3 1 MeOH 10 
4 5 MeCN 10 
5 2.5 MeCN 5 
6 1 MeCN 0 
7 5 EtOH 50 
8 2.5 EtOH 55 
9 1 EtOH 40 
 
In a larger scale reaction besides the cis-product 9-15 a small amount of the corresponding 
trans-fused compound could be isolated (cis/trans = 98:02). As can be seen, the C–H activation 
is regioselective with the insertion taking place only at 6-H. 
9.2.2 Synthesis of Phenanthridinones & their reduction 
With a view towards delineating the scope of this reaction, various 3,4-dialkoxy-substituted N 
(pivaloyloxy)benzamides were prepared (Scheme 90) analogously to 9-6 as mentioned before 
using both ethylbenzoate and acid chloride pathways. 
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Scheme 90. Synthesis of benzamide derivative from corresponding benzoic acid ester or 
chloride. 
 
The benzamides were reacted reacted with cyclohexadiene (9-14) utilizing the optimized 
conditions (2.5 mol% of catalyst, 0.5 equiv of (CsOAc, EtOH 0 °C to rt, 36 h). The results are 
summarized in Scheme 91. With the exception of 9-15, all annulations proceeded in quite good 
yields. In all cases essentially only the cis-fused products were obtained (dr > 98:02). A 
surprising result was obtained with the amide 9-19 derived from 3,4-(methylendioxy)benzoic 
acid. In this case only the isomer resulting from activation of 2-H was observed. This was 
clearly evident from observation of two doublets for the aromatic protons. As is known, the 
electron-donating effect of the methylenedioxy function is significantly reduced due to 
conformational reasons, since the free election pairs of the oxygen atoms cannot be in line with 
the -system. Moreover, the steric demand of the methylenedioxy group might be less. Similar 
regioselectivtiy has been observed for other Rh(III)-catalyzed reactions of 9-19.155 Therefore, 
access to the lycorane skeleton would not be possible from 9-19 via this strategy. Thus, it seems 
that electronic factors govern the regiochemistry in the C–H activation step. 
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Scheme 91. Rhodium(III)-catalyzed synthesis of phenanthridinones using the optimized 
conditions from Table 7. 
 
In order to construct ring D, amide would have to be reduced into amine. The direct reduction 
of the amide function of 9-15 with LiAlH4 did not deliver the product. Charette’s amide 
reduction also failed (entry 3-6, Table 8), which is a mild reduction condition for hindered 
tertiary and secondary amide via activation of amides with Tf2O.156 However, the reagent 
combination LiAlH4/AlCl3 towards reduction was successful.157  
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Table 8. Reduction of amide to sec-amine. 
 
 
entry R reagent solvent temp. (oC) time (h) yield (%) 
1. Bn LiAlH4 THF 0 oC–rt 12 00 
2 Bn LiAlH4 THF 0 oC–reflux 20 00 
3 Bn Tf2O then NaBH4 CH2Cl2 0 oC–rt 02 00 
4 Bn Tf2O then NaBH4 CH2Cl2 0 oC–rt 12 00 
5 Bn Tf2O then NaBH4 CH2Cl2 0 oC–50 oC 18 00 
6 Et Tf2O then NaBH4 CH2Cl2 0 oC–50 oC 18 00 
7 Et LiAlH4/AlCl3 THF 0 oC–rt oC 12 10 
8 Et LiAlH4/AlCl3 THF 0 oC–40 oC 08 60 
9 Me LiAlH4/AlCl3 THF 0 oC–40 oC 08 75 
 
The reduction of amide 9-21 with LiAlH4/AlCl3 at 40 °C led to secondary amines 9-24 with 
75% yield whereas reduction of 9-20 gave lesser yield (60%). The structure of 9-23·HCl was 
secured by X-ray analysis, which proved the B/C-cis-function in the phenanthridinones (Figure 
30).  
 
Figure 30. Amine 9-23 and 9-24 obtained from reduction of 9-20 and 9-21, respectvely and X-
ray structure of amine 9-23 (as hydrochloride) showing the cis-fusion. 
 
9.3 Studies on construction of ring-D of -lycorane 
Accordingly, studies were carried on tetrahydrophenanthridines 9-23 and 9-24 towards the 
formation of ring D. However, this turned out to be rather difficult. Some of these experiments 
with 9-23 and 9-24 are summarized in Scheme 92. Amines 9-23 and 9-24 could be acylated 
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with bromoacetyl bromide to the corresponding amides 9-25, 9-26. However, neither radical 
conditions158 nor reaction in presence of Pd(OAc)2 (30 mol%), t-Bu3P (40 mol%), Et3N (2 
equiv), toluene, 110 °C, 12 h, led to the desired tetracycles 9-27 or 9-28. Rather decomposition 
of these bromoacetamides with the formation of a complex mixture was observed. 
 
Scheme 92. Attempts to form lactams 9-27, 28 by radical cyclization. 
 
Diacylamine 9-29, obtained from amide 9-21, underwent cleavage of the acylic amide bond 
upon reaction with Bu3SnH given back the starting amide 9-21 (Scheme 93). As it is known 
that phenyl selenoesters can serve as precursors for acyl radicals, selenoester 9-32 was prepared 
from amide 9-21 in three steps. However, reaction of 9-32 with Bu3SnH in presence of AIBN 
did not lead to the desired tetracyclic compound. Here only starting material (16 mg of 25 mg) 
was recovered. Using benzoylperoxide as radical initiator led to formation of the intermediate 
acyl radical followed by decarbonylation and formation of N-methylamide 9-34. 
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Scheme 93. Attempts to cyclize amide derivatives 9-29 and 9-32 to the corresponding galanthan 
ring systems. 
 
Our next plans focused on derivatization reactions of the double bond of ring C. This might 
open additional options for creation of ring D. Initially, amine 9-24 was converted to 
sulfonamides (Scheme 94). As it turned out, hydroboration159 of the double bond was highly 
selective, with the borane attacking the double bond at the more hindered position. The alcohol 
derivatives were not further purified (purified for characterization only) but rather oxidized to 
the -aminoketone derivatives 9-38 and 9-39 using the Dess-Martin periodinane reagent. The 
regiochemistry of the hydroboration was inferred from the 1H NMR spectra. Indicative of the 
regiochemistry was the signal for 4a-H in alcohol 9-38 which appeared as a doublet of doublet 
( = 3.90, J = 8.0, 4.0 Hz). The hydroboration was also diastereoselective. While this was not 
further investigated, we assume attack of the borane from the exo face, syn to 4a-H and 10b-H. 
For the other regioisomer a multiplet would be expected instead. 
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Scheme 94. Conversion of tricyclic amine 9-24 to sulfonamides and the regioselective 
hydroboration of the ring C double bond. 
 
In order to attach ring D, extension of the ketone by a suitable C2-building block is required. 
Ketone 9-41 has been screened with phosphonoesters shown in Figure 31 under different 
reaction condition. The results obtained from this reaction are presented in Table 9. Under these 
conditions desired compound formation was not observed. 
 
Figure 31. Phosphonoester reagents for Wittig-Horner and Wittig reaction. 
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Table 9. Optimization of Wittig reaction of 9-41 under different condition. 
 
 
entry reagent solvent temp. (oC) time (h) yield (%) 
1. 9-42a, LiOH·H2O, PPh3 THF rt 12 00 
2 9-42b, NaH/MeOH MeOH rt 12 00 
3 9-42b, KHMDS THF rt 05 00 
4 9-42b, tBuOK THF rt 12 00 
5 9-42c, KHMDS, 18-crown-6 THF rt 12 00 
6 9-42c, LiCl, DBU CH3CN rt 1 to 24  00 
7 9-42a  benzene reflux 48 5 
 
Reaction of the two ketones 9-40 and 9-41 with methyl 2-(triphenylphosphoranylidine) acetate 
9-42a gave the desired enoates 9-43 and 9-44, respectively. However, the yields were too low 
to be of practical value. 
 
Table 10. Optimization of Wittig reaction on 9-40 under different conditions. 
 
 
entry reagent Ar solvent temp. (oC) time (h) yield (%) 
1 9-42a p-tosyl benzene rt 48 00 
2 9-42c, KH p-tosyl THF rt 12 00 
3 9-42a p-tosyl benzene reflux 48 11 
 
In order to check whether the protecting group on the nitrogen influences the regiochemistry of 
the hydroboration reaction, amine 9-24 was converted to the carbamates 9-45 – 9-47 (Scheme 
95). On subjecting these carbamates to the hydroboration/oxidation sequence led to the -
aminoketone derivatives 9-48–9-50, respectively. 
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Scheme 95. Conversion of tricyclic amine 9-24 to carbamates and their regioselective 
hydroboration of the ring C double bond followed by oxidation into ketones. 
 
In order to understand the regioselectivity of the hydroboration oxidation, we subjected 
hydroxyl-carbamate 9-48 for Appel reaction conditions which delivered cyclic carbamate 9-52 
(oxy-lycorane) as a single diastereomer. The diastereoselectivity of the cyclic carbamate 9-52 
was inferred from the 1H NMR spectra (3a1-H, J = 4.3, 7.6 Hz). It confirmed that hydroboration 
is regioselective as well as diastereoselective. 
 
Scheme 96. Synthesis of oxy-lycorane (9-52) from hydroxyl-carbamate 9-48. 
 
Carbamate 9-49 was deprotected under acid conditions giving amine salt 9-53. Then it was 
acylated with 2-bromoacetyl bromide into 2-bromoacetamide 9-54 and then subjected to 
conditions for a Reformatsky reaction. However instead of the desired intramolecular aldol 
reaction, only reductive dehalogenation to acetamide 9-55 could be observed. The reasons for 
the failure of the above-mentioned cyclizations are unclear, as visual inspection of amine 9-23 
indicates that cyclization of an amide derivative via attack at the double bond should be 
possible. Most likely, the tricyclic ring system already suffers from some strain so the additional 
ring D would increase the ring strain even more. 
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Scheme 97. Attempts on intramolecular Reformatsky reaction of keto amide 9-54. 
 
Eventually we turned to transition metal catalyzed cyclization where the cyclization would be 
initiated from a vinylmetal species. Delgado and co-workers described the reaction of amino-
tethered halodienes with Ni(COD)2 followed by trapping of the presumably formed -
alkylmetal intermediates.160 Vinyl bromide containing a distal nitrogen atom displays high 
selectivity in the product 9-60 whereas compounds 9-61 without nitrogen atom undergoes 
elimination and does not exhibit selectivity in the cyclized product 9-62. 
The mechanism of the process is demonstrated in Figure 32. The alkylnickel intermediate III 
originating after oxidative addition and alkene insertion, which after treating with a strong 
nucleophile delievered the product IV. 
 
Figure 32. Mechanism of nickel promoted cyclization of amino-tethered vinyl bromides. 
 
The increased stability of the intermediate nickel complex is due to the coordination of amino 
function which ceases the -elimination process. The trapping reagent also affects the 
elimination; therefore a delicate balance is required to obtain high yields of cyclic products. 
The high selectivity could also be coming from assistance of the amino group (Figure 33). 
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Figure 33. Cyclic products obtained from nickel promoted cyclization of vinyl bromides. 
 
Accordingly, amine 9-24 was alkylated with 2-bromoallyl bromide (9-64) to yield allylamine 
9-65 (Scheme 98). With this substrate successful cyclization was observed in presence of 
Ni(COD)2, Et3N and a suitable nucleophile, like trimethylsilyl cyanide or triethylsilane. This 
way the two tetracyclic compounds 9-66 and 9-67 were obtained. Both feature the cis/cis-ring 
fusion of the -lycorane ring system. 
 
Scheme 98. Conversion of amine 9-24 to 5-(2-bromoallyl)-hexahydrophenanthridine 
derivative 9-65 and its nickel-mediated cyclization to 4-methylene-octahydro-1H-
pyrrolo[3,2,1-de]phenanthridines 9-66 and 9-67. 
 
Brief attempts to epoxidation of 9-67 or oxidative cleavage (O3) were unsuccessful. 
 
In view to construct ring D, we explored other possibility. Thus, a [RhCp*Cl2]2 mediated 
annulation reaction of benzamide 8-6 with alkyne 8-7 (Across) gave cyclic product 9-68 along 
with the N-alkylated benzamide 9-69 (Scheme 99).144 The presence of three singlets in the 
aromatic region of 1H NMR confirms the formation of cyclized product 9-68, whereas in case 
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of no cyclization two doublets in aromatic region along the singlet of acetylenic proton at 2.1 
ppm were found. 
 
Scheme 99. Benzamide 8-6 annulation with alkyne 8-7. 
 
Though the yield of cyclic product 9-68 was quite low, we tried to cyclize it into tricyclic amide 
using LiHMDS in THF at 0 °C, which delivered desired product 8-9. 
 
Scheme 100. Intramolecular amide alkylation. 
 
In order to introduce ring C, a brief attempts toward allylic oxidation of alkene 8-9 into allylic 
alcohol 9-69 were unsuccessful. 
94  Conclusion II 
 
10 Conclusion II 
 
We developed a new approach to lycorane-like structures. Several N-(pivaloyloxy)benzamides 
were reacted with cyclohexa-1,3-diene in presence of a rhodium(III) catalyst which resulted via 
C–H activation in the corresponding tetrahydrophenanthridinones (Figure 34). 
 
Figure 34. Tetrahydrophenanthridinones. 
 
They were reduced into secondary amines using a combination of LiAlH4/AlCl3. Subsequently, 
various strategies were explored to convert these tricyclic phenanthridines to the tetracyclic 
core structure of the lycoranes. However, radical based approaches and Reformatsky reaction 
were unsuccessful. Further tricyclic secondary amine was alkylated with 2-bromoallyl bromide 
and a Ni-induced cyclization led to the tetracyclic -lycorane analogs 9-67 and 9-66. 
 
Figure 35. Analogs of -lycorane. 
 
 In the course of this study we discovered a strong influence of the type of the 3,4-dialkoxy 
substituents on the regiochemistry of the C–H-activation. While for the non-constrained N-
(pivaloyloxy) benzamides activation of 6-H takes place, 1,3-cyclohexadiene insertion to 3,4-
methylendioxyamide occurs selectively at 2-H (9-22). 
Furthermore N-protected phenanthridine derivatives underwent a regio- and stereoselective 
hydroboration/oxidation to the corresponding -aminoketone compounds, which was 
confirmed by the formation oxy-lycorane (9-52) from carbamate 9-48. 
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Figure 36. Alkanolamine and oxy-lycorane. 
 
We also have shown the synthesis of tricyclic amide 8-9 via rhodium catalyzed C–H annulation, 
containg the A,B,D ring system of -lycorane. 
 
Figure 37. Tricyclic amide 8-9. 
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11 Introduction 
 
 Synthetic chemistry has been revolutionized over the last decades by the advent of 
enantioselective catalysis in the development of asymmetric reactions.161 Activation of a 
substrate by a chiral catalyst became a powerful strategy. Asymmetric metal complexes have 
been used as catalysts in the synthesis of chiral compounds.162 For, example many commercial 
therapeutics have been developed using asymmetric hydrogenation.161(a),(b) Organocatalysis is 
distictally advantageous over conventional metal catalysis. Metals are hazardous materials. 
Whereas, very little is known about the toxicity of organo catalyst. Metal catalyzed reactions 
are very sensitive to water and air. Organocatalytic reactions are able to tolerate the presence 
of a little amount of moisture and air.163 Therefore, organocatytic reactions are easy to handle. 
A substance which can cause physiological changes in the body is known as drug. It can be 
injected to the body in different ways such as injection, oral, or through respiration. Antibiotics 
a class of drugs, is used in the treatment or prevention of bacterial infections. Some antibiotics 
are also active against protozoans and viruses. Antibiotics could be obtained from bacteria by 
genomic modification. Though the natural products isolated from plants, animals, fungi and 
bacteria are potentially active against infection. They are present in organisms in ultra-low 
quantities. Their isolation from natural sources could provide insufficient amount, which would 
be the obstacle in clinical trials. Therefore, an alternative route is demanding. Chemical 
synthesis could provide a required amount. Natural product synthesis requires suitable reaction 
sequences which can generate the assigned stereocenters of the natural product. Mostly natural 
products contain a carbon core. Many C–C bond forming reactions have been developed. In 
1877 Charles Friedel and James Craft developed alkylation and acylation of aromatic rings 
using FeCl3. This was the first time when a Lewis acid was used in organic synthesis and 
became a choice of chemists for the alkylation of arenes and heteroarenes. The reaction 
proceeds through electrophilic aromatic substitution. A large group among the alkaloids 
containing an indole unit is known as “indole alkaloids”.  The indole framework has been 
recognized as a “privileged” structure, representing more than 3000 isolated natural products 
where 40 of them are used as therapeutic agents. The first indole alkaloid, strychnine was 
isolated in 1818 and its structural formula was stablished in 1947. The asymmetric Friedel-
Craft alkylation of indoles with imines provides enantiopure indol-3-ylmethamines, which 
serve as precursors of many biologically important natural products.164 
3-Substituted-3-hydroxy-2-oxindoles are biologically important scaffolds, which are present in 
numerous alkaloids, shown in Figure 38. Convolutamydine A (11-3) induces the appearance 
of characteristic features to the differentiated tumor cell line HL-60.165 Maremycins B (11-4) is 
a diketopiperazine alkaloid, which was isolated from the culture broth of marine Streptomyces 
species B 9173.166 Biological studies of TMC-95A (11-6) showed that it inhibits the 
chymotrypsin-like (CT-L), trypsin-like (TL), and post-glutamyl peptide hydrolytic (PGPH) 
activities of the proteasome with IC50 values of 5.4, 200, and 60 nM, respectively.167 A oxindole 
derivative of 11-1 was synthesized by palladium-mediated intramolecular Heck reaction of 
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substituted N-acyl-2,6-dibromoaniline.168 3-Hydroxy-N-methyl-welwitindolone C isonitrile 
(11-5) is present in blue green algae.169 
 
Figure 38. 3-Substituted-3-hydroxy-2-oxindoles embodied in natural products. 
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A Friedel-Craft reaction introduces an alkyl or acyl group into the aromatic system under 
Lewis-acid conditions. In the last decade, much attention has been paid on the development of 
catalytic use of Lewis acid. Alkylation using benzyl-, propargyl- and allyl alcohols, imines or 
styrenes has been employed in place of toxic benzyl halides.170  
 
12.1 Metal-based chiral complex catalysis 
The chiral bisoxazoline-copper(II) complex (S)-12-3 was deployed as a Lewis acid in catalytic 
enantioselective Friedel-Crafts alkylation of heteroaromatics and aromatics.171 It has been 
established that a pyrrole -system is quite much more active towards electrophilic substitution 
reactions than indole.172 Catalyst (S)-12-3 could also catalyze enantioselective addition of 
electron rich aromatics 12-1 to activated carbonyls.173  
 
Scheme 101. Addition of indoles to activated carbonyl compounds. 
 
Phosphorous based ligands in combination with Lewis acid for Friedel-Crafts alkylation were 
to be found inefficient whereas bisoxazoline based chiral catalyst 12-10 shown in Figure 39 
gave surprising results are summarized in Table 11.174  
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Figure 39. Bisoxazoline based ligands and Lewis acids. 
 
Toluene turned out to be the best solvent for such particular transformations. The tridentate 
ligand 12-9 could activate the nitroalkene through coordination of the nitro group to the Lewis 
acid center. The NH group present in between to two phenyl rings of 12-9 would engage in NH ⋯  𝜋 (indole) interaction and direct the indole to attack the nitroalkene preferentially from 
si-face. 
Table 11. Indole alkylation with nitrostyrene under different catalyst conditions. 
 
 
entry ligand cat. (mol%) solvent time (h) yield (%) ee (%) 
1 12-8 12 toluene 5 93 73 
2 12-9 10 toluene 8 99 83 
3 12-10 10 CHCl3 12 79 81 
 
 
Figure 40. Possible bifunctional mode in the transition state of the catalyst 12-9-Zn(OTf)2. 
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Small organic molecules could be used as catalyst to catalyze some organic reactions without 
the involvement of co-catalyst such as Lewis acids. The process of such catalysis is known as 
organocatalysis.175 
12.2 Iminium and SOMO Catalysis 
MacMillan found poor reaction rates and enantioselectivities when N-methylindole (12-18) 
were treated with (E)-crotonaldehyde (12-14) using imidazolidinone 12-15 as a catalyst. Since 
the overall rate of iminium-catalyzed reactions depends upon the iminium formation as well as 
on the C–C bond formation.176 In the enal and enone activation mode the energy of the lowest 
unoccupied molecular orbital of substrate gets lowered resulting enantioselective C–C and C–
N conjugate additions, cycloadditions, hydrogenations, and Friedel-Crafts alkylations. The lone 
pair on nitrogen in catalyst 12-16 is better exposed whereas in catalyst 12-15 it is hidden under 
the methyl unit at C2. Alkylation of N-methylindole with (E)-crotonaldehyde using catalyst 12-
16 in combination with TFA and p-TSA gave better yield and enantioselectivity. 
 
Scheme 102. Pyrole & N-methylindole alkylation with crotonaldehyde. 
 
Now the question is? Why enantioselectivity is improved with catalyst 12-16. The iminium ion 
geometry is controlled by the size difference of substituents at C2 and C5 positions of the 
imidazolidinone. The increased reactivity of the iminium ion 12-22 towards the C–C bond 
formation is due to selectively increased population of (E)-isomer 12-23 to overcome from the 
non-bonding interaction between the olefin of the substrate and the t-butyl unit. Therein benzyl 
unit in (E)-isomer shields the si-face and leaving free re-face for indole addition (Scheme 103). 
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Scheme 103. Iminium ion geometry and selectivity towards C–C bond formation. 
 
The other process of aldehyde and ketone activation via enamine formation raises the energy 
of the highest occupied molecular orbital (HOMO) to promote enantioselective -carbonyl 
functionalization.177 MacMillan hypothesized a three--electron radical cation which is a singly 
occupied molecular orbital (SOMO) and active for a range of enantioselective catalytic 
transformations (Figure 41).178 The pyrrole alkylation using aldehyde 12-25 is shown in 
Scheme 104. 
 
Scheme 104. Enantioselective -heteroarylation of aldehyde via SOMO catalysis. 
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Figure 41. Hypothetical representation of single-electron oxidation of transiently formed 
enamine. 
 
12.3 Organocatalysis via hydrogen bond-activation 
Carbonyl group and related compounds could be activated by the introduction of double 
hydrogen-bonding.179 The discovery of Etter and co-workers towards diaryl ureas such as 12-
28 bearing electron-withdrawing substituents readily form co-crystals with variety of proton 
acceptors, including carbonyl compounds, inspired the development of urea catalysts.180 Ricci 
and co-workers developed different thiourea catalysts for asymmetric alkylation of indole 12-
27a with electronically poor nitroalkenes 12-12 and found best results with the catalyst 12-29. 
The transition state shown in Scheme 105 seems to be more compact due to the hydrogen 
bonding interaction of the alcohol function in the catalyst 12-29 and the indole N–H, bringing 
both substrates closer, together leading to better selectivity. It is also clear from the transition 
state that N-alkylated indole could not interact with the hydroxyl unit of the catalyst 12-29 
therefore the reaction would be less efficient. Thiourea based catalyst 12-32 is used to alkylate 
indole 12-27a with imine 12-31a (Scheme 106).181 
Literature review  103 
 
 
Scheme 105. Friedel-Crafts alkylation of indole 12-27a in presence of 12-29 catalyst and it’s 
triply hydrogen bonded transition state. 
 
 
Scheme 106. Indole addition to aldimine. 
 
12.4 Chiral Brønsted acid catalysis 
A recent review “Complete Field Guide to Asymmetric BINOL-Phosphate Derived Brønsted 
Acid and Metal Catalysis: History and Classification by Mode of Activation; Brønsted Acidity, 
Hydrogen Bonding, Ion Pairing, and Metal Phosphates” describes different aspects of catalysis 
is worthy noting.182 The catalysis described before proceeds via activation of electron deficient 
multiple bonds. A highly enantioselective F-C alkylation of electron-rich alkenes, activated by 
chiral Brønsted acid is shown Scheme 107.183 An important class of asymmetric F-C reaction 
of indole with imines could be catalyzed by phosphoric acid based organocatalysts (Scheme 
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107). The product of this reaction gives an opportunity to access enantiopure 3-indolyl 
methylamine derivatives, which are present in numerous alkaloids having significant biological 
activities.184 
 
Scheme 107. Chiral Brønsted acid catalyzed asymmetric Friedel-Crafts reaction of indole 12-
27a with enamides 12-34, 12-39 and imine 12-41. 
 
The transition state of enamide addition to indole is shown in Figure 42. 
 
Figure 42. Proposed reaction model for reaction of indole and -aryl enamides. 
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13 Goal of the research 
 
Numerous natural and unnatural products with significant biological activities contain an 
indolyl methylamine unit. Several chiral phosphoric acid based catalysts have been developed 
and employed in asymmetric F-C reactions of indoles and imines to get 3-indolyl methylamine 
derivatives. From the literature review it is clear that known catalysts are delivering better 
selectivity at lower temperatures but higher temperatures are required for better conversion. 
Our group (Dr. Anton Khartulyari) has designed a catalyst for indole alkylation with imines 
considering the following points. (1) Moderate acidity, which might bring the lower reaction 
temperature to ambient temperature. (2) Better capability of hydrogen bonding, which could 
engage indole and imine in a tight transition state and (3) a C2 symmetry of the catalyst, would 
block one face for approach of reactants. 
 
Figure 43. A C2 symmetric phosphoric acid based chiral catalyst. 
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The catalyst 13-1 was prepared by few synthetic operations involving a Diels-Alder reaction as 
a key step (Scheme 108). Helmchen’s technique185 using a chiral fumarate derivative 14-2 
provides Diels-Alder adduct 14-4 in enantiomerically pure form after a single recrystallization. 
Ester 14-4 was subjected to react with Grignard reagent 14-3 (excess) to get diol 14-6.186 
Phosphorylation of diol 14-3 with PCl3 in basic medium provides phosphite 14-7 which after 
oxidation furnished catalyst 13-1 [[]20D = –54.1 (c = 1.0, CHCl3)] as a slightly yellow 
powder.187 
 
Scheme 108. Preparation of phosphoric acid based catalyst 13-1. 
 
With the view toward the indole alkylation several aromatic and aliphatic aldimines were 
prepared by reaction of an aldehyde with benzenesulfonamide. Aromatic aldehydes and 
aliphatic aldehydes (having no enolizable α-hydrogen) derived sulfonylimines are very easy to 
prepare as shown in Scheme 109, whereas aliphatic imines could be prepared by addition-
elimination to avoid enolization of imine into enamine.188  
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Scheme 109. Synthesis of N-sulfonyl aldimines from aldehydes and benzenesulfonamide. 
 
In order to test the scope of the catalyst, reaction conditions were optimized which are shown 
in Table 12. Equimolar amounts of indole 12-27a and imine 12-31a were reacted in presence 
of catalyst 13-1 (5 mol%), the delivery of desired product 12-33a was either low or reaction 
was not proceeding. Then the indole concentration was increased up to 2.5 equiv to get better 
yield. Less polar aromatic solvents such as toluene were found useful for a chiral 
monophosphoric acid-catalyzed F-C reaction via the activation of an electron deficient double 
bond (C=NR),189 whereas in the case of carbamate activation a marked retardation was 
observed with non-polar as well highly polar and protophilic solvents (Scheme 107).183 We 
screened the reaction in hexane and toluene. The lower yield in hexane is due to poor solubility 
whereas in toluene reaction is faster forming the bis-indole byproduct. The best yield and 
enantioselectivity were found when toluene and hexane were used in equal ratio (1:1, v/v).  
Table 12. Screening of conditions for the F-C reaction of 12-27a and 12-31a catalyzed by PA 
13-1. 
 
 
entry solvent  T (°C) time yield (%) ee (%) 
1 hexane rt 15 20 – 
2 toluene rt 15 50 – 
3 Toluene/Hexane, (1:1) rt 15 90 96.5 
5 Toluene/hexane, (1:1), 
4 A° MS 
0 °C to rt 15 97 96.5 
 
It is well known that 3-indolyl methylamines 14-14 in presence of acid provoke a SN1 reaction 
with indoles to form bis-indole 14-15 derivatives.190 
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Scheme 110. Formation of bis-indole adduct. 
 
Determination of the absolute configuration of the indolyl methylamine 
Simon and Goodman demonstrated the use of computation models and analytical data in 
identification of the specific indolyl methylamine product obtained from Friedel-Crafts 
reactions of indole with N-tosylimines catalyzed by BINOL-phosphoric acids.191 Tian and co-
workers treated racemic sulfonamide 12-42 with benzyl thiol and chiral phosphoric acid 14-9 
at room temperature which led to formation of racemic thioether in 60% yield and remaining 
36% enantiomerically (98% ee) pure sulfonamide was recovered unreacted (Scheme 111).192 
This could be explained from the transition state shown in Figure 44.  
 
Scheme 111. Kinetic resolution of racemic N-(3-indolyl)(phenyl)methylsulfonamide with 
benzyl thiol. 
 
The N–H groups present in the indole and sulfonamide of 12-42 engage themselves with the 
chiral phosphoric acid through hydrogen bonding and therefore chiral phosphoric acid is able 
to discriminate between two enantiomers of the indolyl-methyl by recognizing the steric 
repulsion between R1 and the Ar unit. In case of (Figure 44,TS-I) the steric repulsion is less 
therefore the sp3 C–N bond cleavage is faster, whereas the other enantiomer (Figure 44, TS-II) 
could feel stronger repulsion, which makes slower C–N bond cleavage to become unreacted. 
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Figure 44. Possible transition states for the chiral phosphoric acid-catalyzed sp3 C–N bond 
cleavage. 
 
On the basis of the above discussion, we propose a possible model for the asymmetric induction 
with our catalyst, shown in Figure 45. The bifunctional catalyst binds with the substrate through 
hydrogen bonding making preferentially the re-face free to indole addition, leading to a (S)-
configuration adduct. 
 
Figure 45. Proposed Reaction Model. 
 
The chiral phosphoric acid and Tol-BINAP-CuPF6 catalysis is only efficient with electron rich 
substrates.193 In order to test the scope of the reaction first we have chosen indole and differently 
substituted aldimines. As evident from Table 13 all the addition reactions give the 3-substituted 
indole derivative. The addition to the electron-rich substrates (Table 13, entry 1–4) gave the 
products up to 99% yield and 98% ee. The aldimines with electron withdrawing substituents 
(Table 13, entry 5, 6) also reacted very well except for bromide substituted (Table 13, entry 7) 
which gave low selectivity as well as yield (36% yield and 87% ee). Hindered aldimine (Table 
13, entry 8–10) did not deliver product with increased catalyst loading (10 mol%) and 
temperature (up to 90 oC). 
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Table 13. Organocatalyzed enantioselective alkylation of indole with different aldimines, 
showing the effect of substituents on the aldimines. 
 
 
entry R solvent temp (oC) time (h) yield (%) ee (%) 
1 Ph (12-31a) Tol/Hex 0 oC–rt 15 97 97 
2 Np (12-31b) Tol/Hex 0 oC–rt 24 97 97 
3 3,4-O2CH2Ph (12-31c) Tol/Hex 0 oC–rt 18 99 98 
4 4-OMePh (12-31d) Tol/Hex 0 oC–rt 18 79 96 
5 4-CF3Ph (12-31e) Tol/Hex 0 oC–rt 15 86 96 
6 4-CO2Me (12-31f) Tol/Hex 0 oC–rt 15 83 90 
7 4-BrPh (12-31g) Tol/Hex 0 oC–rt 35 36 87 
8 2,6-Me2Ph (12-31h) Tol/Hex 0 oC–rt 35 00  
9 2,6-Me2Ph (12-31h) Tol rt–60 oC 35 00  
10 2,6-Me2Ph (12-31h) Tol 90 oC 18 00  
Abbreviations used in table: Tol = Toluene, Hex = Hexane. 
 
The steric effect on this Friedel-Crafts reaction was evaluated using 2-methyl indole (12-27b) 
and imines 12-31 (a-g); the results are summarized in Table 14. Interestingly, both the 
reactivity and the enantioselectivity were enhanced with electron withdrawing substituents on 
the imine to match excess electron density produced by the 2-methyl group in the indole (Table 
14, entries 5–7). On the other hand, for imines having relatively big electron donating groups 
(Table 14, entries 3–4), reactivity and selectivity were found to be decreased. Therefore in the 
first case inductive and in other case steric factors are operative. 
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Table 14. Organocatalytic enantioselective alkylation of methylindole with different aldimines 
to delineate steric effect and week electron donation. 
 
 
entry R solvent temp (oC) time (h) yield (%) ee (%) 
1 Ph (12-31a) Tol/Hex 0 oC–rt 15 99 92 
2 Np (12-31b) Tol/Hex 0 oC–rt 24 84 93 
3 3,4-O2CH2Ph (12-31c) Tol/Hex 0 oC–rt 18 97 84 
4 4-OMePh (12-31d) Tol/Hex 0 oC–rt 18 86 83 
5 4-CF3Ph (12-31e) Tol/Hex 0 oC–rt 15 88 93 
6 4-CO2Me (12-31f) Tol/Hex 0 oC–rt 15 99 97 
7 4-BrPh (12-31g) Tol/Hex 0 oC–rt 35 80 92 
 
In order to understand the effect imposed on this F-C reaction by higher electron density on 
indole, 5-methoxy indole (12-27c) was examined with various imines 12-31 (a-g). Since the 
methoxy group is away from the N–H of indole, therefore it is expected that it would not be 
interfering in hydrogen bonding with the catalyst. For aryl imines (Table 15, entry 1–6), the 
reactions went smoothly to give the corresponding products in 91-99% yield and 93-98% ee. 
In the case of the imine sustituted with bromide (Table 15, entry 7), a strong electron 
withdrawing substituent, lowering of the reactivity as well as selectivity (78%, 65% ee) was 
observed. These results indicate that the methoxy unit does not play any steric role in the 
reaction and only inductive effects seem to be operative. 
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Table 15. Organocatalytic enantioselective alkylation of 5-methoxyindole with aldimines and 
effect of strong electron donation. 
 
 
entry R solvent temp (oC) time (h) yield (%) ee (%) 
1 Ph (12-31a) Tol/Hex 0 oC–rt 15 99 94 
2 Np (12-31b) Tol/Hex 0 oC–rt 24 91 95 
3 3,4-O2CH2Ph (12-31c) Tol/Hex 0 oC–rt 18 99 98 
4 4-OMePh (12-31d) Tol/Hex 0 oC–rt 18 97 98 
5 4-CF3Ph (12-31e) Tol/Hex 0 oC–rt 15 99 98 
6 4-CO2Me (12-31f) Tol/Hex 0 oC–rt 15 94 93 
7 4-BrPh (12-31g) Tol/Hex 0 oC–rt 35 78 65 
 
Our next goal stands to study the effect of an electron-withdrawing group on the indole ring 
which led to a lower reactivity (Table 16, entries 1-7). For aryl imines (Table 16, entries 1, 3, 
4, 6), the reactions did not take place. In the case of imine 12-31e having an electron 
withdrawing unit good results (73%, 94% ee) were obtained. 
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Table 16. Organocatalytic enantioselective alkylation of 4-bromoindole with aldimines and an 
effect of electron-withdrawing group on the reaction. 
 
 
entry R solvent temp (oC) time (h) yield (%) ee (%) 
1 Ph (12-31a) Tol/Hex 0 oC–rt 55 – – 
2 Np (12-31b) Tol/Hex 0 oC–rt 55 51 63 
3 3,4-O2CH2Ph (12-31c) Tol/Hex 0 oC–rt 55 – – 
4 4-OMePh (12-31d) Tol/Hex 0 oC–rt 55 – – 
5 4-CF3Ph (12-31e) Tol/Hex 0 oC–rt 55 73 94 
6 4-CO2Me (12-31f) Tol/Hex 0 oC–rt 55 – – 
7 4-BrPh (12-31g) Tol/Hex 0 oC–rt 55 11 – 
 
In order to test the scope of the reaction, we screened two aliphatic aldimines 12-31 (i-j). The 
aliphatic aldimines (Table 17, entry 1–5) did not react at low temperature; when they were 
allowed to react at elevated temperature (up to 90 °C) or at room temperature for longer (up to 
35 days),  the formation of bisindole derivatives 14-19i and 14-19j were observed. 
Table 17. Organocatalyzed alkylation of indole with different aldimines 
 
 
entry R solvent temp (oC) time (h) yield (%) ee (%) 
1 Cy (12-31i) Tol/Hex 0 oC–rt 22 00  
2 Cy (12-31i) Tol 90 oC 18 60  
3 t-Bu (12-31j) Tol/Hex 0 oC–rt 22 50  
4 t-Bu (12-31j) Tol/Hex 90 oC 18 99  
5 t-Bu (12-31j) Tol/Hex 0 oC–rt 840 (35 d) 99  
Abbreviations used in table: Cy = cyclohexy, t-Bu = tertiary butyl. 
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15 Conclusion III 
 
Indoles were alkylated with imines using a novel C2 symmetric catalyst. The reaction features 
a metal free approach, high efficiency of the catalyst, mild reaction conditions, high yields up 
to 99%, and excellent enantioselectivities up to 98% 
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16 Progress towards the synthesis of tautomycetin fragment 
 
16.1 Tautomycetin 
 Physiological functions of cells are governed by protein regulation, known as 
phosphorylation/dephosphorylation. They are directed by the balance between kinases and 
phosphatases. Protein kinases are responsible for transfer of a phosphate unit from ATP to the 
protein (phosphorylation), whereas the reverse process is catalyzed by protein phosphatases 
(dephosphorylation). It is estimated that 2% of the eukaryotic genome is responsible for 
kinases.194 There are 15 proteins and 13 genes in the PPP family along the additional 10 genes 
in the PPM family. The largest class of protein phosphatase is the phosphoprotein phosphatase 
(PPP) family involving PP1, PP2A, PP2B, PP4, PP5, PP6 and PP7, and the protein phosphatase 
Mg2+- or Mn2+-dependent (PPM) family, composed primarily of PP2C.195 Less than 0.1% of 
human genome covers serine/threonine protein phosphatases. Basically every disease is an 
outcome of defect in cellular signaling. Protein phosphatases had played a role in disease 
detection as well as in treatment. Okadaic acid (OA) is known for its strong inhibitory action 
against protein phosphatases, specifically serine/threonine phosphatases.196 
 
Figure 46. Structure of okadaic acid. 
 
Tautomycin (16-2) and tautomycetin (16-3) are two related polyketides that have been known 
from several years. Tautomycin was discovered in 1987,197 whereas tautomycetin was isolated 
from the culture of Streptomyces griseochromogenes in 1989.198 They exhibit cytotoxicity 
against fungi, yeasts and animal cells; it is named as tautomycin because of its existence as 
tautomeric form in solution. In the meantime they turned out to be protein phosphatase 1 and 2 
(PP1, PP2) inhibitors. Therefore they are analogous to okadaic acid. Tautomycin was found to 
have more than threefold (serine/threonine phosphatase) inhibitory activity than tautomycetin. 
They also seem to have antitumor activity, inducing morphological changes in human leukemia 
cells K5621. In addition, antiviral activity has been noted. Structurally, these two polyketide 
contains a somewhat unusual dialkylmaleic anhydride subunit199 that is attached to the 
remaining part via an ester bond. 
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Figure 47. Structure of tautomycin and tautomycetin. 
 
16.2 Current state of research 
While a total synthesis for tautomycin is known,200 the synthesis of tautomycetin could not be 
finished due to problems in late stage deprotection steps.201 
Oikawa and co-workers a proposed a retrosynthesis of tautomycetin (16-3) as shown in Scheme 
112.  
 
Scheme 112. Retrosynthesis proposed by the Oikawa group. 
 
The alkenol 16-6, which was prepared by Roush crotylation reaction, was deoxygenated to give 
the anti-1,3-dimethyl pattern (Scheme 113). Functionlization of the terminal double bond of 
16-7 led to aldehyde 16-8. The aldehyde 16-8 was extended to propargylic ether 16-9. From 
here a chain extension on the other terminus and refunctionlization of the double bond from the 
crotylation reaction followed by hydrostannylation of the triple bond allowed for access to vinyl 
iodide 16-11. The vinyl substituent could then be introduced by Stille cross-coupling reaction. 
A final aldol reaction of methyl ketone 16-12 with aldehyde 16-13 furnished hydroxyketone 
16-14 as a 2:1 mixture of diastereomers.201 
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Scheme 113. Approach towards tautomycetin by the Oikawa group. 
 
Shibasaki and co-workers published the synthesis of the degradation product 16-24.202 Key 
steps of this route include an organolithium addition to dienal 16-18 (C5–C6 bond) and a HWE 
reaction between ketophosphonate 16-22 and aldehyde 16-21 to form C10–C11 (Scheme 114). 
The organolithium addition led to a mixture of diastereomers at C5. They were separated and 
the synthesis was continued with one of them. The dienal 16-18 was prepared by vinylcuprate 
addition to alkynoate 16-16. 
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Scheme 114. Synthetic study towards tautomycetin by Shibasaki et al. 
 
From the synthetic work on tautomycin it turned out that smaller fragments were essentially 
inactive. In particular the region around C12–C16 seems quite important.203 The anhydride 
region serves to enhance the biological activity. Regarding the apoptosis inducing activity, the 
C1–C18 moiety turned out to be essential. The authors of this article suggest that different parts 
of tautomycin are responsible for protein phosphatase inhibition and the apoptosis inducing 
property. Futher biological studies including an X-ray structure of tautomycin with protein 
phosphatase-1 have been published.204 Because of the unusual structure and the lacking 
biological studies with tautomycetin, the synthesis of this compound appears as worthwhile 
undertaking. 
16.3 Retrosynthetic plan 
After removal of the anhydride unit, the polyketide might be broken up into fragments 16-27 
and 16-28 (Scheme 115), which could be coupled by reductive aldol reaction using chiral 
boranes. The fragment 16-28 is challenging because of the dienone part that as Michael acceptor 
might be sensitive to nucleophiles. Therefore, it would be best to introduce this part late in the 
synthesis. 
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Scheme 115. Retrosynthesis of tautomycetin. 
 
16.4 Results and discussion 
With a view towards of fragment 16-29, diol 16-31 was selectively protected as silyl ether 16-
32, the alcohol function was oxidized to aldehyde 16-33 which was subjected to chain extension 
with S-ethyl 2-(triphenyl-5-phosphanylidene)ethanethioate giving rise to unsaturated thioester 
16-34, the asymmetric methyl cuprate addition, in presence of (S)-Tol-BINAP provided 
thioester 16-35. For iterative asymmetric cuprate addition,205 first the ester function of 16-35 
was reduced into aldehyde and chain extension with S-ethyl 2-(triphenyl-5-
phosphanylidene)ethanethioate furnished thioester 16-37. 
 
Scheme 116. Synthesis of thioester from 16-37 from 1,4-butanediol (16-31). 
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The second fragment 16-27 we envisioned to be prepared by Evans-aldol reaction of 
oxazolidinone 16-43 and aldehyde 16-40. The selectively protection of the inexpensive 1,3-
propanediol (16-38) into silyl ether 16-39 and further oxidation gave aldehyde 16-40 with very 
good yield. Acylation of oxazolidine 16-41 in presence of n-BuLi gave oxazolidinone 16-43 
which on reaction with aldehyde 16-40 furnished exclusively the single syn-diastereomer 16-
44. First the alcohol was reacted with MOMCl in presence of Huenig’s base and 
tetrabutylammonium iodide, which produced ether 16-45 in the quantitative yield. The 
reduction of oxazolidinone 16-45 with LiBH4 followed by oxidation produced aldehyde 16-47.  
 
Scheme 117. Aldehyde synthesis from diol 16-47 via aldol reaction. 
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17 Intramolecular C–H-activation towards Palonosetron  
 
17.1 Palonosetron 
 Phenanthridone derivatives are present in the antineoplatic Amarylldaceae natural 
products.206 Palonosetron is a 5-HT(3) antagonist used in the prevention and treatment of 
chemotherapy-induced nausea and vomiting (CINV).207 There are several traditional syntheses 
along the C–H-activation approach. 
 
Figure 48. Phenantridinone alkaloids. 
 
The synthesis of palonosteron proposed by Clark and co-workers is demonstrated in Scheme 
118.208 Treatment of the N-quinuclidin-3-yl amides 17-7 with 2 equiv of n-BuLi generates the 
dilithio derivatives which on quenching with N,N-dimethylformamide produced 3-hydroxy 
derivative which and dehydration and catalytic hydrogenation of furnished palonosterons. 
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Scheme 118. Synthesis of palonosteron (17-3) from from methyl-1-naphthoate (17-4) by Clark 
and co-workers. 
 
The above synthesis has several drawbacks such as reduction of 1-naphthoic acid into 5,6,7,8-
tetrahydro-1-naphthoic acid, which is very sensitive to reduction and the generation of dianion 
of 17-7 required excess n-BuLi which could be difficult to handle at production scale. The 
improved synthesis of palonosteron by Kowalczyk et al. is shown in Scheme 119.209 They 
observed reduction of 17-10 with H2 at 50 °C and they found selective reduction of imide 17-
11 with NaBH4 in alcohol at low temperature gave best results.  
 
Scheme 119. Synthesis of palonosteron from 1,8-naphthalic anhydride (17-9). 
 
17.2 Results and discussion 
In an alternative plan palanosteron could be fragmented into amide 17-13 and halide 17-14. 
Intramolecular C–H-activation could generate amide fragment 17-13, which after N-alkylation 
with 3-chloroquinuclidine would produce palonosteron (Scheme 120). 
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Scheme 120. Framentation of palonosteron. 
 
The C–H-activation strategies are advantageous over traditional strategies because of obviation 
of prefunctionalization.210 We synthesized N-pivaloxy benzamide in six steps (Scheme 121). 
Thus, Heck reaction of ethyl-3-bromobenzoate (17-15) with 3-butenol (17-16) provided E-
alkene 17-17 which on reduction under Landlar’s condition following PCC oxidation gave 
aldehyde 17-19. The chain extension on aldehyde 17-19 was carried out using a Wittig reaction. 
N-OPiv benzamide 17-22 was prepared from benzoic acid ester 17-20 using our optimized 
procedure in chapter 2 (procedure 3). The intramolecular alkene annulation gave benzamide 
17-13 in 76% yield. The cross peaks between 3a-H and 4-H in COSY spectrum ( Figure 49) of 
compound 17-13 confirms its formation. 
 
 
 
Scheme 121. Intramolecular C–H-activation to generate the core structure of Palanosteron. 
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Figure 49. COSY spectrum of 17-13 (0.5 ppm to 4.0 ppm). 
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18 Palladium-catalyzed redox indanone synthesis  
 
18.1 Indanones 
 Indanones are attractive intermediates in the synthesis of various natural products211 and 
its derivative such as indanocine, which is a potent microtubule-destabilizing agent, binds to 
the colchicine binding site of tubulin.212 A huge number of palladium-catalyzed annulation 
reactions are reported towards the synthesis of carbo- and heterocycles.213 Palladium-catalyzed 
annulation of internal alkynes with aromatic aldehydes and carbonylative annulation of o-
iodostyrenes would deliver indanones (Scheme 122).214,215 The oxidation of benzylic and 
allylic alcohols was achieved in DMSO.216 Gold catalyzed cycloisomerzation reactions were 
also reported.217 There are no such documented reports or examples to make cyclocarbonyles 
in one shot from aryl-allyalcohol halides. In this topic we demonstrate the electronic and steric 
dependency on this reaction. 
 
Scheme 122. Palladium-catalyzed annulation of internal alkyne with o-bromobenzaldehydes 
by carbonylatio of and o-iodostyrenes. 
 
[(3-allyl)PdCl]2 catalyzed arylation of alkenols with a range of aryl halides led to the formation 
of the corresponding ketone 18-9.218 Aryl halides like 18-11 having mild activating functions 
efficiently undergo Pd(0) redox oxidation.219 
 
Scheme 123. Arylation of allyl alcohols with aryl halides under Pd(0) condition. 
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Piperidine and morpholine were found better acid acceptors over trimethylamine in the 
coupling of vinyl halide 18-13 with allyl alcohol 18-14 (Scheme 124).220 In the absence of 
secondary amines, alkenylation of 2-cyclopentenol occurs at both olefinic carbons.221 
 
Scheme 124. Addition of vinyl halides to allyl alcohols. 
 
-Substituted ketones were obtained in Pd(II) mediated coupling of vinyl, aryl and heteroaryl 
halides with homoallylic alcohols (Scheme 125).222 A review describing palladium catalyzed 
reactions of alcohols was published by Muzart.223 
 
Scheme 125. Addition of vinyl halide 18-21 to homoallylic alcohol 18-22. 
 
 
Figure 50. Our work “palladium mediated redox indanone synthesis”. 
 
18.2 Results and discussion 
We began our investigation by making benzyl alcohols from differently substituted 2-
bromobenzaldehydes with allylmagnesium chloride which furnished the corresponding 
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homoallyl alcohols (Scheme 127).224 The pipronol (18-24e) was oxidized into corresponding 
2-bromopipronaldehyde (18-25e) using DBDMH.225  
 
Scheme 126. Oxidation of pipronol (18-24e) into 2-bromopipronaldehyde (18-25e). 
 
The addition of allylmagnesium bromide to the electronically rich 2-bromo-3,4,5-trimethoxy 
benzaldehyde (18-25d) furnished homoallylic alcohol 18-26d in 87% yield whereas addition to 
the electronically poor 2-chloro-6-flurobenzaldehyde (18-25g) delivered benzylic alcohol 18-
26g in 50% yield. The addition of Grignard reagent to the the 3-bromothiophene 
carboxaldehyde (18-25h) led to the formation of homoallylic alcohol 18-26h.  
 
Scheme 127. Allylation of aldehydes 18-25 (a-h) with AllMgBr into homoallylic alcohols 18-
26 (a-h). 
 
We selected methylenedioxy substituted homoallyl alcohol 18-26e as a starting material and 
subjected it to 10 mol% [Pd(OAc)2], 20 mol% P(o-Tol)3 as an additive and Et3N as a base, at 
110 °C under N2 atmosphere in toluene. This set of conditions afforded the unexpected product 
18-28e in 88% yield after 6 h. The doublet of methyl protons at 1.34 ppm in the 1H NMR and 
a resonance at 204.2 of the carbonyl function in 13C spectrum confirm the formation of redox 
product 18-28e. Analogously, other homoallyl alcohols were subjected for this reaction, 
however only 18-28a and 18-28b furnished the redox products. It is expected that in case of 
18-26c and 18-26d palladacycle formation is rather difficult whereas in case of 18-26g benzene 
ring is electron deficient. 
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Scheme 128. Palladium mediated redox synthesis of indanones from corresponding 
homoallylic alcohols. 
 
We again tried to optimize the reaction condition for hindered homoallylic alcohols, choosing 
18-26c as a model compound. A brief analysis of solvent and base is depicted in Table 18. 
Table 18. Effect of base and polarity of solvent on palladium mediated redox reaction. 
 
 
entry base solvent yield (%) 
1 TEA toluene 00 
2 TEA DMSO 00 
3 TEA DMSO 00 
4 DIPEA DMSO 00 
5 DIPEA DMSO 00 
 
The homoallylic alcohols 18-26f undergoes intramolecular Heck reaction to produce indenol 
18-29, whereas the cyclization product from alcohol 18-26h with an exo-cyclic double bond 
rearranges to give the indenol 18-30. 
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Scheme 129. Heck reaction of homoallylic alcohols 18-26f and 18-26h. 
 
The proposed mechanism of the formation of indanones from the derivative of o-bromo benzyl 
alcohols is demonstrated in Scheme 130. 
 
Scheme 130. Proposed mechanistic pathway for the formation of indanone. 
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19 Conclusion IV 
 
A little progress we made towards the synthesis of a Tautomycetin fragment. The ester segment 
16-37 we synthesized from a commercially available and cheap alcohol 16-31 demonstrating 
successful use of Swern-oxidation on a four carbon alcohol. Whereas, the aldehyde segment 
16-47 we synthesized by employing Swern oxidation on three carbon alcohol 16-38. 
Oxazolidine chiral auxiliary enabled us to make syn-alcohol 16-47 via an Evans aldol reaction. 
 
Scheme 131. Synthesis of thioester 16-37 and aldehyde 16-47 from 1,4-butandiol and 1,3-
propanediol, respectively. 
 
We have successfully synthesized the fragment of palonosteron 17-13 via intramolecular C–H-
activation approach. In 2014 Glorius and co-workers disclosed the intramolecular C–H-
activation towards such valuable compounds.210 Therefore, we discontinued this work. 
 
Scheme 132. Synthesis of palonosteron fragment 17-13. 
 
During the intramolecular Heck reaction of some aryl halides, we observed redox products 
(Figure 51). These observations attract us to further investigate this work. Unfornately, the 
developed protocol is operating only on less hindered and mild activated aromatic rings. This 
work needs a further investigation to improve the protocol for a range of aromatics. 
 
Figure 51. 3-Methyl indanones. 
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20 Experimental Section 
 
20.1 General remarks 
 
20.1.1 Chemicals and working techniques 
The chemicals were purchased from the firms Acros, Aldrich, and Merck. All reagents were 
obtained from commercial suppliers, and were used without further purification unless 
otherwise stated. All solvents were distilled and/or dried prior to use by standard methodology 
except for those, which were reagent grades. The applied petroleum ether fraction had a boiling 
point of 40–60 °C. Anhydrous solvents were obtained as follows: THF, diethyl ether and 
toluene by distillation from sodium and benzophenone; dichloromethane and chloroform by 
distillation from calcium hydride; acetone by distillation from phosphorous pentoxide. Absolute 
triethylamine and pyridine and diisopropylethylamine were distilled over calcium hydride prior 
to use. Unless and otherwise mentioned, all the reactions were carried out under a nitrogen 
atmosphere and the reaction flasks were pre-dried by heat gun under high vacuum. All the 
chemicals, which were air or water sensitive, were stored under inert atmosphere. Compounds 
that are not described in the experimental part were synthesized according to the literature. 
 
16.1.2 NMR-spectroscopy 
All the spectra were measured on a Bruker Avance 400 spectrometer, which operated at 400 
MHz for 1H and 100 MHz for 13C nuclei, respectively. 1H (400 MHz) and 13C NMR (100 MHz): 
spectra were recorded at 295 K either in CDCl3 or [D4]MeOH; chemical shifts are calibrated to 
the residual proton and carbon resonance of the solvent: CDCl3 ( H = 7.25 ppm,  C = 77.0 
ppm), [D4]MeOH ( H = 2.49 ppm,  C = 39.5 ppm). Data are reported as follows: chemical 
shift (multiplicity: s = singlet, d = doublet, t = triplet, ddd = doublet of doublet of doublet, dt = 
doublet of triplet, td = triplet of doublet, m = multiplet, br = broadened, J = coupling constant 
(Hz), integration, peak assignment in italic form). 
 
16.1.3 Mass Spectrometry 
High-resolution mass spectra (HRMS) were recorded on an instrument (Brucker maXis 4G) 
with electron spray ionization (ESI) and a TOF mass detector (mass range: 50−20000 m/z, mass 
accuracy: 600 ppb RMS error). Some of the mass spectra were also measured on an Agilent 
1100 series LC-MSD. Analytical HPLC-MS: HP 1100 Series connected with an ESI MS 
detector Agilent G1946C, positive mode with fragmentor voltage of 40 eV, column: Nucleosil 
100–5, C-18 HD, 5 mm, 70 × 3 mm Machery Nagel, eluent: NaCl solution (5 mM)/acetonitrile, 
gradient: 0/10/15/17/20 min with 20/80/80/99/99% acetonitrile, flow: 0.6 mL min–1. High 
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resolution mass (HRMS) are reported as follows: (ESI): calcd mass for the related compound 
followed by found mass. 
 
16.1.4 Polarimetry 
Optical rotations were measured on a JASCO Polarimeter P-1020. They are reported as follows: 
[α]temperature D (concentration, solvent). The unit of c is g/100 mL. Anhydrous CH2Cl2, 
CHCl3 or EtOH were used as solvents. For the measurement the sodium D line = 589 nm was 
used. 
 
16.1.5 Chromatographic Methods 
High performance liquid chromatography (HPLC) analysis was performed on a Hewlett-
Packard 1100 Series instrument equipped with a quaternary pump, using a Eurocell Knauer 
(250 × 4.6 mm). UV absorption was monitored at 220 nm or at 254 nm. Hexanes/isopropanol 
(65/25) mixture was used for elution (0.8 ml/min). Flash column chromatography was 
performed using flash silica gel (40-63 m, 230-400 mesh ASTM) from Macherey-Nagel. 
Analytical thin layer chromatography (TLC) and preparative thin layer chromatography were 
performed on precoated silica gel 60 F254 plates (Merck) or Polygram Sil G/UV254 (Macherey 
Nagel). The compounds were visualized by UV254 light and the chromatography plates were 
developed with an aqueous solution of molybdophosphorous acid or an aqueous solution of 
potassium permanganate (heating with the hot gun). For preparation of the molybdate solution 
20 g ammonium molybdate [(NH4)6Mo7O24·4H2O] and 0.4 g Ce(SO4)2·4H2O were dissolved 
in 400 mL of 10% H2SO4. The potassium permanganate solution was prepared from 2.5 g 
KMnO4 and 12.5 g Na2CO3 in 250 mL H2O. 
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20.2 Experimental procedures 
All the experimental procedures are arranged in the ascending order of number of the 
compound. 
 
meso-2,4-Dimethylpentane-1,5-diol (3-6) 
 
 
To a 0 °C solution of meso-2,4-dimethylglutaric anhydride (10.00 g, 50.35 mmol) in anhydrous 
THF (200 mL), LiAlH4 (8.00 g, 211.00 mmol, 3 equiv) was added in equal portions. The 
reaction was warmed to rt in 5 min., and then heated at reflux for 24 h. The reaction was cooled 
to 0 °C and the excess LiAlH4 was cautiously quenched by the sequential addition of water (150 
mL) and HCl (6N, 60 mL). The resulting white suspension was warmed to rt and the aqeous 
layers was extracted with ethyl acetate (3 × 200 mL). The combined organic extracts were dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The diol was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1/1, 3/1, 4/1) to afford product (9.47 g) as 
colorless oil. 1H NMR (400 MHz, CDCl3):  = 0.76-0.86 (m, 1H, 3-H), 0.88 (d, J = 6.8 Hz, 6H, 
2-CH3), 1.50-1.59 (m, 1H, 3-H), 1.61-1.72 (m, 2H, 2-H), 3.35 (dd, J = 5.8, 10.8 Hz, 2H, 1-H), 
4.43 (dd, J = 5.3, 10.6 Hz, 2H, 1-H), 3.53 (br, 2H, OH); 13C NMR (100 MHz, CDCl3):  = 17.6 
(2-CH3), 32.9 (C-3), 36.8 (C-2), 67.3 (C-1); HRMS (ESI): calcd for C7H16O2 [M+Na]+: 
155.10425, found 155.10436. 
(2S,4R)-5-Hydroxy-2,4-dimethylpentyl acetate (4-24) 
 
 
To a solution of meso-diol 3-6 (14.0 g, 0.107 mol) and vinyl acetate (9.5 g, 10 mL, 0.11 mol) 
in THF (300 mL) was added Amano Lipase AK from Pseudomonas fluorescence, 100 mg, 
(Aldrich Cat. Nr. 53,473-0), and the resulting suspension was stirred at room temperature using 
a mechanical stirrer. After 24 h additional vinyl acetate (2 mL) was added, and stirring 
continued for a total of 80 h. Then the reaction mixture was filtered through a Celite pad (2 cm), 
and the filtrate concentrated in vacuo. The residue was redissolved in CH2Cl2 (150 mL), and 
the solution washed with 15% NaCl water solution (2 × 50 mL), aquous saturated NaCl solution 
(1 × 50 mL), dried over Na2SO4, filtered, and concentrated in vacuo to yield mono-acetate 4-
24 (17.2 g, 80%) as a colorless oil. Our group has performed analytical studies of this 
compound, results are summerized here. The analysis by chiral GC [(column: heptakis(2,3-
diacetyl-6-TBDMS)-ȕ-cyclodextrin (30%) PS 86 (70%), df = 0.13 μ, size: 25 m × 0.25 mm), 
mobile phase: H2, 90/2/4/140, pressure: 80 kPa, retention time (main): 11.1 min, (minor): 11.3 
min] showed 98% ee, which was confirmed by NMR of Mosher ester. Rf = 0.2 
(EtOAc/petroleum ether, 1:5); []22 D = +7.7 (c = 1.0 in CH2Cl2); 1HNMR (400 MHz, CDCl3): 
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 = 0.88-0.94 (m, 6H, 2-CH3, 4-CH3), 0.95-1.0 (m, 1H, 3-H), 1.35-1.45 (m, 1H, 3-H), 1.62-1.76 
(m, 1H, 2-H), 1.78-1.95 (m, 2H, OH, 4-H), 3.32-3.41 (m, 1H, 1-H), 3.42-3.49 (m, 1H, 1-H), 
3.80 (dd, J = 6.8, 10.8 Hz, 1H, 5-H), 3.93 (dd, J = 5.4, 10.8 Hz, 1H, 5-H ); 13C NMR (100 MHz, 
CDCl3):  = 17.2 (2-CH3), 17.8 (4-CH3), 20.9 (COCH3), 29.9 (C-4), 33.0 (C-3), 37.2 (C-2), 
67.9 (C-1), 69.1 (C-5), 171.3 (OCOCH3); HRMS (ESI): calcd for C9H18O3 [M+Na]+ 197.11482, 
found 197.11486. 
(2S,4R)-5-((tert-butyldimethylsilyl)oxy)-2,4-dimethylpentyl acetate (4-26) 
 
 
To a solution of acetate 4-24 (2.0 g, 9.4 mmol) from the previous step and imidazole (1.4 g, 20 
mmol, 2 equiv) in CH2Cl2 (6 mL) was added tert-butyldimethylchlorsilane (1.5 g, 10 mmol, 
1.05 equiv) in small portions over 15 min, and the reaction mixture was stirred for additional 
40 min. The imidazole hydrochloride was filtered off, and the filtrate washed with water (2 × 
20 mL), 3% HCl (2 × 15 mL), saturated aqueous NaHCO3 (2 × 10 mL), and aqueous NaCl (10 
mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified 
by flash chromatography (ethylacetate/petroleum ether, 100:2) to afford pure product 4-26 (3.0 
g 98%) as colorless oil. Rf = 0.5 (ethylacetate/petroleum ether, 1/20) 
(2S,4R)-5-((tert-butyldimethylsilyl)oxy)-2,4-dimethylpentan-1-ol (4-27) 
 
 
To a solution of the silyl ether 4-26 (3.0 g) from the previous step in MeOH (12 mL) was added 
powdered K2CO3 (1.68 g, 12 mmol) and the mixture was stirred for 2 h. Thereafter the solid 
was removed by filtration and the filtrate was concentrated in vacuo. The residue was 
redissolved in petroleum ether (15 mL), washed with water (3 × 10 mL), saturated NaCl 
solution (10 mL), dried over Na2SO4, filtered, and concentrated in vacuo affording the alcohol 
4-27 as a colorless oil (2.1 g, 75% from 2,4-dimethylpentane-1,5-diol). Rf = 0.7 
(EtOAc/petroleum ether, 1:5); []22 D = –3.3 (c 1.0 in CH2Cl2); 1HNMR (400 MHz, CDCl3):  
= 0.02 (s, 6H, (CH3)2Si), 0.88 (s, 9H, (CH3)3CSi), 0.87-0.90 (m, 4H, 3-H, 4-CH3), 0.92 (d, J = 
6.8 Hz, 3H, 2-CH3), 1.37-1.46 (m, 1H, 3-H), 1.63-1.75 (m, 3H, 2-H, 4-H), 3.32-3.52 (m, 4H, 
1-H, 5-H); 13C NMR (100 MHz, CDCl3): δ = –5.4 ((CH3)2Si), 17.7, 17.8 (CH3), 18.3 
((CH3)3CSi), 25.9 ((CH3)3CSi), 33.2, 33.3 (C-2, C-4), 37.3 (C-3), 68.2, 68.3 (C-1, C-5); HRMS 
(ESI): calcd for C13H30O2Si [M+Na] +: 269.19073, found 269.19097. 
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(2S,4R)-5-{(tert-Butyldimethylsilyl)oxy}-2,4-dimethylpentyl-4-methylbenzenesulfonate 
(4-28) 
 
 
To a solution of alcohol 4-27 (1.00 g, 4.06 mmol) in pyridine (2 mL) was added para-
toluenesulfonyl chloride (0.97 g, 5.07 mmol, 1.25 equiv) and DMAP (0.008 g, 0.08 mmol, 0.02 
equiv) at 0 °C. The reaction mixture was allowed to warm and stirred for 3 h at room 
temperature, before it was quenched with HCl (1N, 7 mL), and extracted with ethyl acetate (2 
× 10 mL). The combined organic extracts were washed with saturated Na2CO3 solution (2 × 7 
mL), saturated NaCl solution (1 × 7 ml), dried with anhydrous Na2SO4, filtered, and 
concentrated in vacuo to give 1.60 g (99%) of tosylate 4-28 as a yellow oil. The crude product 
was used in next step without further purification. Rf = 0.3 (petroleum ether/ethyl acetate, 9:1); 
1H NMR (400 MHz, CDCl3):  = 0.00 (s, 6H, (CH3)2Si), 0.82 (d, J = 6.8 Hz, 3H, 4-CH3), 0.86 
(s, 9H, (CH3)2Si), 0.90 (d, J = 6.8 Hz, 3H, 2-CH3), 0.88-0.93 (m, 1H, 3-H), 1.29-1.40 (m, 1H, 
3-H), 1.50-1.64 (m, 1H, 4-H), 1.82-1.95 (m, 1H, 2-H), 2.44 (s, 3H, p-CH3), 3.29 (dd, J = 6.1, 
9.8.Hz, 1H, 1-H), 3.36 (dd, J = 5.6, 9.8 Hz, 1H, 1-H), 3.73 (dd, J = 7.1, 9.3 Hz, 1H, 5-H), 3.89 
(dd, J = 5.0, 9.3 Hz, 1H, 5-H), 7.33 (d, J = 8.6 Hz, 2H, m-H), 7.77 (d, J = 8.3 Hz, 2H, o-H); 13C 
NMR (100 MHz, CDCl3):  = –5.5 ((CH3)2Si), 17.36, 17.40 (4-CH3, 2-CH3), 18.2 ((CH3)2CSi), 
21.6 (p-CH3), 25.8 ((CH3)3CSi), 30.4 (C-2), 32.8 (C-3), 36.8 (C-4), 67.8 (C-5), 75.1 (C-1), 
127.0 (Ar), 127.9 (Ar), 129.8 (Ar), 130.2 (Ar), 133.1 (Ar). 
(3S,5R)-6-{(tert-Butyldimethylsilyl)oxy}-3,5-dimethylhexanenitrile (4-29). 
 
 
To a solution of tosylate 4-28 (1.54 g, 3.84 mmol) in dry DMSO (12 mL) were added KCN 
(0.626 g, 9.61 mmol, 2.5 equiv) and a small amount of potassium iodide (catalytic amount, 
about 10 mg) at room temperature. The reaction mixture was then stirred for 2 h at 85 °C, before 
it was cooled to 0 °C, diluted with water (10 mL), and extracted with ethyl acetate (2 × 10 mL). 
The combined organic layers were washed with water (2 × 10 mL) and saturated NaCl solution 
(10 mL), dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product 
was purified by flash chromatography (ethyl acetate/petroleum ether, 1:20) to afford pure nitrile 
4-29 (0.90 g, 98%) as a colorless oil. Rf = 0.2 (petroleum ether/ethyl acetate, 9:1); []22D = 
+10.8 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 0.87 (s, 9H, 
(CH3)2Si) (d, J = 6.7 Hz, 3H, 5-CH3), 1.07 (d, J = 6.7 Hz, 3H, 3-CH3), 1.01-1.13 (m, 1H, 4-H), 
1.41-1.49 (m, 1H, 4-H), 1.56-1.69 (m, 1H, 3-H), 1.89-2.03 (m, 1H, 5-H), 2.16 (dd, J = 7.1, 16.7 
Hz, 1H, 2-H), 2.31 (dd, J = 5.0, 16.7 Hz, 1H, 2-H), 3.34-3.43 (m, 2H, 6-H); 13C NMR (100 
MHz, CDCl3):  = –5.5 ((CH3)2Si), 17.1 (5-CH3), 18.2 ((CH3)2CSi), 20.1 (3-CH3), 24.3 (C-3), 
25.8 ((CH3)3CSi), 28.0 (C-2), 33.1 (C-5), 40.0 (C-4), 67.9 (C-6), 118.7 (CN); HRMS (ESI) : 
calcd for C14H29NOSi [M+Na]+ 278.19106, found 278.19131. 
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(3S,5R)-6-{(tert-Butyldimethylsilyl)oxy}-3,5-dimethylhexanal (4-30) 
 
 
To a solution of nitrile 4-29 (0.825 g, 3.23 mmol) in CH2Cl2 (35 mL) at –80 °C was added 
DIBAL-H in hexane (1m, 6.5 mL, 6.46 mmol, 2.0 equiv) in a dropwise fashion. After stirring 
the mixture at –80 °C for 3.5 h, excess DIBAL-H was quenched with ethyl acetate (2 mL) 
before saturated NH4Cl solution (30 mL) was added. The mixture was transferred to a 
separation funnel and both layers were separated. The aqueous layer was extracted with ethyl 
acetate (2 × 10 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude aldehyde was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:20) to give pure aldehyde 4-30 (0.705 g, 85%) as colorless oil. Rf = 
0.4 (petroleum ether/ethyl acetate, 20:1); []22D = +0.5 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, 
CDCl3):  = 0.01 (s, 6H, (CH3)2Si), 0.86 (s, 9H, (CH3)2Si) (d, J = 6.7 Hz, 3H, 5-CH3), 0.95 (d, 
J = 6.7 Hz, 3H, 3-CH3), 0.97-1.04 (m, 1H, 4-H), 1.31-1.41 (m, 1H, 4-H), 1.57-1.68 (m, 1H, 5-
H), 2.10-2.19 (m, 2H, 3-H, 2-H), 2.32-2.42 (m, 1H, 2-H), 3.35 (dd, J = 6.1, 9.6 Hz, 1H, 6-H), 
3.41 (dd, J = 5.6, 9.6 Hz, 1H, 6-H), 9.73 (t, J = 2.0 Hz, 1H, 1-H); 13C NMR (100 MHz, CDCl3): 
 = –5.4 ((CH3)2Si), 17.3 (5-CH3), 18.3 ((CH3)2CSi), 20.7 (3-CH3), 25.7 (C-3), 25.9 
((CH3)3CSi), 33.1 (C-5), 40.9 (C-4), 50.8 (C-2), 67.98 (C-6) 203.0 (CHO); HRMS (ESI): calcd 
for C14H30O2Si [M+Na]+ 313.21694, found 313.21723. 
(4S,6S,8R)-9-((tert-Butyldimethylsilyl)oxy)-6,8-dimethylnon-1-en-4-ol (4-32) 
 
 
Preparation of Ipc2BOMe. (a) To a 0 °C cooled solution BH3·SMe2 (50 mmol) and THF (18 
mL) in a 250 mL flask was added (+)--pinene (18.3 mL, 115 mmol, []23D –48.1° (neat), 
91.3% ee) dropwise. After the mixture was stirred at 0 °C for 1 h (Ipc2BH separated as white 
solid during this time), the flask was kept in a cold refrigerater at 0 °C for 2 d. The solid was 
filtered and washed with cold Et2O, and then dried. The crystalline solid was dissolved in THF 
(18 mL) and treated with methanol (4.0 mL, 100 mmol) at 0 °C. After complete addition of 
methanol, the reaction mixture was warmed to rt and stirred at rt for 1 h. The solvents were 
removed under vacuum and the crude product was stored under nitrogen at –4 °C. Pure 
Ipc2BOMe became a transparent solid. 
Preparation of Ipc2B(allyl). (b) Allylmagnesium bromide in ether (1.6 mL 3M, 4.87 mmol, 
1.2 equiv) was added dropwise to a well-stirred solution of B-methoxybis(2-
isocamphanyl)borane (1.60 g, 5.07 mmol) at 0 °C. After complete addition, the reaction mixture 
was vigorously stirred for 1 h at rt, and the solvents were pumped off under vacuum. The residue 
was extracted with pentane (2 × 5 mL) under nitrogen, and the extract was kept without 
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disturbing to settle down the salt MgBr(OMe). The clear supernatant pentane extract (free from 
the magnesium salts) was transferred into another flask using a syringe. 
Allylation of aldehyde 4-30. (c). The Ipc2Ballyl in Et2O (10 mL) was cooled at –80 °C and 
aldehyde 4-30 (1.0 g, 3.9 mmol) in Et2O was added along the wall of the flask. After complete 
addition, the reaction mixture was stirred for 2 h at –80 °C, and then methanol (0.4 mL) was 
added. The reaction mixture was brought to rt within 1 h, and treated with 3N NaOH (3 mL) 
and 60% H2O2 (30 mL) followed by stirring of the resulting mixture overnight. The mixture 
was extracted with Et2O (2 × 10 mL). The combined organic layers were washed with saturated 
aqueous NaCl solution (10 mL), dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The crude material was purified by flash chromatography (ethyl acetate/petroleum ether, 
1:9) to afford pure alcohol 4-32 (160 mg) and aldehyde (345 mg unreacted) as colorless oil. Rf 
= 0.2 (petroleum ether/diethyl ether, 20:1); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, 
(CH3)2Si), 0.88 (s, 9H, (CH3)3CSi), 0.83-0.95 (m, 6H, 7-CH3, 5-CH3), 1.05-1.21 (m, 1H, 7-H), 
1.24-1.51 (m, 3H, 5H, 6-H, 7-H), 1.61-1.81 (m, 3H, 5-H, OH), 2.05-2.18 (m, 1H, 3-H), 2.20-
2.32 (m, 1H, 3-H), 3.27-3.38 (m, 1H, 9-H), 3.40-3.47 (m, 1H, 9-H), 3.69-3.80 (m, 1H, 4-H), 
5.07-5.10 (m, 1H, 1-H), 5.11-5.14 (m, 1H, 1-H), 5.75-5.88 (m, 1H, 2-H); 13C NMR (100 MHz, 
CDCl3):  = –5.4 (CH3)2Si), 17.4, 17.9, 18.3, 20.1, 21.1, 25.9, 26.6, 27.2, 33.0, 40.8, 41.8, 41.9, 
42.8, 44.0, 44.4, 67.9, 68.2, 68.3, 68.7, 118.0, 134.9. 
(5S,7R)-8-{(tert-Butyldimethylsilyl)oxy}-5,7-dimethyloct-1-yn-3-ol (4-31) 
 
 
A solution of trimethylsilylacetylene (0.463 mL, 3.25 mmol, 1.2 equiv) in dry THF (9 mL), 
cooled to –78 °C, was treated dropwise with n-BuLi (2.5m in hexane, 1.3 mL, 3.25 mmol, 1.2 
equiv). The reaction mixture was stirred for 30 min at –78 °C, before a solution of aldehyde 4-
30 (0.70 g, 2.71 mmol) in THF (15 mL) was added dropwise via cannula. After 3 h of stirring 
at –78 °C, the reaction mixture was quenched with saturated NH4Cl (10 mL) and the cooling 
system was removed. The mixture was extracted with Et2O (2 × 20 mL). The combined organic 
layers were washed with saturated aqueous NaCl solution (20 mL), dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:9) to afford pure alkynol 4-31 (0.810 g, 84%) 
as colorless oil (mixture of diastereomers at C3).  
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(5S,7R)-8-{(tert-Butyldimethylsilyl)oxy}-5,7-dimethyl-1-(trimethylsilyl)oct-1-yn-3-one (4-
33) 
 
 
To a solution of alkynol 4-31 (0.810 g, 2.27 mmol) in CH2Cl2 (20 mL) at 0 °C was added DMP 
(0.963 g, 2.27 mmol, 1.0 equiv) and NaHCO3 (0.191 g, 2.27 mmol, 1.0 equiv). After addition, 
the cooling bath was removed and the mixture stirred for 4 h at room temperature. Most of the 
solvent was removed in vacuo and the crude ketone purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:20) to give pure alkynone 4-33 (0.80 g, 99%) as colorless oil. []22D 
= –8.4 (c = 0.5, CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.01 (s, 6H, (CH3)2Si), 0.21 (s, 9H, 
TMS), 0.87 (s, 9H, (CH3)3CSi), (d, J = 6.7 Hz, 3H, 7-CH3), 0.92 (d, J = 6.3 Hz, 3H, 5-CH3), 
0.98 (td, J = 6.3, 12.9 Hz, 1H, 6-H), 1.31 (td, J = 6.3, 13.6 Hz, 1H, 6-H), 1.57-1.69 (m, 1H, 7-
H), 2.11-2.21 (m, 1H, 5-H), 2.25 (dd, J = 9.0, 15.0 Hz, 1H, 4-H), 2.54 (dd, J = 4.0, 15.0 Hz, 
1H, 4-H), 3.32 (dd, J = 6.6, 9.8 Hz, 1H, 8-H), 3.42 (dd, J = 5.3, 9.8 Hz, 1H, 8-H); 13C NMR 
(100 MHz, CDCl3):  = –5.4 (CH3)2Si), 0.80 (TMS), 17.2 (7-CH3), 18.3 ((CH3)2CSi), 20.6 (5-
CH3), 25.9 ((CH3)3CSi), 27.2 (C-5), 33.2 (C-7), 40.7 (C-6), 52.5 (C-4), 68.1 (C-8), 97.3 (C-1), 
102.3 (C-2), 187.7 (C=O). 
(3R,5S,7R)-8-{(tert-Butyldimethylsilyl)oxy}-5,7-dimethyl-1-(trimethylsilyl)oct-1-yn-3-ol 
[((3R)-4-44] 
 
 
To a solution of alkynone 4-33 (0.266 g, 0.75 mmol) in isopropanol (25 mL) was added 
dropwise RuCl[R,R]-NTsCH(Ph)CH(Ph)NH2(6-cymene) (R,R)-4-40 (0.016 g, 10 mol%) in 
CH2Cl2 (0.5 mL) at room temperature. After stirring of the mixture for 50 min at this 
temperature, most of the isopropanol was removed in vacuo. The crude propargylic alcohol was 
purified by flash chromatography (ethyl acetate/petroleum ether, 1:9) to afford pure alkynol 
(3R)-4-44 (0.250 g, 93%) as colorless oil. []22D = +10.9 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, 
CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 0.21 (s, 9H, TMS), 0.88 (s, 9H, (CH3)3CSi), (d, J = 7.6 Hz, 
3H, 7-CH3), 0.92 (d, J = 6.6 Hz, 3H, 5-CH3), 0.92-0.95 (m, 1H, 6-CH), 1.27-1.44 (m, 2H, 6-H, 
7-H), 1.68-1.88 (m, 4H, 5-H, 4-H), 3.30 (dd, J = 6.8, 9.6 Hz, 1H, 8-H), 3.45 (dd, J = 5.0, 9.6 
Hz, 1H, 8-H), 4.40 (dd, J = 5.0, 8.0 Hz, 1H, 3-H); 13C NMR (100 MHz, CDCl3):  = –5.4 
(CH3)2Si), –0.14 (TMS), 17.5 (7-CH3), 18.3 ((CH3)2CSi), 20.3 (5-CH3), 25.9 ((CH3)3CSi), 26.6 
(C-5), 33.1 (C-7), 41.2 (C-6), 45.0 (C-4), 60.9 (C-3), 68.2 (C-8), 88.9 (C-1), 107.4 (C-2); HRMS 
(ESI): calcd for C19H40O2Si [M+Na]+ 379.24590, found 379.24597. 
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(5R,7S,9R)-7,9,12,12,13,13-Hexamethyl-5-((trimethylsilyl)ethynyl)-2,4,11-trioxa-12-
silatetradecane (4-45) 
 
 
To a solution of alcohol (3R)-4-44 (0.210 g, 0.59 mmol) in CH2Cl2 (5 mL) was added at 0 °C 
N-N-diisopropylethylamin (1.1 mL, 5.9 mmol, 10 equiv) and tetrabutylammonium iodide (22 
mg, 0.059 mmol, 0.1 equiv), followed by MOMCl (240 L, 2.94 mmol, 5 equiv). After stirring 
of the mixture overnight, saturated NaHCO3 solution (5 mL) was added. The aqueous layer was 
extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were washed with saturated 
NaHCO3 solution (10 mL), saturated NaCl solution (10 mL), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude MOM-ether was purified by flash 
chromatography (Et2O/petroleum ether, 1:20) to give product 4-45 (240 mg, 100%) as colorless 
oil. Rf = 0.7 (petroleum ether/diethyl ether, 20:1); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, 
(CH3)2Si), 0.14 (s, 9H, TMS), 0.88 (s, 9H, (CH3)3CSi), 0.84-0.97 (m, 6H, 5-CH3, 7-CH3, 6-H), 
1.22-1.44 (m, 2H, 6-H, 5-H), 1.62-1.86 (m, 3H, 4-H, 7-H), 3.29 (dd, J = 7.1, 9.6 Hz, 1H, 8-H), 
3.36 (s, 3H, OMe), 3.45 (dd, J = 5.3, 9.6 Hz, 1H, 8-H), 4.37 (dd, J = 4.0, 9.1 Hz, 1H, 3-H), 4.56 
(d, J = 6.6 Hz, 1H, OCH2O), 4.94 (d, J = 6.6 Hz, 1H, OCH2O); 13C NMR (100 MHz, CDCl3): 
 = –5.4 (CH3)2Si),–0.1 (TMS), 17.5 (7-CH3), 18.3 ((CH3)2CSi, 20.1 (5-CH3), 26.0 ((CH3)3CSi) 
26.6 (C-5), 33.1 (C-7), 41.3 (C-6), 45.9 (C-4), 55-7 (OMe), 64.2 (C-3), 68.3 (C-8), 89.8 (C-1), 
94.1 (OCH2O), 104.9 (C-2). 
(3R,5S,7R)-3,8-Di{(tert-butyldimethylsilyl)oxy}-5,7-dimethyl-1-(trimethylsilyl)-1-octyne 
(4-46) 
 
 
To a solution of alcohol (3R)-4-44 (0.840 g, 2.35 mmol) in CH2Cl2 (20 mL) was added at 0 °C 
2,6-lutidine (0.615 mL, 5.17 mmol, 2.2 equiv), followed by TBSOTf (0.69 mL, 2.60 mmol, 1.1 
equiv). After stirring of the mixture for 2.5 h at 0 °C, saturated NaHCO3 solution (10 mL) was 
added. The aqueous layer was extracted with CH2Cl2 (3 × 15 mL). The combined organic layers 
were washed successively with saturated NaHSO4 solution (2 × 10 mL), saturated NaHCO3 
solution (20 mL), saturated NaCl solution (20 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude silyl ether was purified by flash chromatography (petroleum 
ether/diethyl ether, 50:1) to give product 4-46 (1.100 g, 99%) as a colorless oil. Rf = 0.7 
(petroleum ether/diethyl ether, 49:1); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 
0.10 (s, 6H, (CH3)2Si), 0.13 (s, 6H, (CH3)2Si), 0.14 (s, 9H, TMS), 0.86 (d, J = 5.8 Hz, 6H, 5-
CH3, 7-CH3), 0.88 (s, 9H, (CH3)3CSi), 0.89 (s, 9H, (CH3)3CSi), 0.84-0.91 (m, 1H, 6-H), 1.22-
1.32 (m, 2H, 6-H, 5-H), 1.62-1.86 (m, 3H, 4-H, 7-H), 3.29 (dd, J = 7.1, 9.6 Hz, 1H, 8-H), 3.45 
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(dd, J = 5.3, 9.6 Hz, 1H, 8-H), 4.39 (dd, J = 4.0, 9.1 Hz, 1H, 3-H); 13C NMR (100 MHz, CDCl3): 
 = –5.5 (CH3)2Si), –5.0 (CH3)2Si), –4.3 (CH3)2Si), –0.16 (TMS), 17.2 (7-CH3), 18.2 
((CH3)2CSi), 18.4 ((CH3)2CSi), 20.0 (5-CH3), 25.7, 25.8 ((CH3)3CSi), 26.0 ((CH3)3CSi) 26.2 
(C-5), 33.1 (C-7), 41.2 (C-6), 45.5 (C-4), 61.2 (C-3), 68.4 (C-8), 88.1 (C-1), 108.4 (C-2); HRMS 
(ESI): calcd for C25H54O2Si3 [M+Na]+ 493.33238, found 493.33259. 
(5R,7S,9R)-5-Ethynyl-7,9,12,12,13,13-hexamethyl-2,4,11-trioxa-12-silatetradecane (4-47) 
 
 
A solution of alkyne 4-45 (210 mg, 0.52 mmol) in methanol (2.5 mL) was treated with dry 
K2CO3 (85 mg, 0.62 mmol, 1.2 equiv) and the mixture was stirred at room temperature for 3 h. 
Most of the methanol was removed in vacuo before the residue was re-dissolved in Et2O (10 
mL) and the solution was washed with water (10 mL). The aqueous layer was extracted with 
Et2O (2 × 10 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude alkyne was purified by flash chromatography 
(Et2O/petroleum ether, 20:1) to give product 4-47 (130 mg, 76%) as colorless oil. Rf = 0.5 
(petroleum ether/diethyl ether, 25:1); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 
0.88 (s, 9H, (CH3)3CSi), 0.84-0.97 (m, 6H, 5-CH3, 7-CH3, 6-H), 1.22-1.46 (m, 2H, 6-H, 5-H), 
1.62-1.88 (m, 3H, 4-H, 7-H),2.38 (d, J = 2.0 Hz, 1H, 1-H) 3.31 (dd, J = 6.6, 9.6 Hz, 1H, 8-H), 
3.37 (s, 3H, OMe), 3.45 (dd, J = 5.3, 9.6 Hz, 1H, 8-H), 4.36-4.42 (m, 1H, 3-H), 4.57 (d, J = 6.8 
Hz, 1H, OCH2O), 4.94 (d, J = 6.8 Hz, 1H, OCH2O); 13C NMR (100 MHz, CDCl3):  = –5.4 
(CH3)2Si), 17.5 (7-CH3), 18.3 ((CH3)2CSi, 20.1 (5-CH3), 25.9 ((CH3)3CSi) 26.6 (C-5), 33.1 (C-
7), 41.2 (C-6), 43.0 (C-4), 55-7 (OMe), 63.6 (C-3), 68.2 (C-8), 73.1 (C-1), 83.1(C-2). 94.1 
(OCH2O). 
(3R,5S,7R)-3,8-Di{(tert-butyldimethylsilyl)oxy}-5,7-dimethyl-1-octyne (4-48) 
 
 
A solution of alkyne 4-46 (3.150 g, 6.69 mmol) in methanol (13 mL) was treated with dry 
K2CO3 (1.11 g, 8.03 mmol, 1.2 equiv) and the mixture was stirred at room temperature for 3 h. 
Most of the methanol was removed in vacuo before the residue was re-dissolved in Et2O (30 
mL) and the solution was washed with water (30 mL). The aqueous layer was extracted with 
Et2O (2 × 20 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo. The crude alkyne was purified by flash chromatography 
(Et2O/petroleum ether, 50:1) to give product 4-48 (2.445 g, 92%) as a colorless oil. Rf = 0.5 
(petroleum ether/diethyl ether, 49:1); []22D = +110.1 (c = 1.7, CH2Cl2); 1H NMR (400 MHz, 
CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 0.10 (s, 3H, (CH3)2Si), 0.14 (s, 3H, (CH3)2Si) 0.88 (s, 9H, 
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(CH3)3CSi), 0.89 (s, 9H, (CH3)3CSi), 0.84-0.96 (m, 7H, 7-CH3, 5-CH3, 6-H), 1.22-1.36 (m, 2H, 
6-H, 5-H), 1.63-1.72 (m, 1H, 7-H), 1.73-1.83 (m, 2H, 4-H), 2.35 (d, J = 2.3 Hz, 1H, 1-H), 3.31 
(dd, J = 6.8, 9.8 Hz, 1H, 8-H), 3.44 (dd, J = 5.3, 9.8 Hz, 1H, 8-H), 4.39 (ddd, J = 2.0, 4.3, 8.8 
Hz, 1H, 3-H); 13C NMR (100 MHz, CDCl3):  = –5.4 (CH3)2Si), –5.2 (CH3)2Si), –4.4 
((CH3)2Si), 17.3 (7-CH3), 18.1 ((CH3)2CSi), 18.4 ((CH3)2CSi), 20.1 (5-CH3), 25.7 ((CH3)3CSi), 
26.0 ((CH3)3CSi), 26.2 (C-5), 33.1 (C-7), 41.2 (C-6), 45.0 (C-4), 60.6 (C-3), 68.2 (C-8), 71.8 
(C-1), 86.2 (C-2); HRMS (ESI): calcd for C22H46O2Si2 [M+Na]+ 421.29285, found 421.29314. 
(3R,5S,7R)-3,8-Di{(tert-butyldimethylsilyl)oxy}-5,7-dimethyl-1-octene (4-49) 
 
 
To a solution of alkyne 4-48 (2.445 g, 6.13 mmol) in a mixture of acetone/cyclohexene (65 mL, 
50:15) was added quinoline (7.2 mL, 61.3 mmol, 10 equiv). This solution was flushed with N2 
and treated with (5% Pd) palladium/calcium carbonate (0.526 g, 0.24 mmol, 4 mol%) before 
hydrogen gas was bubbled through the solution via a hydrogen balloon through an inlet needle 
and keeping the thin outlet needle free. The reaction progress was monitored by TLC 
(petroleum ether/diethyl ether, 49:1). After completion of the reaction (after about 30 min), the 
catalyst was filtered off and the filtrate concentrated in vacuo. The residue was re-dissolved in 
Et2O (20 mL) and this solution washed successively with saturated NaHSO4 solution (2 × 10 
mL), saturated NaHCO3 solution (10 mL), saturated NaCl solution (10 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude alkene was purified by flash 
chromatography (Et2O/petroleum ether, 50:1) to give alkene 4-49 (2.40 g, 98%) as a colorless 
oil. Rf = 0.5 (petroleum ether/diethyl ether, 49:1); []22D = +2.8 (c = 1.0, CH2Cl2); 1H NMR 
(400 MHz, CDCl3):  = 0.01 (s, 3H, (CH3)2Si), 0.02 (s, 6H, (CH3)2Si), 0.40 (s, 3H, (CH3)2Si), 
0.88 (s, 18H, (CH3)3CSi), 0.85-0.90 (m, 6H, 7-CH3, 5-CH3), 0.90-0.95 (m, 1H, 6-H), 1.00-1.09 
(m, 1H, 6-H), 1.21-1.29 (m, 1H, 7-H), 1.49-1.58 (m, 1H, 5-H), 1.63-1.75 (m, 2H, 4-H), 3.28 
(dd, J = 6.8, 9.6 Hz, 1H, 8-H), 3.45 (dd, J = 5.3, 9.6 Hz, 1H, 8-H), 4.11-4.18 (m, 1H, 3-H), 4.98 
(ddd, J = 1.0, 1.8, 10.4 Hz, 1H, 1-H), 5.11 (ddd, J = 1.0, 1.5, 16.9 Hz, 1H, 1-H), 5.70-5.83 (m, 
1H, 2-H); 13C NMR (100 MHz, CDCl3):  = –5.3 (CH3)2Si), –4.9 ((CH3)2Si), –4.1 ((CH3)2Si), 
17.4 (7-CH3), 18.2 ((CH3)2CSi), 18.4 ((CH3)2CSi), 20.4 (5-CH3), 25.9 ((CH3)3CSi), 26.0 
((CH3)3CSi), 26.1 (C-5), 33.1 (C-7), 41.2 (C-6), 45.0 (C-4), 68.4 (C-8), 71.9 (C-3), 113.2 (C-
1), 142.6 (C-2); HRMS (ESI): calcd for C22H48O2Si2 [M+Na]+ 423.30850, found 423.30881. 
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(3R,5S,7R)-8-((tert-Butyldimethylsilyl)oxy)-3-(methoxymethoxy)-5,7-dimethyloctan-1-ol 
(4-50) 
 
 
To a solution of BH3·SMe2 complex (22 L, 0.37 mmol, 1.1 equiv) in THF (2 mL) was added 
cyclohexene (76 L, 00.74 mmol, 2.2 equiv) dropwise at 0 °C followed by stirring of the 
mixture for 30 min. Then the ice bath was removed and the mixture was allowed to stir at room 
temperature for 1 h. It was re-cooled to 0 °C before alkyne 4-47 (110 mg, 0.33 mmol, 1 equiv) 
in THF (1 mL) was added dropwise. After 3 h of stirring at 0 °C, NaOH (3N, 6 mL) and H2O2 
solution (30%, 6 mL) were added and the mixture stirred for 3 h. Thereafter, the mixture was 
extracted with Et2O (2 × 5 mL). The combined organic layers were washed with saturated NaCl 
solution (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue 
was purified by flash chromatography (ethyl acetate/petroleum ether, 1:5) to give alcohol 4-50 
(25 mg, 21%) as colorless oil. Rf = 0.3 (petroleum ether/ethyl acetate, 2:1); 1H NMR (400 MHz, 
CDCl3):  = 0.01 (s, 6H, (CH3)2Si), 0.88 (s, 9H, (CH3)3CSi), 0.84-0.97 (m, 6H, 5-CH3, 7-CH3, 
6-H), 1.22-1.38 (m, 2H, 6-H, 5-H), 1.48-1.90 (m, 6H, 4-H, 7-H), 3.29 (dd, J = 6.6, 9.6 Hz, 1H, 
8-H), 3.39 (s, 3H, OMe), 3.45 (dd, J = 5.3, 9.6 Hz, 1H, 8-H), 3.65-3.73 (m, 1H, 3-H), 3.76-3.89 
(m, 2H, 1-H ), 4.85 (d, J = 1.5 Hz, 2H, OCH2O); 13C NMR (100 MHz, CDCl3):  = –5.4 
(CH3)2Si), 17.6 (7-CH3), 18.3 ((CH3)2CSi, 20.6 (5-CH3), 25.9 ((CH3)3CSi) 26.7(C-5), 33.0 (C-
7), 37.4 (C-2), 41.4 (C-6), 42.5 (C-4), 55.8 (OMe), 59.7 (C-1), 68.1 (C-8), 74.7 (C-3), 96.2 
(OCH2O). 
(3R,5S,7R)-3,8-Bis{(tert-butyldimethylsilyl)oxy}-5,7-dimethyloctan-1-ol (4-51) 
 
 
To a solution of BH3·SMe2 complex (2M in THF, 36 mL, 18.00 mmol, 3 equiv) in THF (50 
mL) was added cyclohexene (3.65 mL, 36.00 mmol, 6 equiv) dropwise at 0 °C followed by 
stirring of the mixture for 30 min. Then the ice bath was removed and the mixture was allowed 
to stir at room temperature for 1 h. It was re-cooled to 0 °C before alkene 4-49 (2.31 g, 5.76 
mmol, 1 equiv) in THF (30 mL) was added dropwise. After 3 h of stirring at 0 °C, NaOH (3N, 
60 mL) and H2O2 solution (30%, 60 mL) were added and the mixture stirred for 3 h. Thereafter, 
the mixture was extracted with Et2O (2 × 50 mL). The combined organic layers were washed 
with saturated NaCl solution (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated 
in vacuo. The residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:9) 
to give alcohol 4-51 (2.20 g, 91%) as a colorless oil. Rf = 0.3 (petroleum ether/ethyl acetate, 
9:1); []22D = –2.0 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 
0.07 (s, 6H, (CH3)2Si), 0.09 (s, 3H, (CH3)2Si), 0.88 (s, 18H, (CH3)3CSi), 0.85-0.91 (m, 6H, 7-
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CH3, 5-CH3, 6-H), 1.14-1.22 (m, 2H, 6-H), 1.26-1.36 (m, 1H, 5-H), 1.49-1.72 (m, 4H, 2-H, 7-
H, 4-H), 1.89-1.91 (m, 1H, 2-H), 3.22 (dd, J = 6.5, 9.8 Hz, 1H, 8-H), 3.43 (dd, J = 5.3, 9.8 Hz, 
1H, 8-H), 3.65-3.72 (m, 1H, 3-H), 3.81-3.89 (m, 1H, 1-H), 3.96-4.04 (m, 1H, 1-H); 13C NMR 
(100 MHz, CDCl3):  = –5.4 (CH3)2Si), –4.5 ((CH3)2Si), –4.4 ((CH3)2Si), 17.7 (7-CH3), 17.9 
((CH3)2CSi), 18.3 ((CH3)2CSi), 20.7 (5-CH3), 25.8 ((CH3)3CSi), 25.9 ((CH3)3CSi), 26.6 (C-5), 
33.0 (C-7), 38.5 (C-6), 44.2 (C-4), 44.2 (C-2), 60.1 (C-1), 67.9 (C-8), 69.8 (C-3); HRMS (ESI): 
calcd for C22H50O3Si [M+Na]+ 441.31907, found 441.31939. 
(3R,5S,7R)-8-((tert-Butyldimethylsilyl)oxy)-3-(methoxymethoxy)-5,7-dimethyloctanal (4-
52) 
 
 
To a solution of alcohol 4-50 (20 mg, 0.57 mmol) in CH2Cl2 (2 mL) at 0 °C was added DMP 
(48 mg, 0.114 mmol, 2.0 equiv) and K2CO3 (15 mg, 0.114 mmol, 2.0 equiv). After addition, 
the cooling bath was removed and the mixture stirred for 2 h at room temperature. Most of the 
solvent was removed in vacuo and the crude aldehyde purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:10) to give pure aldehyde 4-52 (15 mg, 98%) as colorless oil. Rf = 
0.5 (petroleum ether/ethyl acetate, 5:1); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 
0.87 (s, 9H, (CH3)3CSi), 0.84-0.97 (m, 7H, 5-CH3, 7-CH3, 6-H), 1.23-1.35 (m, 2H, 6-H, 5-H), 
1.62-1.78 (m, 3H, 4-H, 7-H), 2.15-2.67 (m, 2H, 2-H), 3.34 (s, 3H, OMe), 3.28-3.48 (m, 2H, 8-
H), 4.10-4.20 (m, 1H, 3-H), 4.65 (d, J = 1.3 Hz, 2H, OCH2O), 9.78 (dd, J = 2.0, 2.8 Hz, 1-H); 
13C NMR (100 MHz, CDCl3):  = –5.4 (CH3)2Si), 17.5 (7-CH3), 18.3 (CH3)2CSi, 20.2 (5-CH3), 
25.9 ((CH3)3CSi) 26.6(C-5), 33.0 (C-7), 41.4 (C-6), 42.8 (C-4), 49.6 (C-2), 55.7 (OMe), 68.1 
(C-3), 71.5 (C-8), 96.1 (OCH2O), 200.2 (CHO). 
(3R,5S,7R)-3,8-Bis{(tert-butyldimethylsilyl)oxy}-5,7-dimethyloctan-1-al (4-53) 
 
 
To a solution of oxalyl chloride (0.67 mL, 7.83 mmol, 1.6 equiv) in CH2Cl2 (30 mL) at –80 °C 
was added DMSO (1.11 mL, 15.65 mmol, 3.2 equiv) dropwise. The resulting mixture was 
stirred for 15 min before alcohol 4-51 (2.050 g, 4.89 mmol) in CH2Cl2 (8 mL) was added 
dropwise within 15 min. After stirring the mixture for 1 h at –80 °C, Et3N (4.23 mL, 29.34 
mmol, 6 equiv) was added slowly. Then the reaction mixture was allowed to warm to room 
temperature. For work-up water (20 mL) was added, the layers were separated and the aqueous 
layer was extracted with CH2Cl2 (2 × 20 mL). The combined organic layers were washed with 
saturated NaCl solution, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:20) to give 
aldehyde 4-53 (1.98 g, 98%) as a colorless oil. Rf = 0.6 (petroleum ether/ethyl acetate, 9:1); 
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[]22D = +15.9 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.01 (s, 6H, (CH3)2Si), 0.05 
(s, 3H, (CH3)2Si), 0.60 (s, 3H, (CH3)2Si), 0.86 (s, 9H, (CH3)3CSi), 0.87 (s, 9H, (CH3)3CSi), 0.86 
(d, J = 6.6 Hz, 3H, 7-CH3), 0.88 (d, J = 6.6 Hz, 3H, 5-CH3), 1.08-1.17 (m, 1H, 6-H), 1.19-1.32 
(m, 2H, 6-H, 5-H), 1.54-1.71 (m, 3H, 4-H, 7-H), 2.47 (ddd, J = 3.0, 5.3, 15.7 Hz, 1H, 2-H), 
2.54 (ddd, J = 3.0, 5.6, 15.7 Hz, 1H, 2-H), 3.31 (dd, J = 6.6, 9.6 Hz, 1H, 8-H), 3.42 (dd, J = 5.3, 
9.6 Hz, 1H, 8-H), 4.20-4.27 (m, 1H, 3-H), 9.80 (t, J = 3.0 Hz, 1H, CHO); 13C NMR (100 MHz, 
CDCl3):  = –5.4 ((CH3)2Si), –5.4 ((CH3)2Si), –4.5 ((CH3)2Si), –4.4 ((CH3)2Si), 17.5 (7-CH3), 
17.9 ((CH3)2CSi), 18.3 ((CH3)2CSi), 20.3 (5-CH3), 25.8 ((CH3)3CSi), 25.9 ((CH3)3CSi), 26.4 
(C-5), 33.0 (C-7), 41.3 (C-6), 45.3 (C-4), 51.8 (C-2), 66.1 (C-3), 68.0 (C-8), 200.2 (CHO); 
HRMS (ESI): calcd for C22H48O3Si2 [M+Na]+ 471.32963, found 471.32998. 
S-Ethyl (3R,5S,7R)-3,10-bis{(tert-butyldimethylsilyl)oxy}-7,9-dimethyldec-2-enethioate 
(3-5) 
 
 
To a solution of aldehyde 4-53 (1.94 g, 4.65 mmol) in CH2Cl2 (50 mL) was added S-ethyl 2-
(triphenyl-5-phosphanylidene) ethanethioate (4-54) (2.04 g, 5.58 mmol, 1.2 equiv). The 
resulting solution was refluxed for 2 d, and then cooled to room temperature before it was 
concentrated in vacuo. The residue was purified by flash chromatography (Et2O/petroleum 
ether, 1:50) to give enoate 3-5 (2.08 g, 89%) as a yellow oil. Rf = 0.5 (petroleum ether/diethyl 
ether, 40:1); []22D = +22.5 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, 
(CH3)2Si), 0.04 (s, 3H, (CH3)2Si), 0.40 (s, 3H, (CH3)2Si), 0.85 (d, J = 6.8 Hz, 6H, 9-CH3, 7-
CH3), 0.87 (s, 9H, (CH3)3CSi), 0.88 (s, 9H, (CH3)3CSi), 0.88-0.93 (m, 1H, 8-H), 0.98-1.07 (m, 
1H, 8-H), 1.27 (t, J = 7.5 Hz, 3H, CH3CH2S), 1.20-1.32 (m, 1H, 6-H), 1.42-1.52 (m, 1H, 6-H), 
1.58-1.72 (m, 2H, 7-H, 9-H), 2.25-2.38 (m, 2H, 4-H), 2.93 (q, J = 7.5 Hz, 2H, CH3CH2S), 3.29 
(dd, J = 6.8, 9.8 Hz, 1H, 10-H), 3.43 (dd, J = 5.0, 9.8 Hz, 1H, 10-H), 3.81-3.90 (m, 1H, 5-H), 
6.09 (dt, J = 1.3, 15.7 Hz, 1H, 2-H), 6.81-6.92 (m, 1H, 3-H); 13C NMR (100 MHz, CDCl3):  = 
–5.4 ((CH3)2Si), –5.3 ((CH3)2Si), –4.6 ((CH3)2Si), –4.2 ((CH3)2Si), 14.6 (CH3CH2S), 17.4 (9-
CH3), 18.0 ((CH3)2CSi), 18.4 ((CH3)2CSi), 20.4 (7-CH3), 23.0 (CH3CH2S), 25.8 ((CH3)3CSi), 
26.0 ((CH3)3CSi), 26.2 (C-7), 33.0 (C-9), 41.1 (C-8), 41.5 (C-4), 44.7 (C-6), 68.2 (C-10), 69.0 
(C-5), 130.6 (C-2), 141.7 (C-3), 189.9 (C-1); HRMS (ESI): calcd for C26H54O3SSi2 [M+Na]+ 
525.32244, found 525.32296. 
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S-Ethyl (3R,5R,7S,9R)-5,10-Bis{(tert-butyldimethylsilyl)oxy}-3,7,9 
trimethyldecanethioate (3-4) 
 
 
To a solution of (R)-Tol-BINAP (0.045 g, 0.065 mmol, 0.016 equiv) in dry tert-butyl methyl 
ether (15 mL) was added copper iodide (0.008 g, 0.043 mmol, 0.010 equiv). This suspension 
was stirred for 1 h at room temperature turning into a dark yellow solution. The solution was 
cooled to –78 °C and treated dropwise with a solution of MeMgBr in Et2O (3m 7.4 mL, 26.22 
mmol, 6.6 equiv). The resulting mixture was stirred for 30 min before a solution of enoate 3-5 
(2.000 g, 3.98 mmol) in tert-butyl methyl ether (7 mL) was added dropwise using a syringe 
pump within 2 h. The mixture was stirred overnight during at –78 °C. The reaction was 
quenched with MeOH (1 mL) and saturated NH4Cl solution (10 mL), the cooling system was 
removed, and the layers were separated. The aqueous layer was extracted with Et2O (2 × 20 
mL). The combined organic layers were washed with saturated NaCl solution (20 mL), dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. Purification of the residue by flash 
chromatography (Et2O/petroleum ether, 1:50) afforded pure ester 3-4 (2.00 g, 97%) as colorless 
oil. Rf = 0.6 (petroleum ether/diethyl ether, 40:1); []22D = +23.1 (c = 1.0, CH2Cl2); 1H NMR 
(400 MHz, CDCl3):  = 0.02 (s, 12H, (CH3)2Si), 0.03 (s, 3H, (CH3)2Si), 0.05 (s, 3H, (CH3)2Si), 
0.87 (s, 9H, (CH3)3CSi), 0.88 (s, 9H, (CH3)3CSi), 0.83-0.90 (m, 7H, 7-CH3, 9-CH3, 8-H), 0.92 
(d, J = 6.6 Hz, 3H, 3-CH3), 1.03-1.12 (m, 1H, 8-H), 1.23 (t, J = 7.3 Hz, 3H, CH3CH2S), 1.18-
1.26 (m, 1H, 6-H), 1.29-1.46 (m, 3H, 6-H, 4-H), 1.62-1.73 (m, 2H, 9-H, 7-H), 2.01-2.16 (m, 
1H, 3-H), 2.33 (dd, J = 8.3, 14.6 Hz, 1H, 2-H), 2.55 (dd, J = 5.6, 14.6 Hz, 1H, 2-H), 2.86 (q, J 
= 7.3 Hz, 2H, CH3CH2S), 3.28 (dd, J = 7.0, 9.6 Hz, 1H, 10-H), 9.60 (dd, J = 5.1, 9.6 Hz, 1H, 
10-H), 3.71-3.80 (m, 1H, 5-H); 13C NMR (100 MHz, CDCl3):  = –5.3 ((CH3)2Si), –4.4 
((CH3)2Si), –4.0 ((CH3)2Si), 14.6 (CH3CH2S), 17.4 (9-CH3), 18.0 ((CH3)2CSi), 18.4 
((CH3)2CSi), 19.6 (7-CH3), 20.4 (3-CH3), 23.3 (CH3CH2S), 25.9 ((CH3)3CSi), 26.0 
((CH3)3CSi), 26.1 (C-7), 27.8 (C-3), 33.0 (C-9), 41.8 (C-8), 44.1 (C-4), 44.3 (C-6), 51.8 (C-2), 
68.1 (C-10), 68.4 (C-5), 198.9 (C-1); HRMS (ESI): calcd for C27H58O3SSi2 [M+Na]+ 
541.35374, found 541.35411. 
(3R,5R,7S,9R)-5,10-Bis{(tert-butyldimethylsilyl)oxy}-3,7,9-trimethyldecanal (4-89) 
 
 
To a solution of thioester 3-4 (2.00 g, 3.85 mmol) in CH2Cl2 (70 mL) at –80 °C was added 
DIBAL-H in hexane (1m, 4.04 mL, 4.04 mmol, 1.05 equiv) dropwise. After 30 min of stirring 
at –80 °C the excess DIBAL-H was quenched with ethyl acetate (1 mL) and saturated NH4Cl 
solution (5 mL). After having reached room temperature, the layers were separated and the 
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aqueous layer was extracted with ethyl acetate (2 × 10 mL). The combined organic extracts 
were dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was 
purified by flash chromatography (ethyl acetate/petroleum ether, 1:20) to give pure aldehyde 
4-89 (1.73 g, 98%) as colorless oil. Rf = 0.4 (petroleum ether/diethyl ether, 40:1); []22D = +36.4 
(c = 0.6, CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 0.03 (s, 6H, 
(CH3)2Si), 0.86 (s, 9H, (CH3)3CSi), 0.88 (s, 9H, (CH3)3CSi), 0.84-0.89 (m, 6H, 7-CH3, 9-CH3), 
0.89-0.92 (m, 1H, 8-H), 1.40 (d, J = 6.6 Hz, 3H, 3-CH3), 1.05-1.16 (m, 1H, 8-H), 1.18-1.28 (m, 
1H, 6-H), 1.36-1.46 (m, 3H, 6-H, 4-H), 1.62-1.74 (m, 2H, 9-H, 7-H), 2.07-2.17 (m, 1H, 3-H), 
2.21 (ddd, J = 2.8, 8.3, 16.2 Hz, 1H, 2-H), 2.24 (ddd, J = 1.7, 4.8, 16.2 Hz, 1H, 2-H), 3.28 (dd, 
J = 6.8, 9.6 Hz, 1H, 10-H), 3.44 (dd, J = 5.3, 9.6 Hz, 1H, 10-H), 3.74-3.84 (m, 1H, 3-H), 9.73 
(t, J = 2.0, Hz, 1H, CHO); 13C NMR (100 MHz, CDCl3):  = –5.3 ((CH3)2Si), –4.4 ((CH3)2Si), 
–4.0 ((CH3)2Si), 17.4 (9-CH3), 18.0 ((CH3)2CSi), 18.4 ((CH3)2CSi), 20.2 (3-CH3), 20.4 (7-CH3), 
24.8 (C-3), 25.9 ((CH3)3CSi), 26.0 ((CH3)3CSi), 26.2 (C-7), 33.0 (C-9), 41.8 (C-8), 44.2 (C-4), 
45.4 (C-6), 51.5 (C-2), 68.1 (C-5), 68.4 (C-10), 200.3 (CHO).  
(3R,5R,7S,9R)-5,10-Bis{(tert-butyldimethylsilyl)oxy}-3,7,9-trimethyl-2-methylenedecanal 
(4-90) 
 
 
To a solution of aldehyde 4-89 (1.60 g, 2.53 mmol) in CH2Cl2 (30 mL) was added Et3N (1.1 
mL, 7.59 mmol, 3 equiv) and Eschenmoser's salt (Me2N=CH2+ Cl–) (0.59 g, 6.32 mmol, 2.5 
equiv). The reaction mixture was stirred at room temperature for 2 d and then concentrated in 
vacuo. Purification of the residue by flash chromatography (ethyl acetate/petroleum ether, 1:20) 
gave pure enal 4-90 (1.18 g, 99%) as a colorless oil. Rf = 0.5 (petroleum ether/ethyl acetate, 
33:1). []22D = +34.0 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.01 (s, 3H, (CH3)2Si), 
0.02 (s, 9H, (CH3)2Si), 0.86 (s, 9H, (CH3)3CSi), 0.88 (s, 9H, (CH3)3CSi), 0.83-0.96 (m, 7H, 7-
CH3, 9-CH3, 8-H), 1.05 (d, J = 6.8 Hz, 3H, 3-CH3), 1.09-1.26 (m, 2H, 8-H, 6-H), 1.35-1.52 (m, 
2H, 6-H, 4-H), 1.57-1.74 (m, 3H, 9-H, 7-H, 4-H), 2.67-2.78 (m, 1H, 3-H), 3.27 (dd, J = 7.1, 9.6 
Hz, 1H, 10-H), 3.46 (dd, J = 5.3, 9.8 Hz, 1H, 10-H), 3.68-3.78 (m, 1H, 5-H), 5.96 (s, 1H, 
H2C=CCHO), 6.20 (s, 1H, H2C=CCHO), 9.51 (s, 1H, CHO); 13C NMR (100 MHz, CDCl3):  
= –5.3 ((CH3)2Si), –4.4 ((CH3)2Si), –4.1 ((CH3)2Si), 17.4 (9-CH3), 18.0 ((CH3)2CSi), 18.4 
((CH3)2CSi), 19.8 (3-CH3), 20.4 (7-CH3), 25.9 ((CH3)3CSi), 26.0 ((CH3)3CSi), 26.2 (C-7), 28.3 
(C-3), 33.1 (C-9), 41.8 (C-8), 43.9 (C-4), 44.3 (C-6), 68.4 (C-5), 68.5 (C-10), 132.8 
(CH2=CCHO), 155.7 (CH2=CCHO), 194.4 (CHO); HRMS (ESI): calcd for C26H54O3Si2 
[M+Na]+ 493.35037, found 493.35065. 
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(3R,5R,7S,9R)-5,10-Bis{(tert-butyldimethylsilyl)oxy}-3,7,9-trimethyl-2-methylenedecan-
1-ol (4-91) 
 
 
To a solution of enal 4-90 (1.180 g, 2.50 mmol) in CH2Cl2 (25 mL) at –80 °C was added 
DIBAL-H in hexane (1M 2.62 mL, 2.62 mmol, 1.05 equiv) dropwise. After complete addition, 
the reaction mixture was allowed to warm to –40 °C within 1 h. Excess DIBAL-H was quenched 
with ethyl acetate (1 mL) and saturated NH4Cl solution (3 mL), and after having reached room 
temperature, the layers were separated and the aqueous layer was extracted with ethyl acetate 
(2 × 5 mL). The combined organic extracts were dried with anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:9) to give pure allyl alcohol 4-91 (1.18 g, 100%) as a colorless oil. 
Rf = 0.2 (petroleum ether/ethyl acetate, 20:1); []22D = +9.6 (c = 1.0, CH2Cl2); 1H NMR (400 
MHz, CDCl3):  = 0.03 (s, 6H, (CH3)2Si), 0.04 (s, 6H, (CH3)2Si), 0.87 (s, 9H, (CH3)3CSi), 0.88 
(s, 9H, (CH3)3CSi), 0.83-0.95 (m, 7H, 7-CH3, 9-CH3, 8-H), 1.04 (d, J = 6.8 Hz, 3H, 3-CH3), 
1.07-1.16 (m, 1H, 8-H), 1.18-1.28 (m, 1H, 6-H), 1.36-1.50 (m, 2H, 6-H, 7-H), 1.52-1.74 (m, 
4H, 9-H, 4-H), 2.18-2.28 (m, 1H, 3-H), 3.27 (dd, J = 7.1, 9.8 Hz, 1H, 10-H), 3.45 (dd, J = 5.3, 
9.8 Hz, 1H, 10-H), 3.72-3.80 (m, 1H, 5-H), 4.10 (s, 2H, 1-H), 4.88 (m, 1H, CH2=CCH2OH), 
5.03 (m, 1H, CH2=CCH2OH); 13C NMR (100 MHz, CDCl3):  = –5.3 (CH3)2Si), –4.3 
((CH3)2Si), –4.0 ((CH3)2Si), 17.4 (9-CH3), 18.1 ((CH3)2CSi), 18.4 ((CH3)2CSi), 20.3 (3-CH3), 
20.6 (7-CH3), 25.9 ((CH3)3CSi), 26.0 ((CH3)3CSi), 26.3 (C-7), 33.1 (C-3), 33.1 (C-9), 41.8 (C-
8), 44.3 (C-4), 44.5 (C-6), 64.9 (C-1), 66.5 (C-10), 68.9 (C-5), 108.0 (CH2=CCH2OH), 154.4 
(CH2=CCH2OH); HRMS (ESI): calcd for C26H56O3Si2 [M+Na]+ 495.36602, found 495.36595. 
(3R,5R,7S,9R)-5,10-Bis{(tert-butyldimethylsilyl)oxy}-2-ethyl-3,7,9-trimethyl-1-decene (4-
93) 
 
 
a) Tosylate 4-92: To a cooled (0 °C) solution of alcohol 4-91 (0.250 g, 0.53 mmol) and Et3N 
(0.076 mL, 0.53 mmol, 1.0 equiv) in CH2Cl2 (5 mL) was added para-toluenesulfonic anhydride 
(0.175 g, 0.53 mmol, 1.0 equiv). After being stirred for 30 min at 0 °C, water (2 mL) was added 
to the reaction mixture, the layers were separated and the aqueous layer was extracted with 
ethyl acetate (5 mL). The combined organic layers were dried with anhydrous Na2SO4, filtered, 
and concentrated in vacuo to give crude tosylate 4-92 (0.320 g, 96%) which was used for the 
next step without further purification.  
b) Substitution of tosylate: The crude tosylate 4-92 was dissolved in CH2Cl2 (5 mL) and CuI 
(0.010 g, 0.051 mmol, 10 mol%) was added. This mixture was cooled to –80 °C and treated 
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with a solution of MeMgBr in diethyl ether (3M 0.7 mL, 2.04 mmol, 4 equiv) in a dropwise 
fashion. The reaction mixture was allowed to warm to –50 °C within 1.5 h before it was 
quenched with MeOH (0.2 mL) and saturated NH4Cl solution (1 mL). The cooling system was 
removed, the layers were separated and the aqueous layer was extracted with CH2Cl2 (2 × 5 
mL). The combined organic layers were washed with saturated NaCl solution (5 mL), dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude material was purified 
by flash chromatography (Et2O/petroleum ether, 1/50) to afford pure alkene 4-93 (0.205 g, 
82%) as a colorless oil. Rf = 0.6 (petroleum ether/diethyl ether, 49:1); []20D = +21.8 (c = 1.0, 
CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.03 (s, 6H, (CH3)2Si), 0.04 (s, 6H, (CH3)2Si), 0.87 
(s, 9H, (CH3)3CSi), 0.89 (s, 9H, (CH3)3CSi), 0.83-0.96 (m, 7H, 7-CH3, 9-CH3, 8-H), 0.98-1.13 
(m, 7H, 8-H, 3-CH3, CH3CH2), 1.17-1.29 (m, 1H, 6-H), 1.35-1.46 (m, 2H, 6-H, 7-H), 1.52-1.62 
(m, 1H, 4-H), 1.63-1.77 (m, 2H, 4-H, 9-H), 1.94-2.06 (m, 2H, CH2CH3), 2.09-2.21 (m, 1H, 3-
H), 3.27 (dd, J = 7.1, 9.8 Hz, 1H, 10-H), 3.46 (dd, J = 5.3, 9.8 Hz, 1H, 10-H), 3.68-3.78 (m, 
1H, 5-H), 4.66-4.77 (m, 2H, 1-H); 13C NMR (100 MHz, CDCl3):  = –5.3 ((CH3)2Si), –4.3 
((CH3)2Si), –4.0 ((CH3)2Si), 12.4 (CH3CH2), 17.4 (9-CH3), 18.1 ((CH3)2CSi), 18.4 ((CH3)2CSi), 
20.0 (3-CH3), 20.5 (7-CH3), 25.9 ((CH3)3CSi), 26.0 ((CH3)3CSi), 26.3 (C-7), 26.4 (CH2CH3), 
33.1 (C-3), 36.8 (C-9), 42.0 (C-8), 44.5 (C-4), 44.6 (C-6), 68.5 (C-10), 68.9 (C-5), 106.3 (C-1), 
156.4 (C-2); HRMS (ESI): calcd for C27H58O2Si2 [M+Na]+ 493.38675, found 493.38692. 
(2R,4S,6R,8R)-6-{(tert-Butyldimethylsilyl)oxy}-2,4,8-trimethyl-9-methyleneundecan-1-ol 
(4-94) 
 
 
To a stirred solution of disilyl ether 4-93 (0.190 g, 0.403 mmol) in MeOH/CH2Cl2 (5:1, 6 mL) 
at 10 °C was added pTsOH·H2O (0.010 g, 0.05 mmol, 0.13 equiv). The temperature was 
maintained between 10 °C and 0 °C throughout the reaction which was stirred for 4 h. Solid 
NaHCO3 (10 mg) was added and most of the solvent was removed in vacuo. This solid was re-
dissolved in ethyl acetate (5 mL) and the solution was washed with water (2 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:9) to afford pure alcohol 4-94 (0.100 g, 70%) 
as colorless oil. Rf = 0.2 (petroleum ether/ethyl acetate, 9:1); []21D = +33.7 (c = 1.0, CH2Cl2); 
1H NMR (400 MHz, CDCl3):  = 0.04 (s, 3H, (CH3)2Si), 0.04 (s, 3H, (CH3)2Si), 0.87 (s, 9H, 
(CH3)3CSi), 0.88-0.92 (m, 6H, 2-CH3, 11-H), 0.93-0.98 (m, 1H, 3-H), 0.98-1.05 (m, 6H, 4-CH3, 
8-CH3), 1.06-1.15 (m, 1H, 3-H), 1.98-1.30 (m, 2H, 5-H), 1.34-1.45 (m, 1H, 7-H), 1.51-1.60 (m, 
1H, 4-H), 1.65-1.78 (m, 2H, 2-H), 1.95-2.02 (m, 2H, 10-H), 2.09-2.19 (m, 1H, 8-H), 3.36 (dd, 
J = 6.8, 10.6 Hz, 1H, 1-H), 3.49 (dd, J = 5.3, 10.6 Hz, 1H, 1-H), 3.67-3.77 (m, 1H, 6-H), 4.66-
4.77 (m, 2H, C=CH2); 13C NMR (100 MHz, CDCl3):  = –4.3 (CH3)2Si), –4.0 ((CH3)2Si), 12.4 
(C-11), 17.4 (2-CH3), 18.1 ((CH3)2CSi), 20.0 (8-CH3), 20.4 (4-CH3), 25.9 ((CH3)3CSi), 26.2 
(C-4), 26.4 (C-10), 33.0 (C-8), 36.8 (C-2), 41.8 (C-3), 44.3 (C-7), 44.6 (C-5), 68.5 (C-1), 68.9 
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(C-6), 106.3 (9-CCH2), 156.4 (C-9); HRMS (ESI): calcd for C21H44O2Si [M+Na]+ 379.30028, 
found 379.30052. 
(2R,4S,6R,8R)-6-{(tert-Butyldimethylsilyl)oxy}-2,4,8-trimethyl-9-methyleneundecanal (4-
95) 
 
 
To a solution of oxalyl chloride (0.036 mL, 0.42 mmol, 1.5 equiv) in CH2Cl2 (2 mL) at –80 °C 
was added DMSO (0.060 mL, 0.84 mmol, 3.0 equiv) in a dropwise fashion. The resulting 
mixture was stirred 15 min at this temperature. Then alcohol 4-94 (0.100 g, 0.28 mmol) in 
CH2Cl2 (0.5 mL) was added dropwise within 15 min. After stirring the mixture for 1 h, Et3N 
(0.242 mL, 1.68 mmol, 6 equiv) was added slowly before the reaction mixture was allowed to 
warm to room temperature. Subsequently, water (1 mL) was added, the layers were separated 
and the aqueous layer was extracted with CH2Cl2 (2 × 2 mL). The combined organic layers 
were washed with saturated NaCl solution, dried over anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:20) to give aldehyde 4-95 (0.098 g, 98%) as colorless oil. Rf = 0.6 
(petroleum ether/ethyl acetate, 9:1); 1H NMR (400 MHz, CDCl3):  = 0.03 (s, 3H, (CH3)2Si), 
0.04 (s, 3H, (CH3)2Si), 0.86 (s, 9H, (CH3)3CSi), 0.86-0.94 (m, 3H, 11-CH3), 0.97-1.09 (m, 9H, 
2-CH3, 4-CH3, 8-CH3), 1.12-1.22 (m, 2H, 5-H), 1.32-1.45 (m, 2H, 4-H, 5-H), 1.51-1.77 (m, 4H, 
3-H, 7-H),1.91-2.06 (m, 2H, 10-H), 2.08-2.20 (m, 1H, 8-H), 2.26-2.49 (m, 1H, 2-H), 3.36-3.82 
(m, 1H, 6-H), 4.68-4.75 (m, 2H, C=CH2), 9.57 (d, J = 2.3 Hz, 1H, CHO); 13C NMR (100 MHz, 
CDCl3):  = –4.3 ((CH3)2Si), –4.0 ((CH3)2Si), 12.4 (C-11), 13.8 (2-CH3), 18.0 ((CH3)2CSi), 
20.0 (8-CH3), 20.1 (4-CH3), 25.9 ((CH3)3CSi), 26.2 (C-10), 26.5 (C-4), 36.8 (C-8), 38.7 (C-3), 
44.0 (C-7), 44.2 (C-2), 44.5 (C-5), 68.7 (C-6), 106.0 (C=CH2), 156.4 (C-9), 205.3 (CHO). 
(3R,5S,7R,9R)-7-((tert-Butyldimethylsilyl)oxy)-3,5,9-trimethyl-10-methylenedodecan-2-
one (3-3) 
 
 
a) Addition of MeLi to aldehyde 4-95: To a solution of aldehyde 4-95 (0.382 g, 1.08 mmol) 
in THF (8 mL) at –80 °C was added a solution of MeLi·LiBr in diethyl ether (2.2m, 2.45 mL, 
5.40 mmol, 5 equiv). The reaction mixture was allowed to warm to room temperature within 
15 h. Before quenching with saturated NH4Cl (2 mL) the reaction mixture was re-cooled to –
80 °C, then the mixture was extracted with ethyl acetate (2 × 5 mL). The combined organic 
layers were washed with saturated aqueous NaCl solution (5 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo to the give crude secondary alcohol 4-96 (0.411 g) 
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as colorless oil. This material was subjected to the subsequent oxidation without further 
purification. HRMS (ESI): calcd for C22H46O2Si [M+Na]+ 393.31565, found 393.31607. 
b) Oxidation to ketone 3-3: To a solution of oxalyl chloride (0.260 mL, 3.0 mmol, 2.78 equiv) 
in CH2Cl2 (10 mL) at –80 °C was added DMSO (0.430 mL, 6.0 mmol, 5.5 equiv) dropwise. 
The resulting mixture was stirred for 15 min at this temperature before the foregoing alcohol 4-
96 (0.411 g) in CH2Cl2 (2.5 mL) was added dropwise within 15 min. After stirring of the 
mixture for 1 h at –80 °C, Et3N (1.73 mL, 12.0 mmol) was added slowly. Thereafter, the 
reaction mixture was allowed to warm to room temperature, water (5 mL) was added, the layers 
were separated and the aqueous layer was extracted with CH2Cl2 (2 × 5 mL). The combined 
organic layers were washed with saturated NaCl solution, dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo. The crude product was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:20) to give methyl ketone 3-3 (0.336 g, 84%, 2 steps) as 
colorless oil. Rf = 0.6 (petroleum ether/ethyl acetate, 9:1); []21D = +30.6 (c = 1.17, CH2Cl2); 
1H NMR (400 MHz, CDCl3):  = 0.02 (s, 3H, (CH3)2Si), 0.04 (s, 3H, (CH3)2Si), 0.86 (s, 9H, 
(CH3)3CSi), 0.87-0.94 (m, 3H, 12-H), 0.97-1.08 (m, 9H, 3-CH3, 5-CH3, 9-CH3), 1.10-1.19 (m, 
2H, 6-H), 1.31-1.45 (m, 2H, 5-H, 4-H), 1.51-1.71 (m, 3H, 8-H, 4-H), 1.94-2.04 (m, 2H, 11-H), 
2.11 (s, 3H, 1-H), 2.12-2.18 (m, 1H, 9-H), 2.54-2.66 (m, 1H, 3-H), 3.66-3.77 (m, 1H, 7-H), 
4.67-4.75 (m, 2H, 10-CH2); 13C NMR (100 MHz, CDCl3):  = –4.3 (CH3)2Si), –4.0 ((CH3)2Si), 
12.4 (C-12), 16.7 (3-CH3), 18.0 ((CH3)2CSi), 19.9 (9-CH3), 20.0 (5-CH3), 25.9 ((CH3)3CSi), 
26.3 (C-11), 26.8 (C-5), 27.7 (C-9), 36.8 (C-1), 41.1 (C-4), 44.4 (C-8), 44.5 (C-6), 44.8 (C-3), 
68.7 (C-7), 106.0 (10-CH2), 156.4 (C-10), 212.9 (C-2); HRMS (ESI): calcd for C22H44O2Si 
[M+Na]+ 391.30028, found 391.30024. 
The aldol reaction 
The aldol reaction between methyl ketone 3-3 and aldehyde 3-2 was carried out using the 
following reaction conditions: 
 
Enolate generation with trichloroisopropoxytitanium(IV) [TiCl3(OiPr)]: To solution of 
TiCl4 (0.006 mL, 0.06 mmol, 0.82 equiv) in CH2Cl2 (0.02 mL) was added Ti(OiPr)4] (0.006 
mL, 0.02 mmol, 0.27 equiv) at 0 °C. The solution turned to white and was stirred at 0 °C for 15 
min and at room temperature for 10 min to complete the metathesis. Then it was diluted with 
CH2Cl2 (0.02 mL), resulting in a colorless solution. This colorless solution was added dropwise 
to a cooled solution of methyl ketone 3-3 (0.030 g, 0.07 mmol) and iPr2NEt (0.015 mL, 0.08 
mmol, 1.2 equiv) in CH2Cl2 (0.5 mL) at –78 °C. The resulting dark red solution was stirred for 
30 min at –78 °C. Then neat aldehyde 3-2 (0.022 g, 0.18 mmol, 2.6 equiv) was added dropwise 
and stirring was continued for 30 min at this temperature. The reaction was quenched with 
saturated NH4Cl solution (1 mL), allowed to warm to room temperature and diluted with Et2O 
(10 mL) before the layers were separated. The organic layer was washed with saturated 
NaHCO3 solution (3 mL), saturated NaCl solution (3 mL), dried with anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:9) to give the hydroxy ketone 4-121 (5 mg, 14%, dr 1:1) as colorless 
oil. 
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Enolate generation with lithium diisopropylamide (LDA): To a solution of 
diisopropylamine (0.014 mL, 0.10 mmol, 2.5 equiv) in THF (0.5 mL) was added nBuLi (1.6M 
in hexanes, 0.05 mL, 0.08 mmol, 2 equiv) at –78 °C. The solution was stirred for 15 min at 0 
°C and then cooled again to –78 °C. Next, a solution of methyl ketone 3-3 (0.015 g, 0.04 mmol) 
in THF (0.5 mL) was added to the LDA solution and the mixture stirred for 3 h at –78 °C before 
neat aldehyde 3-2 (0.010 g, 0.08 mmol, 2.0 equiv) was added to the enolate solution. The 
reaction was left to stir overnight at –78 °C. The temperature was allowed to rise to 0 °C and 
then the reaction was quenched with saturated aqueous NH4Cl solution (1 mL). The layers were 
separated and the aqueous layer was extracted with Et2O (3 × 3mL). The combined organic 
layers were dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by 
flash chromatography (ethyl acetate/petroleum ether, 1:9) to give hydroxyl ketone 4-121 (5 mg, 
24%, dr 1:1) as colorless oil. 
Enolate generation with dicyclohexylboron trifluoromethanesulfonate (Cy2BOTf): To a 
cooled solution of methyl ketone 3-3 (0.020 g, 0.054 mmol) and Et3N (0.034 mL, 0.235 mmol, 
4.3 equiv) at –78 °C was added a pre-cooled (–78 °C) solution of cHex2BOTf {0.062 g, 0.19 
mmol, 3.5 equiv, dissolved in hexane (0.020 mL) and diluted with CH2Cl2 (0.040 mL)} 
dropwise. After 3 h of stirring at –78 °C, neat aldehyde 3-2 (0.025 g, 0.19 mmol, 2 equiv) was 
added and the reaction mixture was stirred overnight, while it was allowed to warm to 0 °C. 
For work-up phosphate buffer (pH 7, 1 mL) and 30% H2O2 (1 mL) were added and stirring was 
continued for the next 2 h. The reaction mixture was diluted with water (1 mL) and extracted 
with CH2Cl2 (3 × 3 mL). The combined organic extracts were washed with saturated NaHCO3 
solution (3 mL), saturated NaCl solution (3 mL), dried with anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:9) to give unreacted ketone 3-3 (0.010 g, 0.027 mmol) and the 
product 4-121 (0.010 g, 71%, dr 1:1) as colorless oils. 
Enolate generation with diisopinocampheylboron triflate (–)-(Ipc)2BOTf: To a suspension 
of (–)-(Ipc)2BH (0.500 g, 1.75 mmol) in hexane (0.5 mL) at 0 °C was added 
trifluoromethanesulfonic acid (0.154 mL, 1.75 mmol) dropwise. The resulting two phase 
mixture was stirred at room temperature until completion of the reaction (about 1 h). The upper 
colorless hexane solution was used for the aldol reaction assuming 60% conversion (0.6 mL of 
1.7M solution of the triflate). 
To a cooled solution of methyl ketone 3-3 (0.030 g, 0.07 mmol) and iPr2NEt (0.04 mL, 0.21 
mmol, 2.4 equiv) in CH2Cl2 (0.5 mL) at –78 °C was added a pre-cooled (–78 °C) solution of 
the above (–)-(Ipc)2BOTf (1.7M in hexane, 0.1 mL, 0.17 mmol) dropwise. After stirring of the 
mixture at –78 °C to –50 °C for 4 h, neat aldehyde 3-2 (0.022 g, 0.18 mmol, 2.6 equiv) was 
added at –78 °C and the reaction mixture was stirred overnight, allowing it to warm to 0 °C. 
Thereafter, phosphate buffer (pH 7, 1 mL) and 30% H2O2 (1 mL) were added, and stirring was 
continued for the next 2 h. The reaction mixture was diluted with water (1 mL), and extracted 
with CH2Cl2 (3 × 3 mL). The combined organic extracts were washed with saturated NaHCO3 
solution (3 mL), saturated NaCl solution (3 mL), dried with anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The residue was purified by flash chromatography (ethyl 
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acetate/petroleum ether, 1:9) to give unreacted ketone 3-3 (0.010 g, 0.027 mmol) and the aldol 
product 4-121 (0.025 g, 89%, dr 2:1) as a colorless oil. 
(7R,9S,11R,13R,E)-Methyl 11-((tert-butyldimethylsilyl)oxy)-4-hydroxy-3,7,9,13-
tetramethyl-14-methylene-6-oxohexadec-2-enoate (4-121) 
 
 
Rf = 0.5 (petroleum ether/ethyl acetate, 5:1); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 3H, 
(CH3)2Si), 0.04 (s, 3H, (CH3)2Si), 0.86 (s, 9H, (CH3)3CSi), 0.81-0.90 (m, 3H, 9-CH3), 0.97-1.16 
(m, 10H, 7-CH3, 13-CH3, 16-H, 8-H), 1.28-1.47 (m, 2H, 8-H, 10-H), 1.49-1.68 (m, 4H, 9-H, 
10-H, 12-H), 1.91-2.04 (m, 2H, 15-H), 2.11 (s, 3H, 3-CH3), 2.11-2.19 (m, 2H, 13-H), 2.52-2.68 
(m, 2H, 5-H), 2.68-2.78 (m, 1H, 7-H), 3.70-3.76 (m, 1H, 11-H), 3.69 (s, 3H, OMe), 4.46-4.56 
(m, 1H, 4-H), 4.68-4.76 (m, 2H, 14-CH2), 6.02 (s, 1H, 2-H); 13C NMR (100 MHz, CDCl3):  = 
–4.3 ((CH3)2Si), –4.0 ((CH3)2Si), 12.4 (C-16), 15.4 (3-CH3), 16.5, 18.0 ((CH3)2CSi), 20.0, 25.9 
((CH3)3CSi), 26.3, 26.7, 36.8, 40.8, 44.2, 44.5, 44.6, 44.7, 45.59, 45.3 (C-5, C-7), 51.0 (OMe), 
68.4 (C-11), 71.7 (C-4), 106.4 (14-CH2), 115.0 (C-2), 156.3 (C-14), 157.9 (C-3), 167.2 
(CO2Me), 215.0 (C-6); HRMS (ESI): calcd for C31H58O5Si [M+Na]+ 561.39457, found 
561.39459. 
(7R,9S,11R,13R,E)-Methyl 11-((tert-butyldimethylsilyl)oxy)-3,7,9,13-tetramethyl-14-
methylene-6-oxo-4-((triisopropylsilyl)oxy)hexadec-2-enoate (4-123) 
 
 
To a solution of TIPSOTf (0.065 mL, 0.24 mmol, 4 equiv) in CH2Cl2 (0.5 mL) at –78 °C was 
added 2,6-lutidine (0.035 mL, 0.30 mmol, 5 equiv) dropwise followed by the addition of 
hydroxy ketone 4-121 (0.030 g, 0.06 mmol) in CH2Cl2 (0.025 mL). The mixture was stirred for 
3 h at –78 °C then warmed to –40 °C and stirred at this temperature for 45 h. Thereafter, water 
(1 mL) was added, and the mixture was extracted with ethyl acetate (3 × 3 mL). The combined 
organic layers were washed with saturated NH4Cl solution (3 mL), saturated NaHCO3 solution 
(3 mL), saturated NaCl solution (3 mL), dried with anhydrous Na2SO4, filtered and concentrated 
in vacuo. The residue was purified by flash chromatography (Et2O/petroleum ether, 1:50) to 
give unreacted alcohol 4-121 (5 mg) and silyl ether 4-123 (30 mg, 92%) as colorless oils. Rf = 
0.5 (petroleum ether/ethyl acetate, 20:1); 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 3H, 
(CH3)2Si), 0.04 (s, 3H, (CH3)2Si), 0.86 (s, 9H, (CH3)3CSi), 0.81-0.90 (m, 3H, 9-CH3), 0.96-1.05 
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(m, 29H, ((CH3)2CH)3Si, 7-CH3, 13-CH3, 16-H, 8-H), 1.06-1.14 (m, 3H, ((CH3)2CH)3Si), 1.30-
1.45 (m, 2H, 9-H, 10-H), 1.46-1.59 (m, 2H, 10-H, 12-H), 1.60-1.70 (m, 1H, 12-H), 2.00 (q, J = 
7.5 Hz, 2H, 15-H), 2.10 (d, J = 1.1 Hz, 3H, 3-CH3), 2.10-2.17 (m, 1H, 13-H), 2.45-2.66 (m, 2H, 
5-H, 7-H), 2.68-2.78 (m, 1H, 5-H), 3.67 (s, 3H, OMe), 3.68-3.76 (m, 1H, 11-H), 4.68-4.76 (m, 
2H, 14-CH2), 4.77 (t, J = 5.9 Hz, 1H, 4-H), 5.90-5.96 (m, 1H, 2-H); 13C NMR (100 MHz, 
CDCl3):  = –4.3 ((CH3)2Si), –4.0 ((CH3)2Si), 12.4, 14.5, 15.8, 18.0 ((CH3)2CSi), 20.0, 20.3, 
25.9 ((CH3)3CSi), 26.3, 26.7, 36.8, 40.4, 43.9, 44.5, 44.6, 48.1, 48.7 (C-5), 51.0 (OMe), 68.7 
(C-11), 73.3 (C-4), 106.4 (14-CH2), 115.4 (C-2), 156.3 (C-14), 160.1 (C-3), 167.2 (C-1), 211.0 
(C-6); HRMS (ESI): calcd for C37H72O5Si2 [M+Na]+ 675.48105, found 675.48158. 
(7R,9S,11R,13R,E)-Methyl 11-hydroxy-3,7,9,13-tetramethyl-14-methylene-6-oxo-4-
((triisopropylsilyl)oxy)hexadec-2-enoate (4-133) 
 
 
To a solution of silyl ether 4-123 (0.023 g, 0.035 mmol) in CH3OH/CH2Cl2 (0.3 mL, 2:1) was 
added camphorsulfonic acid (2 mg, 0.007 mmol, 0.2 equiv). After 50 min of stirring at room 
temperature, Et3N (0.020 mL) was added to the mixture, and then the volatiles solvent were 
removed in vacuo. The residue was purified by flash chromatography (ethyl acetate/petroleum 
ether, 1:9, 1:5) to give hydroxy ester 4-133 (15 mg, 79%, 10 mg major isomer, 5 mg minor 
isomer) as a colorless oil. The chromatographic separation on this stage is possible, but it is 
more convenient to perform the separation on the stage of the macrolactones 4-133a and 4-
133b due to larger difference in their retention factors. 
Major isomer (4-133a): Rf = 0.5 (petroleum ether/ethyl acetate, 5:1); []20D = +1.8 (c = 0.83, 
CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.87 (d, J = 6.4 Hz, 3H, 9-CH3), 0.96-1.10 (m, 31H, 
3 x SiCH(CH3)2, 16-H, 7-CH3, 13-CH3, 8-H), 1.34-1.45 (m, 2H, 12-H, 10-H), 1.46-1.54 (m, 
1H, 12-H), 1.60-1.67 (m, 3H, 8-H, 9-H, 10-H), 1.92-2.06 (m, 2H, 15-H), 2.10 (d, J = 1.1 Hz, 
3H, 3-CH3), 2.36-2.47 (m, 1H, 13-H), 2.50-2.59 (m, 1H, 7-H), 2.68 (dd, J = 1.8, 5.8 Hz, 2H, 5-
H), 3.59-3.74 (m, 1H, 11-H), 3.67 (s, 3H, OMe), 4.73-4.82 (m, 3H, 14-CH2, 4-H), 5.90-5.96 
(m, 1H, 2-H); 13C NMR (100 MHz, CDCl3):  = 12.3 (C-16), 14.4 (3-CH3), 16.4 (7-CH3), 18.0 
(SiCH(CH3)2), 20.0 (13-CH3), 20.8 (9-CH3), 25.5 (C-15), 27.3 (C-9), 37.3 (C-13), 40.4 (C-10), 
43.8 (C-12), 44.8 (C-7), 48.1 (C-5), 51.0 (OMe), 67.6 (C-11), 73.1 (C-4), 107.3 (14-CH2), 115.4 
(C-2), 155.8 (C-14), 160.1 (C-3), 167.2 (C-1), 211.3 (C-6); HRMS (ESI): calcd for C31H58O5Si 
[M+Na]+ 561.39457, found 561.39459. 
Minor isomer (4-133b): Rf = 0.6 (petroleum ether/ethyl acetate, 5:1); []22D = - 13.8 (c = 0.38, 
CH2Cl2); 1H NMR (400 MHz, CDCl3):  = 0.84 (d, J = 6.4 Hz, 3H, 9-CH3), 0.97-1.07 (m, 31H, 
3 x SiCH(CH3)2, 16-H, 7-CH3, 13-CH3, 8-H), 1.33-1.46 (m, 2H, 12-H, 10-H), 1.47-1.54 (m, 
1H, 12-H), 1.56-1.68 (m, 3H, 8-H, 9-H, 10-H), 1.93-2.06 (m, 2H, 15-H), 2.11 (d, J = 1.1 Hz, 
3H, 3-CH3), 2.36-2.48 (m, 1H, 13-H), 2.50-2.78 (m, 3H, 7-H, 5-H), 3.59-3.71 (m, 1H, 11-H), 
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3.68 (s, 3H, OMe), 4.73-4.82 (m, 3H, 14-CH2, 4-H), 5.89-5.94 (m, 1H, 2-H); 13C NMR (100 
MHz, CDCl3):  = 12.3 (C-16), 14.4 (3-CH3), 16.5 (7-CH3), 17.7, 18.0 (SiCH(CH3)2), 20.0 (13-
CH3), 20.8 (9-CH3), 25.5 (C-15), 27.3 (C-9), 37.2 (C-13), 40.5 (C-10), 43.7 (C-12), 44.8 (C-8), 
44.9 (C-7), 48.7 (C-5), 51.0 (OMe), 67.5 (C-11), 73.2 (C-4), 107.3 (14-CH2), 115.4 (C-2), 155.8 
(C-14), 160.1 (C-3), 167.2 (C-1), 211.3 (C-6). 
(7R,9S,11R,13R,E)-11-Hydroxy-3,7,9,13-tetramethyl-14-methylene-6-oxo-4-
((triisopropylsilyl)oxy)hexadec-2-enoic acid (2-1) 
 
 
To a solution of ester 4-133 (0.012 g, 0.022 mmol) in 1,2-dichloroethane (0.4 mL) was added 
Me3SnOH (0.017 g, 0.11 mmol, 5 equiv). After stirring for 2 d at 80 °C, the reaction mixture 
was diluted with KHSO4 solution (1 mL, 5% in water) and the layers were separated. The 
aqueous layer was extracted with ethyl acetate (2 × 3 mL), and the combined organic extracts 
were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was 
purified by flash chromatography (ethyl acetate/petroleum ether, 1:3) to give seco acid 2-1 (8 
mg, 69%) as a colorless oil. Rf = 0.4 (petroleum ether/ethyl acetate, 2:1); 1H NMR (400 MHz, 
CDCl3):  = 0.88 (d, J = 4.0 Hz, 3H, 9-CH3), 0.99-1.08 (m, 30H, 3 x SiCH(CH3)2, 16-H, 7-CH3, 
13-CH3), 1.25-1.33 (m, 2H, 8-H, 12-H), 1.35-1.46 (m, 2H, 12-H, 10-H), 1.47-1.54 (m, 1H, 10-
H), 1.56-1.69 (m, 2H, 8-H, 9-H), 1.93-2.07 (m, 2H, 15-H), 2.11 (s, 3H, 3-CH3), 2.36-2.47 (m, 
1H, 13-H), 2.50-2.60 (m, 1H, 7-H), 2.62-2.76 (m, 2H, 5-H), 3.59-3.71 (m, 1H, 11-H), 4.73-4.84 
(m, 3H, 14-CH2, 4-H), 5.90-5.96 (m, 1H, 2-H); 13C NMR (100 MHz, CDCl3):  = 12.3 (C-16), 
14.8 (3-CH3), 16.5 (7-CH3), 17.8, 18.0 (SiCH(CH3)2), 20.0 (13-CH3), 20.8 (9-CH3), 25.4 (C-
15), 27.3 (C-9), 37.3 (C-13), 40.4 (C-10), 43.7 (C-12), 44.8 (C-7), 48.1 (C-5), 67.6 (C-11), 73.1 
(C-4), 107.4 (14-CH2), 115.4 (C-2), 155.7 (C-14), 162.8 (C-3), 170.8 (C-1), 211.1 (C-6); HRMS 
(ESI): calcd for C30H56O5Si [M+Na]+ 547.37892, found 547.37870. 
4-O-Triisopropylsilyl-amphidinolide Q (2-25 and epi-2-25): To a solution of hydroxy acid 2-
1 (5 mg, 0.009 mmol) in benzene (25 mL) were added Et3N (0.021 mL, 0.148 mmol, 16 equiv) 
and 2,4,6-trichlorobenzoyl chloride (TCBC) (0.011 mL, 0.072 μmol, 8 equiv). The reaction 
mixture was stirred at room temperature for 1.5 h before DMAP (0.017 g, 0.142 mmol) was 
added and the reaction mixture was stirred overnight. It was diluted with Et2O (70 mL) and 
washed with saturated NH4Cl solution (30 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude lactone mixture was purified 
(Et2O/petroleum ether, 2:50) to give macrolactones 2-25 and epi-2-25 (2 mg, 1 mg, 62%) as 
colorless oils. The NMR spectra of 2-25 matched with the published one. 
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4-(R)-O-Triisopropylsilyl-amphidinolide Q (2-25) 
 
 
Rf = 0.2 (petroleum ether/ethyl acetate, 33:1); []21D = –32.3 (c = 0.17, CH2Cl2); 1H NMR (400 
MHz, CDCl3):  = 0.92 (d, J = 6.6 Hz, 3H, 19-H), 1.00-1.09 (m, 32H, 3 x SiCH(CH3)2, 16-H, 
18-H, 8-H, 9-H), 1.29 (ddd, J = 1.7, 3.2, 18.5 Hz, 1H, 10-H), 1.43 (ddd, J = 7.5, 11.2, 18.5 Hz, 
1H, 10-H), 1.50-1.62 (m, 2H, 12-H), 1.90 (dd, J = 2.9, 14.4, 1H, 8-H), 1.94-2.05 (m, 2H, 15-
H), 2.06-2.12 (m, 1H, 7-H), 2.14 (d, J = 1.0 Hz, 3H, 17-H), 2.26 (dd, J = 7.1, 14.3 Hz, 1H, 13-
H), 2.60 (dd, J = 6.2, 12.6 Hz, 1H, 5-H), 2.79 (dd, J = 3.2, 12.6 Hz, 1H, 5-H), 4.58 (dd, J = 3.1, 
6.1 Hz, 1H, 4-H), 4.75-4.79 (m, 2H, 21-H), 4.88-5.00 (m, 1H, 11-H), 6.05 (m, 1H, 2-H); 13C 
NMR (100 MHz, CDCl3):  = 12.2 (C-16), 16.7 (C-17), 18.0 (SiCH(CH3)2), 18.2 (C-18), 21.1 
(C-20), 23.6 (C-19), 26.2 (C-15), 29.7 (C-9), 37.0 (C-13), 39.9 (C-8), 41.3 (C-12), 44.9 (C-10), 
46.3 (C-5), 49.6 (C-7), 73.9 (C-4), 75.1 (C-11), 107.1 (C-21), 117.6 (C-2), 155.3 (C-14), 155.9 
(C-3), 168.1 (C-1), 211.5 (C-6); HRMS (ESI): calcd for C30H54O4Si [M+Na]+ 529.36836, found 
529.36842. 
4-(S)-O-Triisopropylsilyl-amphidinolide Q (epi-2-25) 
 
 
Rf = 0.3 (petroleum ether/ethyl acetate, 33:1); []22D = –78.7 (c = 0.17, CH2Cl2); 1H NMR (400 
MHz, CDCl3):  = 0.92 (d, J = 6.6 Hz, 3H, 19-H), 0.98-1.07 (m, 30H, 3 x SiCH(CH3)2, 16-H, 
18-H), 1.27-1.30 (8-H, 9-H), 1.35-1.49 (m, 2H, 10-H) 1.52-1.58 (m, 2H, 12-H), 1.90-2.11 (m, 
4H, 15-H, 8-H, 7-H), 2.18 (d, J = 1.1 Hz, 3H, 17-H), 2.15-2.27 (m, 1H, 13-H), 2.51 (dd, J = 
5.0, 11.0 Hz, 1H, 5-H), 2.94 (t, J = 11.0 Hz, 1H, 5-H), 4.50 (dd, J = 4.9, 10.6 Hz, 1H, 4-H), 
4.73-4.79 (m, 2H, 21-H), 4.98-5.07 (m, 1H, 11-H), 5.59 (m, 1H, 2-H); 13C NMR (100 MHz, 
CDCl3):  = 12.3 (C-16), 17.7 (C-17), 17.9 (SiCH(CH3)2), 18.0 (C-18), 21.1 (C-20), 23.7 (C-
19), 26.1 (C-15), 29.7 (C-9), 33.0 (C-13), 37.0 (C-7), 39.9 (C-12), 41.3 (C-10), 44.5 (C-5), 49.5 
(C-8), 74.3 (C-4), 76.8 (C-11), 107.1 (C-21), 116.8 (C-2), 155.1 (C-14), 155.8 (C-3), 166.8 (C-
1), 213.6 (C-6); HRMS (ESI): calcd for C30H54O4Si [M+Na]+ 529.36836, found 529.36860. 
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4-epimer-Amphidinolide Q (epi-1-14) 
 
To a solution of silyl ether (epi)-2-25 (2 mg, 4.0 μmol) in THF (1 mL) was added a solution of 
TBAF (50 L, 50 mol) in THF (1.0 M) at –30 °C. After complete addition the color of the 
reaction mixture became milky. It was allowed to stir at the same temperature for 2 h before it 
was quenched with aqueous NH4Cl (1 mL), and extracted with EtOAc (3 × 3 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. 
Purification by flash chromatography (petroleum ether/ethyl acetate, 5:1) provided epi-
amphidinolide Q (1.0 mg, 72%) as a colorless oil. Rf = 0.3 (petroleum ether/ethyl acetate, 2:1); 
1H NMR (600 MHz, CDCl3):  = 0.98-1.11 (m, 14H), 1.37-1.44 (m, 2H), 1.56-1.65 (m, 2H), 
1.75 (d, J = 6.3 Hz, 1H), 1.94-2.02 (m, 1H), 2.07-2.14 (m, 2H), 2.15-2.25 (m, 4H), 2.31-2.39 
(m, 1H), 2.59-2.65 (m, 1H), 2.92 (t, J = 11.0 Hz, 1H), 4.48-4.53 (m, 1H), 4.74-4.78 (m, 2H), 
4.95-5.02 (m, 1H), 5.67 (s, 1H); 13C NMR (150 MHz, CDCl3):  = 12.3, 17.7, 21.1, 23.3, 26.2, 
29.7, 32.6, 36.9, 40.3, 41.3, 44.5, 47.7, 49.8, 74.7, 75.6, 107.1, 118.0, 139.1, 155.1, 166.8, 
213.7; HRMS (ESI): calcd for C21H34O4 [M+Na]+ 373.23493, found 373.23475. 
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Table 19: 13C Chemical shift (, ppm) comparison of Amphidinolide Q, 4-(R)-O-
Triisopropylsilyl-amphidinolide Q, reported and synthesized. 
 
C (No) Q () reported () synthetic () () 
1 169.6 168.05 168.05 0.0 
2 117.4 117.54 117.59 +0.05 
3 155.4 155.87 155.86 –0.01 
4 73.1 73.83 73.86 +0.03 
5 44.6 46.26 46.26 +0.04 
6 215.1 211.59 211.53 –0. 06 
7 50.5 49.61 49.59 –0.02 
8 40.3 39.84 39.89 +0. 05 
9 33.0 29.69 29.69 0.0 
10 45.5 44.86 44.88 +0.02 
11 74.3 75.09 75.13 +0.04 
12 41.8 41.21 41.26 +0.05 
13 37.2 36.94 36.96 +0.02 
14 155.5 155.21 155.25 +0.04 
15 27.0 26.11 26.15 +0.03 
16 12.6 12.09 12.11 +0.02 
17 16.6 16.69 16.68 –0.01 
18 17.9  18.16 - 
19 23.0 23.57 23.55 –0.02 
20 21.5 21.07 21.07 0.0 
21 107.3 107.05 107.06 +0. 01 
Abbreviation: Q = Amphidinolide Q 
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Preparation of catalyst [Cp*RhCl2]2 
To a stirred solution of RhCl3 (0.5 g, 1.95 mmol) in MeOH (12 mL) was added excess 
pentamethylcyclopentadiene (0.5 mL). The mixture was reflux for 21 h, cooled to room 
temperature, and filtered through a sintered funnel. The filter cake washed with diethyl ether (2 
× 5 mL), and dried under vacuum to give the rhodium catalyst (1.02 g, 85%) as dark brown 
powder. 
4-(Benzyloxy)-3-methoxybenzaldehyde (9-2) 
 
 
To a suspension of vanilin (5.0 g, 32.9 mmol, 1.0 equiv) and K2CO3 (11.4 g, 82.2 mmol, 2.5 
equiv) in acetone (50 mL), benzyl bromide (4.3 mL, 36.1 mmol, 1.1 equiv) was added and the 
resulting mixture was refluxed for 10 h. After being cooled to room temperature, the suspension 
was filtered through a sintered funnel. The filtrate was evaporated to dryness and treated with 
(50 mL) water and extracted with ethyl actate (3 × 20 mL). The combined organic layers were 
washed with (20 mL) saturated NaCl solution, dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:20) to afford the pure benzyl ether 9-2 (6.66 g, 82%) as a yellow 
solid. 1H NMR (400 MHz, CDCl3):  = 3.95 (s, 3H, OMe), 5.25 (s, 2H, OCH2Ph), 6.98 (d, J = 
8.1Hz, 1H, 5-H), 7.30-7.36 (m, 1H, 2-H), 7.36-7.42 (m, 3H, Ar), 7.42-7.48 (m, 3H, Ar), 9.84 
(s, 1H, CHO); 13C NMR (100 MHz, CDCl3):  = 56.0 (OMe), 70.8 (CH2Ph), 109.3 (C-2), 112.3 
(C-5), 126.5 (Ar), 127.2 (Ar), 128.2 (Ar), 128.7 (Ar), 130.2 (Ar), 136.0 (Ar), 150.0 (Ar), 153.5 
(Ar), 190.9 (CHO). 
4-(Benzyloxy)-3-methoxybenzoic acid (9-3) 
 
 
To a stirred solution of aldehyde 9-2 (2.5 g, 10.33 mmol, 1.0 equiv), NaH2PO4·2H2O (0.483 g, 
3.10 mmol, 0.3 equiv) and H2O2 (60%, 0.31 mL, 10.84 mmol, 1.04 equiv) in MeCN/H2O (60 
mL, 5:1, v/v) was added a solution of NaClO2 (1.64 g, 14.46 mmol, 1.4 eq) in H2O (15 mL) 
dropwise while keeping the temperature of the mixture below 10 °C with a water bath. The 
mixture was stirred at room temperature for 90 min, before solid Na2S2O3 (0.254 g, 1.6 mmol) 
was added followed by stirring of the mixture at room temperature for 5 min to decompose 
excess H2O2. The mixture was diluted with saturated NaCl solution (20 mL) and extracted with 
EtOAc (3 × 20 mL). The combined organic layers were washed with saturated NaCl solution 
(2 × 20 mL) and with saturated NaHCO3 solution (3 × 20 mL). The organic layers were 
discarded. The combined aqueous layers were acidified with concentrated HCl until pH4 
followed by extraction with EtOAc (3 × 20 mL). These organic extracts were dried over 
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Na2SO4, filtered and concentrated in vacuo to give the crude acid (2.55 g, 99%) as white solid, 
which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3):  = 
3.94 (s, 3H, OMe), 5.23 (s, 2H, CH2Ph), 6.92 (d, J = 8.6 Hz, 1H, 5-H), 7.28-7.34 (m, 1H, Ar), 
7.35-7.40 (m, 2H, Ar), 7.41-7.46 (m, 2H, Ar), 7.61(d, J = 2.0 Hz, 2-H), 7.70 (dd, J = 2.0, 8.3 
Hz, 1H, 6-H); 13C NMR (100 MHz, CDCl3):  = 56.0 (OMe), 70.7 (CH2Ph), 112.3 (C-5), 112.7 
(C-2), 121.9 (C-6), 124.4 (Ar), 127.2 (Ar), 128.1 (Ar), 128.7 (Ar), 136.2 (Ar), 149.1 (Ar), 152.8 
(Ar), 172.0 (CO2H). 
Ethyl 4-(benzyloxy)-3-methoxybenzoate (9-4) 
 
 
To the stirred solution of acid 9-3 (0.5 g, 1.94 mmol, 1.0 equiv) and K2CO3 (0.655 g, 4.75 
mmol, 2.5 equiv) in DMF (10 mL) was added bromoethane (350 µL, 4.75 mmol, 2.5 equiv). 
The reaction mixture was stirred at room temperature overnight under N2 atmosphere. The 
reaction was quenched with water (30 mL) and extracted with ethyl acetate (3 × 10 mL). The 
combined organic layers were washed with water (2 × 10 mL) and saturated NaCl solution (20 
mL). They were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
ester was purified by flash chromatography (ethyl acetate/petroleum ether, 5:1) to afford pure 
ester 9-4 (0.508 g, 93%) as white solid. 1H NMR (400 MHz, CDCl3):  = 1.36 (t, J = 7.1 Hz, 
3H, OCH2CH3), 3.92 (s, 3H, OMe), 4.33 (q, J = 7.3, 14.4 Hz, 2H, OCH2CH3), 5.20 (s, 2H, 
CH2Ph), 6.88 (d, J = 8.3 Hz, 1H, 5-H), 7.26-7.32 (m, 1H, Ar), 7.33-7.38 (m, 2H, Ar), 7.39-7.45 
(m, 2H, Ar), 7.56 (d, J = 2.0 Hz, 1H, 2-H), 7.60 (dd, J = 2.0, 8.3 Hz, 1H, 6-H); 13C NMR (100 
MHz, CDCl3):  = 14.3 (OCH2CH3), 56.0 (OMe), 60.7 (OCH2CH3), 70.7 (CH2Ph), 112.3 (C-
5), 123.2 (C-2), 123.2 (Ar), 127.1 (Ar), 128.0 (Ar), 128.6 (Ar), 136.3 (Ar), 149.0 (Ar), 151.9 
(Ar), 166.3 (CO2Et). 
Preparation of O-pivaloyl hydroxamic acids 
(Procedure 1, via hydroxamic acid) 
(a) To a stirred solution of ethyl benzoate (1.0 equiv) and hydroxylamine hydrochloride (4.0 
equiv) in MeOH (2 mL per mmol of benzoate) was added KOH solution (1M in methanol, 5.0 
equiv) in a dropwise fashion. The resulting solution was stirred 48 h at room temperature. 
Thereafter most of the MeOH was distilled out in vacuo and the solid residue was dissolved in 
a mixture of acetic acid/water (1/1, 4 mL per mmol of benzoate). The mixture was extracted 
with EtOAc (3 × 5 mL (per mmol of benzoate)). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to provide the crude hydroxamic acid 
which was washed with diethyl ether (5 mL per mmol of benzoate) to afford the pure 
hydroxamic acid as transparent solid.  
(b) To the suspension of hydroxamic acid (1.0 equiv) in CH2Cl2 (5 mL per mmol of acid) was 
added pivalic anhydride (0.8 equiv). The resulting mixture was stirred for 16 h at room 
temperature. The reaction mixture was diluted with saturated NaHCO3 (4 mL per mmol of acid) 
and extracted with EtOAc (2 × 5 mL (per mmol of acid)). The combined organic layers were 
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washed with saturated NaHCO3 solution (4 mL per mmol of acid), dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography to afford the pure O-pivaloyl hydroxamic acid. 
Procedure 2 (reaction of acid chloride with O-pivaloylhydroxylamine) 
To a solution of benzoic acid (1.0 equiv) in dry CH2Cl2 (3 mL per mmol of acid) was added 
SOCl2 (5.0 equiv) at room temperature followed by the addition of a catalytic amount of DMF 
(4 drops per 10 mmol of acid). The mixture was refluxed for 8 h. After cooling, solvent and 
excess reagent were removed in vacuo to afford the crude acid chloride, which was used in the 
next step without further purification. 
O-Pivaloylhydroxylamine triflate (1.2 equiv) was added to a biphasic mixture of Na2CO3 (2.0 
equiv) in EtOAc/H2O (9 mL per mmol of acid chloride, 2:1). To the cooled mixture containing 
the pivaloylhydroxylamine at 0 °C was added crude acid chloride (1.0 equiv) in EtOAc (1 mL 
per mmol of acid chloride) dropwise. The reaction mixture was allowed to reach room 
temperature within 5 h. The layers were separated and the aqueous layer was extracted with 
EtOAc (2 × 10 mL (per mmol of acid chloride)). The combined organic layers were dried over 
Na2SO4, filtered and concentrated in vacuo to provide. The crude product was purified by flash 
chromatography to afford pure O-pivaloyl hydroxamic acid. 
4-(Benzyloxy)-N-hydroxy-3-methoxybenzamide (9-5) 
 
 
Prepared from benzoic acid 9-3 (300 mg, 1.05 mmol) according to procedure 1 (a). The crude 
product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) to give 
hydroxamic acid 9-5 (280 mg, 95%) as colorless solid. 1H NMR (400 MHz, DMSO-d6):  = 
3.78 (s, 3H, OMe), 5.11 (s, 2H, CH2Ph), 7.1 (d, J = 8.3 Hz, 1H, Ar), 7.28-7.47 (m, 7H, Ar); 13C 
NMR (100 MHz, DMSO-d6):  = 55.8 (OMe), 70.0 (CH2Ph), 110.6 (C-5), 112.8 (C-2), 120.1 
(C-6), 125.4 (Ar), 128.14 (Ar), 128.3 (Ar), 128.7 (Ar), 136.9 (Ar), 148.8 (Ar), 150.3 (Ar), 164.2 
(CONHOH); HRMS (ESI): calcd for C15H15NO4 [M+Na]+ 296.08933, found 296.08989. 
N-(Pivaloyloxy)benzamide (8-1) 
 
 
Prepared from the corresponding N-hydroxybenzamide (850 mg, 6.20 mmol) according to 
procedure 1 (b). The crude product was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:10) to give pure N-(pivaloyloxy)benzamide 8-1 (1.260 g, 92%) as 
colorless solid. 1H NMR (400 MHz, CDCl3):  = 1.34 (s, 9H, OPiv), 7.39-7.46 (m, 2H, Ar), 
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7.50-7.57 (m, 1H, Ar), 7.76-7.82 (m, 2H, Ar), 9.48 (s, 1H, NH); 13C NMR (100 MHz, CDCl3): 
 = 27.0 (OPiv), 38.4 (tBu), 127.4 (Ar), 128.8 (Ar), 130.8 (Ar), 132.6 (Ar), 166.7 (CONH), 
177.0 (tBuCO2). 
4-(Benzyloxy)-3-methoxy-N-(pivaloyloxy)benzamide (9-6) 
 
 
Prepared from N-hydroxybenzamide 9-5 (250 mg, 0.91 mmol) according to procedure 1 (b). 
The crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:5) to 
give pure N-(pivaloyloxy)benzamide 9-6 (240 mg, 75%) as yellow solid. 1H NMR (400 MHz, 
CDCl3):  = 1.35 (s, 9H, OPiv), 3.91 (s, 3H, OMe), 5.21 (s, 2H, CH2Ph), 6.87 (d, J = 8.6 Hz, 
1H, 5-H), 7.28-7.47 (m, 7H, Ar), 9.24 (s, 1H, NH); 13C NMR (100 MHz, CDCl3):  = 27.0 
(OPiv), 38.4 (tBu), 56.1 (OMe), 70.84 (CH2Ph), 111.0 (C-5), 112.7 (C-2), 120.3 (C-6), 123.5 
(Ar), 127.2 (Ar), 128.1 (Ar), 128.7 (Ar), 136.2 (Ar), 149.7 (Ar), 151.9 (Ar), 177.3 (CONH), 
177.7 (tBuCO2); HRMS (ESI): calcd for C20H23NO5 [M+Na]+ 380.14684, found 380.14715. 
4-Ethoxy-3-methoxy-N-(pivaloyloxy)benzamide (9-18) 
 
 
Prepared from the corresponding benzoic acid (1.00 g, 5.09 mmol) according to procedure 2. 
The crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:5) to 
give pure N-(pivaloyloxy)benzamide 9-18 (1.5 g, 98%) as colorless solid. 1H NMR (400 MHz, 
CDCl3):  = 1.28 (s, 9H, OPiv), 1.41 (t, J = 7.1 Hz, 3H, OCH2CH3), 3.79 (s, 3H, OMe), 4.05 
(q, J = 7.1 Hz, OCH2CH3), 6.71-6.77 (m, 1H, Ar), 7.29-7.35 (m, 2H, Ar), 9.79 (s, 1H, NH); 13C 
NMR (100 MHz, CDCl3):  = 14.4 (OCH2CH3), 26.9 (OPiv), 38.3 (tBu), 55.7 (OMe), 64.2 
(OCH2CH3), 110.5 (Ar), 111.17 (Ar), 120.5 (Ar), 122.7 (Ar), 148.9 (Ar), 151.8 (Ar), 166.5 
(CONH), 177.0 (tBuCO2); HRMS (ESI): calcd for C15H21NO5 [M+Na]+ 318.13119, found 
318.13121. 
3,4-(Dimethoxy)-N-(pivaloyloxy)benzamide (8-6) 
 
 
Prepared either from the corresponding N-hydroxybenzamide (3.00 g, 15.2 mmol, procedure 1) 
or the benzoic acid (3.0 g, 14.48 mmol, procedure 2). The crude product was purified by flash 
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chromatography (ethyl acetate/petroleum ether, 1:3) to give pure N-(pivaloyloxy)benzamide 8-
6 (3.70 g, 86%, procedure 1; 3.70 g, 80%, procedure 2) as colorless solid. 1H NMR (400 MHz, 
CDCl3):  = 1.24 (s, 9H, OPiv), 3.75 (s, 3H, OMe), 3.78 (s, 3H, OMe), 6.65-6.73 (m, 1H, 5-H), 
7.26-7.36 (m, 2H, 2-H, 3-H), 9.65 (br, 1H, NH); 13C NMR (100 MHz, CDCl3):  = 26.8 (OPiv), 
38.2 (tBu), 55.6 (OMe), 55.7 (OMe), 110.1 (Ar), 110.2 (Ar), 120.5 (Ar), 122.9 (Ar), 148.6 (Ar), 
152.2 (Ar), 166.3 (CONH), 176.9 (tBuCO2); HRMS (ESI): calcd for C14H19NO5 [M+Na]+ 
304.11554, found 304.11566. 
N-(pivaloyloxy) benzo[d][1,3]dioxole-5-carboxamide (9-19) 
 
 
Prepared from the corresponding benzoyl chloride (500 mg, 2.71 mmol) according to procedure 
2. The crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:3) 
to give pure N-(pivaloyloxy)benzamide 9-19 (650 mg, 90%) as colorless solid. 1H NMR (400 
MHz, CDCl3):  = 1.31 (s, 9H, OPiv), 5.99 (s, 2H, OCH2O), 6.76 (d, J = 8.3 Hz, 5-H), 7.21 (d, 
J = 2.0 Hz, 2-H), 7.22 (dd, J = 8.3, 2.0 Hz, 1H, 6-H), 9.58 (s, 1H, NH); 13C NMR (100 MHz, 
CDCl3):  = 26.9 (OPiv), 38.5 (tBu), 101.8 (OCH2O), 107.8 (C-5), 108.1 (C-2), 122.6 (C-6), 
124.6 (Ar), 147.9 (Ar), 151.2 (Ar), 166.2 (CONH), 177.1 (tBuCO2); HRMS (ESI): calcd for 
C13H15NO5 [M+Na]+ 288.08424, found 288.08450. 
Rhodium catalyzed annulation (Procedure 3) 
An oven dried, cooled Schlenk tube under N2, was charged with N-(pivaloyloxy)benzamide 
(1.0 equiv), [Cp*RhCl2]2 (2.5 mol%), CsOAc (50 mol%) and dry EtOH (1 mL per mmol of 
amide). The mixture was cooled to 0 °C, whereupon 1,3-cyclohexadiene (1.3 equiv) was added 
in one shot. The screw cap was closed tightly under positive pressure of N2 followed by stirring 
of the reaction mixture at room temperature for 35 h (TLC control). The mixture was 
concentrated in vacuo and the residue purified by flash chromatography to afford the pure 
annulation product. 
1,4a,5,10b-Tetrahydrophenanthridin-6(2H)-one (8-3) 
 
 
Prepared from N-(pivaloyloxy)benzamide 8-1 (100 mg, 0.45 mmol) according to procedure 3. 
TLC showed consumption of starting material after 19 h. The crude product was purified by 
flash chromatography (ethyl acetate/petroleum ether, 1:1) to give pure phenanthridinone 8-3 
(74 mg, 82%) as colorless solid. 1H NMR (400 MHz, CDCl3):  = 1.62-1.73 (m, 1H, 1-H), 1.88-
2.05 (m, 1H, 2-H), 2.10-2.28 (m, 2H, 1-H, 2-H), 2.92 (td, J = 3.8, 12.2 Hz, 1H, 10b-H), 4.22-
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4.30 (m, 1H, 4a-H), 5.79 (ddt, J = 2.1, 4.5, 9.3 Hz, 1H, 4-H), 5.94-6.06 (m, 1H, 3-H), 6.26 (s, 
br, 1H, NH), 6.23 (d, J = 7.5 Hz, 1H, Ar), 7.33 (td, J = 1.1, 7.6 Hz, 1H, Ar), 7.46 (td, J = 1.3, 
7.5 Hz, 1H, Ar), 8.06 (dd, J = 1.2, 7.8 Hz, 1H, Ar); 13C NMR (100 MHz, CDCl3):  = 25.0 (C-
2), 25.1 (C-1), 37.7 (C-10b), 47.9 (C-4a), 124.4 (Ar), 127.0 (Ar), 127.2 (Ar), 127.5 (Ar), 127.9 
(Ar) 132.2 (C-4), 132.5 (C-3), 142.7 (Ar), 165.4 (CONH); HRMS (ESI): calcd for C13H13NO 
[M+Na]+ 222.08893, found 222.08894. 
9-(Benzyloxy)-8-methoxy-1,4a,5,10b-tetrahydrophenanthridin-6(2H)-one (9-15) 
 
 
Prepared from N-(pivaloyloxy)benzamide 9-6 (50 mg, 0.14 mmol) according to procedure 3. 
TLC showed consumption of starting material after 39 h. The crude product was purified by 
flash chromatography (ethyl acetate/petroleum ether, 1:1) to give pure phenanthridinone 9-15 
(26 mg, 55%) as slightly yellow solid. 1H NMR (400 MHz, CDCl3):  = 1.54-1.65 (m, 1H, 1-
H), 1.82-1.97 (m, 1H, 1-H), 2.06-2.26 (m, 2H, 1-H), 2.78 (td, J = 3.3, 12.1 Hz, 1H, 10a-H), 
3.92 (s, 3H, OMe), 4.21 (m, 1H, 4a-H), 5.20 (OCH2Ph), 5.57 (s, br, NH), 5.68-5.78 (m, 1H, 4-
H), 5.94-6.05 (m, 1H, 3-H), 6.70 (s, 1H, 10-H), 7.28-7.34 (m, 1H, Ar), 7.34-7.41 (m, 2H, Ar), 
7.41-7.48 (m, 2H, Ar), 7.58 (s, 1H, 7-H); 13C NMR (100 MHz, CDCl3):  = 24.9 (C-2), 25.0 
(C-1), 37.4 (C-10b), 48.2 (C-4a), 56.1 (OMe), 70.9 (OCH2Ph), 110.4 (C-7), 111.6 (C-10), 120.4 
(Ar), 124.4, 127.2, 128.0, 128.6, 132.2, 136.2, 136.4, 148.6 (Ar), 151.6 (Ar), 164.9 (CONH); 
HRMS (ESI): calcd for C21H21O3 [M+H]+ 336.159420, found 336.159327. 
9-Ethoxy-8-methoxy-1,4a,5,10b-tetrahydrophenanthridin-6(2H)-one (9-20) 
 
 
Prepared from N-(pivaloyloxy)benzamide 9-18 (100 mg, 0.34 mmol) according to procedure 3. 
TLC showed consumption of starting material after 20 h. The crude product was purified by 
flash chromatography (ethyl acetate/petroleum ether, 2:1) to give pure phenanthridinone 9-20 
(75 mg, 81%) as colorless solid. 1H NMR (400 MHz, CDCl3):  = 1.45 (t, J = 6.8 Hz, 3H, 
OCH2CH3), 1.58-1.68 (m, 1H, 1-H), 1.82-1.95 (m, 1H, 1-H), 2.11-2.21 (m, 2H, 2-H), 2.78 (td, 
J = 3.3, 12.4 Hz, 1H, 10a-H), 3.87 (s, 3H, OMe), 4.11 (q, J = 6.8 Hz, 2H, OCH2CH3), 4.18-4.23 
(m, 1H, 4a-H), 5.72-5.80 (m, 1H, 4-H), 5.93-6.01 (m, 1H, 3-H), 6.40 (s, 1H, NH), 6.65 (s, 1H, 
10-H), 7.51 (s, 1H, 7-H); 13C NMR (100 MHz, CDCl3):  = 14.6 (OCH2CH3), 24.9 (C-2), 25.1 
(C-1), 37.4 (C-10b), 48.1 (C-4a), 56.0 (OMe), 64.3 (OCH2CH3), 110.0 (C-7), 110.2 (C-10), 
119.6 (Ar), 124.3 (C-4), 132.0 (Ar), 136.5 (C-3), 148.1 (Ar), 151.9 (Ar), 165.4 (CONH). 
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8,9-Dimethoxy-1,4a,5,10b-tetrahydrophenanthridin-6(2H)-one (9-21) 
 
 
Prepared from N-(pivaloyloxy)benzamide 8-6 (500 mg, 1.78 mmol) according to procedure 3. 
TLC showed consumption of starting material after 55 h. The crude product was purified by 
flash chromatography (ethyl acetate/petroleum ether, 4:1) to give pure phenanthridinone 9-21 
(325 mg, 70%) as slightly brown solid. 1H NMR (400 MHz, CDCl3):  = 1.61-1.71 (m, 1H, 1-
H), 1.84-1.99 (m, 1H, 1-H), 2.15-2.24 (m, 2H, 2-H), 2.82 (td, J = 4.0, 12.4 Hz, 1H, 10b-H), 
3.91 (s, 3H, OMe), 3.91 (s, 3H, OMe), 4.23 (t, J = 4.0 Hz, 1H, 4a-H), 5.72-5.84 (m, 2H, 4-H, 
NH), 5.97-6.05 (m, 1H, 3-H), 6.67 (s, 1H, 10-H), 7.51 (s, 1H, 7-H); 13C NMR (100 MHz, 
CDCl3):  = 24.9 (C-2), 25.2 (C-1), 37.7 (C-10b), 48.2 (C-4a), 56.0 (OMe), 56.1 (OMe), 109.3 
(C-7), 109.9 (C-10), 120.0 (Ar), 124.4 (C-4), 132.2 (Ar), 136.6 (C-3), 148.0 (Ar), 152.5 (Ar), 
164.9 (CONH); HRMS (ESI): calcd for C15H17NO3 [M+Na]+ 282.11006, found 282.11030. 
7a,8,9,11a-Tetrahydro-[1,3]dioxolo[4,5-k]phenanthridin-6(7H)-one (9-22) 
 
 
Prepared from N-(pivaloyloxy)benzamide 9-19 (500 mg, 2.00 mmol) according to procedure 3. 
TLC showed consumption of starting material after 35 h. The crude product was purified by 
flash chromatography (ethyl acetate/petroleum ether, 4:1) to give pure phenanthridinone 9-22 
(435 mg, 89%) as colorless solid. 1H NMR (400 MHz, CDCl3):  = 1.69-1.78 (m, 1H, 11-H), 
1.80-1.97 (m, 1H, 11-H), 2.14-2.26 (m, 2H, 10-H2), 2.98-3.12 (m, 1H, 11a-H), 4.14-4.26 (m, 
1H, 7a-H), 5.68-5.85 (m, 2H, 8-H, NH), 6.00-6.11 (m, 1H, 9-H), 6.02 (d, J = 1.3 Hz, 2-H), 6.79 
(d, J = 1.3 Hz, 2-H), 6.79 (d, J = 8.2 Hz, 1H, 4-H), 7.68 (d, J = 8.3 Hz, 1H, 5-H); 13C NMR 
(100 MHz, CDCl3):  = 22.6 (C-10), 25.2 (C-11), 32.4 (C-11a), 47.6 (C-7a), 101.9 (C-2), 107.1 
(C-4), 121.7 (Ar), 123.4 (C-5), 123.9 (Ar), 124.0 (C-8), 132.6 (C-9), 143.9 (Ar), 150.6 (Ar), 
164.6 (CONH); HRMS (ESI): calcd for C14H13NO3 [M+Na]+ 266.07876, found 266.07918. 
Reduction of the tetrahydrophenanthridinones to hexahydrophenanthridines 
(Procedure 4) 
To a cooled (0 °C) solution of AlCl3 (1 equiv) in THF (10 mL per mmol AlCl3) under N2 was 
added LiAlH4 (3 equiv). The mixture was allowed to stir at room temperature for 1 h, before it 
was added dropwise via cannula to a separately stirred solution of the amide (1 equiv) in THF 
(20 mL per mmol of amide). The reaction mixture was allowed to reach room temperature 
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within 1 h. Then the flask was moved to a preheated oil bath (40 °C) and the mixture stirred for 
8 h. Thereafter, the reaction mixture was cooled to 0 °C and quenched with saturated NH4Cl 
solution (10 mL per mmol of AlCl3). The organic layer was separated and the aqueous semisolid 
washed with diethyl ether (10 mL per mmol of amide). The combined organic layers were dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude material was dissolved 
in diethyl ether (10 mL per mmol of amide) and cooled to 0 °C, and then ethereal HCl (3m, 0.5 
mL per mmol of amide) was added dropwise. The white solid amine salt which precipitated 
was collected by filtration through a G4 frit. It was found to be of sufficient purity. 
9-Ethoxy-8-methoxy-1,2,4a,5,6,10b-hexahydrophenanthridin-5-iumchloride (9-23) 
 
 
Prepared from tetrahydrophenanthridinone 9-20 (127 mg, 0.46 mmol) according to procedure 
4 to give pure hydrochloride 9-23 (115 mg, 80%) as colorless solid. 1H NMR (400 MHz, 
CD3OD):  = 1.40 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.79-1.91 (m, 1H, 1-H), 2.04-2.12 (m, 1H, 1-
H), 2.16-2.35 (m, 2H, 2-H), 3.16 (dt, J = 4.3, 12.1 Hz, 1H, 10b-H), 3.82 (s, 3H, OMe), 4.06 (q, 
J = 7.1 Hz, 3H, OCH2CH3, 4a-H), 4.28 (dd, J = 11.4, 15.4 Hz, 2H, 6-H), 5.86-5.93 (m, 1H, 4-
H), 6.28-6.34 (m, 1H, 3-H), 6.79 (s, 1H, 10-H), 6.93 (s, 1H, 7-H); 13C NMR (100 MHz, 
CD3OD):  = 15.2 (OCH2CH3), 25.8 (C-2), 27.8 (C-1), 35.5 (C-10b), 45.2 (C-6), 52.2 (C-4a), 
56.7 (OMe), 65.8 (OCH2CH3), 110.7 (C-7), 114.2 (C-10), 120.5 (Ar), 122.0 (C-4), 129.2 (Ar), 
138.2 (C-3), 150.2 (Ar), 150.3 (Ar); HRMS (ESI): calcd for C16H22ClNO2 [M]+ 260.164505, 
found 260.164354. 
8,9-Dimethoxy-1,2,4a,5,6,10b-hexahydrophenanthridin-5-iumchloride (9-24) 
 
 
Prepared from tetrahydrophenanthridinone 9-21 (500 mg, 1.90 mmol) according to procedure 
4 to give pure hydrochloride 9-24 (425 mg, 75%) as colorless solid. 1H NMR (400 MHz, 
CD3OD):  = 1.77-1.93 (m, 1H, 1-H), 2.04-2.17 (m, 1H, 1-H), 2.18-2.37 (m, 2H, 2-H), 3.18 
(dt, J = 4.0, 12.0 Hz, 1H, 10b-H), 3.82 (s, 3H, OMe), 3.84 (s, 3H, OMe), 4.02-4.10 (m, 1H, 4a-
H), 4.29 (dd, J = 14.4, 15.7 Hz, 2H, 6-H), 5.84-5.91 (m, 1H, 4-H), 6.28-6.37 (m, 1H, 3-H), 6.78 
(s, 1H, 10-H), 6.95 (s, 1H, 7-H); 13C NMR (100 MHz, CD3OD):  = 25.8 (C-2), 27.8 (C-1), 
35.6 (C-10b), 45.2 (C-6), 52.3 (C-4a), 56.6 (OMe), 56.7 (OMe), 110.5 (C-7), 112.9 (C-10), 
120.5 (Ar), 121.9 (C-4), 129.3 (Ar), 138.3 (C-3), 150.2 (Ar), 151.0 (Ar); HRMS (ESI): calcd 
for C15H20ClNO2 [M+Na]+ 246.14886, found 246.14873. 
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Preparation of -haloamides from amine hydrochlorides (Procedure 5) 
To a stirred solution of the amine·HCl (1 equiv) and trimethylamine (2 equiv) in THF (3 mL 
per mmol of salt) at 0 °C was added 2-bromoacetyl bromide (2 equiv). The stirred reaction 
mixture was allowed to reach room temperature within 1 h. For work-up the mixture was diluted 
with saturated NaHCO3 solution (20 mL per mmol of salt) and extracted with Et2O (3 × 15 mL 
(per mmol of salt). The combined organic layers were dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude amide was purified by flash chromatography (petroleum 
ether/ethyl acetate, 3:1) to provide pure product. 
2-Bromo-1-(9-ethoxy-8-methoxy-2,4a,6,10b-tetrahydrophenanthridin-5(1H)-yl)ethan-1-
one (9-25) 
 
 
Prepared from amine hydrochloride 9-23 (50 mg, 0.16 mmol) according to procedure 5 to give 
pure bromoacetylamide 9-25 (67 mg, 99%) as brown solid. Rf = 0.5 (petroleum ether/ethyl 
acetate, 1:1); 1H NMR (400 MHz, CDCl3, mixture of rotamers):  = 1.43 (t, J = 7.1 Hz, 3H, 
OCH2CH3), 1.68-1.93 (m, 2H, 1-H, 2-H), 1.93-2.09 (m, 1H, 1-H), 2.21-2.43 (m, 1H, 2-H), 3.16-
3.43 (m, 1H, 10b-H), 3.81 (s, 3H, OMe), 4.00-4.23 (m, 5H, OCH2CH3, CH2Br, 4a-H), 4.40-
4.64 (m, 1H, 6-H), 5.12-5.46 (m, 1H, 6-H), 5.46-5.58 (m, 1H, 4-H), 5.70-5.85 (m, 1H, 3-H), 
6.54 (s, 1H, 7-H), 6.80 (s, 1H, 10-H); 13C NMR (100 MHz, CDCl3):  = 14.8, 20.1, 25.3, 33.1, 
34.4, 40.7, 41.1, 41.5, 44.6, 48.6, 53.4, 55.8, 64.5, 64.6, 108.5, 108.9, 111.0, 111.2, 124.4, 
125.2, 125.6, 126.0, 132.1, 132.6, 147.3, 147.7, 147.8, 148.0, 165.3 (CO); HRMS (ESI): calcd 
for C18H22BrNO3 [M]+ 402.067527, found 402.067526. 
2-Bromo-1-(8,9-dimethoxy-2,4a,6,10b-tetrahydrophenanthridin-5(1H)-yl)ethan-1-one 
(9-26) 
 
 
Prepared from amine hydrochloride 9-24 (200 mg, 0.71 mmol) according to procedure 5 to give 
pure bromoacetylamide 9-26 (145 mg, 56%) as brown solid. Rf = 0.2 (petroleum ether/ethyl 
acetate, 1:1); 1H NMR (400 MHz, CDCl3, mixture of rotamers):  = 1.66-1.92 (m, 2H, 1-H, 2-
H), 1.93-2.11 (m, 1H, 1-H), 2.22-2.48 (m, 1H, 2-H), 3.13-3.48 (m, 1H, 10b-H), 3.81 (s, 3H, 
OMe), 3.84 (s, 3H, OMe), 3.97-4.24 (m, 1H, 4a-H), 4.15 (s, 2H, CH2Br), 4.43-4.83 (m, 1H, 6-
H), 5.12-5.45 (m, 1H, 6-H), 5.46-5.60 (m, 1H, 4-H), 5.71-5.88 (m, 1H, 3-H), 6.53 (s, 1H, 7-H), 
6.78 (s, 1H, 10-H); 13C NMR (100 MHz, CDCl3):  = 20.1, 25.3, 33.2, 34.4, 40.7, 41.1, 41.4, 
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44.6, 48.6, 53.4, 55.7, 56.0, 108.2, 108.7, 109.2, 109.5, 124.4, 125.1, 125.6, 125.9, 132.1, 132.6, 
148.1, 148.5, 165.4 (CO); HRMS (ESI): calcd for C17H20BrNO3 [M+Na]+ 388.05188, found 
388.05197. 
5-(2-Chloroacetyl)-8,9-dimethoxy-1,4a,5,10b-tetrahydrophenanthridin-6(2H)-one (9-29) 
 
 
To a solution of amide 9-21 (40 mg, 0.15 mmol) and 2-dimethylaminopyridine (37 L, 0.30 
mmol) in CH3CN (0.5 mL) at 0 °C was added dropwise chloroacetyl chloride (24 L, 0.30 
mmol), then the mixture was allowed to warm to room temperature and stirred for 2 d. The 
solvent was removed in vacuo, and the remainder diluted with EtOAc (1.0 mL). The solution 
was washed with saturated NaCl solution, dried over Na2SO4, filtered, and concentrated in 
vacuo. The crude amide was purified by flash chromatography (petroleum ether/ethyl acetate, 
2:1) to provide pure amide 9-29 (35 mg, 69%), as a yellow amorphous solid. Rf = 0.4 (petroleum 
ether/ethyl acetate, 1:1); 1H NMR (400 MHz, CDCl3):  = 1.86-2.04 (m, 2H, 1-H, 2-H), 2.05-
2.17 (m, 1H, 1-H), 2.41-2.51 (m, 1H, 2-H), 3.40-3.48 (m, 1H, 10b-H), 3.89 (s, 3H, OMe), 3.94 
(s, 3H, OMe), 4.78 (d, J = 16.2 Hz, 1H, COCH2Cl), 4.93 (d, J = 16.2 Hz, 1H, COCH2Cl), 5.31-
5.41 (m, 1H, 4a-H), 5.46-5.53 (m, 1H, 4-H), 5.56-5.65 (m, 1H, 3-H), 6.81 (s, 1H, 10-H), 7.57 
(s, 1H, 7-H); 13C NMR (100 MHz, CDCl3):  = 20.4 (C-2), 23.8 (C-1), 33.3 (C-10b), 47.4 
(COCH2Cl), 53.3 (C-4a), 55.9 (OMe), 56.1 (OMe), 107.5 (C-7), 111.1 (C-10), 120.0 (Ar), 126.5 
(C-4), 129.6 (C-3), 134.9 (Ar), 148.0 (Ar), 154.0 (Ar), 164.6 (CON), 169.9 (NCOCH2Cl); 
HRMS (ESI): calcd for C17H18ClNO4 [M+Na]+ 358.08166, found 358.08153. 
8,9-Dimethoxy-1,4a,5,10b-tetrahydrophenanthridin-6(2H)-one (9-21) 
 
 
To a boiling solution of chloroacetyl amide 9-29 (20 mg, 60 mol) in benzene (6 mL) was 
added dropwise a solution of Bu3SnH (19 L, 70 mol, 1.2 equiv), Bu3SnCl (81 L, 0.30 mmol, 
5 equiv) and AIBN (2 mg, 12 mol, 20 mol%) in benzene (3 mL) over 3 h by employing a 
syringe pump. After complete addition, the reaction mixture was refluxed for further 2 h. The 
solvent was evaporated in vacuo and the remainder diluted with Et2O (5 mL). This solution was 
washed with 10% aqueous solution of KF (2 × 5 mL), dried over Na2SO4, filtered, concentrated 
in vacuo. The residue was purified by flash chromatography (petroleum ether/ethyl acetate, 1:1) 
to give pure amide 9-21 (13 mg, 83%), as a brown solid. 
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tert-Butyl 2-(8,9-dimethoxy-6-oxo-2,4a,6,10b-tetrahydrophenanthridin-5(1H)-yl)acetate 
(9-30) 
 
 
Sodium hydride (20 mg, 0.50 mmol, 1.3 equiv, 60% dispersion in mineral oil) was added to a 
stirred, cold (0 °C) solution of amide 9-21 (100 mg, 0.38 mmol) in dry DMF (2 mL). The 
solution was allowed to warm to room temperature for 20 min and then cooled to 0 °C, before 
tert-butyl bromoacetate (86 L, 0.57 mmol, 1.5 equiv) was added. Then the reaction mixture 
was warmed to room temperature within 45 min. The reaction mixture was diluted with water 
(30 mL) and the aqueous phase was basified (10% NaOH, 5 mL) and extracted with ether (5 × 
10 mL). The combined ether extracts were washed with saturated NaCl solution, dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography (petroleum ether/ethyl acetate, 3:1) to provide pure N-alkyation product 9-30 
(90 mg, 63%) as an amorphous solid. Rf = 0.6 (petroleum ether/ethyl acetate, 1:1); 1H NMR 
(400 MHz, CDCl3):  = 1.45 (s, 9H, tBu), 1.70-1.80(m, 1H, 1-H), 2.03-2.20 (m, 3H, 1-H, 2-H), 
2.99-3.09 (m, 1H, 10b-H), 3.86 (d, J = 17.2 Hz, 1H, NCH2CO), 3.89 (s, 3H, OMe), 3.91 (s, 3H, 
OMe), 4.33 (m, 1H, 4a-H), 4.70 (d, J = 17.2 Hz, 1H, NCH2CO), 5.66-5.72 (m, 1H, 4-H), 5.91-
5.99 (m, 1H, 3-H), 6.67 (s, 1H, 10-H), 7.58 (s, 1H, 7-H); 13C NMR (100 MHz, CDCl3):  = 
24.3 (C-2), 24.4 (C-1), 28.0 (tBu), 36.7 (C-10b), 46.0 (NCH2CO), 53.5 (C-4a), 56.0 (OMe), 
81.6 (C-(CH3)3), 108.5 (C-7), 110.7 (C-10), 120.6 (Ar), 123.8 (C-4), 132.6 (C-3), 135.2 (Ar), 
147.8 (Ar), 152.2 (Ar), 164.3 (CON), 169.0 (CO2tBu); HRMS (ESI): calcd for C21H27NO5 
[M+Na]+ 396.17814, found 396.17849. 
2-(8,9-Dimethoxy-6-oxo-2,4a,6,10b-tetrahydrophenanthridin-5(1H)-yl)acetic acid (9-31) 
 
 
Through a solution of ester 9-30 (67 mg, 0.18 mmol) in CH2Cl2 (5 mL) was bubbled HCl gas 
at 0 °C for 5 h. The solution was stirred for additional 1.5 h at 0 °C, warmed to room temperature 
over 30 min, and evaporated to dryness. This way acid 9-31 was obtained as a white solid in 
pure form; 1H NMR (400 MHz, CD3OD):  = 1.73-1.92 (m, 1H, 1-H), 2.08-2.30 (m, 3H, 1-H, 
2-H), 3.06-3.22 (m, 1H, 10b-H), 3.84 (s, 3H, OMe), 3.89 (s, 3H, OMe), 4.07 (d, J = 17.4 Hz, 
1H, NCH2CO), 4.35-4.42 (m, 1H, 4a-H), 4.62 (d, J = 17.4 Hz, 1H, NCH2CO), 5.74-5.81 (m, 
1H, 4-H), 5.94-6.01 (m, 1H, 3-H), 6.91 (s, 1H, 10-H), 7.41 (s, 1H, 7-H); 13C NMR (100 MHz, 
CD3OD):  = 25.3 (C-2), 25.3 (C-1), 37.7 (C-10b), 46.0 (NCH2CO), 55.8 (C-4a), 56.6 (OMe), 
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56.7 (OMe), 110.5 (C-7), 111.8 (C-10), 121.4 (Ar), 124.9 (C-4), 133.9 (C-3), 137.6 (Ar), 149.5 
(Ar), 154.5 (Ar), 166.3 (CON), 173.1 (CO2H). 
Se-phenyl 2-(8,9-dimethoxy-6-oxo-2,4a,6,10b-tetrahydrophenanthridine-5(1H)-
yl)ethaneselenoate (9-32) 
 
 
(PhSe)2 (60 mg, 0.20 mmol, 1.5 equiv) was added to a solution of acid 9-31 in CH2Cl2 (10 mL). 
The solution was cooled to 0 °C before n-Bu3P (66 L, 0.26 mmol, 2.0 equiv) was added. The 
reaction mixture was refluxed for 24 h, poured into water (20 mL) and then the mixture was 
extracted with CH2Cl2 (3 × 10 mL). The combined extracts were washed with saturated NaCl 
solution, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product 
was purified by flash chromatography (petroleum ether/ethyl acetate, 3:1) to provide pure 
selenoester 9-32 (50 mg, 84%), as an amorphous solid. Rf = 0.5 (petroleum ether/ethyl acetate, 
1:1); 1H NMR (400 MHz, CDCl3):  = 1.75-1.94 (m, 1H, 1-H), 2.06-2.28 (m, 3H, 1-H, 2-H), 
3.18-3.37 (m, 1H, 10b-H), 3.91 (s, 3H, OMe), 3.93 (s, 3H, OMe), 4.11 (d, J = 16.9 Hz, 1H, 
NCH2CO), 4.37-4.44 (m, 1H, 4a-H), 5.05 (d, J = 16.9 Hz, 1H, NCH2CO), 5.64-5.73 (m, 1H, 4-
H), 5.92-6.01 (m, 1H, 3-H), 6.72 (s, 1H, 10-H), 7.32-7.40 (m, 3H, Ar), 7.46-7.53 (m, 2H, Ar), 
7.62 (s, 1H, 7-H); 13C NMR (100 MHz, CDCl3):  = 23.8 (C-2), 24.3 (C-1), 36.2 (C-10b), 54.7 
(NCH2CO), 56.0 (OMe), 56.05 (OMe), 56.5 (C-4a), 108.3 (C-7), 110.8 (C-10), 120.1 (Ar), 
123.4 (C-4), 125.4 (Ar), 128.9 (C-3), 129.1 (Ar),129 (Ar), 131.4 (Ar), 132.8 (Ar), 135.0 (Ar), 
136.0 (Ar), 148.0 (Ar), 152.6 (Ar), 164.8 (CON), 199.0 (COSePh); HRMS (ESI): calcd for 
C23H23NO4Se [M+Na]+ 480.06845, found 480.06836. 
8,9-Dimethoxy-5-methyl-1,4a,5,10b-tetrahydrophenanthridin-6(2H)-one (9-34) 
 
 
To a boiling solution of compound selenoester 9-32 (16 mg, 0.035 mmol) in benzene (2 mL) 
was added dropwise a solution of Bu3SnH (14 L, 0.052 mmol, 1.5 equiv), and benzoyl 
peroxide (2 mg, 0.008 mmol, 23 mol%) in benzene (1 mL) over 1 h by employing a syringe 
pump. After complete addition, the reaction mixture was further refluxed for 2 h. The solvent 
was evaporated in vacuo, and the residue diluted with Et2O (3 mL). This solution was washed 
with 10% aqueous solution of KF (2 × 5 mL), dried over Na2SO4, filtered, and concentrated in 
vacuo. The crude product was purified by flash chromatography (petroleum ether/ethyl acetate, 
1:2) to provide N-methylamide 9-34 (6 mg, 63%), as a colorless solid. Rf = 0.1 (petroleum 
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ether/ethyl acetate, 1:1); 1H NMR (400 MHz, CDCl3):  = 1.79-1.92(m, 1H, 1-H), 2.02-2.15 
(m, 2H, 1-H, 2-H), 2.16-2.27 (m, 1H, 2-H), 3.14 (s, 3H, NCH3), 3.17-3.28 (m, 1H, 10b-H), 3.91 
(s, 3H, OMe), 3.92 (s, 3H, OMe), 4.08-4.20 (m, 1H, 4a-H), 5.64-5.75 (m, 1H, 4-H), 5.78-5.90 
(m, 1H, 3-H), 6.71 (s, 1H, 10-H), 7.60 (s, 1H, 7-H); 13C NMR (100 MHz, CDCl3):  = 22.9 (C-
2), 24.0 (C-1), 32.2 (NCH3), 35.3 (C-10b), 56.0 (OMe), 56.2 (C-4a), 107.9 (C-7), 110.7 (C-10), 
121.5 (Ar), 124.5 (C-4), 130.6 (C-3), 133.4 (Ar), 147.8 (Ar), 151.9 (Ar), 164.1 (CON); HRMS 
(ESI): calcd for C16H19NO2 [M+Na]+ 296.12571, found 296.12582. 
Preparation of sulfonamides from amine hydrochlorides (Procedure 6) 
To a cooled (0 °C) suspension of amine·HCl (1.0 equiv) in CH2Cl2 (9 mL per mmol of 
hydrochloride) were added Et3N (2.0 equiv) and arylsulfonyl chloride (1.5 equiv). The stirred 
reaction mixture was allowed reach room temperature within 2 h. Thereafter, saturated NaHCO3 
solution (9 mL per mmol of hydrochloride) was added. After separation of the layers the 
aqueous layer was extracted with CH2Cl2 (2 × 9 mL per mmol of hydrochloride). The combined 
organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash chromatography to afford the pure sulfonamides. 
8,9-Dimethoxy-5-tosyl-1,2,4a,5,6,10b-hexahydrophenanthridine (9-35) 
 
 
Prepared from amine hydrochloride 9-24 (305 mg, 1.03 mmol) according to procedure 6 to give 
pure sulfonamide 9-35 (435 mg, 99%) as colorless solid. Rf = 0.3 (petroleum ether/ethyl acetate, 
2:1); 1H NMR (400 MHz, CDCl3):  = 1.55-1.83 (m, 2H, 1-H, 2-H), 1.85-1.98 (m, 1H, 1-H), 
2.18-2.31 (m, 1H, 2-H), 2.38 (s, 3H, SO2CH2Ph), 3.07-3.21 (m, 1H, 10b-H), 3.81 (s, 6H, 2 
OMe), 4.13 (d, J = 15.6 Hz, 1H, 6-H), 4.59 (d, J = 15.6 Hz, 1H, 6-H), 4.76-4.88 (m, 1H, 4a-H), 
5.10-5.20 (m, 1H, 4-H), 5.56-5.73 (m, 1H, 3-H), 6.48 (s, 1H, 7-H), 6.69 (s, 1H, 10-H), 7.22 (d, 
J = 8.0 Hz, 2H, Ar), 7.69 (d, J = 8.0 Hz, 2H, Ar); 13C NMR (100 MHz, CDCl3):  = 20.2 (C-
2), 21.4 (Me), 25.5 (C-1), 34.0 (C-10b), 43.2 (C-6), 52.4 (C-4a), 55.7 (OMe), 56.0 (OMe), 108.4 
(C-8), 109.4 (C-10), 124.7 (Ar), 125.2 (C-4), 126.5 (Ar), 127.1 (Ar), 129.6 (Ar), 132.6 (C-3), 
137.4 (Ar), 143.2 (Ar), 147.3 (Ar), 148.2 (Ar); HRMS (ESI): calcd for C22H25NO4S [M+Na]+ 
422.13965, found 422.13960. 
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8,9-Dimethoxy-5-((2-nitrophenyl)sulfonyl)-1,2,4a,5,6,10b-hexahydrophenanthridine (9-
36) 
 
 
Prepared from amine hydrochloride 9-24 (350 mg, 1.01 mmol) according to procedure 6 to give 
pure sulfonamide 9-36 (377 mg, 87%) as yellow amorphous solid. Rf = 0.2 (petroleum 
ether/ethyl acetate, 2:1); 1H NMR (400 MHz, CDCl3):  = 1.63-1.87 (m, 2H, 1-H, 2-H), 1.93-
2.03 (m, 1H, 1-H), 2.25-2.37 (m, 1H, 2-H), 3.26-3.36 (m, 1H, 10b-H), 3.82 (s, 3H, OMe), 3.83 
(s, 3H, OMe), 4.39 (d, J = 16.2 Hz, 1H, 6-H), 4.56 (d, J = 16.2 Hz, 1H, 6-H), 4.81-4.89 (m, 1H, 
4a-H), 5.34-5.43 (m, 1H, 4-H), 5.68-5.79 (m, 1H, 3-H), 6.52 (s, 1H, 7-H), 6.76 (s, 1H, 10-H), 
7.58-7.70 (m, 3H, Ar), 8.01-8.08 (m, 1H, Ar); 13C NMR (100 MHz, CDCl3):  = 20.1 (C-2), 
25.5 (C-1), 33.9 (C-10b), 43.5 (C-6), 52.9 (C-4a), 55.8 (OMe), 56.0 (OMe), 108.4 (C-7), 109.4 
(C-10), 124.7 (Ar), 124.2 (Ar), 124.7 (Ar), 126.2 (Ar), 130.7 (C-4), 131.7 (C-3), 133.1 (Ar), 
133.3 (Ar), 133.7 (Ar), 147.4 (Ar), 147.9 (Ar), 148.3 (Ar); HRMS (ESI): calcd for C21H22N2O6S 
[M+Na]+ 453.10908, found 453.10940. 
8,9-Dimethoxy-5-((4-nitrophenyl)sulfonyl)-1,2,4a,5,6,10b-hexahydrophenanthridine (9-
37) 
 
 
Prepared from amine hydrochloride 9-24 (100 mg, 0.35 mmol) according to procedure 6 to give 
pure sulfonamide 9-37 (140 mg, 99%) as yellow amorphous solid. Rf = 0.2 (petroleum 
ether/ethyl acetate, 2:1); 1H NMR (400 MHz, CDCl3):  = 1.62-1.73 (m, 1H, 1-H), 1.74-1.85 
(m, 1H, 2-H), 1.85-1.98 (m, 1H, 1-H), 2.18-2.31 (m, 1H, 2-H), 2.99-3.13 (m, 1H, 10b-H), 3.80 
(s, 3H, OMe), 3.82 (s, 3H, OMe), 4.23 (d, J = 15.9 Hz, 1H, 6-H), 4.64 (d, J = 15.9 Hz, 1H, 6-
H), 4.81-4.89 (m, 1H, 4a-H), 5.14-5.21 (m, 1H, 4-H), 5.67-5.75 (m, 1H, 3-H), 6.49 (s, 1H, 7-
H), 6.66 (s, 1H, 10-H), 7.97 (d, J = 8.8 Hz, 2H, Ar), 8.26 (d, J = 8.8 Hz, 2H, Ar); 13C NMR 
(100 MHz, CDCl3):  = 20.1 (C-2), 25.5 (C-1), 33.8 (C-10b), 43.4 (C-6), 52.8 (C-4a), 55.8 
(OMe), 56.0 (OMe), 108.4 (C-7), 109.4 (C-10), 124.7 (Ar), 124.2 (Ar), 124.7 (C-4), 126.5 (Ar), 
128.2 (Ar), 133.5 (C-3), 146.4 (Ar), 147.6 (Ar), 148.5 (Ar), 149.8 (Ar); HRMS (ESI): calcd for 
C21H22N2O6S [M+Na]+ 453.10908, found 453.10940. 
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Directed hydroboration of arylsulfonyl)-hexahydrophenanthridines and carbamates 
(Procedure 8) 
To a magnetically stirred suspension of NaBH4 (6.0 equiv) in dry THF (3 mL per mmol of 
NaBH4) was added neat BF3·OEt2 (5.5 equiv) at 0 °C. The reaction mixture was allowed to stir 
at room temperature for 30 min before the alkene 9-(35, 37) or 9-(45-47) (1.0 equiv) 
respectively, in dry THF (30 mL per mmol of alkene) was added dropwise to the mixture at 0 
°C. Thereafter, the mixture was allowed to reach room temperature within 1.5 h. For work-up 
3n aqueous NaOH (30 mL per mmol of alkene) and 30% H2O2 (30 mL per mmol of alkene) 
were added sequentially to the reaction mixture at 0 °C. The mixture was stirred at room 
temperature for 5 h, before it was extracted with Et2O (3 × 50 mL per mmol of alkene). The 
combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in 
vacuo. Purification of the residue by flash chromatography gave the pure secondary alcohol. 
8,9-Dimethoxy-5-tosyl-1,2,3,4,4a,5,6,10b-octahydrophenanthridin-4-ol (9-38) 
 
 
Prepared from alkene 9-35 (220 mg, 0.55 mmol) according to procedure 8 to give alcohol 9-38 
(206 mg, 90%) as colorless solid. Rf = 0.4 (petroleum ether/ethyl acetate, 1:1); 1H NMR (400 
MHz, CDCl3):  = 1.11-1.26 (m, 1H, 2-H), 1.29-1.43 (m, 1H, 2-H), 1.48-1.68 (m, 2H, 1-H), 
1.94-2.05 (m, 1H, 3-H), 2.23-2.33 (m, 1H, 3-H), 2.36 (s, 3H, CH3), 2.87-2.98 (m, 1H, 10b-H), 
3.44 (td, J = 10.6, 4.8 Hz, 1H, 4-H), 3.80 (s, 3H, OMe), 3.81 (s, 3H, OMe), 3.90 (dd, J = 8.0, 
4.0 Hz, 1H, 4a-H), 4.41 (d, J = 16.0 Hz, 1H, 6-H), 4.64 (d, J = 16.0 Hz, 1H, 6-H), 6.53 (s, 1H, 
7-H), 6.64 (s, 1H, 10-H), 7.23 (d, J = 8.1 Hz, 2H, Ar), 7.71 (d, J = 8.1 Hz, 2H, Ar); 13C NMR 
(100 MHz, CDCl3):  = 19.2 (C-2), 21.5 (CH3), 27.6 (C-1), 33.9 (C-3), 36.0 (C-10b), 43.5 (C-
6), 55.8 (OMe), 56.0 (OMe), 60.6 (C-4), 66.3 (C-4a), 108.6 (C-7), 108.9 (C-10), 123.8 (Ar), 
126.4 (Ar), 127.1 (Ar), 129.7 (Ar), 137.0 (Ar), 143.5 (Ar), 147.6 (Ar), 148.2 (Ar); HRMS (ESI): 
calcd for C22H27NO5S [M+Na]+ 440.15021, found 440.15022. 
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8,9-Dimethoxy-5-((4-nitrophenyl)sulfonyl)-1,2,3,4,4a,5,6,10b-octahydrophenanthridin-4-
ol (9-39) 
 
 
Prepared from alkene 9-37 (120 mg, 0.29 mmol) according to procedure 8 to give alcohol 9-39 
(80 mg, 63%) as yellow solid. Rf = 0.4 (petroleum ether/ethyl acetate, 1:1); 1H NMR (400 MHz, 
CDCl3):  = 1.15-1.30 (m, 1H), 1.34-1.48 (m, 1H), 1.54-1.75 (m, 3H), 1.97-2.08 (m, 1H), 2.31-
2.43 (m, 1H), 3.01-3.10 (m, 1H, 4a-H), 3.5 (td, J = 10.4, 4.5 Hz, 1H, 4-H), 3.81 (s, 3H, OMe), 
3.83 (s, 3H, OMe), 3.90 (dd, J = 10.1, 5.0 Hz, 1H, 4a-H), 4.40 (d, J = 16.4 Hz, 1H, 6-H), 4.72 
(d, J = 16.4 Hz, 1H, 6-H), 6.53 (s, 1H, 7-H), 6.67 (s, 1H, 10-H), 8.04 (d, J = 8.8 Hz, 2H, Ar), 
8.28 (d, J = 8.8 Hz, 2H, Ar); 13C NMR (100 MHz, CDCl3):  = 19.3 (C-2), 27.7 (C-1), 34.5 (C-
3), 36.8 (C-10b), 43.5 (C-6), 55.9 (OMe), 56.0 (OMe), 60.9 (C-4), 66.2 (C-4a), 108.6 (C-7), 
108.7 (C-10), 123.2 (Ar), 124.2 (Ar), 126.1 (Ar), 128.3 (Ar), 146.2 (Ar), 147.8 (Ar), 148.5 (Ar). 
Oxidation of the secondary alcohols to the corresponding ketones using Dess-Martin 
periodinane (Procedure 9) 
To a stirred solution of alcohol (1 equiv) in CH2Cl2 (50 mL per mmol of alcohol) was added 
DMP (1.5 equiv) and the mixture was allowed to stir at room temperature for 1.5 h. Then it was 
diluted with saturated NaHCO3 solution (30 mL per mmol of alcohol) and concentrated sodium 
thiosulfate solution (30 mL per mmol of alcohol). This mixture was stirred until both the organic 
and aqueous layers appeared clear. The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (2 × 30 mL per mmol of alcohol). The combined organic layers were 
dried over anhydrous Na2SO4, filtered and concentrated in vacuo. Purification of the residue by 
flash chromatography afforded the pure ketone. 
8,9-Dimethoxy-5-tosyl-2,3,4,4a,5,6,10b-hexahydrophenanthridin-4-(1H)-one (9-40) 
 
 
Prepared from alcohol 9-38 (120 mg, 0.30 mmol) according to procedure 9 to give ketone 9-40 
(98 mg, 79%) as colorless solid. Rf = 0.5 (petroleum ether/ethyl acetate, 1:1); 1H NMR (400 
MHz, CDCl3):  = 1.45-1.96 (m, 2H, 2-H), 2.07-2.24 (m, 1H, 1-H), 2.25-2.36 (m, 2H, 1-H, 3-
H), 2.42 (s, 3H, CH3), 2.52-2.66 (m, 1H, 3-H), 3.59-3.72 (m, 1H, 10b-H), 3.81 (s, 3H, OMe), 
3.84 (s, 3H, OMe), 4.47 (d, J = 15.2 Hz, 1H, 6-H), 4.58 (d, J = 15.2 Hz, 1H, 6-H), 4.79 (d, J = 
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5.6 Hz, 1H, 4a-H), 6.49 (s, 1H, 7-H), 6.70 (s, 1H, 10-H), 7.29 (d, J = 8.1 Hz, 2H, Ar), 7.73 (d, 
J = 8.1 Hz, 2H, Ar); 13C NMR (100 MHz, CDCl3):  = 21.4 (C-1), 21.5 (CH3), 27.6 (C-2), 41.0 
(C-3), 41.1 (C-10b), 44.2 (C-6), 55.7 (OMe), 56.0 (OMe), 62.5 (C-4a), 108.1 (C-7), 108.8 (C-
10), 124.5 (Ar), 125.0 (Ar), 127.4 (Ar), 129.4 (Ar), 136.2 (Ar), 143.3 (Ar), 148.0 (Ar), 148.1 
(Ar), 205.1 (CO); HRMS (ESI): calcd for C22H25NO5S [M+Na]+ 438.13456, found 438.13454. 
8,9-Dimethoxy-5-((4-nitrophenyl)sulfonyl)-2,3,4,4a,5,6,10b-hexahydrophenanthridin-4-
(1H)-one (41) 
 
 
Prepared from alcohol 9-39 (50 mg, 0.10 mmol) according to procedure 9 to give ketone 9-41 
(47 mg, 99%) as yellow amorphous solid, Rf = 0.5 (petroleum ether/ethyl acetate, 1:1); 1H NMR 
(400 MHz, CDCl3):  = 1.54-1.61 (m, 1H, 2-H), 1.82-1.92 (m, 1H, 2-H), 2.12-2.34 (m, 3H, 1-
H, 3-H), 2.56-2.67 (m, 1H, 3-H), 3.70-3.77 (m, 1H, 10b-H), 3.80 (s, 3H, OMe), 3.83 (s, 3H, 
OMe), 4.39 (d, J = 14.6 Hz, 1H, 6-H), 4.68 (d, J = 14.6 Hz, 1H, 6-H), 4.85 (d, J = 6.1 Hz, 1H, 
4a-H), 6.48 (s, 1H, 7-H), 6.70 (s, 1H, 10-H), 8.00 (d, J = 8.8 Hz, 2H, Ar), 8.34 (d, J = 8.8 Hz, 
2H, Ar); 13C NMR (100 MHz, CDCl3):  = 21.4 (C-1), 27.6 (C-2), 40.9 (C-10b), 41.0 (C-3), 
44.3 (C-6), 55.8 (OMe), 56.1 (OMe), 62.8 (C-4a), 108.1 (C-7), 108.8 (C-10), 124.1 (Ar), 124.3 
(Ar), 128.6 (Ar), 144.9 (Ar), 148.4 (Ar), 150.0 (Ar), 204.9 (CO). HRMS (ESI): calcd for 
C21H22N2O7S [M+Na]+ 469.10399, found 469.10415. 
Methyl (E)-2-(8,9-dimethoxy-5-tosyl-2,3,4a,5,6,10b-hexahydrophenanthridin-4(1H)-
ylidene)acetate (9-43) 
 
 
To a stirred solution of ketone 9-40 (82 mg, 0.2 mmol) in benzene (2 mL) was added methyl 2-
(triphenyl-5-phosphanylidene)acetate (330 mg, 0.99 mmol, 5 equiv) followed by refluxing of 
the mixture for 48 h. After cooling, the mixture was concentrated in vacuo. The crude product 
was purified by flash chromatography (petroleum ether/ethyl acetate, 3:1) to afford the pure 
enoate 9-43 (10 mg, 11%) as yellow solid. Rf = 0.6 (ethyl acetate/petroleum ether, 1:2); 1H 
NMR (400 MHz, CDCl3):  = 1.32-1.50 (m, 2H, 2-H), 1.63-1.74 (m, 1H, 1-H), 1.85-2.08 (m, 
2H, 1-H, 3-H), 2.40 (s, 3H, CH3), 2.35-2.47 (m, 1H, 3-H), 2.97-3.07 (m, 1H, 10b-H), 3.58 (s, 
3H, OMe), 3.80 (s, 3H, OMe), 3.81 (s, 3H, OMe), 4.36 (d, J = 15.4 Hz, 1H, 6-H), 4.48 (d, J = 
Experimental section  175
 
15.4 Hz, 1H, 6-H), 4.73 (dd, J = 5.6, 2.2 Hz, 1H, 4a-H), 5.66-5.70 (m, 1H, CHCO2Me), 6.55 
(s, 1H, 7-H), 6.62 (s, 1H, 10-H), 7.28 (d, J = 8.3 Hz, 2H, Ar), 7.73 (d, J = 8.3 Hz, 2H, Ar); 13C 
NMR (100 MHz, CDCl3):  = 21.5 (two signals in DEPT-135, C-1, CH3), 27.5 (C-2), 28.6 (C-
3), 39.5 (C-10b), 44.8 (C-6), 50.9 (CO2CH3), 55.9 (OMe), 56.0 (OMe), 59.4 (C-4a), 108.5 (C-
7), 109.2 (C-10), 114.4 (CHCO2Me), 124.1 (Ar), 126.0 (Ar), 127.2 (Ar), 129.8 (Ar), 136.3 (Ar), 
143.6 (Ar), 147.7 (Ar), 148.2 (Ar), 157.5 (Ar), 166.6 (CO2Me). 
Preparation of carbamates from amine hydrochlorides (Procedure 7) 
To a cooled (0 °C) suspension of amine·HCl (1.0 equiv) in CH2Cl2 (9 mL per mmol of 
hydrochloride) were added Et3N (2.0 equiv) and the corresponding chloroformate (2.0 equiv) 
or Boc2O (2.5 equiv). The stirred reaction mixture was allowed reach room temperature within 
1 h (in case chloroformate) or 2 h (in case of Boc2O), respectively. Thereafter, saturated 
NaHCO3 solution (9 mL per mmol of hydrochloride) was added. After separation of the layers 
the aqueous layer was extracted with CH2Cl2 (2 × 9 mL per mmol of hydrochloride). The 
combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The residue was purified by flash chromatography to afford the pure carbamates. 
tert-Butyl (4aR,10bR)-8,9-dimethoxy-2,4a,6,10b-tetrahydrophenanthridine-5(1H)-
carboxylate (9-45) 
 
 
Prepared from amine hydrochloride 9-24 (173 mg, 0.68 mmol) according to procedure 7 to give 
pure carbamate 9-45 (210 mg, 89%) as colorless amorphous solid. Rf = 0.3 (petroleum 
ether/ethyl acetate, 2:1); 1H NMR (400 MHz, CDCl3):  = 1.47 (s, 9H, OtBu), 1.69-1.89 (m, 
2H, 1-H, 2-H), 1.91-2.06 (m, 1H, 1-H), 2.26-2.38 (m, 1H, 2-H), 3.16-3.26 (m, 1H, 10b-H), 3.83 
(s, 3H, OMe), 3.84 (s, 3H, OMe), 4.12 (d, J = 16.7 Hz, 6-H), 4.75 (d, J = 16.7 Hz, 1H, 6-H), 
4.87-5.20 (m, 1H, 4a-H), 5.41-5.53 (m, 1H, 4-H), 5.63-5.76 (m, 1H, 3-H), 6.52 (s, 1H, 7-H), 
6.81 (s, 1H, 10-H); 13C NMR (100 MHz, CDCl3):  = 20.3 (C-2), 25.4 (C-1), 28.4 (OtBu), 33.6 
(C-10b), 42.2 (C-6), 55.7 (OMe), 56.0 (C-4a), 56.1 (OMe), 79.8 (OtBu), 108.6 (C-7), 109.5 (C-
10), 127.6 (C-4), 130.8 (C-3), 147.3 (Ar), 147.9 (Ar), 154.8 (CO). HRMS (ESI): calcd for 
C20H27NO4 [M+Na]+ 368.18323, found 368.18325. 
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Ethyl 8,9-dimethoxy-2,4a,6,10b-tetrahydrophenanthridine-5(1H)-carboxylate (9-46) 
 
 
Prepared from amine hydrochloride 9-24 (10 mg, 0.03 mmol) according to procedure 7 to give 
pure carbamate 9-46 (9 mg, 94%) as colorless amorphous solid. Rf = 0.5 (petroleum ether/ethyl 
acetate, 2:1); 1H NMR (400 MHz, CDCl3):  = 1.27 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.71-1.91 
(m, 2H, 1H, 2-H), 1.94-2.08 (m, 1H, 1-H), 2.28-2.38 (m, 1H, 2-H), 3.19-3.29 (m, 1H, 10b-H), 
3.83 (s, 3H, OMe), 3.85 (s, 3H, OMe), 4.18 (q, J = 7.1 Hz, 3H, OCH2, 6-H) 4.81 (d, J = 15.7 
Hz, 1H, 6-H), 4.96-5.28 (m, 1H, 4a-H), 5.44-5.55 (m, 1H, 4-H), 5.65-5.78 (m, 1H, 3-H), 6.52 
(s, 1H, 7-H), 6.81 (s, 1H, 10-H); 13C NMR (100 MHz, CDCl3):  = 14.7 (OCH2CH3), 20.3 (C-
2), 25.3 (C-1), 33.5 (C-10b), 42.2 (C-6), 50.3 (C-4a), 55.8 (OMe), 56.1 (OMe), 61.5 (OCH2), 
108.5 (C-7), 109.5 (C-10), 127.3 (C-4), 131.2 (C-3), 147.4 (Ar), 148.0 (Ar), 155.4 (CO). 
Benzyl 8,9-Dimethoxy-2,4a,6,10b-tetrahydrophenanthridine-5(1H)-carboxylate (9-47) 
 
 
Prepared from amine hydrochloride 9-24 (100 mg, 0.34 mmol) according to procedure 7 to give 
pure carbamate 9-47 (50 mg, 39%) as colorless amorphous solid. Rf = 0.2 (petroleum ether/ethyl 
acetate, 2:1); 1H NMR (400 MHz, CDCl3):  = 1.69-1.90 (m, 2H, 1-H, 2-H), 1.91-2.09 (m, 1H, 
1-H), 2.26-2.41 (m, 2H, 2-H), 3.18-3.35 (m, 1H, 10b-H), 3.82 (s, 3H, OMe), 3.85 (s, 3H, OMe), 
4.21 (d, J = 16.0 Hz, 1H, 6-H), 4.84 (d, J = 16.0 Hz, 1H, 6-H), 5.02-5.26 (m, 1H, 4a-H), 5.17 
(s, 2H, OCH2Ph), 5.46-5.55 (m, 1H, 4-H), 5.67-5.77 (m, 1H, 3-H), 6.52 (s, 1H, 7-H), 6.81 (s, 
1H, 10-H), 7.28-7.34 (m, 1H, Ar), 7.35-7.44 (m, 4H, Ar); 13C NMR (100 MHz, CDCl3):  = 
20.2 (C-2), 25.2 (C-1), 33.4 (C-10b), 42.3 (C-6), 50.4 (C-4a), 55.7 (OMe), 56.0 (OMe), 67.2 
(OCH2Ph), 108.5 (C-7), 109.4 (C-10), 127.6 (C-4), 128.4 (Ar), 128.9 (Ar), 131.8 (C-3), 136.6 
(Ar), 147.3 (Ar), 148.0 (Ar), 155.4 (CO); HRMS (ESI): calcd for C23H25NO4 [M+Na]+ 
402.16758, found 402.16774. 
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tert-Butyl 8,9-dimethoxy-4-oxo-2,3,4,4a,6,10b-hexahydrophenanthridine-5(1H)-
carboxylate (9-49) 
 
 
Prepared from alkene 9-45 (112 mg, 0.324 mmol) according to procedures 8 and 9 to give 
ketone 9-49 (88 mg, 75%, 2 steps) as colorless amorphous solid. Rf = 0.4 (petroleum ether/ethyl 
acetate, 2:1); 1H NMR (400 MHz, CDCl3):  = 1.50 (s, 9H, OtBu), 1.57-1.79 (m, 1H, 2-H), 
1.82-2.00 (m, 1H, 2-H), 2.08-2.25 (m, 1H, 1-H), 2.26-2.43 (m, 2H, 1-H, 3-H), 2.52-2.66 (m, 
1H, 3-H), 3.54-3.68 (m, 1H, 10b-H), 3.82 (s, 3H, OMe), 3.83 (s, 3H, OMe), 4.46-4.80 (m, 2H, 
6-H2), 5.02 (d, J = 6.1 Hz, 1H, 4a-H), 6.54 (s, 1H, 7-H), 6.71 (s, 1H, 10-H); 13C NMR (100 
MHz, CDCl3):  = 21.4 (C-1), 27.3 (C-2), 28.4 (OtBu), 39.5 (C-10b), 40.8 (C-3), 44.5 (C-6), 
55.8 (OMe), 56.1 (OMe), 60.8 (C-4a), 80.4 (OtBu), 107.9 (C-7), 109.1 (C-10), 124.8 (Ar), 
126.4 (Ar), 147.9 (Ar), 148.1, 206.4 (CO); HRMS (ESI): calcd for C20H27NO5 [M+Na]+ 
384.17814, found 384.17828. 
 
Ethyl 8,9-Dimethoxy-4-oxo-2,34,4a,6,10b-tetrahydrophenanthridine-5(1H)-carboxylate 
(9-50) 
 
 
Prepared from alkene 9-46 (5 mg, 0.016 mmol) according to procedures 8 and 9 to give ketone 
9-50 (4 mg, 74%, 2 steps) as colorless amorphous solid. Rf = 0.6 (petroleum ether/ethyl acetate, 
1:1); 1H NMR (400 MHz, CDCl3):  = 1.31 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.86-1.95 (m, 1H, 
2-H), 2.14-2.27 (m, 1H, 1-H), 2.29-2.43 (m, 2H, 1-H, 3-H), 2.54-2.65 (m, 1H, 3-H), 3.58-3.66 
(m, 1H, 10b-H), 3.83 (s,3H, OMe), 3.84 (s, 3H, OMe), 4.20 (q, J = 7.1 Hz, OCH2CH3), 4.58 (d, 
J = 16.4 Hz, 1H, 6-H), 4.67 (d, J = 16.4 Hz, 1H, 6-H), 5.05 (d, J = 6.1 Hz, 1H, 4a-H), 6.55 (s, 
1H, 7-H), 6.72 (s, 1H, 10-H); HRMS (ESI): calcd for C18H23NO5 [M+Na]+ 365.14684, found 
356.14695.  
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Benzyl 8,9-dimethoxy-4-oxo-2,3,4,4a,6,10b-hexahydrophenanthridine-5(1H)-carboxylate 
(9-51) 
 
 
Prepared from alkene 9-47 (19 mg, 0.05 mmol) according to procedures 8 and 9 to give ketone 
9-51 (6 mg, 30%, 2 steps) as colorless amorphous solid. Rf = 0.5 (petroleum ether/ethyl acetate, 
1:1); 1H NMR (400 MHz, CDCl3):  = 1.53-1.70 (m, 2H, 2-H), 1.82-1.99 (m, 1H, 1-H), 2.30-
2.45 (m, 2H, 1-H, 3-H), 2.54-2.66 (m, 1H, 3-H), 3.56-3.69 (m, 1H, 10b-H), 3.84 (s, 6H, 2 × 
OMe), 4.53-4.76 (m, 2H, 6-H), 5.07 (d, J = 6.1Hz, 1H, 4a-H), 5.14-5.26 (m, 2H, OCH2Ph), 
6.52 (s, 1H, 7-H), 6.72 (s, 1H, 10-H), 7.28-7.45 (m, 5H, Ar); 13C NMR (100 MHz, CDCl3):  
= 21.3 (C-1), 27.2 (C-2), 39.4 (C-10b), 40.8 (C-3), 44.3 (C-6), 55.8 (OMe), 56.1 (OMe), 61.4 
(C-4a), 67.6 (OCH2Ph), 108.0 (C-7), 109.1 (C-10), 124.5(Ar), 125.9 (Ar), 127.9 (Ar), 128.0 
(Ar), 128.1 (Ar), 128.5 (Ar), 136.5 (Ar), 148.0 (Ar), 148.2 (Ar), 156.3 (NCO2Ph), 206.0 (CO); 
HRMS (ESI): calcd for C23H25NO5 [M+Na]+ 418.16249, found 418.16264. 
(3aS,3a1R,11bR)-9,10-Dimethoxy-2,3,3a,3a1,4,5,7,11b-octahydro-1H-pyrrolo[3,2,1-
de]phenanthridine (9-52) 
 
 
Iodine (84 mg, 0.33 mmol, 4.0 equiv) was added to a solution of Ph3P (115 mg, 0.44 mmol, 4.0 
equiv) in toluene (3 mL) and the mixture was stirred at rt for 10 min. A solution of the alcohol 
(40 mg, 0.11 mmol) in toluene (1 mL) was then added and the mixture was further stirred at 
room temperature overnight, TLC shows only starting material, then the reaction mixture was 
heated up to 80 °C for 4 h, the reaction was monitored by TLC. Saturated aqueous Na2S2O3 (5 
mL) was added and the mixture was stirred up to 10 min. It was then diluted with EtOAc (10 
mL), organic phase was separated and washed with H2O (2 × 5 mL) and saturated aqueous 
NaCl (10 mL) successively, after which it was dried with anhydrous Na2SO4 and concentrated 
in vacuo. The crude was purified by flash chromatography (petroleum ether/ethyl acetate, 9:1) 
to give carbamate 9-52 (30 mg, 94%) as colorless solid. 1H NMR (400 MHz, CDCl3):  = 1.31-
1.48 (m, 2H, 1-H 2-H), 1.62-1.91 (m, 3H, 1-H, 2-H, 3-H), 2.01-2.17 (m, 1H, 3-H), 2.75-2.92 
(m, 1H, 11b-H), 3.84 (s, 3H, OMe), 3.85 (s, 3H, OMe), 3.93 (dd, J = 4.3, 7.6 Hz, 1H, 3a1-H), 
4.25 (d, J = 16.2 Hz, 1H, 6-H), 4.63 (d, J = 16.2 Hz, 1H, 6-H), 4.77 (q, J = 7.6 Hz, 1H, 3a-H), 
6.58 (s, 1H, 7-H), 6.60 (s, 1H, 10-H); 13C NMR (100 MHz, CDCl3):  = 19.3 (C-2), 26.4 (C-3), 
28.9 (C-1), 37.4 (C-11b), 42.8 (C-6), 53.4 (C-3a1), 55.9 (OMe), 56.0 (OMe), 74.1 (C-3a), 109.0 
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(C-7), 111.6 (C-10), 122.1 (Ar), 128.6 (Ar), 148.1 (Ar), 148.3 (Ar), 158.3 (C-5); HRMS (ESI): 
calcd for C16H19NO4 [M+Na]+ 312.12063, found 312.12086. 
5-(2-Bromoacetyl)-8,9-dimethoxy-2,3,4a,5,6,10b-hexahydrophe-nanthridin-4(1H)-one (9-
54) 
 
 
To a cooled (0 °C) stirred solution of carbamate 9-49 (30 mg, 0.08 mmol) in CH2Cl2 (1 mL) 
was added TFA (0.5 mL). The reaction mixture was allowed to stir at room temperature for 4 
h. Excess solvent and TFA were removed on a rotavapor in vacuo and the residual TFA was 
removed by adding several times CH2Cl2 and concentration of the solution in vacuo to give the 
solid amine salt, which was directly used in next step without further purification.  
To a cooled (0 °C) solution of salt and Et3N (36 L, 0.25 mmol, 3 equiv) in CH2Cl2 (1 mL) was 
added bromoacetyl bromide (8 L, 0.10 mmol, 1.2 equiv) dropwise. The stirred reaction 
mixture was allowed to reach room temperature within 1 h. For work-up, the mixture was 
treated with saturated NaHCO3 (2 mL), and this mixture was extracted with Et2O (3 × 2 mL). 
The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The crude amide was purified by flash chromatography (petroleum ether/ethyl acetate, 
2:1) to provide pure amide 9-54 (20 mg, 65% over two steps) as yellow solid. Rf = 0.3 
(petroleum ether/ethyl acetate, 2:1); 1H NMR (400 MHz, CDCl3, mixture of rotamers):  = 
1.53-1.81 (m, 2H, 2-H), 1.82-2.01 (m, 1H, 2-H), 2.13-2.27 (m, 2H, 1-H), 2.28-2.46 (m, 2H, 1-
H, 3-H), 2.54-2.75 (m, 1H, 3-H), 3.52-3.67 (m, 1H, 10b-H), 3.78-3.86 (6H, 2 OMe), 3.90-4.08 
(s, 1H, COCH2Br), 4.14-4.31 (m, 1H, COCH2Br), 4.59-4.73 (m, 1H, 6-H), 4.76-4.92 (m, 1H, 
6-H), 5.44 (d, J = 6.1 Hz, 1H, 4a-H), 6.52-6.59 (1H, 7-H), 6.68-6.75 (1H, 10-H); 13C NMR (100 
MHz, CDCl3):  = 21.0, 21.1, 25.9, 26.1, 27.0, 27.2, 38.9, 40.8, 41.2, 45.4, 45.8, 55.8, 55.8, 
56.0, 56.1, 59.6, 59.64, 107.8, 107.9, 108.8, 109.2, 123.5, 124.4, 124.5, 124.7, 124.7, 148.3, 
148.4, 166.5, 166.8, 205.1, 205.2; HRMS (ESI): calcd for C17H20BrNO4 [M+Na]+ 404.04679, 
found 404.04670. 
5-Acetyl-8,9-dimethoxy-2,3,4a,5,6,10b-hexahydrophenanthridin-4(1H)-one (9-55) 
 
 
(a) Using (RhCl(PPh3)3 and Et2Zn: To a stirred solution of (RhCl(PPh3)3 (8 mg, 9 mol, 17.5 
mol%) in THF (250 L) at 0 °C were added -bromo amide 9-54 (18 mg, 0.047 mmol), and a 
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solution of Et2Zn (1M in hexane 100 L, 0.10 mmol, 2.2 equiv). After stirring of the mixture 
for 5 min at 0 °C, saturated NaHCO3 solution (2 mL) was added and the mixture extracted with 
Et2O (3 × 3mL). The combined extracts were washed with saturated NaCl solution, dried with 
anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification of the residue by flash 
chromatography (petroleum ether/ethyl acetate, 2:1) gave pure acetamide 9-55 (8 mg, 56%) as 
colorless oil. 
(b) Using zinc dust: To zinc dust (34 mg, 0.52 mmol, 5 equiv, activated by diluted HCl) at 0 °C 
was added dropwise a solution of -bromo amide 9-54 (40 mg, 0.10 mmol) in DMF (0.5 mL). 
The resulting paste was allowed to stir for 1 h at room temperature, before saturated NaHCO3 
solution (5 mL) was added and the mixture extracted with Et2O (3 × 5mL). The combined 
organic layers were washed with saturated NaCl solution (5 mL), dried with anhydrous Na2SO4, 
filtered, concentrated in vacuo. Purification by flash chromatography (petroleum ether/ethyl 
acetate, 2:1) gave pure acetamide 9-55 (15 mg, 49%) as a colorless oil. Rf = 0.2 (petroleum 
ether/ethyl acetate, 1:1); 1H NMR (400 MHz, CDCl3, mixture of rotamers):  = 1.78-1.92 (m, 
2H, 2-H), 1.96-2.02 (m, 1H, 2-H), 2.09-2.21 (m, 1H, 1-H), 2.24 (s, 3H, COCH3), 2.28-2.46 (m, 
2H, 1-H, 3-H), 2.50-2.72 (m, 1H, 3-H), 3.49-3.65 (m, 1H, 10b-H), 3.83 (s, 3H, OMe), 3.85 (s, 
3H, OMe), 4.54 (d, J = 15.4 Hz, 1H, 6-H), 4.78 (d, J = 15.4 Hz, 1H, 6-H), 5.53 (d, J = 6.1 Hz, 
1H, 4a-H), 6.54 (s, 1H, 7-H), 6.73 (1H, 10-H); 13C NMR (100 MHz, CDCl3):  = 21.3 (COCH3), 
21.7 (C-1), 27.2 (C-2), 39.2 (C-10b), 40.9 (C-3), 46.1 (C-6), 55.8 (OMe), 56.1 (OMe), 59.1 (C-
4a), 110.0 (C-7), 109.0 (C-10), 125.1 (Ar), 125.3 (Ar), 148.2 (Ar), 170.7 (NCOCH3), 205.8 
(CO); HRMS (ESI): calcd for C17H21NO4 [M+Na]+ 326.13628, found 326.13639. 
5-(2’-Bromoallyl)-8,9-dimethoxy-1,2,4a,5,6,10b-hexahydro phenanthridine (9-65) 
 
 
To a stirred solution of amine·HCl 9-24 (110 mg, 0.34 mmol) in DMF (1 mL) was added NaH 
(60% dispersion in oil, 35 mg, 0.85 mmol, 2.5 equiv) and bromoallyl bromide (51 L, 0.51 
mmol, 1.5 equiv). The reaction mixture was allowed to stir at room temperature for 1 h, before 
it was cooled to 0 °C and quenched with H2O (2 mL). The mixture was extracted with EtOAc 
(3 × 3mL). The combined organic layers were washed with H2O (3 × 3 mL) and saturated NaCl 
solution (3 mL), dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification 
of the residue by flash chromatography (petroleum ether/ethyl acetate, 3:1) provided pure 
allylamine 9-65 (80 mg, 65%) as yellow oil. Rf = 0.6 (petroleum ether/ethyl acetate, 1:1); 1H 
NMR (400 MHz, CDCl3):  = 1.80-1.89 (m, 1H, 1-H), 1.92-2.03 (m, 2H, 2-H), 2.11-2.24 (m, 
1H, 1-H), 2.92-3.01 (m, 1H, 10b-H), 3.40 (d, J = 16.0 Hz, 1H, 1'-H), 3.46-3.50 (m, 1H, 4a-H), 
3.53 (d, J = 16.0 Hz, 1H, 1'-H), 3.58 (d, J = 15.2 Hz, 1H, 6-H), 3.81 (s, 3H, OMe), 3.84 (d, J = 
15.2 Hz, 6-H), 3.85 (s, 3H, OMe), 5.57 (s, 1H, 3'-H), 5.71-5.79 (m, 1H, 4-H), 5.82-5.89 (m, 1H, 
3-H), 5.91 (s, 1H, 3'-H), 6.48 (s, 1H, 10-H), 6.74 (s, 1H, 7-H); 13C NMR (100 MHz, CDCl3):  
= 23.4 (C-2), 26.6 (C-1), 35.2 (C-10b), 51.3 (C-6), 55.7 (OMe), 55.9 (C-1'), 56.0 (OMe), 60.9 
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(C-4a), 109.0 (C-7), 110.2 (C-10), 117.8 (C-2'), 126.0 (C-3'), 126.6 (Ar), 129.1 (Ar), 131.7 (C-
4), 132.1 (C-3), 147.1 (Ar), 147.8 (Ar).  
9,10-Dimethoxy-4-methylene-2,3,3a,3a,1,4,5,7,11b-octahydro-1H-pyrrolo[3,2,1-
de]phenanthridine-3-carbonitrile (9-66) 
 
 
To a solution of Ni(COD)2 (149 mg, 0.54 mmol, 2.0 equiv) in dry acetonitrile (1 mL), at room 
temperature and under nitrogen atmosphere, was added a solution of vinyl bromide 9-65 (100 
mg, 0.27 mmol) and Et3N (117 L, 0.81 mmol, 3.0 equiv) in dry acetonitrile (1 mL). The 
reaction mixture was stirred at room temperature for about 15 min, resulting in a color change 
from yellow to black. When all starting material had been consumed (checked by TLC), the 
quencher TMSCN (100 L, 0.66 mmol, 2.5 equiv) was added and the mixture stirred for 
additional 3 h. It was filtered through Celite and the filter cake washed several times with 
CH2Cl2. The filtrate was washed with saturated Na2CO3 solution. The organic layer was dried 
over Na2SO4, filtered and concentrated in vacuo. Purification of the residue by flash 
chromatography (CH2Cl2/MeOH, 9/1) afforded the cyclization product 9-66 (67 mg, 80%) as 
yellow solid. Rf = 0.6 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, CDCl3):  = 1.68 (tt, J = 3.3, 
13.6 Hz, 1H, 1-H), 1.75-2.87 (m, 1H, 2-H), 1.91-2.02 (m, 1H, 1-H), 2.02-2.13 (m, 1H, 2-H), 
2.68 (t, J = 4.8 Hz, 1H, 3a-H), 2.72-2.82 (m, 2H, 3-H, 11b-H), 2.94 (d, J = 14.1 Hz, 1H, 5-H), 
3.00-3.07 (m, 1H, 3b-H), 3.28 (d, J = 14.1 Hz, 1H, 5-H), 3.82 (s, 3H, OMe), 3.84 (s, 3H, OMe), 
4.09 (d, J = 14.4 Hz, 1H, 7-H), 4.11 (d, J = 14.4 Hz, 1H, 7-H), 5.08 (s, 1H, 4-CH2), 5.13 (s, 1H, 
4-CH2), 6.52 (s, 1H, 11-H), 6.62 (s, 1H, 8-H); 13C NMR (100 MHz, CDCl3):  = 26.6 (C-3), 
27.3 (C-2), 31.1 (C-1), 38.1 (C-11b), 44.8 (C-3a), 55.7 (C-7), 55.89 (OMe), 55.92 (OMe), 59.5 
(C-5), 61.1 (C-3b), 107.6 (4-CH2), 109.2 (C-8), 111.2 (C-11), 121.6 (CN), 126.0 (Ar), 129.9 
(Ar), 147.5 (Ar), 147.6 (Ar), 148.4 (C-4); HRMS (ESI): calcd for C19H22N2O2 [M+H]+ 
311.17540, found 311.17548. 
9,10-Dimethoxy-4-methylene-2,3,3a,3a,1,4,5,7,11b-octahydro-1H-pyrrolo[3,2,1-
de]phenanthridine (9-67) 
 
 
To a solution of Ni(COD)2 (149 mg, 0.54 mmol, 2.0 equiv) in dry acetonitrile (1 mL), at room 
temperature and under nitrogen atmosphere, was added a solution of vinyl bromide 9-65 (100 
mg, 0.27 mmol) and Et3N (117 L, 0.81 mmol, 3.0 equiv) in dry acetonitrile (1 mL). The 
reaction mixture was stirred at room temperature for about 15 min, resulting in a color change 
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from yellow to black. When all starting material had been consumed (checked by TLC), the 
quencher Et3SiH (137 L, 0.85 mmol, 3.2 equiv) was added and the mixture stirred for 
additional 3 h. It was filtered through Celite and the filter cake washed several times with 
CH2Cl2. The filtrate was washed with saturated Na2CO3 solution. The organic laywer was dried 
over Na2SO4, filtered and concentrated in vacuo. Purification of the residue by flash 
chromatography (CH2Cl2/MeOH, 9/1) afforded the cyclization product 9-67 (54 mg, 70%) as 
yellow solid. Rf = 0.5 (CH2Cl2/MeOH, 9:1); 1H NMR (400 MHz, CDCl3):  = 1.23-1.48 (m, 
3H, 3-H, 2-H), 1.55-1.80 (m, 3H, 2-H, 1-H), 2.48-2.59 (m, 2H, 3a-H, 11b-H), 2.64-2.75 (m, 
1H, 3b-H), 2.83 (d, J = 14.0 Hz, 1H, 5-H), 3.20 (d, J = 14.0 Hz, 1H, 5-H), 3.75 (s, 3H, OMe), 
3.78 (s, 3H, OMe), 3.88 (d, J = 14.0 Hz, 1H, 7-H), 3.97 (d, J = 14.0 Hz, 1H, 7-H), 4.81 (s, 1H, 
4-H), 4.82 (s, 1H, 4-H), 6.45 (s, 1H, 11-H), 6.57 (s, 1H, 8-H); 13C NMR (100 MHz, CDCl3):  
= 24.8 (C-2), 29.8 (C-3), 31.4 (C-1), 38.5 (C-11b), 43.5 (C-3a), 55.8 (OMe), 56.4 (C-7), 59.9 
(C-5), 62.9 (C-3b), 103.9 (4-CH2), 109.2 (C-8), 111.3 (C-11), 125.7 (Ar), 131.5 (Ar), 147.2 
(Ar), 147.6 (Ar), 152.2 (C-4); HRMS (ESI): calcd for C18H23NO2 [M+H]+ 286.18016, found 
286.18043. 
3-(3-Chloropropyl)-6,7-dimethoxyisoquinolin-1(2H)-one (9-68) 
 
 
Prepared from N-(pivaloyloxy)benzamide 8-6 (200 mg, 0.71 mmol) according to procedure 3. 
TLC showed consumption of starting material after 35 h. The crude product was purified by 
flash chromatography (ethyl acetate/petroleum ether, 2:1) to give pure isoquinolone 9-68 (70 
mg, 35%) along the N-alkylation product 9-69 (30 mg, 17%) as colorless solids. 1H NMR (400 
MHz, CDCl3):  = 2.21-2.35 (m, 2H, 2b-H), 2.83 (t, J = 7.6 Hz, 2H, 2a-H), 3.62 (t, J = 6.3 Hz, 
2H, 2c-H), 3.97 (s, 3H, OMe), 4.00 (s, 3H, OMe), 6.30 (s, 1H, 1-H), 6.84 (s, 1H, 5-H), 6.84 (s, 
1H, 8-H), 11.92 (NH); 13C NMR (100 MHz, CDCl3):  = 30.4 (C-2b), 31.1 (C-2a), 44.0 (C-2c), 
56.0 (OMe), 56.1 (OMe), 104.3 (C-1), 105.8 (C-5), 106.9 (C-8), 118.1, 134.2, 138.8, 148.8, 
153.8, 164.2 (C-4). 
3,4-Dimethoxy-N-(pent-4-yn-1-yl)benzamide (9-69) 
 
 
1H NMR (400 MHz, CDCl3):  = 2.02 (s, 1H, 1-H), 2.20-2.37 (m, 2H, 4-H), 2.77-2.93 (m, 2H, 
3-H), 3.62 (t, J = 6.2 Hz, 2H, 5-H), 3.89 (s, 3H, OMe), 3.96 (s, 3H, OMe), 6.62 (s, 1H, Ar), 
7.09 (d, J = 8.8 Hz, 1H, Ar), 8.12 (d, J = 8.8 Hz, 1H, Ar), 11.68 (s, 1H, NH); 13C NMR (100 
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MHz, CDCl3):  = 30.8 (C-4), 31.1 (C-3), 44.0 (C-5), 56.0 (OMe), 61.0 (C-1), 98.6, 111.6, 
124.2, 133.7, 140.4, 141.8, 154.9, 164.6 (CONH). 
7,8-dimethoxy-2,3-dihydropyrrolo[1,2-b]isoquinolin-5(1H)-one (8-9) 
 
 
To the cooled (0 oC) solution of compound 9-68 (50 mg, 0.18 mmol) in THF (3 mL) was added 
LiHMDS (0.27 mmol, 1.5 equiv) dropwise, then the reaction mixture was allowed to reach at 
rt in overnight. Excess of LiHMDS was quenched with saturated solution of NH4Cl (5 mL) at 
0 oC, and then the mixture was extracted with EtOAc (3 × 3 mL). The combined organic extracts 
were washed with saturated NaCl (5 mL), dried with anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography 
(ethylacetate/petroleum ether, 1:3) to get pure compound 8-9 (32 mg, 72%) as colorless solid; 
1H NMR (400 MHz, CDCl3):  = 2.15-2.21 (m, 2H, 3-H), 3.07 (td, J = 1.3, 7.8 Hz, 2H, 2-H), 
3.95 (s, 3H, OMe), 3.98 (s, 3H, OMe), 4.16 (t, J = 7.1 Hz, 2H, 4-H), 6.32 (s, 1H, 1-H), 6.80 (s, 
1H, 6-H), 7.74 (s, 1H, 9-H); 13C NMR (100 MHz, CDCl3):  = 22.1 (C-3), 31.1 (C-2), 48.0 (C-
4), 56.0 (OMe), 56.1 (OMe), 99.8 (C-1), 105.8 (C-6), 107.2 (C-9), 118.5, 133.6, 142.3, 148.4, 
153.2, 160.9 (C-5); HRMS (ESI): calcd for C12H15NO3 [M+Na]+ 268.09441 found 268.09477. 
Asymmetric addition of indoles to N-Sulfonyl imines (procedure 10) 
 
A hot oven dried Schlenk tube (10 cm) equipped with magnetic stir bar and rubber septum, was 
cooled under nitrogen atmosphere. Thereafter, it was charged with N-sulfonyl imine (0.1 
mmol), catalyst 13-1 (5 mol%) and molecular sieves (0.4 nm, 50 mg). Then the mixture was 
allowed to stir for 2 min under N2 before dry toluene and hexane (1 mL, 1:1 mixture) were 
added. The reaction mixture was cooled to 0 °C and indole (2.5 mmol) was added in one portion. 
The reaction was allowed to stir for 15 h (0 °C to rt), diluted with EtOAc (2 mL) and the mixture 
was syringed out and filtered through a PTFE-20/25 (0.20 µm) filter. The Schlenk tube was 
rinsed with EtOAc (2 × 2 mL), which was also filtered. The filtrates were combined and 
concentrated in vacuo. The residue was purified by preparative TLC (solvent mixture is 
mentioned along the compounds). 
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(S)-N-((1H-indol-3-yl)(phenyl)methyl)benzenesulfonamide (12-33a) 
 
 
Prepared from imine 12-31a (25 mg, 0.1 mmol) and indole (12-27a) (29 mg, 0.25 mmol) 
according to procedures 10 to give product 12-33a as colorless amorphous solid (33 mg, 97%). 
Rf = 0.3 (petroleum ether/EtOAc, 1:3); ee = 97% [n-hexanes/2-propanol = 75/25, 0.8 mL/min, 
 = 254 nm, t (major) = 31.0 min, t (minor) = 19.8 min]; []D25= –8.8 (c 1.0, Acetone); 1H NMR 
(400 MHz, CD3OD):  = 5.86 (s, 1H), 6.64 (s, 1H), 6.89 (td, J = 7.1, 1.0 Hz, 1H), 7.05 (td, J = 
7.1, 1.0 Hz, 1H), 7.10-7.18 (m, 3H), 7.20-7.32 (m, 6H), 7.35-7.43 (m, 1H), 7.63 (d, J = 8.1 Hz, 
2H); 13C NMR (100 MHz, CD3OD):  = 56.4, 112.4, 116.9, 120.9, 120.1, 120.3, 122.8, 125.2, 
127.3, 128.0, 128.2, 128.6, 129.2, 129.7, 133.1, 138.4, 142.6, 142.9; HRMS (ESI): calcd for 
C21H18N2O2S [M+Na]+ 385.09812; found 385.09874. 
(S)-N-((1H-indol-3-yl)(naphthalen-2-yl)methyl)benzenesulfonamide (12-33b) 
 
 
Prepared from imine 12-31b (30 mg, 0.1 mmol) and indole (12-27a) (29 mg, 0.25 mmol) 
according to procedures 10 to give product 12-33b (40 mg, 97%) as colorless amorphous pink. 
Rf = 0.3 (petroleum ether/EtOAc, 3:1); ee = 97% [n-hexanes/2-propanol = 75/25, 0.8 mL/min, 
 = 254 nm, t (major) = 36.7 min, t (minor) = 27.5 min]; []D25= –18.1 (c 1.0, acetone); 1H 
NMR (400 MHz, CD3OD):  = 6.02 (s, 1H), 6.69 (d, J = 1.0 Hz, 1H), 6.89 (td, J = 7.1, 1.0 Hz 
1H), 7.06 (td, J = 7.1, 1.0 Hz, 1H), 7.13-7.20 (m, 2H), 7.23-7.30 (m, 2H), 7.31-7.38 (m, 2H), 
7.40 (d, J = 3.5 Hz, 1H), 7.42 (d, J = 3.0 Hz 1H), 7.60-7.71 (m, 5H), 7.75 (dd, J = 5.6, 5.3 Hz, 
1H); 13C NMR (100 MHz, CD3OD):  = 56.6, 112.4, 116.8, 120.1, 120.3, 122.8, 125.3, 126.9, 
127.0, 127.1, 127.3, 127.4, 128.1, 128.6, 129.0, 129.1, 129.6, 133.0, 134.2, 134.7, 138.5, 139.9, 
143.0; HRMS (ESI): calcd for C25H20N2O2S [M+Na]+ 435.11377; found 435.11382. 
Experimental section  185
 
(S)-N-(benzo[d][1,3]dioxol-5-yl(1H-indol-3-yl)methyl)benzenesulfonamide (12-33c) 
 
 
Prepared from imine 12-31c (30 mg, 0.1 mmol) and indole (12-27a) (29 mg, 0.25 mmol) 
according to procedures 10 to give product 12-33c (42 mg, 99%) as colorless amorphous solid. 
Rf = 0.2 (petroleum ether/EtOAc, 3:1); ee = 98% [n-hexanes/2-propanol = 75/25, 0.8 mL/min, 
 = 254 nm, t (major) = 46.2 min, t (minor) = 40.2 min]; []D25= –7.7 (c 1.0, acetone); 1H NMR 
(400 MHz, CD3OD):  = 5.77 (s, 1H), 5.82 (d, J = 8.1 Hz, 2H), 6.58 (d, J = 7.8 Hz 1H), 6.65-
6.74 (m, 3H), 6.91 (td, J = 7.8, 1.0 Hz, 1H), 7.06 (td, J = 8.0, 1.0 Hz, 1H), 7.23-7.36 (m, 4H), 
7.41 (t, J = 7.1 Hz, 1H), 7.63 (dd, J = 8.1, 1.0 Hz, 2H); 13C NMR (100 MHz, CD3OD):  = 56.5, 
102.3, 108.7, 109.1, 112.4, 116.9, 120.1, 120.4, 122.2, 122.8, 125.0, 127.2, 128.1, 129.7, 130.1, 
133.0, 136.5, 138.5, 143.0, 148.0, 148.2, 149.0; HRMS (ESI): calcd for C22H18N2O2S [M+Na]+ 
415.10868; found 415.10936. 
(S)-N-((1H-indol-3-yl)(4-methoxyphenyl)methyl)benzenesulfonamide (12-33d) 
 
 
Prepared from imine 12-31d (28 mg, 0.1 mmol) and indole (12-27a) (29 mg, 0.25 mmol) 
according to procedures 10 to give product 12-33d (31 mg, 79%) as colorless solid. yield:. Rf 
= 0.2 (petroleum ether/EtOAc, 3:1); ee = 96% [n-hexanes/2-propanol = 75/25, 0.8 mL/min,  
= 254 nm, t (major) = 46.0 min, t (minor) = 275 min]; []D25= –12.7 (c 1.0, acetone); 1H NMR 
(400 MHz, CD3OD):  = 3.72 (s, 3H), 5.80 (s, 1H), 6.66-6.72 (m, 3H), 6.89 (td, J = 7.07, 1.0 
Hz, 1H), 7.05 (td, J = 8.1, 1.0 Hz, 1H), 7.09-7.15 (m, 2H), 7.24-7.32 (m, 4H), 7.40 (tt, J = 7.3, 
1.8 Hz, 1H), 7.59-7.65 (m, 2H); 13C NMR (100 MHz, CD3OD)  = 55.8, 56.1, 112.3, 114.6, 
117.2, 120.0, 120.4, 122.7, 125.1, 127.2, 128.1, 129.7, 129.8, 133.0, 134.7, 138.5, 143.1, 160.3; 
HRMS (ESI): calcd for C22H20N2O3S [M+Na]+ 415.10868; found 415.10936. 
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(S)-N-((1H-Indol-3-yl)(4-(trifluoromethyl)phenyl)methyl)benzenesulfonamide (12-33e) 
 
 
Prepared from imine 12-31e (31 mg, 0.1 mmol) and indole (12-27a) (32 mg, 0.26 mmol) 
according to procedures 10 to give product 12-33e (37 mg, 86%) as colorless solid, yield: Rf = 
0.2 (petroleum ether/EtOAc, 2:1); ee = 96% [n-hexanes/2-propanol = 75/25, 0.8 mL/min,  = 
254 nm, t (major) = 28.7 min, t (minor) = 19.5 min]; []D25= –19.3 (c 1.0, acetone); 1H NMR 
(400 MHz, CD3OD):  = 5.93 (s, 1H), 6.62 (s, 1H), 6.91 (td, J = 7.1, 1.0 Hz, 1H), 7.07 (td, J = 
7.1, 1.0 Hz, 1H), 7.27 (t, J = 7.3 Hz, 2H), 7.30 (t, J = 7.8 Hz 2H), 7.40-7.50 (m, 5H), 7.65 (dd, 
J = 8.8, 1.0 Hz, 2H); 13C NMR (100 MHz, CD3OD):  = 56.0, 112.5, 116.0, 120.1, 120.3, 123.0, 
125.3, 126.1 (q, J = 4.1 Hz), 127.1, 128.1, 128.4 (CF3, J = 267.0 Hz), 129.3, 129.8, 133.2, 138.5, 
142.8, 147.3; HRMS (ESI): calcd for C22H17F3N2O2S [M+Na]+ 453.08550; found 453.08577. 
Methyl (S)-4-((1H-indol-3-yl)(phenylsulfonamido)methyl)benzoate (12-33f) 
 
 
Prepared from imine 12-31f (30 mg, 0.1 mmol) and indole (12-27a) (22 mg, 0.25 mmol) 
according to procedures 10 to give product 12-33f (40 mg, 52%) as colorless amorphous pink. 
Rf = 0.2 (petroleum ether/EtOAc, 2:1); ee = 90% [n-hexanes/2-propanol = 75/25, 0.8 mL/min, 
 = 254 nm, t (major) = 47.4 min, t (minor) = 26.9 min]; []D25= –15.7 (c 1.0, acetone); 1H 
NMR (400 MHz, CDCl3):  = 3.90 (s, 3H), 5.38 (d, J = 6.8 Hz, 1H), 5.92 (d, J = 6.8 Hz, 1H), 
6.55 (s, 1H), 7.01 (t, J = 7.3 Hz, 1H), 7.15-7.23 (m, 2H), 7.28-7.36 (m, 5H), 7.44-7.50 (m, 1H), 
7.67-7.72 (m, 2H), 7.85-7.89 (m, 2H), 8.13 (br, 1H); 13C NMR (100 MHz, CDCl3):  = 52.1, 
54.6, 111.37, 111.4, 115.37, 115.4, 118.9, 120.1, 120.1, 122.7, 123.7, 123.8, 125.0, 125.1, 
127.1, 127.1, 128.8, 129.2, 129.6, 132.5, 136.3, 136.4, 140.1, 140.14, 145.3, 166.8; HRMS 
(ESI): calcd for C23H20N2O4S [M+Na]+ 443.10360; found 443.10358. 
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(S)-4-Bromo-N-((4-bromophenyl)(1H-indol-3-yl)methyl)benzenesulfonamide (12-33g) 
 
 
Prepared from imine 12-31g (32 mg, 0.1 mmol) and indole (12-27a) (29 mg, 0.25 mmol) 
according to procedures 10 to give product 12-33g (16 mg, 36%) as brown amorphous solid. Rf 
= 0.2 (petroleum ether/EtOAc, 2:1); ee = 87% [n-hexanes/2-propanol = 75/25, 0.8 mL/min,  
= 254 nm, t (major) = 34.0 min, t (minor) = 22.2 min]; []D25= –18.7 (c 1.0, acetone); 1H NMR 
(400 MHz, CDCl3):  = 5.18 (d, J = 6.6, 1H), 5.84 (d, J = 6.6 Hz, 1H), 6.63 (m, 1H), 7.06-7.00 
(m, 1H), 7.23-7.13 (m, 4H), 7.40-7.31 (m, 5H), 7.55-7.49 (m, 1H), 7.72-7.68 (m, 2H), 8.04 (br, 
1H); 13C NMR (100 MHz, CDCl3):  = 54.5, 111.4, 115.7, 119.0, 120.2, 121.4, 122.8, 123.7, 
125.0, 127.1, 128.8, 128.9, 131.4, 132.4, 136.5, 139.2, 140.2; HRMS (ESI): calcd for 
C21H17BrN2O2S [M+Na]+ 463.00863; found 463.00818. 
 (S)-4-bromo-N-((2-methyl-1H-indol-3-yl)(phenyl)methyl)benzenesulfonamide (14-16a) 
 
 
Prepared from imine 12-31a (25 mg, 0.1 mmol) and 2-methylindole (12-27b) (33 mg, 0.25 
mmol) according to procedures 10 to give product 14-16a (45 mg, 99%) as yellow amorphous 
solid. Rf = 0.3 (petroleum ether/EtOAc, 3:1); ee = 92% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 18.1 min, t (minor) = 12.0 min]; []D25= –20.6 (c 1.0, acetone); 
1H NMR (400 MHz, CD3OD):  = 2.07 (s, 3H), 5.85 (s, 1H), 6.75 (t, J = 7.1 Hz, 1H), 6.91 (t, J 
= 7.1, 1H), 7.12-7.04 (m, 2H), 7.26-7.13 (m, 5H), 7.40-7.29 (m, 3H), 7.50-7.45 (m, 1H), 7.57-
7.51 (m, 2H); 13C NMR (100 MHz, CD3OD):  = 11.7, 54.0, 111.4, 111.7, 119.6, 120.0, 121.5, 
127.7, 127.8, 128.1, 128.4, 129.1, 129.3, 132.6, 134.4, 143.1, 143.4; HRMS (ESI): calcd for 
C22H20N2O2S [M+Na]+ 399.11377; found 399.11403. 
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(S)-N-((2-Methyl-1H-indol-3-yl)(naphthalen-2-yl)methyl)benzenesulfonamide (14-16b) 
 
 
Prepared from imine 12-31b (28 mg, 0.1 mmol) and 2-methylindole (12-27b) (33 mg, 0.25 
mmol) according to procedures 10 to give product 14-16b (34 mg, 84%) as yellow amorphous 
solid. Rf = 0.7 (petroleum ether/EtOAc, 2:1); ee = 93% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 28.1 min, t (minor) = 17.6 min]; []D25= –38.9 (c 0.25, 
acetone); 1H NMR (400 MHz, CDCl3):  = 1.96 (s, 3H), 5.39 (d, J = 7.1 Hz, 1H), 5.90 (d, J = 
7.33 Hz, 1H), 6.75 (t, J = 7.6 Hz, 1H), 6.89-6.97 (m, 2H), 7.02-7.15 (m, 3H), 7.25 (t, J = 7.3 
Hz, 1H), 7.29-7.36 (m, 3H), 7.51 (d, J = 7.3 Hz, 2H), 7.56-7.62 (m, 2H), 7.64-7.68 (m, 1H), 
7.71 (br, 1H), 7.81 (br s, 1H); 13C NMR (100 MHz, CDCl3):  = 11.5, 53.9, 110.3, 110.4, 118.3, 
119.7, 121.4, 125.3, 125.4, 125.9, 126.0, 126.1, 126.8, 127.4, 128.0, 128.1, 128.4, 132.1, 132.5, 
132.8, 133.0, 135.2, 137.8, 140.1; HRMS (ESI): calcd for C26H22N2O2S [M+Na]+ 449.12942; 
found 449.12924. 
(S)-N-(benzo[d][1,3]dioxol-5-yl(2-methyl-1H-indol-3-yl)methyl)benzenesulfonamide (14-
16c) 
 
 
Prepared from imine 12-31c (30 mg, 0.1 mmol) and 2-methylindole (12-27b) (33 mg, 0.25 
mmol) according to procedures 10 to give product 14-16c (42 mg, 97%) as yellow amorphous 
solid. yield: Rf = 0.2 (petroleum ether/EtOAc, 3:1); ee = 84% [n-hexanes/2-propanol = 75/25, 
0.8 mL/min,  = 254 nm, t (major) = 29.4 min, t (minor) = 21.6 min]; []D25= –14.9 (c 0.8, 
acetone); 1H NMR (400 MHz, CD3OD):  = 2.08 (s, 3H), 5.75 (s, 1H), 5.86 (dd, J = 6.3, 1.0 
Hz, 2H), 6.64 (dd, J = 6.1, 2.3 Hz, 1H), 6.75-6.86 (m, 3H), 6.92 (td, J = 7.1, 1.0 Hz, 1H), 7.09 
(d, J = 8.1 Hz, 2H), 7.15 (t, J = 7.6 Hz, 2H), 7.30 (tt, J = 7.6, 1.0 Hz 1H), 7.51 (dd, J = 8.1 Hz, 
2H); 13C NMR (100 MHz, CD3OD):  = 11.7, 54.6, 102.2, 108.5, 108.9, 110.9, 111.3, 119.7, 
119.8, 121.5, 121.6, 127.5, 129.2, 132.7, 134.3, 136.5, 137.0, 142.1, 147.8, 148.9; HRMS (ESI): 
calcd for C23H20N2O4S [M+Na]+ 443.10360; found 443.10357. 
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(S)-N-((4-methoxyphenyl)(2-methyl-1H-indol-3-yl)methyl)benzenesulfonamide (14-16d) 
 
 
Prepared from imine 12-31d (26 mg, 0.1 mmol) and 2-methylindole (12-27b) (33 mg, 0.25 
mmol) according to procedures 10 to give product 14-16d (33 mg, 86%) as yellow foam. Rf = 
0.2 (petroleum ether/EtOAc, 3:1); ee = 83% [n-hexanes/2-propanol = 75/25, 0.8 mL/min,  = 
254 nm, t (major) = 28.8 min, t (minor) = 16.7 min]; []D25= –11.7 (c 1.0, acetone); 1H NMR 
(400 MHz, CD3OD):  = 2.08 (s, 3H), 3.72 (s, 3H), 5.80 (s, 1H), 6.76 (t, J = 8.1 Hz, 3H), 6.91 
(t, J = 7.3 Hz, 1H), 7.08 (d, J = 8.8 Hz, 2H), 7.13 (t, J = 8.1 Hz, 2H), 7.24 (d, J = 8.8 Hz, 2H), 
7.29 (t, J = 7.3 Hz, 1H), 7.50 (dd, J = 8.3, 1.0 Hz, 2H); 13C NMR (100 MHz, CD3OD):  = 11.7, 
54.5, 55.8, 111.2, 111.4, 114.5, 119.7, 120.0, 121.6, 127.6, 128.0, 129.2, 129.6, 132.8, 134.4, 
134.6, 137.2, 142.5, 160.2; HRMS (ESI): calcd for C23H22N2O3S [M+Na]+ 429.12433; found 
429.12438. 
(S)-N-((2-methyl-1H-indol-3-yl)(4-(trifluoromethyl)phenyl)methyl)benzenesulfonamide 
(14-16e) 
 
 
Prepared from imine 12-31e (33 mg, 0.1 mmol) and 2-methylindole (12-27b) (36 mg, 0.25 
mmol) according to procedures 10 to give product 14-16a (39 mg, 88%) as yellow amorphous 
solid. Rf = 0.2 (petroleum ether/EtOAc, 3:1); ee = 93% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 21.7 min, t (minor) = 10.6 min]; []D25= –37 (c 1.0, acetone); 
1H NMR (400 MHz, CDCl3):  = 1.96 (s, 3H), 5.27 (d, J = 6.8 Hz, 1H), 5.73 (d, J = 6.8 Hz, 
1H), 6.78-6.92 (m, 2H), 6.99 (td, J = 8.0, 1.0 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 7.17-7.24 (m, 
2H), 7.33-7.39 (m, 1H), 7.44 (q, J = 8.6 Hz, 4H), 7.53-7.58 (m, 2H), 7.75 (br, 1H); 13C NMR 
(100 MHz, CDCl3):  = 11.4, 53.4, 110.0, 110.6, 118.1, 120.0, 121.8, 125.2, 125.2, 125.3, 125.5, 
126.9, 127.4, 128.6, 129.0, 129.1, 132.4, 132.8, 135.3, 139.8, 144.6; HRMS (ESI): calcd for 
C23H19F3N2O2S [M+Na]+ 467.10115; found 467.10152. 
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Methyl (S)-4-((2-methyl-1H-indol-3-yl)(phenylsulfonamido)methyl)benzoate (14-16f) 
 
 
Prepared from imine 12-31f (31 mg, 0.1 mmol) and 2-methylindole (12-27b) (34 mg, 0.25 
mmol) according to procedures 10 to give product 14-16f (49 mg, 99%) as yellow amorphous 
amorphous solid. Rf = 0.3 (petroleum ether/EtOAc, 3:1); ee = 97% [n-hexanes/2-propanol = 
75/25, 0.8 mL/min,  = 254 nm, t (major) = 33.2 min, t (minor) = 16.8 min]; []D25= –33.1 (c 
1.0, acetone); 1H NMR (400 MHz, CDCl3):  = 1.95 (s, 3H), 3.80 (s, 3H), 5.30 (d, J = 6.8 Hz, 
1H), 5.75 (d, J = 7.1 Hz, 1H), 6.79 (td, J = 8.1, 1.0 Hz, 1H), 6.86 (d, J = 7.8 Hz, 1H), 6.96 (td, 
J = 8.1, 1.0 Hz, 1H), 7.08 (d, J = 8.1 Hz, 1H), 7.16-7.22 (m, 2H), 7.34 (tt, J = 7.6, 1.0 Hz, 1H), 
7.40 (d, J = 7.8, 2H), 7.53-7.57 (m, 2H), 7.79-7.85 (m, 3H); 13C NMR (100 MHz, CDCl3):  = 
11.5, 52.1, 53.6, 110.1, 110.5, 118.1, 119.9, 121.6, 125.6, 126.9, 127.0, 128.6, 128.9, 129.5, 
132.8, 132.3, 135.2, 139.9, 145.9, 166.9; HRMS (ESI): calcd for C24H22N2O4S [M+Na]+ 
457.11925; found 457.11944. 
(S)-N-((4-Bromophenyl)(2-methyl-1H-indol-3-yl)methyl)benzenesulfonamide (14-16g) 
 
 
Prepared from imine 12-31g (32 mg, 0.1 mmol) and 2-methylindole (12-27b) (32 mg, 0.25 
mmol) according to procedures 10 to give product 14-16g (39 mg, 80%) as brown amorphous 
solid. Rf = 0.4 (petroleum ether/EtOAc, 3:1); ee = 92% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 23.0 min, t (minor) = 11.9 min]; []D25= –14.4 (c 1.0, acetone); 
1H NMR (400 MHz, CD3OD):  = 2.05 (s, 3H), 5.78 (s, 1H), 6.77 (td, J = 7.1, 1.0 Hz, 1H), 6.92 
(td, J = 7.3, 1.0 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 7.18 (t, J = 7.6 Hz, 
2H), 7.25-7.40 (m, 5H), 7.55 (dd, J = 8.1, 1.0 Hz, 2H); 13C NMR (100 MHz, CD3OD):  = 11.6, 
54.4, 110.6, 111.5, 119.7, 119.9, 121.7, 121.8, 127.7, 129.4, 130.4, 132.2, 133.0, 134.7, 137.2, 
142.3; HRMS (ESI): calcd for C22H19BrN2O2S [M+Na]+ 477.02428; found 477.02422. 
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(S)-N-((5-methoxy-1H-indol-3-yl)(phenyl)methyl)benzenesulfonamide (14-17a) 
 
 
Prepared from imine 12-31a (25 mg, 0.1 mmol) and 5-methoxyindole (12-27c) (37 mg, 0.25 
mmol) according to procedures 10 to give product 14-17a (40 mg, 99%) as colorless amorphous 
solid. Rf = 0.2 (petroleum ether/EtOAc, 3:1); ee = 94% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 68.1 min, t (minor) = 15.0 min]; []D25= –19.6 (c 1.0, acetone); 
1H NMR (400 MHz, CD3OD):  = 3.69 (s, 3H), 5.83 (s, 1H), 6.59 (s, 1H), 6.72 (dd, J = 8.8, 2.5 
Hz, 1H), 6.88 (d, J = 2.3 Hz, 1H), 7.11-7.20 (m, 4H), 7.22-7.30 (m, 4H), 7.38 (tt, J = 7.6, 1.0 
Hz, 1H), 7.63 (dd, J = 8.3, 1.0 Hz, 2H); 13C NMR (100 MHz, CD3OD):  = 56.3, 56.5, 102.2, 
113.0, 113.2, 116.7, 125.9, 127.7, 128.0, 128.2, 128.6, 129.2, 129.7, 133.1, 133.6, 142.7, 143.0, 
155.1; HRMS (ESI): calcd for C22H20N2O3S [M+Na]+ 415.10868; found 415.10841. 
(S)-N-((5-methoxy-1H-indol-3-yl)(naphthalen-2-yl)methyl)benzenesulfonamide (14-17b) 
 
 
Prepared from imine 12-31b (28 mg, 0.1 mmol) and 5-methoxyindole (12-27c) (37 mg, 0.25 
mmol) according to procedures 10 to give product 14-17b (38 mg, 91%) as yellow amorphous 
solid. Rf = 0.3 (petroleum ether/EtOAc, 3:1); ee = 95% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 66.7 min, t (minor) = 20.2 min]; []D25= –52.7 (c 1.0, acetone); 
1H NMR (400 MHz, CDCl3):  = 3.61 (s, 3H), 5.38 (d, J = 7.3 Hz, 1H), 6.43-6.47 (m, 1H), 6.73 
(dd, J = 8.6, 2.3 Hz, 1H), 6.81 (d, J = 2.5 Hz, 1H), 7.02-7.09 (m, 3H), 7.14-7.23 (m, 2H), 7.30-
7.39 (m, 2H), 7.50-7.58 (m, 5H), 7.63-7.69 (m, 1H), 7.85 (br, 1H); 13C NMR (100 MHz, 
CDCl3):  = 55.2, 55.8, 100.9, 112.1, 112.9, 115.7, 124.6, 125.2, 125.8, 125.9, 126.0, 126.1, 
126.3, 126.9, 127.5, 127.9, 128.1, 128.5, 129.1, 131.5, 133.0, 137.2, 140.4, 154.2; HRMS (ESI): 
calcd for C26H22N2O3S [M+Na]+ 465.12433; found 465.12446. 
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(S)-N-(benzo[d][1,3]dioxol-5-yl(5-methoxy-1H-indol-3-yl)methyl)benzenesulfonamide 
(14-17c) 
 
 
Prepared from imine 12-31c (30 mg, 0.1 mmol) and 5-methoxyindole (12-27c) (37 mg, 0.25 
mmol) according to procedures 10 to give product 14-17c (45 mg, 99%) as colorless crystalline 
solid. Rf = 0.2 (petroleum ether/EtOAc, 3:1); recrystallized (CH2Cl2/petroleum ether, 2:1); ee 
= 98% [n-hexanes/2-propanol = 75/25, 0.8 mL/min,  = 254 nm, t (major) = 93.1 min, t (minor) 
= 27.1 min]; []D25= –17.5 (c 1.0, acetone); 1H NMR (400 MHz, CDCl3):  = 3.77 (s, 3H), 5.05 
(d, J = 6.8 Hz, 1H), 5.78 (d, J = 6.8 Hz, 1H), 5.90 (dd, J = 6.8, 1.3 Hz,2H), 6.62-6.77 (m, 4H), 
6.82-6.89 (m, 2H), 7.21 (dd, J = 8.1, 1.0 Hz, 1H), 7.36 (t, J = 7.6 Hz, 2H), 7.47 (t, J = 7.3, 1H), 
7.71 (d, J = 7.8 Hz, 2H), 7.91 (br, 1H); 13C NMR (100 MHz, CDCl3):  = 55.0, 55.8, 101.0, 
101.0, 107.7, 107.9, 112.0, 113.0, 116.0, 120.7, 124.2, 125.7, 127.1, 128.6, 131.6, 132.2, 134.0, 
140.6, 146.9, 147.6, 154.3; HRMS (ESI): calcd for C23H20N2O5S [M+Na]+ 459.09851; found 
459.09862. 
(S)-N-((5-methoxy-1H-indol-3-yl)(4-methoxyphenyl)methyl)benzenesulfonamide (14-
17d) 
 
 
Prepared from imine 12-31d (28 mg, 0.1 mmol) and 5-methoxyindole (12-27c) (37 mg, 0.25 
mmol) according to procedures 10 to give product 14-17d (41 mg, 97%) as colorless amorphous 
solid. Rf = 0.2 (petroleum ether/EtOAc, 2:1); ee = 98% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 94.4 min, t (minor) = 20.6 min]; []D25= –16.8 (c 1.0, acetone); 
1H NMR (400 MHz, CDCl3):  = 3.65 (s, 3H), 3.67 (s, 3H), 5.19 (d, J = 7.1, 1H), 5.73 (d, J = 
7.1 Hz, 1H), 6.53 (d, J = 2 Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 6.72-6.77 (m, 2H), 7.03 (d, J = 
8.6 Hz, 2H), 7.09 (d, J = 8.8 Hz, 1H), 7.20 (t, J = 7.8 Hz, 2H), 7.34 (t, J = 7.6 Hz, 1H), 7.57 (d, 
J = 7.3 Hz, 2H), 7.85 (br s, 1H); 13C NMR (100 MHz, CDCl3)  = 54.7, 55.2, 55.8, 101.0, 112.0, 
112.8, 113.7, 116.1, 124.3, 125.8, 126.3, 127.0, 128.3, 128.6, 129.1, 131.6, 132.1, 140.5, 154.1, 
158.8; HRMS (ESI): calcd for C23H22N2O4S [M+Na]+ 445.11925; found 445.11920. 
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(S)-N-((5-Methoxy-1H-indol-3-yl)(4-
(trifluoromethyl)phenyl)methyl)benzenesulfonamide (14-17e) 
 
 
Prepared from imine 12-27e (31 mg, 0.1 mmol) and 5-methoxyindole (12-27c) (37 mg, 0.25 
mmol) according to procedures 10 to give product 14-17e (46 mg, 99%) as red solid. Rf = 0.2 
(petroleum ether/EtOAc, 3:1); ee = 98% [n-hexanes/2-propanol = 75/25, 0.8 mL/min,  = 254 
nm, t (major) = 65.7 min, t (minor) = 11.7 min]; []D25= –37.5 (c 1.0, acetone); 1H NMR (400 
MHz, CD3OD):  = 3.69 (s, 3H), 5.91 (s, 1H), 6.56 (s, 1H), 6.74 (dd, J = 8.8, 2.5 Hz, 1H), 6.86 
(d, J = 2.3 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.24-7.31 (m, 5H), 7.64 (dd, J = 8.1, 1.0 Hz, 2H); 
13C NMR (100 MHz, CD3OD):  = 56.1, 56.3, 101.0, 113.2, 113.4, 115.7, 125{(q, J = 271.2 
Hz) 121.8, 124.4, 127.1, 129.9}, 125.9, 126.1 (q, J = 4.1 Hz), 127.5, 128.1, 129.1, 128.8, 130 
{-CF3 (q, J = 32.3 Hz), 129.8, 130.1, 130.5, 130.9}, 133.2, 133.6, 142.8, 147.1, 155.3; HRMS 
(ESI): calcd for C23H19F3N2O3S [M+Na]+ 483.09607; found: 483.09635. 
Methyl (S)-4-((5-methoxy-1H-indol-3-yl)(phenylsulfonamido)methyl)benzoate (14-17f) 
 
 
Prepared from imine 12-31f (28 mg, 0.1 mmol) and 5-methoxyindole (12-27c) (36 mg, 0.25 
mmol) according to procedures 10 to give product 14-17f (39 mg, 94%) as a slightly yellow 
solid. Rf = 0.2 (petroleum ether/EtOAc, 2:1); ee = 93% [n-hexanes/2-propanol = 75/25, 0.8 
mL/min,  = 254 nm, t (major) = 113.9 min, t (minor) = 23.3 min]; []D25= –28.4 (c 1.06, 
acetone); 1H NMR (400 MHz, CDCl3):  = 3.62 (s, 3H), 3.81 (s, 3H), 5.48 (d, J = 6.8 Hz, 1H), 
5.80 (d, J = 6.8 Hz, 1H), 6.37 (s, 1H), 6.73 (d, J = 7.6 Hz, 2H), 7.07 (d, J = 8.8 Hz, 1H), 7.13-
7.21 (m, 4H), 7.33 (t, J = 7.3 Hz, 1H), 7.58 (d, J = 7.3 Hz, 2H), 7.74 (d, J = 7.6 Hz, 2H), 8.03 
(br s, 1H); 13C NMR (100 MHz, CDCl3):  = 52.1, 54.7, 55.8, 100.6, 112.2, 113.0, 115.0, 124.5, 
125.6, 126.9, 127.1, 128.7, 129.1, 129.6, 131.5, 132.4, 140.2, 145.3, 154.2, 166.8; HRMS: calcd 
for C24H22N2O5S [M+Na]+ 473.11416; found 473.11457. 
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(S)-N-((4-Bromophenyl)(5-methoxy-1H-indol-3-yl)methyl)benzenesulfonamide (14-17g) 
 
 
Prepared from imine 12-31g (32 mg, 0.1 mmol) and 5-methoxyindole (12-27c) (37 mg, 0.25 
mmol) according to procedures 10 to give product 14-17g (37 mg, 78%) as brown solid. Rf = 
0.3 (petroleum ether/EtOAc, 3:1); ee = 65% [n-hexanes/2-propanol = 75/25, 0.8 mL/min,  = 
254 nm, t (major) = 78.9 min, t (minor) = 14.3 min]; []D25= –21.3 (c 1.0, acetone); 1H NMR 
(400 MHz, CD3OD):  = 3.73 (s, 3H), 5.83 (s, 1H), 6.61 (s, 1H), 6.75 (dd, J = 8.8, 2.5 Hz, 1H), 
6.88 (d, J = 2.5 Hz, 1H), 7.23-7.17 (m, 3H), 7.36-7.28 (m, 4H), 7.45 (tt, J = 7.3, 1.3 Hz, 1H), 
7.63-7.52 (m, 1H), 7.7-7.64 (m, 2H), 7.96-7.91 (m, 1H); 13C NMR (100 MHz, CD3OD):  = 
55.7, 56.1, 101.9, 112.9, 113.1, 115.8, 121.7, 125.6, 127.0, 127.3, 127.8, 129.6, 129.9, 130.4, 
132.0, 132.9, 133.1, 133.4, 141.8, 142.7, 145.0, 155.0; HRMS (ESI): calcd for C22H19BrN2O3S 
[M+Na]+ 493.01920; found 493.01888. 
(S)-N-((4-bromo-1H-indol-3-yl)(naphthalen-2-yl)methyl)benzenesulfonamide (14-18b) 
 
 
Prepared from imine 12-31b (30 mg, 0.1 mmol) and 4-bromoindole (12-27d) (50 mg, 0.25 
mmol) according to procedures 10 to give product 14-18b (30 mg, 51%) as a brown solid; 
Reaction time 55 h; Rf = 0.4 (petroleum ether/EtOAc, 3:1); ee = 63% [n-hexanes/2-propanol = 
75/25, 0.8 mL/min,  = 254 nm, t (major) = 30.8 min, t (minor) = 16.2 min]; []D25= +1.0 (c 
1.0, acetone); 1H NMR (400 MHz, CD3OD):  = 6.83 (s, 1H), 6.93 (t, J = 7.8 Hz, 1H), 7.10 (s, 
1H), 7.12 (dd, J = 7.6, 1.0 Hz, 1H), 7.18-7.24 (m, 2H), 7.27-7.43 (m, 5H), 7.49 (s, 1H), 7.60 
(dd, J = 7.1, 2.3 Hz, 1H), 7.64-7.71 (m, 3H), 7.76 (dd, J = 7.1, 2.0 Hz, 1H); 13C NMR (100 
MHz, CD3OD):  = 55.2, 112.1, 114.4, 117.0, 123.7, 124.9, 125.7, 127.0, 127.2, 127.5, 127.6, 
128.1, 128.6, 128.9, 129.1, 129.6, 130.1, 133.1, 133.3, 134.2, 134.7, 139.4, 141.4, 143.0; 
HRMS (ESI): calcd for C25H19BrN2O2S [M+Na]+ 513.02428; found 513.02396. 
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(S)-N-((4-Bromo-1H-indol-3-yl)(4-(trifluoromethyl)phenyl)methyl)benzenesulfonamide 
(14-18e) 
 
 
Prepared from imine 12-31e (33 mg, 0.11 mmol) and 4-bromoindole (12-27e) (50 mg, 0.25 
mmol) according to procedures 10 to give product 14-18e (39 mg, 73%) as a brown solid; 
Reaction time 55 h; Rf = 0.3 (petroleum ether/EtOAc, 3:1); ee = 94% [n-hexanes/2-propanol = 
75/25, 0.8 mL/min,  = 254 nm, t (major) = 25.6 min, t (minor) = 9.4 min]; []D25= +1.0 (c 1.0, 
acetone); 1H NMR (400 MHz, CD3OD):  : 6.74 (s, 1H), 6.94 (t, J = 7.8 Hz, 1H), 7.04 (d, J = 
0.5 Hz, 1H), 7.13 (dd, J = 7.8, 1.0 Hz, 1H), 7.26-7.21 (m, 2H), 7.28 (dd, J = 8.1, 1.0 Hz, 1H), 
7.40-7.34 (m, 3H), 7.48 (d, J = 8.1 Hz, 2H), 7.67-7.62 (m, 2H); 13C NMR (100 MHz, CD3OD): 
δ = 54.6, 112.2, 114.2, 123.7, 125.0, 125.5, 126.1 (q, J = 4.1 Hz), 127.2, 128.1, 128.8 {-CF3 (J 
= 271.2 Hz), 127.4, 130.1}, 129.6, 129.7, 133.2, 139.4, 142.9, 148.5; HRMS (ESI): calcd for 
C22H16BrF3N2O2S [M+Na]+ 530.99602; found 530.99614. 
3,3'-(2,2-dimethylpropane-1,1-diyl)bis(1H-indole) (14-19j) 
 
 
Prepared from imine 12-31j (23 mg, 0.1 mmol) and indole 12-27a (29 mg, 0.25 mmol) 
according to procedures 10 to give product 14-19j (35 mg, 99%) as colorless amorphous solid, 
Rf = 0.2 (petroleum ether/EtOAc, 3:1); 1H NMR (400 MHz, CDCl3):  = 1.13 (s, 9H), 4.57 (s, 
1H), 7.17-7.07 (m, 4H), 7.22 (d, J = 2.5 Hz, 2H), 7.33-7.29 (m, 2H), 7.73 (d, J = 7.88, 2H), 
7.97 (br, 2H); 13C NMR (100 MHz, CDCl3)  = 29.0, 35.8, 43.0, 110.7, 119.1, 119.2, 119.4, 
121.6, 121.9, 128.7, 135.3. 
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4-((tert-Butyldimethylsilyl)oxy)butan-1-ol (16-31) 
 
 
To a stirred solution of 1,4-butanediol (16.0 g, 174.0 mmol) in CH2Cl2 (500 mL) at room 
temperature was added TBSCl (21.7 g, 144.0 mmol, 0.83 equiv). The resulting mixture was 
cooled to 0 °C before Et3N (20.0 mL, 144.0 mmol, 0.83 equiv) was slowly added. The resulting 
mixture was warmed to room temperature and stirred for 3 h, then quenched with saturated 
aqueous  NH4Cl (250 mL). The layers were separated and the organic layer was washed with 
H2O (200 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The crude product 
was purified by flash chromatography (ethyl acetate/petroleum ether, 1:10) to give mono-
protected alcohol (6.0 g, 17%) as a colorless oil; 1H NMR (400 MHz, CDCl3):  = 0.03 (s, 6H, 
(CH3)2Si), 0.86 (s, 9H, (CH3)2Si), 1.55-1.66 (m, 4H, 2-H, 3-H), 2.75 (br, 1H, OH), 3.60 (t, J = 
5.8 Hz, 2H, 1-H), 3.63 (t, J = 5.6 Hz, 2H, 4-H); 13C NMR (100 MHz, CDCl3):  = –5.5 
(CH3)2Si), 18.2 ((CH3)3CSi), 25.4 ((CH3)3CSi), 29.8 (C-2), 30.1 (C-3), 62.6, 63.3; HRMS 
(ESI): calcd for C10H24O2Si [M+Na]+ 227.14378, found 227.14410. 
4-((tert-Butyldimethylsilyl)oxy)butanal (16-33) 
 
 
To a solution of oxalyl chloride (2.55 mL, 29.78 mmol, 1.3 equiv) in CH2Cl2 (120 mL) at –80 
°C was added DMSO (2.68 mL, 34.36 mmol, 1.5 equiv) dropwise. The resulting mixture was 
stirred for 15 min before alcohol 16-32 (4.683 g, 22.91 mmol) in CH2Cl2 (25 mL) was added 
dropwise within 15 min. After stirring the mixture for 1 h at –80 °C, Et3N (17.19 mL, 119.12 
mmol, 4 equiv) was added slowly. Then the reaction mixture was allowed to warm to room 
temperature. For work-up water (50 mL) was added, the layers were separated and the aqueous 
layer was extracted with CH2Cl2 (2 × 50 mL). The combined organic layers were washed with 
saturated NaCl solution, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:20) to give 
aldehyde 16-33 (3.536 g, 76%) as a colorless oil; 1H NMR (400 MHz, CDCl3):  = 0.01 (s, 6H, 
(CH3)2Si), 0.85 (s, 9H, (CH3)3CSi), 1.78-1.87 (m, 2H, 3-H), 2.47 (td, J = 1.5, 7.1 Hz, 2H, 2-H), 
3.62 (t, J = 6.0 Hz, 2H, 4-H), 9.7 (t, J = 1.8 Hz, 1H, 1-H); 13C NMR (100 MHz, CDCl3):  = –
5.5 ((CH3)2Si), 18.2 (C-3), 18.3 (C-3), 25.4 ((CH3)2CSi), 25.8 ((CH3)3CSi), 40.7 (C-2), 62.0 (C-
4), 202.5 (C-1). 
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S-Ethyl (E)-6-((tert-butyldimethylsilyl)oxy)hex-2-enethioate (16-34) 
 
 
To a solution of aldehyde 16-33 (3.54 g, 17.47 mmol) in CH2Cl2 (270 mL) was added S-ethyl 
2-(triphenyl-5-phosphanylidene)ethanethioate (8.28 g, 22.71 mmol, 1.3 equiv). The resulting 
solution was refluxed for 2 d, and then cooled to room temperature before it was concentrated 
in vacuo. The residue was purified by flash chromatography (Et2O/petroleum ether, 1:50) to 
give enoate 16-34 (3.50 g, 69%) as yellow oil. Rf = 0.5 (petroleum ether/diethyl ether, 33:1); 
1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 0.87 (s, 9H, (CH3)2CSi), 1.25 (t, J = 
7.3 Hz, 3H, SCH2CH3), 1.60-1.70 (m, 2H, 5-H), 2.25 (ddd, J = 1.5, 7.1, 13.4 Hz, 2H, 4-H), 2.92 
(q, J = 7.3 Hz, 2H, SCH2CH3), 3.61 (t, J = 6.1 Hz, 2H, 6-H, 6.09 (dt, J = 1.5, 15.7 Hz, 1H, 2-
H), 6.89 (dt, J = 7.1, 15.7 Hz, 1H, 3-H); 13C NMR (100 MHz, CDCl3):  = –5.38 ((CH3)2Si), 
14.8 (SCH2CH3), 18.2 ((CH3)3CSi), 23.0 (SCH2CH3), 25.9 ((CH3)3CSi), 28.6 (C-4), 31.02 (C-
5), 62.1 (C-6), 128.8 (C-2); 144.9 (C-3), 190.0 (C-1); HRMS (ESI): calcd for C14H28O2SSi 
[M+Na]+ 311.14715, found 311.14758. 
S-Ethyl (R)-6-((tert-butyldimethylsilyl)oxy)-3-methylhexanethioate (16-35) 
 
 
To a solution of (S)-Tol-BINAP (0.036 g, 0.052 mmol, 0.015 equiv) in dry tert-butyl methyl 
ether (7 mL) was added copper iodide (0.007 g, 0.035 mmol, 0.010 equiv). This suspension was 
stirred for 1 h at room temperature turning into a dark yellow solution. The solution was cooled 
to –70 °C and treated dropwise with a solution of MeMgBr in Et2O (3M 5.8 mL, 17.5 mmol, 
5.0 equiv). The resulting mixture was stirred for 30 min before a solution of enoate 16-34 (1.000 
g, 3.5 mmol) in tert-butyl methyl ether (2 mL) was added dropwise using a syringe pump within 
2 h. The mixture was stirred overnight at –40 °C. The reaction was quenched with MeOH (1 
mL) and saturated NH4Cl solution (5 mL), the cooling system was removed, and the layers 
were separated. The aqueous layer was extracted with Et2O (2 × 10 mL). The combined organic 
layers were washed with saturated NaCl solution (10 mL), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. Purification of the residue by flash chromatography 
(Et2O/petroleum ether, 1:50) afforded pure ester 16-35 (0.868 g, 81%) as colorless oil. Rf = 0.5 
(petroleum ether/diethyl ether, 33:1); []20D = –5.1 (c = 1.0, CH2Cl2); 1H NMR (400 MHz, 
CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 0.86 (s, 9H, (CH3)2Si), 0.92 (d, J = 6.6 Hz, 3H, 3-CH3), 
1.14-1.21(m, 1H, 4-H), 1.22 (t, J = 7.6 Hz, 3H, SCH2CH3), 1.30-1.40 (m, 1H, 4-H), 1.42-1.57 
(m, 2H, 5-H), 1.91-2.12 (m, 1H, 3-H), 2.33 (dd, J = 8.1, 14.4 Hz, 1H, 2-H), 2.51 (dd, J = 6.1, 
14.4 Hz, 1H, 2-H), 2.84 (q, J = 7.6 Hz, 2H, SCH2CH3), 3.56 (t, J = 6.6 Hz, 2H, 6-H); 13C NMR 
(100 MHz, CDCl3):  = –5.31 ((CH3)2Si), 14.8 (SCH2CH3), 18.3 ((CH3)3CSi), 19.5 (3-CH3), 
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23.2 (SCH2CH3) 25.9 ((CH3)3CSi), 30.1 (C-5), 30.9 (C-3), 32.7 (C-4), 51.3 (C-2), 63.2 (C-6), 
199.1 (C-1); HRMS (ESI): calcd for C15H32O2SSi [M+Na]+ 327.17845, found 327.17875. 
(S)-6-((tert-Butyldimethylsilyl)oxy)-3-methylhexanal (16-36) 
 
 
To a stirred mixture of the thioester 16-35 (800 mg, 2.6 mmol) and Pd/C (138 mg, 10% wt) in 
CH2Cl2 (5 mL) was added Et3SiH (1.25 mL, 7.8 mmol, 3 equiv) at 0 °C under nitrogen. The 
reaction mixture was warmed to room temperature and stirred for 30 min. The catalyst was 
filtered off through a pad of Celite and washed with CH2Cl2. The filtrate was concentrated under 
reduced pressure and purified by flash chromatography (petroleum ether/EtOAc, 20:1) to give 
the pure aldehyde 16-36 (300 mg, 47%) as slightly yellow oil. 
S-Ethyl (S,E)-8-((tert-butyldimethylsilyl)oxy)-5-methyloct-2-enethioate (16-37) 
 
 
To a solution of aldehyde 16-36 (0.30 g, 1.23 mmol) in CH2Cl2 (18 mL) was added S-ethyl 2-
(triphenyl-5-phosphanylidene)ethanethioate (0.57 g, 1.56 mmol, 1.3 equiv). The resulting 
solution was refluxed for 2 d, and then cooled to room temperature before it was concentrated 
in vacuo. The residue was purified by flash chromatography (Et2O/petroleum ether, 1:50) to 
give enoate 16-37 (0.15 g, 69%) as yellow oil. Rf = 0.6 (petroleum ether/diethyl ether, 33:1); 
1H NMR (400 MHz, CDCl3):  = 0.03 (s, 6H, (CH3)2Si), 0.88 (s, 9H, (CH3)2Si), 0.90 (d, J = 
6.6 Hz, 3H, 5-CH3), 1.10-1.22 (m, 1H, 6-H), 1.26 (t, J = 7.3 Hz, 3H, SCH2CH3), 1.30-1.41 (m, 
1H, 6-H), 1.43-1.57 (m, 2H, 5-H, 7-H), 1.57-1.67 (m, 1H, 7-H), 1.96-2.07 (m, 1H, 4-H), 2.13-
2.25 (m, 1H, 4-H), 2.93 (q, J = 7.3 Hz, 2H, SCH2CH3), 3.57 (t, J = 6.6 Hz, 2H, 8-H), 6.80 (dt, 
J = 1.3, 15.4 Hz, 1H, 2-H), 6.85 (m, 1H, 3-H); 13C NMR (100 MHz, CDCl3):  = –5.3 
((CH3)2Si), 14.8 (SCH2CH3), 18.3((CH3)3CSi), 19.6 (5-CH3), 25.9 ((CH3)3CSi), 23.0 
(SCH2CH3), 30.3 (C-7), 32.4 (C-5), 32.7 (C-6), 39.6 (C-4), 63.3 (C-8), 129.8 (C-2), 144.1 (C-
3), 190.0 (C-1). 
3-((tert-Butyldimethylsilyl)oxy)propan-1-ol (16-39) 
 
 
To a stirred solution of 1,3-propanediol (10.0 g, 131.42 mmol) in THF (225 mL) at 0 °C was 
added NaH (5.04 g, 131.42 mmol, 1.0 equiv) in five equal proportions at every 5 min duration, 
followed by the addition of TBSCl (19.51 g, 129.42 mmol, 0.98 equiv). The resulting reaction 
mixture was warmed to room temperature and stirred for 1 h, then quenched with saturated 
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aqueous NH4Cl (5 mL) at 0 °C and then excess of saturated aqueous NH4Cl solution (100 mL) 
was added. The layers were separated, and the organic layer was dried over anhydrous Na2SO4, 
and concentrated in vacuo. The crude product was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:10) to give mono-protected alcohol 16-39 (11.00 g, 44%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3):  = 0.02 (s, 6H, (CH3)2Si), 0.84 (s, 9H, (CH3)3CSi), 
1.72 (m, 2H, 2-H), 2.91 (br, 1H, OH), 3.72 (t, J = 6.0 Hz, 2H, 1-H), 3.76 (t, J = 6.0 Hz, 2H, 3-
H 
3-((tert-Butyldimethylsilyl)oxy)propanal (16-40) 
 
To a solution of oxalyl chloride (2.23 mL, 26.03 mmol, 1.5 equiv) in CH2Cl2 (150 mL) at –80 
°C was added DMSO (3.70 mL, 52.10 mmol, 3.0 equiv) dropwise. The resulting mixture was 
stirred 15 min before alcohol 16-39 (3.300 g, 17.35 mmol) in CH2Cl2 (40 mL) was added 
dropwise within 15 min. After stirring the mixture for 1 h at –80 °C, Et3N (15.00 mL, 104.1 
mmol, 6 equiv) was added slowly. Then the reaction mixture was allowed to warm to room 
temperature. For work-up water (30 mL) was added, the layers were separated and the aqueous 
layer was extracted with CH2Cl2 (2 × 30 mL). The combined organic layers were washed with 
saturated NaCl solution, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:25) to give 
aldehyde 16-40 (2.330 g, 71%) as a colorless oil; 1H NMR (400 MHz, CDCl3):  = 0.04 (s, 6H, 
(CH3)2Si), 0.85 (s, 9H, (CH3)3CSi), 2.57 (td, J = 2.0, 6.1 Hz, 2H, 2-H), 3.96 (t, J = 6.1 Hz, 2H, 
3-H); 13C NMR (100 MHz, CDCl3):  = –5.5 ((CH3)2Si), 18.2 ((CH3)3CSi), 25.8 ((CH3)3CSi), 
46.5 (C-2), 57.4 (C-3), 201.9 (C-1); HRMS (ESI): calcd for C9H20O2Si [M+ MeOH+Na]+ 
243.13869, found 243.13887. 
(S)-4-Benzyl-3-propionyloxazolidin-2-one (16-43) 
 
 
To the solution of (S)-4-benzyloxazolidin-2-one (0.42 g, 2.37 mmol) in THF (4 mL) was added 
dropwise a solution of n-BuLi (1.3 mL, 2.0 M, 2.63 mmol, 1.1 equiv) at –78 °C for 30 min. The 
resulting reaction mixture was further stirred for 30 min before the dropwise addition of 
propionyl chloride (320 L, 3.41 mmol, 1.4 equiv). The reaction was allowed to warm to rt 
within 1 h, quenched with saturated aqueous NH4Cl (2 mL) and extracted with Et2O (3 × 10 
mL). The combined extracts were washed with aqueous NaOH (5 mL, 1N), dried over 
anhydrous Na2SO4 and filtered concentrated in vacuo to give a residue, which was purified by 
flash chromatography (ethyl acetate/petroleum ether, 1:3) to afford compound 16-43 as a 
colorless oil (0.51 g, 92%); 1H NMR (400 MHz, CDCl3):  = 1.21 (t, J = 7.3 Hz, 3H, CH3), 
2.78 (dd, J = 9.4, 13.1 Hz, 1H, CH2Ph), 2.88-3.06 (m, 2H, COCH2), 3.31 (dd, J = 9.4, 13.1 Hz, 
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1H, CH2Ph), 4.14-4.24 (m, 2H, OCH2), 4.64-4.72 (m, 1H, NCH), 7.19-7.24 (m, 2H, Ar), 7.25-
7.30 (m, 1H, Ar), 7.31-7.37 (m, 1H, Ar); 13C NMR (100 MHz, CDCl3):  = 8.2 (CH3), 29.1 
(COCH2), 37.9 (CH2Ph), 55.1 (NHCH), 66.2 (OCH2), 127.3 (Ar), 128.9 (Ar), 129.4 (Ar), 135.3 
(Ar), 153.4 (OCON), 174.0 (NCO); HRMS (ESI): calcd for C13H15NO3 [M+Na]+ 256.09441, 
found 256.09452. 
(S)-4-Benzyl-3-((2S,3R)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxy-2-
methylpentanoyl)oxazolidin-2-one (16-44) 
 
 
To a solution of (S)-4-benzyl-3-propionyloxazolidin-2-one (16-43) (0.48 g, 2.06 mmol) in 
CH2Cl2 (5 mL) at 0 °C was added dropwise Bu2BOTf  solution (2.7 mL, 1M, 2.67 mmol, 1.3 
equiv) and triethylamine (0.43 mL, 3.01 mmol, 1.4 equiv). The obtained red solution was stirred 
at 0 °C for 45 min and cooled to –78 °C. To this solution aldehyde 16-40 (0.35 g, 1.87 mmol, 
and 0.9 equiv) was added dropwise. The reaction was stirred at –78 °C for 30 min, and then 
allowed to stir at 0 °C overnight. Aqueous phosphate buffer (2.0 mL, 1.0 M, pH 4) and methanol 
(6 mL) were added, followed by slow addition of mixture of methanol/H2O2 (15 mL, 2:1). The 
reaction mixture was extracted with CH2Cl2 (3 × 10 mL). The layers were combined, dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to give a residue, which was purified by 
flash chromatography (ethyl acetate/petroleum ether, 1:2 to 1:1) to afford the aldol product 16-
44 (0.426 g, 49%); 1H NMR (400 MHz, CDCl3):  = 0.06 (s, 6H, (CH3)2Si ), 0.88 (s, 9H, 
(CH3)3CSi ), 1.27 (d, J = 7.1 Hz, 3H, 2’-CH3), 1.59-1.67 (m, 1H, 4’-H), 1.71-1.82 (m, 1H, 4’-
H) 2.76 (dd, J = 9.6, 13.4 Hz, 1H, CH2Ph), 3.26 (dd, J = 3.0, 13.4 Hz, 1H, CH2Ph), 3.55 (br, 
1H, OH), 3.75-3.89 (m, 3H, 3’-H, 5’-H), 4.12-4.24 (m, 3H, 2-H, 5-H), 4.64-4.73 (m, 1H, 4-H), 
7.17-7.22 (m, 2H, Ar), 7.25-7.35 (m, 3H, Ar); 13C NMR (100 MHz, CDCl3):  = –5.5 (CH3)2Si), 
11.2 (2-CH3), 18.2 (CH3)3CSi), 25.9 (CH3)3CSi), 35.9 (C-4’), 37.8 (CH2Ph), 42.8 (C-2’), 55.3 
(C-4), 61.9 (C-5’), 66.1 (C-5), 71.2 (C-3’), 127.3 (Ar), 128.9 (Ar), 129.4 (Ar), 135.2 (Ar), 153.1 
(C-2), 176.4 (C-1’); HRMS (ESI): calcd for C22H35NO5Si [M+Na]+ 444.21767, found 
444.21811. 
(S)-4-benzyl-3-((2S,3R)-5-((tert-butyldimethylsilyl)oxy)-3-(methoxymethoxy)-2-
methylpentanoyl)oxazolidin-2-one (16-45) 
 
 
To a solution of alcohol (3S)-16-44 (0.324 g, 0.77 mmol) in CH2Cl2 (7 mL) was added at 0 °C 
N-N-diisopropylethylamin (1.3 mL, 7.7 mmol, 10 equiv) and tetrabutylammonium iodide (28 
mg, 0.077 mmol, 0.1 equiv), followed by MOMCl (310 L, 3.85 mmol, 5 equiv). After stirring 
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of the mixture for 2 d, saturated NaHCO3 solution (5 mL) was added. The aqueous layer was 
extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were washed with saturated 
NaHCO3 solution (10 mL), saturated NaCl solution (10 mL), dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The crude MOM-ether was purified by flash 
chromatography (Et2O/petroleum ether, 1:5) to give product 16-45 (412 mg, 99%) as colorless 
oil. Rf = 0.6 (petroleum ether/diethyl ether, 2:1); 1H NMR (400 MHz, CDCl3):  = 0.03 (s, 3H, 
(CH3)2Si ), 0.04 (s, 3H, (CH3)2Si ), 0.87 (s, 9H, (CH3)3CSi ), 1.23 (d, J = 6.8 Hz, 3H, 2’-CH3), 
1.71-1.89 (m, 2H, 4’-H), 2.76 (dd, J = 9.6, 13.4 Hz, 1H, CH2Ph), 3.37-3.40 (m, 1H, CH2Ph), 
3.63-3.76 (m, 2H, 3’-H, 5’-H), 3.92-4.06 (m, 2H, 2’-H, 5’-H), 4.11-4.20 (m, 2H, 5-H), 4.61 (s, 
2H, OCH2O), 7.17-7.23 (m, 2H, Ar), 7.25-7.35 (m, 3H, Ar); 13C NMR (100 MHz, CDCl3):  = 
–5.4 (CH3)2Si), 11.9 (2’-CH3), 18.2 (CH3)3CSi), 25.9 (CH3)3CSi), 35.8 (C-4’), 37.7 (CH2Ph), 
41.6 (C-2’), 55.9 (C-4) 56.0 (OCH3), 59.5 (C-5’), 66.1 (C-5), 76.4 (C-3’), 96.7 (OCH2O), 127.3 
(Ar), 128.9 (Ar), 129.4 (Ar), 135.4 (Ar), 153.2 (C-2), 174.9 (C-1’); HRMS (ESI) : calcd for 
C24H39NO6Si [M+Na]+ 488.24389, found 488.24423. 
(2R,3R)-5-((tert-butyldimethylsilyl)oxy)-3-(methoxymethoxy)-2-methylpentan-1-ol (16-
46) 
 
 
To a solution of compound 16-45 (0.41 g, 0.88 mmol) in THF (20 mL) at 0 °C was added solid 
LiBH4 (97 mg, 4.4 mmol, 5 equiv) and MeOH (180 L, 4.4 mmol, 5 equiv) dropwise. The 
resulting solution was allowed to stir for 3 d. Thereafter, aqueous NaOH solution (1N 2 mL) 
was added and after 30 min of stirring at rt, the reaction mixture was extracted with Et2O (3 × 
10 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated in 
vacuo. The crude alcohol was purified by flash chromatography (petroleum ether/diethyl ether, 
3:1) to give pure alcohol 16-46 (155 mg, 60%) as a colorless liquid. Rf = 0.4 (petroleum 
ether/diethyl ether, 2:1); 1H NMR (400 MHz, CDCl3):  = 0.03 (s, 6H, (CH3)2Si ), 0.82 (d, J = 
7.1 Hz, 3H, 2-CH3), 0.88 (s, 9H, (CH3)3CSi ), 1.61-1.80 (m, 2H, 2-H, 4-H), 1.89-2.00 (m, 1H, 
4-H), 3.40 (s, 3H, OMe), 3.52 (dd, J = 5.4, 11.1 Hz, 1H, 1-H), 3.57-3.73 (m, 3H, 1-H, 3-H, 5-
H), 3.85-3.93 (m, 1H, 5-H), 4.64 (d, J = 6.6 Hz, 1H, OCH2O), 4.69 (d, J = 6.6 Hz, 1H, OCH2O); 
13C NMR (100 MHz, CDCl3):  = –5.4 (CH3)2Si), –5.3 (CH3)2Si), 11.2 (2-CH3), 18.2 
(CH3)3CSi), 25.9 (CH3)3CSi), 34.6 (C-4), 38.5 (C-2), 55.9 (OCH3), 59.7 (C-5), 65.3 (C-1), 76.9 
(C-3), 97.0 (OCH2O). 
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(2S,3R)-5-((tert-butyldimethylsilyl)oxy)-3-(methoxymethoxy)-2-methylpentanal (16-47) 
 
 
To a solution of oxalyl chloride (60 L, 0.72 mmol, 1.5 equiv) in CH2Cl2 (3 mL) at –80 °C was 
added DMSO (100 L, 1.44 mmol, 3.0 equiv) dropwise. The resulting mixture was stirred 15 
min before alcohol 16-46 (140 mg, 0.48 mmol) in CH2Cl2 (1 mL) was added dropwise within 
15 min. After stirring the mixture for 1 h at –80 °C, Et3N (415 L, 2.87 mmol, 6 equiv) was 
added slowly. Then the reaction mixture was allowed to warm to room temperature. For work-
up water (5 mL) was added, the layers were separated and the aqueous layer was extracted with 
CH2Cl2 (2 × 5 mL). The combined organic layers were washed with saturated NaCl solution 
(10 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to get crude 
aldehyde 16-47 (120 mg, 86%) as a colorless oil. 1H NMR (400 MHz, CDCl3, crude):  = 0.02 
(s, 6H, (CH3)2Si ), 0.86 (s, 9H, (CH3)3CSi ), 1.08 (d, J = 7.0 Hz, 3H, 2-CH3), 1.64-1.82 (m, 2H), 
2.51-2.60 (m, 1H), 2.59 (s, 2H), 3.29 (s, 3H), 3.67 (dd, J = 5.1, 6.9 Hz, 2H), 4.15-4.23 (m, 1H), 
4.58 (d, J = 7.0 Hz, 1H), 4.68 (d, J = 7.0 Hz, 1H); 13C NMR (100 MHz, CDCl3):  = –5.5, 7.8, 
25.8, 35.2, 40.9, 50.3, 55.6, 59.3, 74.9, 96.6, 204.3; HRMS (ESI): calcd for C14H30O4Si 
[M+Na]+ 345.20677, found 345.20702. 
Ethyl (E)-3-(4-hydroxybut-1-en-1-yl)benzoate (17-18) 
 
 
To a stirred solution of the aryl bromide 17-16 (3.00 g, 13.1 mmol) in Et3N (3.7 mL, 25.6 mmol, 
2.0 equiv) were successively added 3-buten-1-ol (17-17) (1.9 mL, 22.9 mmol, 1.8 equiv), 
Pd(OAc)2 (295 mg, 1.37 mmol, 0.1 equiv), and P(o-tol)3 (0.834 g, 2.74 mmol, 0.2 equiv), and 
the mixture was stirred at 75 °C for 21 h, cooled, and concentrated in vacuo. The residue was 
dissolved in EtOAc (20 mL) and H2O (20 mL). The layers were separated and the aqueous layer 
was extracted with EtOAc (2 × 10 mL). The combined extracts were washed with saturated 
solution of NaCl (2 × 20 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
Purification of the residue by flash chromatography (EtOAc/petroleum ether, 1:2) afforded pure 
ester 17-18 (2.515 g, 87%) as colorless oil. Rf = 0.5 (EtOAc/petroleum ether, 1:1); 1H NMR 
(400 MHz, CDCl3):  = 1.34 (t, J = 7.1 Hz, 3H, OCH2CH3), 2.27 (br, 1H, OH), 2.46 (qd, J = 
1.3, 6.6 Hz, 2H, 2-H), 3.73 (t, J = 6.3 Hz, 2H, 1-H), 4.34 (q, J = 7.1, Hz, 2H, OCH2CH3), 6.27 
(dt, J = 7.1, 16.0 Hz, 1H, 3-H), 6.47 (d, J = 16.0 Hz, 1H, 4-H), 7.31 (t, J = 7.6 Hz, 1H, Ar), 7.47 
(dt, J = 1.3, 7.6 Hz, 1H, Ar), 7.84 (dt, J = 1.3, 7.8 Hz, 1H, Ar), 7.99 (t, J = 2.0 Hz, 1H, Ar); 13C 
NMR (100 MHz, CDCl3):  = 14.2 (OCH2CH3), 36.2 (C-2), 60.9 (OCH2CH3), 61.8 (C-1), 
126.9, 127.9, 128.0, 128.4, 130.2, 130.6, 131.4, 137.5, 166.6 (CO); HRMS (ESI): calcd for 
C13H16O3 [M+Na]+ 243.09917, found 243.09911. 
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Ethyl 3-(4-hydroxybutyl)benzoate (17-19) 
 
 
To a gently stirred solution of styrene derivative 17-18 (1.211 g, 5.5 mmol) in MeOH/hexane 
(60 mL, 1:1) was added Pd/C (10%, 267 mg), then the septum having a needle inlet (normal 
capillary) and an outlet (fine capillary) was closed. The reaction flask was first purged with N2 
for 2 min then with H2 for 10 min at room temperature. The outlet needle was removed and a 
hydrogen balloon was attached to the inlet needle. Thereafter, the reaction mixture was allowed 
to stir at rt for 2 h. The mixture was filtered through Celite, and the filtrate concentrated in 
vacuo. The residue was purified by flash chromatography (EtOAc/petroleum ether, 1:2 to 1:1) 
which afforded pure ester 17-19 (0.848 g, 69%) as colorless oil. Rf = 0.4 (EtOAc/petroleum 
ether, 1:1); 1H NMR (400 MHz, CDCl3):  = 1.38 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.55-1.66 (m, 
2H, 2-H), 1.67-1.76 (m, 2H, 3-H), 2.69 (t, J = 7.6 Hz, 2H, 4-H), 3.66 (t, J = 6.3 Hz, 2H, 1-H), 
4.36 (q, J = 7.1, Hz, 2H, OCH2CH3), 7.30-7.40 (m, 2H, Ar), 7.82-7.90 (m, 2H, Ar); 13C NMR 
(100 MHz, CDCl3):  = 14.3 (OCH2CH3), 27.5 (C-3), 32.2 (C-2), 35.4 (C-4), 60.9 (OCH2CH3), 
62.7 (C-1), 127.1, 128.3, 129.4, 130.5, 132.9, 142.6, 166.8 (CO); HRMS (ESI): calcd for 
C13H18O3 [M+Na]+ 245.11482, found 245.11502. 
Ethyl 3-(4-oxobutyl)benzoate (17-20) 
 
 
A flask was charged with PCC (0.29 g, 1.35 mmol, 3.0 equiv) and silica gel (0.29 g). The 
contents were mixed with the help of glass rod until a homogenous mixture was formed. To 
this, alcohol 17-19 (100 mg, 0.45 mmol) in CH2Cl2 (3 mL) was added dropwise within 30 min, 
then the reaction mixture was filtered through a small silica gel column using CH2Cl2 as eluent, 
the obtained filtrate was concentrated in vacuo and the crude residue was purified by flash 
chromatography (EtOAc/petroleum ether, 1:20) to give aldehyde 17-20 (76 mg, 77%) as yellow 
oil. 1H NMR (400 MHz, CDCl3):  = 1.38 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.92-2.05 (m, 2H, 3-
H), 2.45 (td, J = 1.5, 7.3 Hz, 2H, 2-H), 2.70 (t, J = 7.6 Hz, 2H, 4-H), 4.32 (q, J = 7.1, Hz, 2H, 
OCH2CH3), 7.32-7.38 (m, 2H, Ar), 7.82-7.91 (m, 2H, Ar), 9.75 (t, J = 1.5 Hz, 1H, 1-H); 13C 
NMR (100 MHz, CDCl3):  = 14.3 (OCH2CH3), 23.5 (C-3), 34.7 (C-4), 43.0 (C-2), 60.9 
(OCH2CH3), 127.4, 128.4, 129.4, 130.6, 132.9, 141.5, 166.7 (CO2Et), 202.0 (C-1); HRMS 
(ESI): calcd for C13H16O3 (dimer, 2 × C13H16O3) [2M+Na]+ 463.20911, found 463.20927. 
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Ethyl 3-(pent-4-en-1-yl)benzoate (17-21) 
 
 
To a solution of CH3PPh3Br (3.243 g, 9.0 mmol, 2.0 equiv) in THF (40 mL) at 0 °C was added 
NaH (0.194 g, 8.1 mmol, 1.8 equiv). The resulting mixture was allowed to reach rt within 2 h. 
Thereafter, the reaction mixture was re-cooled to 0 °C and before aldehyde 17-20 (1.00 g, 4.5 
mmol) in THF (10 mL) was added dropwise. After complete addition, the reaction mixture was 
stirred for 2 h, quenched with water (1 mL) at 0 °C, then excess water (10 mL) was added, and 
the mixture extracted with Et2O (3 × 10 mL). The organic layers were combined, washed with 
saturated solution of NaCl (20 mL), dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. Purification of the residue by flash chromatography (EtOAc/petroleum ether, 1:20) 
afforded aldehyde 17-20 (0.50 g, 2.25 mmol) and pure alkene-ester 17-21 (0.300 g, 61%) as 
colorless oil. Rf = 0.6 (EtOAc/petroleum ether, 1:20); 1H NMR (400 MHz, CDCl3):  = 1.39 (t, 
J = 7.1 Hz, 3H, OCH2CH3), 1.67-1.81 (m, 2H, 4-H), 2.09 (q, J = 5.6 Hz, 2H, 3-H), 2.67 (t, J = 
7.6 Hz, 5H), 4.37 (q, J = 7.1, Hz, 2H, OCH2CH3), 4.92-5.08 (m, 2H, 1-H), 5.63-5.89 (m, 1H, 
2-H), 7.30-7.43 (m, 2H, Ar), 7.83-7.94 (m, 2H, Ar); 13C NMR (100 MHz, CDCl3):  = 14.3 
(OCH2CH3), 29.7 (C-4), 30.5 (C-3), 33.2 (C-5), 60.9 (OCH2CH3), 114.9 (C-1), 127.0, 128.2, 
129.5, 130.5, 133.0, 138.3, 147.7, 166.8 (CO2Et); HRMS (ESI): calcd for C17H23NO3 [M+Na]+ 
312.15701, found 312.15728. 
N-Hydroxy-3-(pent-4-en-1-yl)benzamide (17-22) 
 
 
To a stirred solution of ethyl benzoate 17-21 (0.300 g, 1.4 mmol) and hydroxylamine 
hydrochloride (0.382 g, 5.5 mmol, 4.0 equiv) in MeOH (3 mL) was added KOH solution (1M 
in methanol, 7 mL, 5.0 equiv) in a dropwise fashion. The resulting solution was stirred 48 h at 
room temperature. Thereafter most of the MeOH was distilled out in vacuo and the solid residue 
was dissolved in a mixture of acetic acid/water (1/1, 5 mL). The mixture was extracted with 
EtOAc (3 × 7 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo to provide the crude hydroxamic acid which was washed with diethyl 
ether (7 mL) to afford the pure hydroxamic acid 17-22 as transparent solid (0.24 g, 89%); 13C 
NMR (100 MHz, CDCl3):  = 30.3 (C-4), 32.9 (C-3), 34.7 (C-4), 115.3 (C-1), 124.6, 127.1, 
128.6, 131.5, 132.9, 137.1, 138.6, 142.6, 164.7 (CONH).  
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3-(pent-4-en-1-yl)-N-(pivaloyloxy)benzamide (17-23) 
 
 
To the suspension of hydroxamic acid 17-22 (0.24 g, 1.2 mmol) in CH2Cl2 (6 mL) was added 
pivalic anhydride (0.22 mL, 1.1 mmol, 0.9 equiv). The resulting mixture was stirred for 35 h at 
room temperature. The reaction mixture was diluted with saturated NaHCO3 (5 mL) and 
extracted with EtOAc (2 × 6 mL). The combined organic layers were washed with saturated 
NaHCO3 solution (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. 
The crude product was purified by flash chromatography to afford the pure O-pivaloyl 
hydroxamic acid 17-23 (0.20 g, 60%) as colorless solid. 1H NMR (400 MHz, CDCl3):  = 1.33 
(s, 9H, OPiv), 1.58 (pent, J = 7.6 Hz, 2H, 4-H), 2.06 (q, J = 7.1 Hz, 2H, 3-H), 2.62 (t, J = 7.8 
Hz, 2H, 5-H), 4.90-5.06 (m, 2H, 1-H), 5.58-5.87 (m, 1H, 2-H), 7.27-7.40 (m, 2H, Ar), 7.55-
7.69 (m, 2H, Ar), 9.57 (s, 1H, NH); 13C NMR (100 MHz, CDCl3):  = 27.0 (C(CH)3), 30.3 (C-
4), 33.1 (C-3), 35.0 (C-5), 38.3 (C(CH)3), 115.0 (C-1), 124.7, 127.5, 128.6, 130.8, 132.8, 138.2, 
143.2, 169.9 (CONH), 177.0 (OC(O)tBu). 
2,3,3a,4,5,6-Hexahydro-1H-benzo[de]isoquinolin-1-one (17-14) 
 
 
An oven dried, cooled Schlenk tube under N2, was charged with N-(pivaloyloxy)benzamide 17-
23 (20 mg, 0.07 mmol), [Cp*RhCl2]2 (2 mg, 2.5 mol%), CsOAc (32 mg, 0.17 mmol, 2.5 equiv) 
and dry EtOH (0.1 mL). The screw cap was closed tightly under positive pressure of N2 
followed by stirring of the reaction mixture at room temperature for 8 h (TLC control). The 
mixture was concentrated in vacuo and the residue purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:1) to afford the pure annulation product 17-14 (10 mg, 76%). 1H 
NMR (400 MHz, CDCl3):  = 1.31-1.45 (m, 1H, 4-H), 1.68-1.83 (m, 1H, 5-H), 1.96-2.11 (m, 
2H, 4-H, 5-H), 2.74-2.95 (m, 2H, 6-H), 3.05-3.17 (m, 1H, 3a-H), 3.24 (dd, J = 11.6, 13.1 Hz, 
1H, 3-H), 3.41 (dd, J = 6.1, 11.6 Hz, 1H, 3-H), 6.07 (br, 1H, HN), 7.26 (d, J = 4.6 Hz, 2H, 7-
H, 9-H), 7.88 (t, J = 4.6 Hz, 8-H); HRMS m/z (ESI): calcd for C12H13NO (M+H)+ 188.10699, 
found 188.10692. 
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6-Bromobenzo[d][1,3]dioxole-5-carbaldehyde (18-25e)  
 
To a mixture of piperonal (152 mg, 0.66 mmol) in CH2Cl2 (20ml) was added DBDMH (286 
mg, 1.0 mmol) at room temperature. Then the reaction mixture was stirred for 0.5 h, washed 
with water (3 × 30 ml), dried with anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
residue was purified by flash chromatography (petroleum ether/ethyl acetate, 20:1) to afford 
the aldehyde 18-25e as light yellow solid (70 mg, 46% yield). Rf = 0.7 (EtOAc/petroleum ether, 
1:5); 1H NMR (400 MHz, CDCl3):  = 6.06 (s, 2H, OCH2O), 7.03 (s, 1H, Ar), 7.33 (s, 1H, Ar), 
10.15 (s, 1H, CHO); 13C NMR (100 MHz, CDCl3):  = 102.7, 108.1, 113.2, 121.5, 128.0, 148.1, 
153.3, 190.3. 
Addition of allylMgBr to the o-bromoaldehydes (Procedure 11): To a solution of aldehyde 
(1.0 equiv) in THF (3.5 mL per mmol of aldehyde) at 0 °C was added a solution of allylMgBr 
(1 M in Et2O, 3 equiv). The reaction mixture was allowed to warm to room temperature. Before 
quenching with saturated NH4Cl (5 mL), the reaction mixture was re-cooled to 0 °C, then the 
mixture was extracted with ethyl acetate (2 × 10 mL per mmol of aldehyde). The combined 
organic layers were washed with saturated aqueous NaCl solution (10 mL per mmol of 
aldehyde), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to the give crude 
secondary alcohol. 
1-(2-Bromophenyl)but-3-en-1-ol (18-26a) 
 
 
Prepared from 2-bromobenzaldehyde (1.00 g, 5.5 mmol) according to general procedure. 
Reaction time 2 h. The crude product was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:20) to give alcohol 18-26a (0.80 g, 64%) as brown oil. 
1-(2-Bromo-5-methoxyphenyl)but-3-en-1-ol (18-26b) 
 
 
Prepared from 2-bromo-5-methoxybenzaldehyde (0.50 g, 2.32 mmol) according to general 
procedure 11. Reaction time 1 h. The crude product was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:5) to give alcohol 18-26b (0.390 g, 65%) as brown oil. Rf = 
0.7 (EtOAc/petroleum ether, 1:3); 1H NMR (400 MHz, CDCl3):  = 2.24 (br, 1H), 2.26-2.36 
(m, 1H), 2.56-2.65 (m, 1H), 3.79 (s, 3H), 5.03 (dd, J = 3.5, 8.6 Hz, 1H), 5.13-5.23 (m, 2H), 
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5.80-5.93 (m, 1H), 6.68 (dd, J = 3.0, 8.6 Hz, 1H), 7.11 (d, 3.0 Hz, 1H), 7.37 (d, J = 8.8 Hz, 1H); 
13C NMR (100 MHz, CDCl3):  = 42.0, 55.4, 71.8, 111.9, 112.5, 114.8, 118.6, 133.2, 134.3, 
143.8, 159.2; HRMS (ESI): calcd for C11H13BrO2 [M+Na]+ 278.99911, found 278.99934. 
1-(2-Bromo-4,5-dimethoxyphenyl)but-3-en-1-ol (18-26c) 
 
 
Prepared from 2-bromo-4,5-dimethoxybenzaldehyde (0.500 g, 2.04 mmol) according to general 
procedure 11. Reaction time 1 h. The crude product was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:5) to give alcohol 18-26c (0.390 g, 75%) as brown oil. Rf = 
0.5 (EtOAc/petroleum ether, 1:3); 1H NMR (400 MHz, CDCl3):  = 2.21-2.61 (br, 3H), 3.80 (s, 
6H), 4.91-5.00 (m, 1H), 5.06-5.19 (m, 2H), 5.74-5.89 (m, 1H), 6.90 (s, 1H), 7.0 (s, 1H); 13C 
NMR (100 MHz, CDCl3):  = 42.2, 55.9, 56.0, 71.6, 109.6, 111.3, 115.0, 118.2, 118.3, 134.3, 
134.8, 148.5.  
1-(2-Bromo-3,4,5-trimethoxyphenyl)but-3-en-1-ol (18-26d) 
 
 
Prepared from 2-bromo-3,4,5-trimethoxybenzaldehyde (0.400 g, 1.45 mmol) according to 
general procedure 11. Reaction time 1 h. The crude product was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:5) to give alcohol 18-26d (0.400 g, 87%) as 
brown oil. Rf = 0.4 (EtOAc/petroleum ether, 1:3); 1H NMR (400 MHz, CDCl3):  = 2.16 (br, 
1H), 2.23-2.33 (m, 1H), 2.56-2.66 (m, 1H), 3.83-3.90 (3s, 9H), 5.07 (dd, J = 3.5, 8.6 Hz, 1H), 
5.13-5.23 (m, 2H), 5.81-5.95 (m, 1H), 6.95 (s, 1H); 13C NMR (100 MHz, CDCl3):  = 42.0, 
56.1, 61.0, 71.8, 105.8, 107.8, 118.6, 134.4, 138.4, 142.1, 150.4, 153.0; HRMS (ESI): calcd for 
C13H17BrO4 [M+Na]+ 339.02024, found 339.02044. 
1-(6-bromobenzo[d][1,3]dioxol-5-yl)but-3-en-1-ol (18-26e) 
 
 
Prepared from piperonal (65 mg, 0.28 mmol) according to general procedure 11. Reaction time 
2 h. The crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 
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1:10) to give alcohol 18-26e (60 mg, 79%) as colorless solid. 1H NMR (400 MHz, CDCl3):  = 
2.20 (br, 1H, OH), 2.25-2.37 (m, 1H, 2-H), 2.48-2.59 (m, 1H, 2-H), 5.01 (dd, J = 3.8, 8.3 Hz, 
1H, 4-H), 5.13-5.21 (m, 2H, 1-H, 4-H), 5.78-5.91 (m, 1H, 3-H), 5.95 (d, J = 1.5 Hz, 1H, 2’-H), 
5.96 (d, J = 1.5 Hz, 1H, 2’-H), 6.94 (s, 1H, 7’-H), 7.03 (s, 1H, 4’-H); 13C NMR (100 MHz, 
CDCl3):  = 42.2 (C-2), 71.7 (C-1), 101.7 (C-2’), 107.2, 111.9, 112.4, 118.6, 134.2, 136.1, 
147.4, 147.6. 
1-(1-Bromonaphthalen-2-yl)but-3-en-1-ol (18-26f) 
 
 
Prepared from 1-bromo-2-naphthaldehyde (0.50 g, 1.83 mmol) according to general procedure 
11. Reaction time 1 h. The crude product was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:5) to give alcohol 18-26f (0.300 g, 59%) as colorless oil. 1H NMR 
(400 MHz, CDCl3):  = 2.26 (br, 1H), 2.40-2.52 (m, 1H), 2.63-2.73 (m, 1H), 5.14-5.30 (m, 2H), 
5.45 (dd, J = 3.9, 8.4 Hz, 1H), 5.86-5.98 (m, 1H), 7.48-7.54 (m, 1H), 7.56-7.62 (m, 1H), 7.69 
(dd, J = 4.0, 8.6 Hz, 1H), 7.77-7.86 (m, 1H), 8.32 (d, J = 8.6 Hz, 1H); 13C NMR (100 MHz, 
CDCl3):  = 42.2, 72.6, 118.7, 121.5, 124.3, 126.5, 127.3, 127.4, 128.0, 128.1, 132.1, 134.1, 
134.2, 140.7; HRMS (ESI): calcd for C14H13BrO [M+Na]+ 299.00420, found 299.00439. 
1-(2-Chloro-6-fluorophenyl)but-3-en-1-ol (18-26g) 
 
 
Prepared from 2-chloro-6-fluorobenzaldehyde (2.00 g, 12.6 mmol) according to general 
procedure 11. Reaction time 12 h. The crude product was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:10) to give alcohol 18-26g (1.258 g, 50%) as colorless oil. 1H 
NMR (400 MHz, CDCl3):  = 2.56 (br, 1H), 2.58-2.66 (m, 1H), 2.70-2.80 (m, 1H), 5.04-5.17 
(m, 2H), 5.26 (t, J = 7.1 Hz, 1H), 5.73-5.86 (m, 1H), 6.91-7.02 (s, 1H), 7.11-7.20 (s, 1H); 13C 
NMR (100 MHz, CDCl3):  = 41.0, 69.3, 114.8, 115.0, 118.3, 125.7, 128.4, 128.5, 129.0, 129.1, 
133.4, 133.5, 133.6, 160.4, 162.9; HRMS (ESI): calcd for C10H10ClFO [M+Na]+ 223.02964, 
found 223.03007. 
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1-(3-Bromothiophen-2-yl)but-3-en-1-ol (18-26h) 
 
 
Prepared from 3-bromothiophene-2-carbaldehyde (0.200 g, 1.05 mmol) according to general 
procedure 11. Reaction time 10 min. The crude product was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:5) to give alcohol 18-26h (0.135 g, 55%) as yellow oil. Rf = 
0.5 (EtOAc/petroleum ether, 1:3); 1H NMR (400 MHz, CDCl3):  = 2.42 (s, 1H), 2.48-2.68 (m, 
2H), 5.09 (dd, J = 5.3, 7.5 Hz, 1H), 5.13-5.23 (m, 1H), 5.77-7.90 (m, 1H), 6.92 (d, J = 5.3 Hz, 
1H), 7.23 (d, J = 5.3 Hz, 1H); 13C NMR (100 MHz, CDCl3):  = 42.6, 68.8, 107.3, 119.1, 124.7, 
129.8, 133.4, 142.1; HRMS (ESI): calcd for C8H9BrOS [M+Na]+ 254.94497, found 254.94488. 
Redox cyclization (Procedure 12) 
To a stirred solution of the aryl bromide (1.0 equiv) in toluene (2.5 mL per mmol) under N2 atm 
was added Et3N (2.0 equiv), Pd(OAc)2 (0.1 equiv), and P(o-tol)3 (0.2 equiv), and the reaction 
mixture was stirred at 110 °C for 6 h, then cooled, and concentrated in vacuo. The residue was 
dissolved in EtOAc (10 mL per mmol of aryl bromide) and H2O (10 mL per mmol of aryl 
bromide). The layers were separated and the aqueous layer was extracted with EtOAc (2 × 10 
mL (per mmol of aryl bromide)),.The combined extracts were washed with saturated NaCl 
solution (20 mL per mmol of aryl bromide), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to afford crude product. 
3-Methyl-2,3-dihydro-1H-inden-1-one (18-28a) 
 
 
Prepared from aryl bromide 18-26a (100 mg, 0.44 mmol) according to general procedure 12. 
The crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:10) 
to give indanone 18-28a (40 mg, 62%) as colorless oil. 1H NMR (400 MHz, CDCl3):  = 1.39 
(d, J = 7.1 Hz, 3H, 3-CH3), 2.26 (dd, J = 3.3, 19.0 Hz, 1H, 2-H), 2.92 (dd, J = 7.6, 19.0 Hz, 1H, 
2-H), 3.36-3.48 (m, 1H, 3-H), 7.35 (dd, J = 7.3, 7.6 Hz, 1H, Ar), 7.49 (dd, J = 1.0, 7.8 Hz, 1H, 
Ar), 7.59 (ddd, J = 1.3, 7.6, 8.6 Hz, 1H, Ar), 7.35 (dd, J = 7.8 Hz, 1H, Ar); 13C NMR (100 MHz, 
CDCl3):  = 21.3 (3-CH3), 32.7 (C-3), 45.3 (C-2), 123.4, 125.2, 127.3, 134.7, 136.4, 159.9 (Ar), 
206.4 (C-1). 
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6-methoxy-3-methyl-2,3-dihydro-1H-inden-1-one (18-28b) 
 
 
Prepared from aryl bromide 18-26b (100 mg, 0.39 mmol) according to general procedure 12. 
The crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:10) 
to give indanone 18-28b (46 mg, 72%) as colorless oil. Rf = 0.7 (EtOAc/petroleum ether, 1:3); 
1H NMR (400 MHz, CDCl3):  = 1.34 (d, J = 7.1 Hz, 3H, 3-CH3), 2.27 (dd, J = 3.3, 19.0 Hz, 
1H, 2-H), 2.94 (dd, J = 7.3, 19.0 Hz, 1H, 2-H), 3.30-3.41 (m, 1H, 3-H), 3.81 (s, 3H, OCH3), 
7.10-7.20 (m, 2H, Ar), 7.35-7.39 (m, 1H, Ar); 13C NMR (100 MHz, CDCl3):  = 21.5 (3-CH3), 
32.1 (C-3), 46.0 (C-2), 55.6 (OCH3), 104.0 (Ar), 124.1, 126.0, 137.6, 152.9, 159.4 (Ar), 206.3 
(C-1); HRMS (ESI): calcd for C11H12O2 [M+Na]+ 199.07295, found 199.07324. 
7-Methyl-6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-5-one (18-28e) 
 
 
Prepared from aryl bromide 18-26e (50 mg, 1.05 mmol) according to general procedure 12. The 
crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:5) to give 
indanone 18-28e (30 mg, 88%) as colorless oil. Rf = 0.3 (EtOAc/petroleum ether, 1:3); 1H NMR 
(400 MHz, CDCl3):  = 1.34 (d, J = 7.1 Hz, 3H, 7-CH3), 2.24 (dd, J = 3.0, 19.0 Hz, 1H, 6-H), 
2.90 (dd, J = 7.3, 19.0 Hz, 1H, 6-H), 3.30 (dq, J = 3.0, 7.1 Hz, 7-H), 6.05 (s, 2H, 2-H), 6.84 (s, 
1H, 8-H), 7.05 (s, 1H, 4-H; 13C NMR (100 MHz, CDCl3):  = 21.4 (7-CH3), 32.6 (C-7), 45.7 
(C-6), 102.0 (Ar), 102.2 (C-2), 104.5 (Ar), 131.1 (Ar), 148.3 (Ar), 154.3 (Ar), 157.7 (Ar), 204.2 
(C-5); HRMS (ESI): calcd for C11H10O3 [M+Na]+ 213.05221, found 213.05221. 
1-methylene-2,3-dihydro-1H-cyclopenta[a]naphthalen-3-ol (18-29) 
 
 
Prepared from aryl bromide 18-26f (100 mg, 0.36 mmol) according to general procedure 12. 
The crude product was purified by flash chromatography (ethyl acetate/petroleum ether, 1:10) 
to give indenol 18-29 (30 mg, 42%) as colorless oil. 1H NMR (400 MHz, CDCl3):  = 1.99 (br, 
1H, OH), 2.62-2.71 (m, 1H, 2-H), 3.19 (ddt, J = 1.7, 7.0, 15.5 Hz, 1H, 2-H), 5.20 (dd, J = 4.4, 
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7.0 Hz, 1H, 3-H), 5.27 (t, J = 1.7 Hz, 1H, 1-CH2), 5.80 (t, J = 2.1 Hz, 1H, 2-CH2), 7.38-2.56 
(m, 4H, Ar), 7.68 (d, J = 8.3 Hz, 1H, Ar), 7.79 (dd, J = 1.0, 8.0 Hz, 1H, Ar), 8.35 (d, J = 8.4 
Hz, 1H, Ar); 13C NMR (100 MHz, CDCl3):  = 45.6 (C-2), 73.1 (C-3), 108.1 (1-CH2), 122.3, 
122.6, 124.4, 125.8, 126.5, 126.9, 127.1, 128.5, 129.1, 130.1, 146.6. 
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21 Appendix 
21.1 NMR-Spectra 
Not all NMR spectra are included here. The remaining ones can be found in the supporting 
information from the following publications: 
Chapter 1. Formal Total Synthesis of Amphidinolide Q. J. Org. Chem. 2016, 81, 9728-9737. 
Chapter 2. C–H-Activation approach towards the core structure of the alkaloid Ȗ-lycorane 
Tetrahedron 2016, 72, 6499-6509. 
Chapter 3. All NMR spectra along with few chromatograms are included here. 
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1H NMR (400 MHz) spectrum of hydroxyl-alkene 4-32 in CDCl3. 
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13C NMR (100 MHz) spectrum of hydroxyl-alkene 4-32 in CDCl3. 
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1H NMR (400 MHz) spectrum of alkyne 4-45 in CDCl3. 
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13C NMR (100 MHz) spectrum of internal-alkyne 4-45 in CDCl3. 
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1H NMR (400 MHz) spectrum of terminal-alkyne 4-47 in CDCl3. 
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13C NMR (100 MHz) spectrum of terminal-alkyne 4-47 in CDCl3. 
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1H NMR (400 MHz) spectrum of alcohol 4-50 in CDCl3. 
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13C NMR (100 MHz) spectrum of alcohol 4-50 in CDCl3. 
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1H NMR (400 MHz) spectrum of aldehyde 4-52 in CDCl3. 
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13C NMR (100 MHz) spectrum of aldehyde 4-52 in CDCl3. 
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1H NMR (400 MHz) spectrum of OTMS-acetone 4-98 in CDCl3. 
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13C NMR (100 MHz) spectrum of OTMS-acetone 4-98 in CDCl3. 
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1H NMR (400 MHz) spectrum of oxo-ester 3-2 in CDCl3. 
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13C NMR (100 MHz) spectrum of oxo-ester 3-2 in CDCl3. 
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1H NMR (400 MHz) spectrum of macrolactone 2-25 in CDCl3 (–0.5 – 7.5 ppm). 
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1H NMR (400 MHz) spectrum of macrolactone 2-25 in CDCl3 (–0.5 – 6.5 ppm). 
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13C NMR (100 MHz) spectrum of macrolactone 2-25 in CDCl3. 
224  Appendix
 
6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
F2 Chemical Shift (ppm)
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
F
1
 C
h
e
m
ic
a
l 
S
h
if
t 
(p
p
m
)
2
11
21
4 5 5 13
17
7 15
8
12 10
8, 9, 16, 18, 20 19
COSY (400 MHz) spectrum of macrolactone 2-25 in CDCl3 (0.5 – 6.1 ppm). 
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1H NMR (600 MHz) spectrum of 4-epi-amphidinolide Q (epi-1-14) in CDCl3. 
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13C NMR (150 MHz) spectrum of 4-epi-amphidinolide Q (epi-1-14) in CDCl3. 
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1H NMR (400 MHz) spectrum of tetracycle 9-67 in CDCl3. 
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13C NMR (100 MHz) spectrum of tetracycle 9-67 in CDCl3. 
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1H NMR (400 MHz) spectrum of iso-indole 9-68 in CDCl3. 
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13C NMR (100 MHz) spectrum of iso-indole 9-68 in CDCl3. 
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1H NMR (400 MHz) spectrum of amide 9-69 in CDCl3. 
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13C NMR (100 MHz) spectrum of amide 9-69 in CDCl3. 
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1H NMR (400 MHz) spectrum of pyrolo-isoquinoline 8-9 in CDCl3. 
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13C NMR (100 MHz) spectrum of pyrolo-isoquinoline 8-9 in CDCl3. 
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1H NMR (400 MHz) spectrum of 12-33a in CD3OD. 
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13C NMR (100 MHz) spectrum of 12-33a in CD3OD. 
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Chromatograms of compounds (−) & (±) 12-33b. 
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1H NMR (400 MHz) spectrum of 12-33b in CD3OD. 
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13C NMR (100 MHz) spectrum of 12-33b in CD3OD. 
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1H NMR (400 MHz) spectrum of 12-33c in CD3OD. 
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13C NMR (100 MHz) spectrum of 12-33c in CD3OD. 
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7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
3.96 3.032.951.97 1.05 0.99
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1H NMR (400 MHz) spectrum of 12-33d in CD3OD. 
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13C NMR (100 MHz) spectrum of 12-33d in CD3OD. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 12-33e in CD3OD. 
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13C NMR (100 MHz) spectrum of 12-33e in CD3OD. 
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Chromatograms of compounds (−) & (±) 12-33f. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
5.62 3.152.11 1.06 1.021.00 0.530.52 0.00
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1H NMR (400 MHz) spectrum of 12-33f in CDCl3. 
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
1
6
6
.8
1
4
5
.3
1
4
0
.1
1
3
6
.3
1
3
2
.5
1
2
9
.6
1
2
9
.6
1
2
9
.2
1
2
8
.8
1
2
7
.2
1
2
7
.1
1
2
3
.8
1
2
3
.7
1
2
2
.7
1
2
0
.1
1
1
8
.9
1
1
5
.4
1
1
5
.4
1
1
1
.4
7
7
.0
5
4
.6
5
4
.5
5
2
.1
13C NMR (100 MHz) spectrum of 12-33f in CDCl3. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
5.102.01 1.13 1.03 1.00 0.810.77
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1H NMR (400 MHz) spectrum of 12-33g in CDCl3. 
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13C NMR (100 MHz) spectrum of 12-33g in CDCl3. 
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Chromatograms of compounds (−) & (±) 14-10a. 
240  Appendix
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-16a in CD3OD. 
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13C NMR (100 MHz) spectrum of 14-16a in CD3OD.  
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Chromatogrms of compounds (−) & (±) 14-16b. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
3.603.08 3.072.031.14 1.10 0.96 0.93
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1H NMR (400 MHz) spectrum of 14-16b in CDCl3. 
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13C NMR (100 MHz) spectrum of 14-16b in CDCl3. 
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Chromatogrms of compounds (−) & (±) 14-16c. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-16c in CD3OD. 
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13C NMR (100 MHz) spectrum of 14-16c in CD3OD. 
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Chromatogrms of compounds (−) & (±) 14-16d. 
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7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
3.98 3.223.193.021.98 1.00
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1H NMR (400 MHz) spectrum of 14-16d in CD3OD (00 – 10.0 ppm). 
 
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10
Chemical Shift (ppm)
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13C NMR (100 MHz) spectrum of 14-16d in CD3OD (0.0 – 190 ppm). 
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Chromatogrms of compounds (−) & (±) 14-16e. 
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9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-16e in CDCl3. 
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
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13C NMR (100 MHz) spectrum of 14-16e in CDCl3. 
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Chromatograms of compounds (−) & (±) 14-16f. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-16f in CDCl3. 
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13C NMR (100 MHz) spectrum of 14-16f in CDCl3. 
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Chromatograms of compounds (−) & (±) 14-16g. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
4.78 3.001.93 1.000.97 0.95
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1H NMR (400 MHz) spectrum of 14-16g in CD3OD. 
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13C NMR (100 MHz) spectrum of 14-16g in CD3OD. 
 
Appendix  253 
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-17a in CD3OD. 
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13C NMR (100 MHz) spectrum of 14-17a in CD3OD. 
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Chromatograms of compounds (−) & (±) 14-17b. 
 
Appendix  255 
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-17b in CDCl3. 
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13C NMR (100 MHz) spectrum of 14-17b in CDCl3. 
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Chromatograms of compounds (−) & (±) 14-17c. 
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9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
3.92 3.001.94 1.931.90 0.910.82
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1H NMR (400 MHz) spectrum of 14-17c in CDCl3. 
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
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13C NMR (100 MHz) spectrum of 14-17c in CDCl3. 
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Chromatograms of compounds (−) & (±) 14-17d. 
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9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
6.012.30 1.961.78 0.98 0.88 0.870.81
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1H NMR (400 MHz) spectrum of 14-17d in CDCl3. 
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13C NMR (100 MHz) spectrum of 14-17d in CDCl3. 
 
260  Appendix
 
 
 
 
 
 
 
 
 
Chromatograms of compounds (−) & (±) 14-17e. 
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9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-17e in CD3OD. 
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13C NMR (100 MHz) spectrum of 14-17e in CD3OD. 
 
262  Appendix
 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
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1H NMR (400 MHz) spectrum of 14-17f in CDCl3. 
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13C NMR (100 MHz) spectrum of 14-17f in CDCl3. 
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9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
3.82 2.951.92 1.04 0.950.90
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1H NMR (400 MHz) spectrum of 14-17g in CD3OD. 
 
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
Chemical Shift (ppm)
1
5
5
.1
1
4
2
.8
1
4
1
.9
1
3
3
.5
1
3
3
.2
1
3
3
.0
1
3
2
.1
1
3
0
.5
1
3
0
.0
1
2
9
.6
1
2
7
.9
1
2
7
.4
1
2
7
.1
1
2
5
.7
1
2
1
.8
1
1
5
.9
1
1
3
.2
1
1
3
.0
1
0
1
.9
5
6
.2
5
5
.8
4
9
.0
13C NMR (100 MHz) spectrum of 14-17g in CD3OD. 
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Chromatograms of compounds (−) & (±) 14-18b. 
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9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5
Chemical Shift (ppm)
5.233.10 2.091.07 1.04
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1H NMR (400 MHz) spectrum of 14-18b in CD3OD (4.5 – 10.0 ppm). 
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Chemical Shift (ppm)
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13C NMR (100 MHz) spectrum of 14-18b in CD3OD (0.0 – 190 ppm). 
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Chromatograms of compounds (−) & (±) 14-18e. 
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1H NMR (400 MHz) spectrum of 14-12e in CD3OD (4.5 – 10.0 ppm). 
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13C NMR (100 MHz) spectrum of 14-18e in CD3OD (0.0 – 190 ppm). 
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1H NMR (400 MHz) spectrum of 14-19j in CDCl3. 
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13C NMR (100 MHz) spectrum of 14-19j in CDCl3.  
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1H NMR (400 MHz) spectrum of alcohol 16-32 in CDCl3. 
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13C NMR (100 MHz) spectrum of alcohol 16-32 in CDCl3. 
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1H NMR (400 MHz) spectrum of aldehyde 16-33 in CDCl3. 
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13C NMR (100 MHz) spectrum of aldehyde 16-33 in CDCl3. 
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1H NMR (400 MHz) spectrum of unsaturated thioester 16-34 in CDCl3. 
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13C NMR (100 MHz) spectrum of unsaturated thioester 16-34 in CDCl3. 
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1H NMR (400 MHz) spectrum of thioester 16-35 in CDCl3. 
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13C NMR (100 MHz) spectrum of thioester 16-35 in CDCl3. 
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1H NMR (400 MHz) spectrum of unsaturated thioester 16-37 in CDCl3. 
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13C NMR (100 MHz) spectrum of unsaturated thioester 16-37 in CDCl3. 
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1H NMR (400 MHz) spectrum of aldehyde 16-40 in CDCl3. 
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13C NMR (100 MHz) spectrum of aldehyde 16-40 in CDCl3. 
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1H NMR (400 MHz) spectrum of oxazolidinone 16-43 in CDCl3. 
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13C NMR (100 MHz) spectrum of oxazolidinone 16-43 in CDCl3. 
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1H NMR (400 MHz) spectrum of aldol-adduct 16-44 in CDCl3. 
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13C NMR (100 MHz) spectrum of aldol-adduct 16-44 in CDCl3. 
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1H NMR (400 MHz) spectrum of adduct-ether 16-45 in CDCl3. 
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13C NMR (100 MHz) spectrum of adduct-ether 16-45 in CDCl3. 
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1H NMR (400 MHz) spectrum of alcohol 16-46 in CDCl3. 
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13C NMR (100 MHz) spectrum of alcohol 16-46 in CDCl3. 
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1H NMR (400 MHz) spectrum of crude aldehyde 16-47 in CDCl3. 
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13C NMR (100 MHz) spectrum of crude aldehyde 16-47 in CDCl3. 
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1H NMR (400 MHz) spectrum of alkenol 17-18 in CDCl3. 
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13C NMR (400 MHz) spectrum of alkenol 17-18 in CDCl3. 
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1H NMR (400 MHz) spectrum of alcohol 17-19 in CDCl3. 
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13C NMR (100 MHz) spectrum of alcohol 17-19 in CDCl3. 
 
282  Appendix
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
3.412.252.13 2.082.08 2.001.580.58
1
.3
6
1
.3
8
1
.4
0
1
.9
7
2
.4
5
2
.4
6
2
.7
0
4
.3
5
4
.3
7
7
.3
4
7
.3
4
7
.3
5
7
.3
6
7
.8
5
9
.7
5
1H NMR (400 MHz) spectrum of aldehyde 17-20 in CDCl3. 
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13C NMR (100 MHz) spectrum of aldehyde 17-20 in CDCl3. 
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1H NMR (400 MHz) spectrum of alkene 17-21 in CDCl3. 
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13C NMR (100 MHz) spectrum of alkene 17-21 in CDCl3. 
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13C NMR (100 MHz) spectrum of hydroxamic acid 17-22 in DMSO. 
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1H NMR (400 MHz) spectrum of O-Pivaloate 17-23 in CDCl3. 
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13C NMR (100 MHz) spectrum of O-Pivaloate 17-23 in CDCl3. 
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1H NMR (400 MHz) spectrum of 17-14 in CDCl3. 
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1H NMR (400 MHz) spectrum of 3-methyl indanone 18-28a in CDCl3. 
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13C NMR (100 MHz) spectrum of 3-methyl indanone 18-28a in CDCl3. 
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1H NMR (400 MHz) spectrum of 3-methyl-6-methoxy indanone 18-28b in CDCl3. 
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13C NMR (100 MHz) spectrum of 3-methyl-6-methoxy indanone 18-28b in CDCl3. 
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1H NMR (400 MHz) spectrum of 7-methyl-1,3-methylenedioxy indanone 18-28e in CDCl3. 
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13C NMR (100 MHz) spectrum of 7-methyl-1,3-methylenedioxy indanone 18-28e in CDCl3. 
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1H NMR (400 MHz) spectrum of naphthyl indenone 18-29 in CDCl3. 
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13C NMR (100 MHz) spectrum of naphthyl indenone 18-29 in CDCl3. 
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